

October 3-7 • San Francisco, CA • www.idweek.org



IDWeek²⁰¹⁸TM

Advancing Science, Improving Care

FINAL PROGRAM

A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS



Copyright IDWeek 2018TM

All Rights Reserved

Printed in the United States of America

access IDWeek™ 2018 abstracts via OFID

All conference abstracts have been published as a supplement to *Open Forum Infectious Diseases (OFID)*, the online only, fully open access journal from IDSA and HIVMA. Oral, poster, and late-breaking abstracts are being permanently archived as part of the journal and are accessible to all journal readers, not only meeting attendees or society members.



To access the IDWeek™ abstracts published via *OFID*, download the IDSA Journals app from the iTunes app store or go to academic.oup.com/ofid.



Welcome Letter



Dear Colleagues,

As the **IDWeek™** Program Chairs, it is our pleasure to welcome you to **IDWeek 2018**! We are excited to launch the program this year, as it is the first iteration of the **IDWeek** strategic vision developed to ensure **IDWeek 2018** evolves and advances this critical education. Leveraging the experience of the Program Committee and past attendees, we implemented new programs, like the **IDea** Incubator, the new live forum in the exhibition hall on Thursday, October 4, at 5 p.m., and continued cornerstone events, like the **IDBugBowl** on Saturday, October 6 at 4:45 p.m.

IDWeek, now in its seventh year, strategically builds on the expertise of members from the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society to create a compelling educational program featuring the latest science and bench-to-bedside approaches.

There is no better forum than **IDWeek** to feature the impact and need of epidemiology, diagnosis, treatment, and prevention of infectious diseases across all ages and locations. **IDWeek** is designed to energize you and validate the important work you do EVERY DAY. Every attendee here has a role in improving patients' lives. **IDWeek** is the opportunity to see this by learning from the best and the brightest in the field who are taking their work to the next level when it comes to managing current infectious diseases outbreaks; implementing the newest diagnostic and treatment modalities; practicing the latest prevention strategies; and applying state-of-the-art science to clinical care.

We hope you will take advantage of the opportunity to meet and network with your colleagues from around the world while you are here. One of the most important benefits of attending **IDWeek 2018** is the chance to build strategic networks and share your passion with others who have similar passions and goals to form relationships that far outlast the conference!

IDWeek is constantly improving so if you have suggestions for topics or ideas you would like to see at **IDWeek 2019**, please tell a staff member.

We hope you enjoy the program as much as we enjoyed creating it. Enjoy San Francisco, and set your calendars for **IDWeek 2019**, scheduled for October 2 - 6, 2019, in Washington, DC.

With best regards,

Andrew T. Pavia, MD,
FIDSA, FSHEA, FPIDS
IDWeek Chair, IDSA

Ebbing Lautenbach,
MD, FIDSA, FSHEA
IDWeek Chair, SHEA

Jeanne M. Mraz,
MD, MPH, FIDSA
IDWeek Chair, HIVMA

Marsha S. Anderson,
MD, FIDSA
IDWeek Chair, PIDS

Acknowledgements

The **IDWeek** partners wish to extend a special **Thank You** to the following organizations who developed sessions in collaboration with the **IDWeek** Program Committee (see Allied Partners on page 13 for specific session details):

- American Society of Transplantation
- Centers for Disease Control and Prevention
- European Society of Clinical Microbiology and Infectious Diseases
- European Society for Paediatric Infectious Diseases
- IDSA Clinical Affairs Committee
- IDSA ID Training Program Directors' Committee
- IDSA Medical Education Workgroup
- IDSA Education Committee
- IDSA Standards and Practice Guidelines Committee
- IDSA Telehealth Committee
- Johns Hopkins University School of Medicine Div. of Infectious Diseases
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Network of STD Clinical Prevention Training Centers
- Pan-American Society of Infectious Diseases, Brazilian Society of Infectious Diseases

The **IDWeek** Program Committee would like to extend a special **Thank You** to the following individuals who generously donated their time and expertise to review abstracts for **IDWeek 2018**:

- | | | |
|---|--|--|
| Paul Ambrose, PharmD, FIDSA, Institute for Clinical Pharmacodynamics, Inc., Schenectady, NY | Andrew Chou, MD, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX | Bishara Freij, MD, FIDSA, Beaumont Hospital - Dearborn, Royal Oak, MI |
| Evan J. Anderson, MD, Emory University School of Medicine, Atlanta, GA | Cornelius J. Clancy, MD, University of Pittsburgh, Pittsburgh, PA | Bettina C. Fries, MD, FIDSA, Stony Brook University, Stony Brook, NY |
| Senu Apewokin, MD, University of Cincinnati College of Medicine, Cincinnati, OH | Christopher Crnich, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, WI | Julia Garcia-Diaz, MD, FIDSA, Ochsner Clinic Foundation, New Orleans, LA |
| Kevin Ard, MD, Massachusetts General Hospital, Boston, MA | Louise Dembry, MD, MS, MBA, FIDSA, FSHEA, Yale School of Medicine, New Haven, CT | Kathleen Gensheimer, MD, MPH, FIDSA, US Food and Drug Administration, College Park, MD |
| David Aronoff, MD, FIDSA, Vanderbilt University School of Medicine, Nashville, TN | Sarah B. Doernberg, MD, Yale University, New Haven, CT | Michael Glickman, MD, FIDSA, Memorial Sloan-Kettering Cancer Center, New York, NY |
| Muhammad Salman Ashraf, MBBS, East Carolina University, Greenville, NC | Yohei Doi, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA | Rachel Gordon, MD, MPH, Columbia University College of Physicians and Surgeons, New York, NY |
| Ritu Banerjee, MD, PhD, Vanderbilt University, Nashville, TN | Dimitri M. Drekonja, MD, MS, FIDSA, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN | Rana Hamdy, MD, MPH, MSCE, Children's National Health System, Washington, DC |
| Miriam Barshak, MD, FIDSA, Harvard Medical School, Boston, MA | Jennifer Duchon, MDCM, MPH, Columbia Presbyterian Medical Center, New York, NY | Nada Harik, MD, Children's National Health System, Washington, DC |
| Ingrid V. Bassett, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA | Joseph Duncan, MD, PhD, FIDSA, University of North Carolina School of Medicine, Chapel Hill, NC | Joshua Hartzell, MD, FIDSA, Walter Reed National Military Medical Center, Bethesda, MD |
| Robert Bednarczyk, PhD, Rollins School of Public Health, Emory University, Atlanta, GA | Marlene Durand, MD, FIDSA, Harvard Medical School, Boston, MA | Mary K. Hayden, MD, FIDSA, FSHEA, Rush University Medical Center, Chicago, IL |
| Elie F. Berbari, MD, FIDSA, Mayo Clinic, Rochester, MN | Michael J. Durkin, MD, MPH, Washington University School of Medicine, St. Louis, MO | Marisa Holubar, MD, MS, Stanford Health Care, Stanford, CA |
| Luiz Bermudez, MD, Oregon State University, Corvallis, OR | Kathryn Edwards, MD, FIDSA, Vanderbilt University School of Medicine, Nashville, TN | Saul Hymes, MD, Stony Brook Children's Hospital, Stony Brook, NY |
| Anne J. Blaschke, MD, PhD, FIDSA, FPIDS, University of Utah School of Medicine, Salt Lake City, UT | Nathan Erdmann, MD, PhD, University of Alabama at Birmingham, Birmingham, AL | Kengo Inagaki, MD, University of Mississippi Medical Center, Jackson, MS |
| Chloe Bryson-Cahn, MD, University of Washington School of Medicine, Seattle, WA | Claudia Espinosa, MD, MSc, University of Louisville, Louisville, KY | Michael G. Ison, MD, FIDSA, Northwestern University, Chicago, IL |
| Angela P. Campbell, MD, MPH, FIDSA, FPIDS, Centers for Disease Control and Prevention, Atlanta, GA | Andras Farkas, PharmD, Mount Sinai, New York, NY | Lisa Jackson, MD, MPH, FIDSA, Center for Health Studies, Seattle, WA |
| Ann Chahroudi, MD, PhD, Emory University, Atlanta, GA | Cynthia Fisher, MD, PhD, University of Washington School of Medicine, Seattle, WA | Seema Jain, MD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA |
| Archana Chatterjee, MD, PhD, FIDSA, FPIDS, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD | Michelle Floris-Moore, MD, MS, University of North Carolina School of Medicine, Chapel Hill, NC | Vivek Jain, MD, MAS, University of California San Francisco, San Francisco, CA |
| Natasha Chida, MD, Johns Hopkins University School of Medicine, Elkridge, MD | Donald Forthal, MD, FIDSA, University of California Irvine School of Medicine, Orange, CA | Erica Johnson, MD, Johns Hopkins Medicine, Baltimore, MD |
| Pearlie Chong, MD, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, NC | Ricardo Franco, MD, University of Alabama at Birmingham, Alabama, AL | Melissa Johnson, PharmD, MHS, Duke University School of Medicine, Durham, NC |

Acknowledgements (continued)

- Ameeta Kalokhe, MD, Emory University School of Medicine, Atlanta, GA
- Susana Keeshin, MD, University of Utah, Salt Lake City, UT
- Jennie Kwon, DO, Washington University School of Medicine, St. Louis, MO
- Maryrose Laguio-Vila, MD, Rochester Regional Health, Rochester, NY
- Francesca Lee, MD, University of Texas Southwestern Medical Center, Dallas, TX
- Alexander Lepak, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI
- Michael Y. Lin, MD, MPH, Rush University Medical Center, Chicago, IL
- Matt Linam, MD, MS, Emory University School of Medicine, Atlanta, GA
- Vera Luther, MD, Wake Forest School of Medicine, Winston-Salem, NC
- Anurag Malani, MD, FIDSA, FSHEA, St. Joseph Mercy Health System, Ypsilanti, MI
- Michael Mansour, MD, Massachusetts General Hospital, Boston, MA
- Trini Mathew, MD, MPH, FIDSA, Conemaugh Health System, Johnstown, PA
- Larissa May, MD, MSPH, FIDSA, University of California-Davis, Sacramento, CA
- Dana Mazo, MD, Mount Sinai, New York, NY
- Daniel McQuillen, MD, FIDSA, Lahey Hospital & Medical Center, Burlington, MA
- Sanjay Mehta, MD, University of California, San Diego, La Jolla, CA
- Asuncion Mejias, MD, PhD, MSCS, The Research Institute at Nationwide Children's Hospital, Columbus, OH
- Andre G. Melendez, MD, Emory University School of Medicine, Atlanta, GA
- Michael T. Melia, MD, Johns Hopkins University School of Medicine, Baltimore, MD
- Ian C. Michelow, MD, DTM&H, Rhode Island Hospital/Medical School of Brown University, Providence, RI
- William Miller, MD, FIDSA, UTHealth McGovern Medical School, Houston, TX
- Christopher Moore, MD, University of Virginia, Charlottesville, VA
- David Mushatt, MD, MPH & TM, FIDSA, Tulane University School of Medicine, New Orleans, LA
- Sandra Nelson, MD, FIDSA, Massachusetts General Hospital, Boston, MA
- Priya Nori, MD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
- Brianna L. Norton, DO, MPH, Duke University Medical Center, Durham, NC
- Ann-Christine Nyquist, MD, MSPH, FPIDS, University of Colorado School of Medicine/Children's Hospital Colorado, Aurora, CO
- Christopher Ohl, MD, FIDSA, Wake Forest Baptist Health, Winston-Salem, NC
- Nwora Lance Okeke, MD, MPH, Duke University Medical Center, Durham, NC
- Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA, McGovern Medical School, Houston, TX
- April Palmer, MD, FPIDS, University of Mississippi Medical Center, Jackson, MS
- Federico Perez, MD, MS, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
- Steven Pergam, MD, MPH, FIDSA, Fred Hutchinson Cancer Research Center, Seattle, WA
- Varun Phadke, MD, Emory University, Atlanta, GA
- Jason M. Pogue, PharmD, Detroit Medical Center, Detroit, MI
- Kyle J Popovich, MD, MS, FIDSA, Rush University Medical Center, Chicago, IL
- Paul S. Pottinger, MD, FIDSA, University of Washington, Seattle, WA
- Jennifer S. Read, MD, MS, MPH, DTM&H, FIDSA, University of Vermont, Burlington, VT
- Maria Rodriguez-Barradas, MD, FIDSA, Michael E. DeBakey VA Medical Center, Houston, TX
- Nadine Rouphael, MD, Emory University, Atlanta, GA
- Rafik Samuel, MD, FIDSA, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- Maurizio Sanguinetti, Università Cattolica del Sacro Cuore, Milano, Italy
- Patrice Savard, MD, FRCPC, CHUM, Montreal, QC
- Jennifer Schuster, MD, MSCI, Children's Mercy Kansas City, Kansas City, MO
- Brian Schwartz, MD, University of California, San Francisco, San Francisco, CA
- Andi L. Shane, MD, MPH, MSc, FIDSA, FPIDS, Emory University School of Medicine, Atlanta, GA
- Dawd Siraj, MD, FIDSA, University of Wisconsin-Madison, Madison, WI
- Michael Smit, MD, MSPH, Rhode Island Hospital, Providence, RI
- Becky Smith, MD, Duke University Medical Center, Durham, NC
- Geeta Sood, MD, Johns Hopkins University School of Medicine, Baltimore, MD
- Pranavi Sreeramouju, MD, MPH, FIDSA, University of Texas Southwestern Medical Center, Dallas, TX
- Arjun Srinivasan, MD, FSHEA, Centers for Disease Control and Prevention, Washington, DC
- R. Scott Stienecker, MD, Parkview Health, Fort Wayne, IN
- Sankar Swaminathan, MD, FIDSA, University of Utah, Salt Lake City, UT
- Tina Q. Tan, MD, FIDSA, Northwestern University Feinberg School of Medicine, Chicago, IL
- Jesus Vallejo, MD, FIDSA, Baylor College of Medicine and Texas Children's Hospital, Houston, TX
- Rebecca Wallihan, MD, The Research Institute at Nationwide Children's Hospital, Columbus, OH
- David J. Weber, MD, MPH, FIDSA, FSHEA, University of North Carolina, School of Public Health, Chapel Hill, NC
- Zachary Willis, MD, MPH, University of North Carolina School of Medicine, Chapel Hill, NC
- Joshua Wolf, MBBS, FRACP, St. Jude Children's Research Hospital, Memphis, TN
- Heather Yun, MD, FIDSA, Brooke Army Medical Center, JBSA Fort Sam Houston, TX
- Gary Zeitlin, MD, White Plains Medical Associates, White Plains, NY
- Annelies Zinkernagel, MD, PhD, MSc, University Hospital Zurich, Zurich, Switzerland

DOWNLOAD THE OFFICIAL

IDWeek 2018™ mobile application

Search the Apple App Store and Google Play for “**IDWeek**”.

- Join the Scavenger Hunt and Trivia activities for a chance to win prizes.
- Search for sessions
- Participate in audience response
- Create your schedule
- Read abstracts and view posters
- Browse the exhibitors
- Find helpful meeting information
- Connect with other attendees

**Use your registration email address to gain access.*



Table of Contents

General Information	8	Plenaries	15
Headquarters Office.....	8	Special Opening Plenary Session: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space.....	15
Certificate of Attendance.....	8	Closing Plenary Session: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections	16
Childcare, Child Safety, and Nursing Mothers.....	8	Named Lectures	18
IDWeek Booth / Society Booths	8	Awards Presentation Schedule.....	25
IDSA-HIVMA-PIDS Advocacy Education Breakfast.....	8	IDSA Society Awards.....	26
Newsroom	8	IDSA Education and Research Foundation Awards.....	34
Smoking Policy	8	SHEA Society Awards.....	35
IDWeek Mobile App	8	HIVMA Awards	39
IDWeek Digital Session Library	8	PIDS Society Awards.....	41
 		Abstract Awards.....	42
IDWeek 2018 Program Committee	9	CME/CPE/MOC Credit Tracker	52
Program Information	10	IDWeek 2018 Program Tracks.....	57
IDWeek Description	10	Scientific Sessions.....	81
Accreditation Statement for Physicians.....	10	Oral Abstract Sessions	119
Accreditation Statement for Pharmacists	10	Poster Abstract Sessions	127
ACCME Guidelines for Moderators	10		
Credit Designation Statement.....	10		
ABIM MOC Statement.....	10		
ABP MOC Statement	10		
Claim CME/CPE/MOC Credit	10		
Continuing Education Credit for Pharmacists.....	10		
Faculty Disclosures.....	11		
Commercial Support Statement.....	11		
Scientific Sessions and Room Capacity	11		
Opening Reception and “Posters in the Park”	11		
IDWeek Partnering Societies Business Meetings	11		
Abstracts.....	11		
Poster Discussion Rounds	11		
Speaker Ready Room	12		
IDWeek Supporters	12		
Allied Partners.....	13		



General Information

Headquarters Office

The IDWeek Headquarters Office will be located in Room N 21 in the North Building of the Moscone Center. On Sunday, October 7, please visit the IDWeek information desk in the lobby of Moscone West for headquarter services.

Certificate of Attendance

Attendees may obtain certificates of attendance at the designated IDWeek registration desk in the lobby of Moscone West or after the meeting at www.idweek.org/post-meeting-tools/.

Childcare, Child Safety, and Nursing Mothers

For childcare services at the meeting, please contact your hotel concierge.

A nursing mothers' lounge will be available during the meeting hours on the second floor of the West building of the Moscone Center. Only nursing mothers and their infants are permitted in this room. Water and temporary refrigeration for storage will be available for your convenience.

IDWeek Booth / Society Booths

All attendees are invited to stop by the IDWeek booth and individual societies' booths in the registration area in the lobby of West Building to learn more about the meeting and membership in IDWeek's partnering societies. At the society booths, learn more about what each society is doing to advocate for better federal policies on your behalf and how you can get more engaged. Please visit the individual booths to get the latest advocacy news from Washington, DC and sign up for each society's Member Advocacy Program. You can also join and become a member on site or renew your membership for 2019. Stop by and say hello!

IDSA-HIVMA-PIDS Advocacy Education Breakfast

The Advocacy Education Breakfast session highlights the work of IDSA, HIVMA, and PIDS members to improve federal policy for ID and HIV physicians, scientists, and patients. IDSA, HIVMA, and PIDS members will discuss and demonstrate the key elements of effective advocacy. The session will feature testimonials from IDSA, HIVMA, and PIDS members about their experience participating in advocacy activities and information about current opportunities for members to get involved. IDSA, HIVMA, and PIDS policy staff will share the latest policy news from Washington, DC. The session is scheduled for Friday, October 5, from 7 - 9 a.m. in S 155 in the Moscone Center.

Newsroom

The Newsroom will be located in Room N 20 in the North Building of the Moscone Center. Press conferences will be held on selected abstracts. Interviews with authors can also be arranged for the media.

Smoking Policy

No smoking is allowed at IDWeek.

IDWeek Mobile App

- Browse for IDWeek 2018 in the Apple App Store or Google Play market to download.
- Registered attendees may download the IDWeek mobile application for their iPhone, iPad, or Android devices for free.
- Participate in the Interactive Sessions with the mobile app, which will be used as the audience response system.
- The mobile app helps you navigate event details, manage your personal meeting agenda, connect with other attendee colleagues on Facebook and Twitter, view full abstracts and posters, and search the list of exhibiting companies.
- Authenticate the app using the email address you used to register for IDWeek.

View the App for the following information:

- Moderator and Presenter Information
- Detailed Map of Sessions
- Attendees with Disabilities
- Badge Policies
- Baggage and Coat Check
- Lost and Found
- Financial Disclosures

IDWeek Digital Session Library

- View sessions in premier format from your Mac, PC, smartphone, or tablet.
- The recordings feature high-quality digital audio and visuals.
- All sessions will include synchronized speaker slides, animations, procedural videos, and pointer movements displayed at the event.
- Access the digital library through the IDWeek app or online at www.IDWeek.org.
- Access will be free for all scientific attendees.



IDWeek 2018 Program Committee

Chairs:

Andrew T. Pavia, MD, FIDSA, FSHEA, FPIDS, Chair, IDSA, University of Utah, Salt Lake City, UT

Ebbing Lautenbach, MD, FIDSA, FSHEA, Chair, SHEA, University of Pennsylvania School of Medicine, Philadelphia, PA

Jeanne M. Mrazek, MD, MPH, FIDSA, Chair, HIVMA, University of Alabama at Birmingham School of Medicine, Birmingham, AL

Marsha S. Anderson, MD, FIDSA, Chair, PIDS, University of Colorado School of Medicine, Aurora, CO

Vice-Chairs:

Cesar Arias, MD, PhD, FIDSA, Vice-Chair, IDSA, University of Texas Health Science Center at Houston, Houston, TX

Kristina A. Bryant, MD, FPIDS, Vice-Chair, SHEA, University of Louisville, Louisville, KY

Eric Daar, MD, Vice-Chair, HIVMA, Harbor-UCLA Medical Center, Torrance, CA

Roberta L. DeBiasi, MD, MS, FIDSA, FPIDS, Vice-Chair, PIDS, Children's National Health System/George Washington University School of Medicine, Washington, DC

Members:

David Andes, MD, FIDSA, University of Wisconsin School of Medicine and Public Health, Madison, WI

Hilary Babcock, MD, MPH, Washington University in St. Louis, Saint Louis, MO

Adarsh Bhimraj, MD, FIDSA, Cleveland Clinic, Cleveland, OH

Robert Bonomo, MD, FIDSA, Louis Stokes Cleveland VA Medical Center, Cleveland, OH

Karen C. Carroll, MD, FIDSA, Johns Hopkins University School of Medicine, Baltimore, MD

Christina Coyle, MD, Albert Einstein College of Medicine, Bronx, NY

Inger Damon, MD, PhD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA

Jeff Duchin, MD, FIDSA, Public Health - Seattle & King County, Seattle, WA

Hana M. El Sahly, MD, FIDSA, Baylor College of Medicine, Houston, TX

Debra Goff, PharmD, Ohio State University, Columbus, OH

Marcia Goldberg, MD, FIDSA, Massachusetts General Hospital, Boston, MA

David Greenberg, MD, FIDSA, University of Texas Southwestern Medical Center, Dallas, TX

Patricia Griffin, MD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA

Natasha B. Halasa, MD, MPH, FIDSA, FPIDS, Vanderbilt University School of Medicine, Nashville, TN

Randall Hayden, MD, St. Jude Children's Research Hospital, Memphis, TN

Tobias M. Hohl, MD, PhD, FIDSA, Memorial Sloan Kettering Cancer Center, New York, NY

John B. Lynch, MD, MPH, Harborview Medical Center, Seattle, WA

Shelley Magill, MD, PhD, Centers for Disease Control and Prevention, Atlanta, GA

Rachel Miller, MD, FIDSA, Duke University Medical Center, Durham, NC

Susanna Naggie, MD, MHS, FIDSA, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC

Joshua Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine, Bronx, NY

Tara Palmore, MD, National Institute of Allergy and Infectious Diseases, Bethesda, MD

Mario Poljak, MD, University of Ljubljana, Ljubljana, Slovenia

Raymund R. Razonable, MD, FIDSA, Mayo Clinic, Rochester, MN

Samuel Shelburne, MD, PhD, FIDSA, The University of Texas MD Anderson Cancer Center, Houston, TX

H. Keipp Talbot, MD, MPH, FIDSA, Vanderbilt University Medical Center, Nashville, TN

Thomas Talbot, MD, MPH, FIDSA, FSHEA, Vanderbilt University, Nashville, TN

Virginia Triant, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA

David Van Duin, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC

Wesley Van Voorhis, MD, PhD, FIDSA, University of Washington, Seattle, WA

Vincent B. Young, MD, PhD, FIDSA, University of Michigan, Ann Arbor, MI

Ex-officio:

Paul G. Auwaerter, MD, FIDSA, IDSA President, Johns Hopkins University School of Medicine, Baltimore, MD

Cynthia Sears, MD, FIDSA, IDSA President-Elect, Johns Hopkins University School of Medicine, Baltimore, MD

Chris Busky, CAE, Chief Executive Officer, IDSA, Arlington, VA

Sandra Vura Harwood, CMP, Meeting Secretariat, IDWeek, Arlington, VA

Eve Humphreys, MBA, CAE, Executive Director, SHEA, Arlington, VA

Andrea Weddle, MSW, Executive Director, HIVMA, Arlington, VA

Terri Christene Phillips, MSA, Executive Director, PIDS, Arlington, VA

Infectious Diseases Society
of America
www.idsociety.org

The Society for Healthcare
Epidemiology of America
www.shea-online.org

HIV Medicine Association
www.hivma.org

Pediatric Infectious Diseases
Society
www.pids.org

IDWeek 2018 1300 Wilson Blvd., Suite 300, Arlington, VA 22209, 703-740-4961
info@idweek.org • www.idweek.org

Program Information

IDWeek Description

IDWeek 2018 is a joint meeting of IDSA, SHEA, HIVMA, and PIDS, focusing on the theme—Advancing Science, Improving Care—and featuring the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek is geared toward healthcare professionals in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists, and public health officials, including those who see HIV and pediatric patients. There are no prerequisites for attendance. The meeting will provide state-of-the-art science and clinical care updates on key topics and issues. It is a must-attend meeting.

IDWeek Objectives

- Update infectious diseases clinicians and investigators with state-of-the-art developments in the field, including timely reviews of recent advances in clinical care and research, and original reports of clinical, translational, and basic research.
- Bridge the widening gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research.
- Promote multi-disciplinary dialogue and collaboration among clinicians and investigators, thus facilitating advances in the prevention, diagnosis, and treatment of infectious diseases.

Accreditation Statement for Physicians

The Infectious Diseases Society of America (IDSA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Accreditation Statement for Pharmacists

The continuing education activities for pharmacists have been developed through a joint providership of ProCE, Inc. and the Infectious Diseases Society of America (IDSA).

ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-18-178-L01-P through 0221-9999-18-281-L04-P, and 0221-9999-18-301-L01-P through 0221-9999-18-316-L01-P have been assigned to these live knowledge-based and application-based sessions (initial release date October 2–7, 2018). This conference is acceptable for up to 32.85 contact hours (3.285 CEUs) in states that recognize ACPE providers. The registration fee covers the cost of CE credits. CE Statements will be issued by the Infectious Diseases Society of America (IDSA) at the conclusion of the conference. Participants must complete an evaluation for each session they attended to receive pharmacy CE credit. The deadline for completing the evaluations is Monday, November 26, 2018.

ACCME Guidelines for Moderators

In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session.

Credit Designation Statement

IDSA designates this live activity for a maximum of 35.5 *AMA PRA Category 1 Credits™*. The core IDWeek sessions are designated for 23.5 credit hours and premeeting workshops are an additional 12. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement

Successful completion of this CME activity enables the participant to earn up to 23.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

IDWeek 2018 physician participation information will be shared with ABIM through ACCME PARS.

ABP MOC Statement

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 15 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Claim CME/CPE/MOC Credit

Statements of credit must be claimed either at the CME Pavilion or online after the meeting. Attendees will be required to complete a short evaluation for every session for which credit is claimed.

The deadline to claim credit is Monday, November 26, 2018.

Attendees must attend each selected session in its entirety to receive CME/CPE/MOC credit. Partial credit is not available.

Continuing Education Credit for Pharmacists

Pharmacy credit will be available for select sessions at IDWeek 2018. Please refer to the CME/CPE/MOC Credit Tracker on pages 53 - 57 for a detailed list and ACPE number assigned to each applicable session. Pharmacists must attend each select session in its entirety to receive CPE credit.

Program Information (continued)

Faculty Disclosures

In accordance with the ACCME Standards for Commercial Support, IDWeek must provide balance, objectivity, and scientific rigor in all sponsored educational activities accredited for CME. The intent of the disclosures is to provide the audience with information on which they can make their own independent judgments pertaining to program content. IDWeek requires all faculty to disclose relevant financial relationships that they or a spouse/partner have, or have had, within the past 12 months with companies or commercial supporters of any products/services that are related to the research being presented at IDWeek (for example, employee, grants, research support, speaker, sponsors, stockholder, etc.). In addition to verbal and written disclosures, faculty are required to provide on the first slide of PowerPoint presentations any significant financial interest(s) / relationship(s) or note that there is “Nothing to disclose.” These disclosures can be found on the IDWeek App.

Commercial Support Statement

IDWeek and ProCE, Inc. follow and support the ACCME/ACPE guidelines for commercial support.

Scientific Sessions and Room Capacity

Scientific sessions will be held at the Moscone Center. For floor plans and maps please check the meeting app. IDWeek has made every effort to assign sessions to the appropriate room. Attendance is on a first-come, first-served basis and we ask that attendees use all available seating before standing. We apologize in advance if attendance exceeds available seating.

Opening Reception and “Posters in the Park”

The IDWeek Opening Reception and the “Posters in the Park” event will be held together on Wednesday, October 3, from 5:30 - 6:30 p.m. in the North Hall D Opening Reception Area, immediately following the Opening Plenary Session. Mingle with colleagues and talk to poster presenters whose research has been specially selected by each of the partner societies. This event is open to all registered attendees.

IDWeek Partnering Societies Business Meetings

Cocktails and Conversation with CDC Director Robert Redfield, MD, and an IDSA/HIVMA update: “Reflecting the New Face of ID”

Join IDSA and HIVMA leadership for a special session with CDC Director Robert Redfield, MD, on Friday, October 5, from 5 - 6 p.m. in North Hall D in the Moscone Center. Hear Dr. Redfield’s perspective as a public leader actively engaged in clinical research

and clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years. In addition, hear an update from IDSA and HIVMA leadership on key projects in the works and successful accomplishments over the past year. Please join us for cocktails and to catch up with friends!

PIDS Business Meeting

Join PIDS Leadership for the PIDS Business Meeting on Thursday, October 4 from 6 - 6:45 p.m. in the Moscone Center, North 23. Several PIDS Society Awards will be presented along with a wrap up from the year and a look forward at the year to come.

SHEA President’s Reception & Business Meeting

Join SHEA Leadership for SHEA President’s Reception & Business Meeting on Thursday, October 4 from 6 - 7:30 p.m. in the Embarcadero Room at the Parc 55 Hotel. SHEA’s newly elected leadership will be announced along with a wrap up of SHEA’s activities for the past year. SHEA will present the NEW SHEA Research Scholar Grant and the top fundraisers of the Race Against Resistance. Please join us for light refreshments as we discuss SHEA’s successful year!

Abstracts

Abstracts are available online through the Interactive Program Planner at www.IDWeek.org. You can also access them on the IDWeek app. See IDWeek Mobile App for details.

IDWeek 2018 abstracts will be published as an online supplement to *Open Forum Infectious Diseases (OFID)*, the open access journal from IDSA. They will be permanently archived as part of the journal and will be accessible to all journal readers, not only meeting attendees or society members.

Poster Discussion Rounds

These sessions emphasize poster presentations of highlighted abstracts chosen through peer review. For each session, an expert in the field will summarize the research findings in context and participants will have the opportunity to ask questions of the authors. The group leader will determine the objectives and scope of discussion.

Pre-registration is not required. Participants are asked to meet in the Poster Discussion area 10 minutes prior to the beginning of the session. All of these will be held in the South Poster Hall of the Moscone Center during the time below.

Thursday, October 4	12:30 - 1:45 p.m.
Friday, October 5	12:30 - 1:45 p.m.
Saturday, October 6	12:30 - 1:45 p.m.

continued on next page

Program Information (continued)

Speaker Ready Room

Check-in is required for all speakers. All speakers must use PowerPoint presentations. Speakers should check in at the onsite Speaker Ready Room at least 24 hours prior to presentation time. Please bring an electronic copy of your presentation. The Speaker Ready Room will be located in the lobby of the South Hall of the Moscone Center. For those speaking the West Building of the Moscone Center, there will be a smaller Speaker Ready Room located near registration in the Lobby of West. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual consultants and IDWeek staff will be available for assistance. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems, and make corrections as necessary before your presentation. All speakers are requested to leave a version of their PowerPoint presentation in the Speaker Ready Room for posting in the IDWeek digital library after the meeting.

Speaker Ready Room Hours of Operation:

Monday, October 1 2 - 6 p.m.
Tuesday, October 2 7 a.m. - 6 p.m.
Wednesday, October 3 6:30 a.m. - 6 p.m.
Thursday, October 4 6:30 a.m. - 6 p.m.
Friday, October 5 6:30 a.m. - 6 p.m.
Saturday, October 6 6:30 a.m. - 6 p.m.
*Sunday, October 7 7 - 9 a.m.

*Speaker Ready Room will be in the Lobby of the West Building

IDWeek Supporters

IDWeek gratefully acknowledges the support of the following companies:

DIAMOND

Gilead Sciences, Inc.

PLATINUM

ViiV Healthcare

GOLD

Astellas
BioFire Diagnostics, LLC
Genentech

SILVER

Merck

BRONZE

Healix
Leadiant Biosciences, Inc.
Medical Device Business Services, Inc.
Roche Diagnostics Corporation

Supported by a grant from Pfizer Inc.
Supported by Shire through an educational grant

Program Information (continued)

Allied Partners

- **American Society of Transplantation**

INTERACTIVE SESSION

Challenging Cases in Transplant: When the ID Expert Says, "What?"

Friday, October 5, 2 - 3:15 p.m.

- **Centers for Disease Control and Prevention**

MEET-THE-PROFESSOR SESSION

Antimicrobial and Diagnostic Stewardship

Thursday, October 4, 7:15 - 8:30 a.m.

Combating Antimicrobial Resistance: Relevance of the One Health Concept

Thursday, October 4, 8:45 - 10 a.m.

SYMPOSIUM

Pandemic Influenza

Friday, October 5, 8:45 - 10 a.m.

- **European Society of Clinical Microbiology and Infectious Diseases**

INTERACTIVE SESSION

Challenging Cases in Infectious Diseases

Friday, October 5, 10:30 - 11:45 a.m.

- **European Society for Paediatric Infectious Diseases**

SYMPOSIUM

Pediatric Immunization: Perspectives from Both Sides of the Pond

Friday, October 5, 2 - 3:15 p.m.

- **IDSA Clinical Affairs Committee**

SYMPOSIUM

ID Physicians in the Age of Value-Based Healthcare

Friday, October 5, 3:30 - 4:45 p.m.

SYMPOSIUM

ID Physicians and Addiction Medicine

Saturday, October 6, 8:45 - 10 a.m.

SYMPOSIUM

I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID

Saturday, October 6, 10:30 - 11:45 a.m.

- **IDSA ID Training Program Directors' Committee**

PREMEETING WORKSHOP

Fellows' Day Workshop (\$)

Wednesday, October 3, 8 a.m. - Noon

- **IDSA Medical Education Workgroup, IDSA Education Committee**

SYMPOSIUM

Hot Topics in Medical Education 2018

Thursday, October 4, 10:30 - 11:45 a.m.

MEET-THE-PROFESSOR SESSION

Educating Trainees about Stewardship

Saturday, October 6, 7:15 - 8:15 a.m.

MEET-THE-PROFESSOR SESSION

Clinical Teaching for the ID Provider

Saturday, October 6, 7:15 - 8:15 a.m.

- **IDSA Standards and Practice Guidelines Committee and Johns Hopkins University School of Medicine Div. of Infectious Diseases**

SYMPOSIUM

New and Updated Guidelines

Thursday, October 4, 10:30 - 11:45 a.m.

- **IDSA Telehealth Committee**

SYMPOSIUM

Can You Hear and See Me Now? ID Telehealth

Thursday, October 4, 8:45 - 10 a.m.

- **National Institute of Allergy and Infectious Diseases**

PREMEETING WORKSHOP

NIH Initiatives / Grant Writing Workshop

Tuesday, October 2, 1 - 5 p.m.

SYMPOSIUM

Migration and Immigration: Global Diseases at Your Doorstep

Thursday, October 4, 2 - 3:15 p.m.

SYMPOSIUM

Novel Clinical Risks for Fungal Disease

Thursday, October 4, 2 - 3:15 p.m.

- **National Institutes of Health**

INTERACTIVE SESSION

Controversies in Infection Prevention

Thursday, October 4, 2 - 3:15 p.m.

MEET-THE-PROFESSOR SESSION

Designing a QI Project You Can Publish

Friday, October 5, 7:15 - 8:15 a.m.

- **National Network of STD Clinical Prevention Training Centers**

INTERACTIVE SESSION

STIs in the HIV Care Setting

Thursday, October 4, 10:30 - 11:45 a.m.

- **Pan-American Society of Infectious Diseases, Brazilian Society of Infectious Diseases**

SYMPOSIUM

Non-Zika Arboviruses in the Americas

Saturday, October 6, 8:45 - 10 a.m.



Special Opening Plenary Session:

Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space

Wednesday, October 3, 2018

3:45 - 5:15 p.m.

Moscone Center: North Hall D



Kathleen "Kate" Rubins,
PhD

Kathleen "Kate" Rubins, PhD, was selected by the National Aeronautics and Space Administration (NASA) in 2009. Dr. Rubins completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. She spent 115 days in space and conducted two spacewalks. She holds a Bachelor of Science in Molecular Biology from the University of California and a PhD in Cancer Biology from Stanford University Medical School Biochemistry Department and Microbiology and Immunology Department.

Dr. Rubins conducted her undergraduate research on HIV-1 integration in the Infectious Diseases Laboratory at the Salk Institute for Biological Studies. She worked as a Fellow/Principal Investigator at the Whitehead Institute for Biomedical Research and headed 14 researchers studying viral diseases that primarily affect Central and West Africa.

Dr. Rubins' talk, "Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space," will focus on improving the microbiome research.

Closing Plenary Session:

From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections

Sunday, October 7, 2018

9:15 - 10:45 a.m.

Moscone Center: West 2005-2024

Turning the Phage on Antibiotics




Steffanie Strathdee, PhD, is an infectious disease epidemiologist who is renowned for her research on the intersection of HIV and drug use, having generated over 500 scholarly publications. She is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego, where she directs a campus-wide Global Health Institute. She is married to Thomas L. Patterson, Professor of Psychiatry at UC

Steffanie Strathdee, PhD

San Diego, where they co-direct a research and training program on the Mexico-U.S. border.

Dr. Strathdee is credited with saving her husband's life from a deadly superbug infection using bacteriophage therapy. The case, which involved cooperation from three universities, the U.S. Navy, and researchers across the globe, shows how phage therapy is a future weapon against multidrug-resistant bacterial infections, which are expected to kill 10 million people per year by 2050.



Tom Patterson, PhD, is distinguished professor of Psychiatry at the University of California San Diego. Dr. Patterson's HIV research has focused primarily on counseling interventions for high-risk individuals to increase condom use and reduce HIV transmission risk. He has published over 500 peer reviewed journal articles and numerous book chapters.

Tom Patterson, PhD

Together, Drs. Strathdee and Patterson are working on a book which chronicles how phages were used to save Dr. Patterson's life and why they have been largely ignored by clinicians. Their presentation will focus on this experience in a talk titled "Turning the Phage on Antibiotics."

From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections



Robert T. "Chip" Schooley, MD, FIDSA

Robert T. "Chip" Schooley, MD, FIDSA, is a Professor of Medicine in the Department of Medicine, Division of Infectious Diseases and Global Public Health, at the University of California San Diego. Dr. Schooley received his medical degree from the Johns Hopkins University School of Medicine in 1974 and completed his medical house staff training at the Johns Hopkins Hospital in 1976. He completed fellowships in infectious diseases at the National Institute of

Allergy and Infectious Diseases and at the Massachusetts General Hospital before joining the faculty of Harvard Medical School in 1981.

Dr. Schooley began his research career studying the immunopathogenesis of herpesvirus infections in

immunocompromised patients but shifted his focus to AIDS in 1981 when the first cases of this syndrome began to appear in Boston. His research group was among the first to delineate the humoral and cellular immune responses to HIV infection. Over the next 15 years he became increasingly involved in the discovery and development of antiretroviral chemotherapeutic agents, including reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors.

His current research interests include HIV and HCV pathogenesis and therapy and infections that cause morbidity and mortality in resource limited settings.

We are pleased to welcome Dr. Schooley to discuss his experience on the use of phage to treat antibiotic-resistant infections in his talk titled "From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections."

Using Phage Lysins to Treat Antibiotic-Resistant Infections



Vincent A. Fischetti, PhD

Vincent A. Fischetti, PhD, is Professor and Head of the Laboratory of Bacterial Pathogenesis and Immunology at the Rockefeller University, in New York. He has over 40 years of experience in the anti-infectives field. Over those years his laboratory has been involved in understanding the earliest events in gram-positive bacterial infection, so that strategies may be devised to prevent infection. His laboratory was the first to

identify lytic enzymes as novel therapeutics to decolonize human mucous membranes of bacterial pathogens and treat systemic


infections caused by antibiotic-resistant organisms. His laboratory also identified the mechanism by which gram-positive bacteria attach their surface proteins in the cell, a target for antibiotic development. He has published over 230 primary research articles and over 70 textbook chapters and is a co-editor of two major books on gram-positive pathogens. He is an inventor of over 40 issued patents dealing with the control of infectious diseases. Dr. Fischetti received a PhD in Microbiology with honors from New York University.

Dr. Fischetti's presentation will focus on "Using Phage Lysins to Treat Antibiotic-Resistant Infections."

Named Lectures

2018 John F. Enders Lecture

Thursday, October 4, 2018: 3:30 - 3:55 p.m.
 Moscone Center: North Hall D



John F. Enders, PhD
 1897-1985

JOHAN F. ENDERS, PhD, served as the second president of IDSA. Dr. Enders and two of his colleagues received the 1954 Nobel Prize in Medicine for their discovery of the ability of poliomyelitis viruses to grow in cultures of various types of tissue. This discovery led to the development of vaccines against polio, measles, rubella, and mumps, as well as other advances. For almost 15 years, he worked in Dr. Hans Zinnser's department at Harvard where his early use of tissue cultures for the growth of viruses in vitro began in collaboration with Dr. Zinnser. Dr. Enders received numerous awards in addition to the Nobel Prize, including the Albert Lasker Award of the American Public Health Association, Germany's Koch Medal, and the Cameron Prize of the University of Edinburgh. He received the Presidential Medal of Freedom and honorary degrees from many universities. Dr. Enders has been described as "one of the most modest, magnificent men in the history of sciences." His contributions also include major advances in the field of genetics, links between viruses and cancer, and insights into the pattern and process of tumor growth, and are noted among the most important of the 20th century. The John F. Enders Distinguished Lecture in Medical Virology, which bears his name, was first given in 1988 by Thomas Weller, MD.

2018 Featured Lecturer

The Cost of Our Drugs: Branded, Generics and Why We Should Care

Rochelle Walensky, MD, MPH, FIDSA, is the Chief of Infectious Diseases and Co-Director of the Medical Practice Evaluation Center at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Walensky has been a member of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) team since 1998. Her research interests have focused on HIV/AIDS policy and cost-effective strategies of HIV care in the U.S. and in resource-limited settings. She is internationally recognized for motivating U.S. policy toward the promotion of routine HIV screening and for her work on effective and efficient strategies of HIV care in South Africa. She is a member of the American Society for Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and she is past Chair of the NIH Office of AIDS Research Advisory Council. She has also been an advisor to the World Health Organization and UNAIDS. Dr. Walensky received her BA from Washington University in St. Louis (1991), her MD from the Johns Hopkins School of Medicine (1995), and her MPH from the Harvard School of Public Health (2001). She trained in Internal Medicine at the Johns Hopkins Hospital (1995-1998) and in Infectious Disease at the MGH/BWH combined fellowship program (1998-2001).



Rochelle Walensky, MD,
 MPH, FIDSA

Dr. Walensky's presentation, "The Cost of Our Drugs: Branded, Generics and Why We Should Care," will review healthcare costs and physician's contributions to these costs and discuss issues and challenges in the use of some generic antimicrobial therapy. She will also discuss the question of whether use of generic antiretroviral therapy in the U.S. will help curb overall HIV costs.


Past Lecturers

2017	Connie Celum	2009	Stanley M. Lemon	2001	Lawrence Corey	1993	Caroline Breese Hall
2016	Judith Currier	2008	Bruce Walker	2000	Richard J. Whitley	1992	Barry Bloom
2015	Lynne Mofenson	2007	Thomas C. Quinn	1999	Samuel L. Katz	1991	Robert Schooley
2014	Roger Glass	2006	Frederick G. Hayden	1998	Richard Johnson	1990	Gertrude Elion
2013	Nancy J. Cox	2005	Stephen E. Straus	1997	Diane Griffin	1989	George Miller
2012	David Thomas	2004	Martin S. Hirsch	1996	Anne Gershon	1988	Thomas Weller
2011	Angela M. Caliendo	2003	Catherine M. Wilfert	1995	Ciro De Quadros		
2010	Don Ganem	2002	Ann M. Arvin	1994	Clarence Peters		

Named Lectures (continued)

2018 Maxwell Finland Lecture

Thursday, October 4, 2018: 4:20 - 4:45 p.m.
Moscone Center: North Hall D



Maxwell Finland, MD,
DSci, 1902-1987

MAXWELL FINLAND, MD, DSci, served as the first president of IDSA. His prestigious medical career spanned more than 50 years at Harvard University and Boston City Hospital. He was internationally recognized for his study of the incidence and character of infectious diseases and their specific treatments. Dr. Finland's unbiased judgment on the role of antimicrobial agents in medical treatment was universally respected.

He is credited with influencing pioneering studies of antibiotic therapy and the treatment for pneumonia and respiratory injuries linked to exposure to noxious gases. He was noted as establishing early identification of new infectious hazards and the emergence of dangerous new infections in hospitalized patients. The Maxwell Finland Lecture, which bears his name, was first given in 1972 by Theodore E. Woodward, MD.

2018 Featured Lecturer

Antibiotic Stewardship: Looking Back and Moving Forward

Arjun Srinivasan, MD (CAPT, USPHS), FSHEA, is associate director for healthcare-associated infection prevention programs in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention's National Center for Emerging and Zoonotic Infectious Diseases. Dr. Srinivasan is also a captain in the U.S. Public Health Service. An infectious disease doctor, Dr. Srinivasan oversees several CDC programs aimed at eliminating healthcare-associated infections and improving antibiotic use. For much of his CDC career, Dr. Srinivasan ran the healthcare outbreak investigation unit, helping hospitals and other healthcare facilities track down bacteria and stop them from infecting other patients. Today, Dr. Srinivasan leads CDC's work to improve antibiotic prescribing and works with a team of CDC experts researching new strategies to eliminate healthcare-associated infections.



Arjun Srinivasan, MD
(CAPT, USPHS), FSHEA

As assistant professor of medicine in the Infectious Diseases Division at the Johns Hopkins School of Medicine and a staff physician, Dr. Srinivasan founded the Johns Hopkins Antibiotic Management Program. A graduate of the Vanderbilt University School of Medicine, Dr. Srinivasan is a member of Alpha Omega Alpha medical honor society. He completed an internal medicine residency and infectious disease fellowship at Johns Hopkins University Hospital. Dr. Srinivasan is an adjunct assistant professor of medicine at Emory University Medical Center and sees patients at the Atlanta Veteran's Affairs Medical Center.

Dr. Srinivasan's presentation, "Antibiotic Stewardship: Looking Back and Moving Forward," will cover the past, present, and future of antibiotic stewardship from a U.S. nationwide perspective. He will summarize some of the key next steps for antibiotic stewardship in hospitals to move into the future.

Past Lecturers

2017	Steven Holland	2006	W. Michael Scheld	1994	Carol J. Baker	1982	Jack S. Remington
2016	Robert C. Read	2005	William Dismukes	1993	Stanley Falkow	1981	Abraham I. Braude
2015	Henry "Chip" Chambers	2004	King Holmes	1992	John E. Bennett	1980	Maclyn McCarty
2014	Liise-Anne Pirofski	2003	Robert C. Moellering, Jr.	1991	Michael Blaese	1979	Harry A. Feldman
2013	Victoria J. Fraser	2002	Jerome Klein	1990	Robert Gallo	1978	Dorothy M. Horstmann
2012	George McCracken	2001	Margaret K. Hostetter	1989	John Robbins	1977	George G. Jackson
2011	Julie Parsonnet	2000	P. Frederick Sparling	1988	Thomas Merigan	1976	Edward H. Kass
2010	Gerald Friedland	1999	Frederick S. Southwick	1987	R. Palmer Beasley	1975	George Meiklejohn
2009	Cynthia L. Sears	1998	Elaine Toumanen	1986	Alexander D. Langmuir	1974	Robert Austrian
2008	Anthony Fauci	1997	Gerald Keusch	1985	Harry F. Dowling	1973	Louis Weinstein
2007	Louis B. Rice	1996	Barbara Murray	1984	Albert B. Sabin	1972	Theodore E. Woodward
		1995	Theodore Eickhoff	1983	Paul G. Quie		

continued on next page

Named Lectures (continued)

2018 Caroline B. Hall Lectureship

Friday, October 5, 2018: 10:30 -11:45 a.m.
Moscone Center: South 214-216



Caroline B. Hall, MD
1929-2012

The lectureship is dedicated to and honors Caroline B. Hall, MD, a world-renowned pediatrician, teacher, researcher, and a founding member of PIDS. Dr. Hall held the position of professor of pediatrics and medicine at the University of Rochester School of Medicine for over 40 years. She was a legend in pediatric infectious diseases for her groundbreaking and prolific research on respiratory syncytial virus, human herpesvirus 6, and other respiratory viral pathogens and authored over 500 peer-reviewed publications. Her contributions significantly enhanced our understanding of diverse respiratory viral infections and resulted in the development of diagnostic and management guidelines for infections that continue to be important clinical references. Dr. Hall served as the fifth president of PIDS and was the society's historian. She was a member of the Institute of Medicine and the Royal College of Physicians and received numerous honors, including the Distinguished Physician and Distinguished Service awards from PIDS, the IDSA John F. Enders Lectureship, the Pan American Society for Virology Award, and the Robert M. Chanock Lifetime Achievement Award.

2018 Featured Lecturer

RSV Vaccines: Where Do We Go From Here?

Ruth A. Karron, MD, FIDSA, is a Professor in the Department of International Health, Johns Hopkins Bloomberg School of Public Health, Director of the Center for Immunization Research, and Founding Director of the Johns Hopkins Vaccine Initiative.

Dr. Karron is a pediatrician, trained in infectious diseases, who has extensive experience in the evaluation of respiratory virus vaccines (including vaccines for respiratory syncytial virus, parainfluenza viruses, avian influenza, and pandemic influenza) in adult and pediatric populations. Dr. Karron's research interests also include the pathogenesis of enhanced RSV disease, the development of immune responses to respiratory viral infections in early life, the epidemiology of RSV and other respiratory viral diseases in resource-poor settings, and public policy issues related to vaccine development and distribution. She has served on a number of national and international vaccine advisory committees and panels, and chaired the FDA's Vaccine and Related Biological Products Advisory Committee from 2006-2008.



Ruth A. Karron, MD,
FIDSA

Dr. Karron's talk, titled "RSV Vaccines: Where Do We Go From Here?" will focus on her experience and thoughts on the future for respiratory syncytial virus vaccination across all settings.

Past Lecturers

2017 Janet Englund
2016 Octavio Ramilo
2015 John V. Williams

Named Lectures (continued)

2018 SHEA Lectureship

Friday, October 5, 2018: 3:30 - 3:55 p.m.
Moscone Center: North Hall D

The SHEA Lectureship award is given annually to recognize the career contributions of a senior investigator in healthcare epidemiology and infection prevention and control. Awardees have shown leadership through notable contributions to the science of healthcare epidemiology, demonstration of ongoing dedication to advancing the field, demonstration of mentorship, and dedication to SHEA and its mission to prevent healthcare-associated infections.

2018 Featured Lecturer

A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology

Jan E. Patterson, MD, MS, FIDSA, FSHEA, is currently Professor and Associate Dean for Quality and Lifelong Learning and also directs the Center for Patient Safety and Health Policy at the University of Texas Health Science Center at San Antonio. Dr. Patterson served as the president of the Society for Healthcare Epidemiology in 2012. She graduated from the University of Texas Medical School at Houston and completed her Internal Medicine residency at Vanderbilt University Medical Center. She completed her postdoctoral fellowship in Infectious Diseases at Yale University School of Medicine where she trained in healthcare epidemiology with Dr. Walter J. Hierholzer, Jr., a former SHEA President. She received a Master of Science in Health Care Management from Harvard School of Public Health in May 2010.



Jan E. Patterson, MD, MS, FIDSA, FSHEA

Dr. Patterson's presentation, titled "Reflections on Advances and Unmet Needs in Healthcare Epidemiology," will focus on the gaps in knowledge and research related to infection prevention.

Past Lecturers


2017	Neil Fishman	2011	Victoria Fraser	2005	Robert Weinstein	1998	John E. McGowan
2016	Daniel Sexton	2010	David Henderson	2004	Lindsay Nicole	1997	Richard Wenzel
2015	Richard Platt	2009	Elaine Larson	2003	William Jarvis	1996	William Schaffner
2014	Lisa Saiman	2008	Didier Pittet	2001	William Scheckler	1995	Philip S. Brachman
2013	Denise Cardo	2007	Dale Gerding	2000	Walter Hierholzer	1993	John V. Benett
2012	William Rutala	2006	C. Glen Mayhall	1999	Dennis Maki		

continued on next page

Named Lectures (continued)

2018 Stanley A. Plotkin Lectureship in Vaccinology

Friday, October 5, 2018: 3:45 - 4:45 p.m.
Moscone Center: Room N 25



Stanley A. Plotkin, MD

The Stanley A. Plotkin Lecture in Vaccinology is presented annually to an individual who has made significant contributions to the field of vaccinology or areas of related science that have impacted the lives of children and the specific area of pediatric infectious diseases.


2018 Featured Lecturer

Vaccine Hesitancy, History and Human Nature

Gary S. Marshall, MD, is a professor of pediatrics at the University of Louisville School of Medicine and is chief of the Division of Pediatric Infectious Diseases, director of the Pediatric Clinical Trials Unit, and author of *The Vaccine Handbook: A Practical Guide for Clinicians* (The Purple Book).

Dr. Marshall received his medical degree from Vanderbilt University School of Medicine and completed his residency in Pediatrics at Vanderbilt University Hospital. Dr. Marshall completed his fellowship in Pediatric Infectious Diseases at the Children’s Hospital of Philadelphia.

Dr. Marshall’s presentation will focus on vaccine hesitancy in the broader context of human thought patterns and belief systems and discuss how to engage stakeholders in developing strategies to improve immunization rates despite pervasive anti-vaccinationism.



Gary S. Marshall, MD


Past Lecturers

2017	Peter F. Wright	2014	Eugene D. Shapiro	2010	Dan Granoff	2006	Walter A. Orenstein
2016	Carol J. Baker	2013	Anne A. Gershon	2009	James A. Cherry	2005	Samuel L. Katz
2016	Larry K. Pickering	2012	John B. Robbins	2008	Paul A. Offit	2004	Stanley A. Plotkin
2015	Neal A. Halsey	2011	David I. Bernstein	2007	Kathryn M. Edwards		

Named Lectures (continued)

2018 Joseph E. Smadel Lecture

Saturday, October 6, 2018: 3:30 - 3:55 p.m.
Moscone Center: North Hall D



Joseph E. Smadel, MD,
 MA, DSci
 1907-1963

JOSEPH E. SMADEL, MD, MA, DSci, was a physician and investigator who created a bridge between basic laboratory science and the clinician, making significant contributions to the knowledge of psittacosis, vaccinia, variola, myxomatosis, and viral encephalitis. During World War II, Dr. Smadel led a study of control measures of typhus fever in Egypt and southern Italy. Dr. Smadel served at the Department of Virus and Rickettsial Diseases of the Army Medical School, Walter Reed Army Institute of Research and National Institutes of Health (NIH). He held the position of chief of virology and rickettsiology in the Division of Biologic Standards at NIH until his death. The Joseph E. Smadel Lecture is intended to honor someone who has made a significant impact in public health.

2018 Featured Lecturer

Academic Partnership with Public Health: Infectious Diseases at the Population-Level

Monica M. Farley, MD, FIDSA, is the Jonas A. Shulman Professor of Medicine and the Director of the Division of Infectious Diseases at Emory University School of Medicine and a Staff Physician at the Atlanta VA Medical Center. She is past-President of the American Federation for Medical Research and a longstanding council member and past-President of the Southern Society for Clinical Investigation. She has served on the Women's Committee, the Program Planning Committee, and the Public Health Committee in IDSA. Dr. Farley leads a large infectious diseases division at Emory made up of nearly 70 faculty members with a large research portfolio. She serves as the academic Principal Investigator for the Georgia Emerging Infections Program (EIP), a CDC-funded surveillance network conducting applied epidemiologic and laboratory research focused on invasive bacterial pathogens, influenza, foodborne diseases, and healthcare-associated infections. She is a past member of the U.S. Food and Drug Administration (FDA) Advisory Committee on Vaccines and Related Biological Products, and she currently serves on the Pneumococcal Vaccine Working Group for CDC's Advisory Committee on Immunization Practices (ACIP). The collaborative EIP research program has been highly productive, providing population-based assessment of the epidemiology and risk factors for a number of important bacterial infections, including adult and pediatric Group B Streptococcal infections, pneumococcal disease and community-associated MRSA, and performing post-licensure vaccine effectiveness studies.



Monica M. Farley, MD,
 FIDSA

Dr. Farley's presentation on "Academic Partnership with Public Health: Infectious Diseases at the Population-Level" gives a broad look at how academic institutions and public health can partner for the benefit of the communities they serve.

Past Lecturers


2017	Ruth Lynfield	2007	Kathryn M. Edwards	1996	Scott B. Halstead	1985	Franklin A. Neva
2016	Patricia Griffin	2006	Allan R. Ronald	1995	David T. Dennis	1984	Maurice R. Hilleman
2015	Bruno Moonen* (in honor of Alan Magill)	2005	Lyle Peterson	1994	Roy Anderson	1983	Garrison Rapmund
2014	Robert Weinstein	2004	Eric Otteson	1993	Richard Guerrant	1982	Richard B. Hornick
2013	Myron S. Cohen	2003	Didier Raoult	1992	Alfred Sommer	1981	Baruj Benacerraf
2012	Diane Havlir	2002	Donald A. Henderson	1991	Charles Carpenter	1980	Robert M. Chanock
2011	William Schaffner	2001	Karl M. Johnson	1990	Zenvil Cohen	1979	Philip K. Russell
2010	Kathleen Neuzil	2000	Anne Schuchat	1989	Thomas Grayston	1978	Philip Y. Paterson
2009	Myron Levine	1999	Lou H. Miller	1988	P. Frederick Sparling	1977	D. Carleton Gajdusek
2008	Jane E. Koehler	1998	Thomas Wellems	1987	Jack M. Gwaltney		
		1997	Brett Finlay	1986	Richard T. Johnson		

continued on next page

Named Lectures (continued)

2018 Edward H. Kass Lecture

Saturday, October 6, 2018: 4:20 - 4:45 p.m.
Moscone Center: North Hall D




Edward H. Kass, MD
1917-1990

EDWARD H. KASS, MD, was one of the founding leaders of IDSA. He served as the Society's seventh president in 1970 as well as the Society's secretary from 1964 to 1967. He helped to create not only IDSA, but also the Channing Memorial Laboratory and the International Congress on Infectious Diseases. Dr. Kass was instrumental in securing IDSA's role in publishing *The Journal of Infectious Diseases*, and he developed the concept for *Reviews of Infectious Diseases* – now *Clinical Infectious Diseases*. Not only was he a pioneer in the study of infection, he was an advocate for social justice and passionate about addressing poverty, racism, and discrimination. Dr. Kass held the positions of William Ellery Channing Professor of Medicine at Harvard Medical School and director of the Channing Laboratory at Harvard Medical School and Brigham and Women's Hospital. In his memory, IDSA maintains the annual Edward H. Kass Lectureship in the History of Medicine and the Kass Awards, which assist medical students and residents with travel expenses to IDWeek. The first Kass Lectureship was given in 1991 by Theodore E. Woodward, MD.

2018 Featured Lecturer

The Evolution of HIV Related Opportunistic Infections: From Basic Science and Clinical Trials to Guidelines and Implementation Science

Henry Masur, MD, FIDSA, trained in internal medicine at the New York Hospital-Cornell Medical Center and Johns Hopkins Medical Center. At Cornell Medical Center, he trained in infectious diseases with a focus on pneumocystis. While serving on the faculty at Cornell, he saw some of the earliest cases of AIDS. In 1982 he was recruited to the National Institutes of Health as Assistant Chief of Critical Care Medicine, a logical fit in an era when most AIDS patients ultimately spent time in the ICU, and when formal training in critical care was just being developed.



Henry Masur, MD, FIDSA

He became the Chief of the Critical Care Medicine Department at the NIH Clinical Center in 1989. At NIH, Dr. Masur was active in defining AIDS related opportunistic infections, and focused on developing new diagnostics, new therapeutics, and new prevention strategies for a wide range of pathogens. He initiated the first HIV related clinical guideline in 1989, which has evolved into the "IDSA-NIH-CDC Guideline for Management of HIV Related Opportunistic Infections in Adults and Adolescents." Dr. Masur has also taken leadership roles in developing the IDSA-AASLD Guidance on HCV Management, and the IDSA-SCCM Guideline in Prevention of Catheter Related Infections, and had an active role on the Surviving Sepsis Guidelines. In addition to continuing to serve as Chief of the Critical Care Medicine Department at the NIH Clinical Center, Dr. Masur is the co-director of the District of Columbia Partnership for AIDS Progress, a joint program between NIH, academic and community partners, and the DC Department of Health to create a model for how urban areas can reduce the impact that HIV has on their communities. Dr. Masur is a past president of the Infectious Diseases Society of America.

Past Lecturers

2017	James M. Hughes	2010	Richard Wenzel	2003	Seymour J. Klebanoff	1996	Charles S. Bryan
2016	John Perfect	2009	Paul A. Volberding	2002	Stanley A. Plotkin	1995	Alfred Evans
2015	Karen C. Carroll	2008	Arturo Casadevall	2001	John G. Bartlett	1994	Jay Sanford
2014	Janet Gilsdorf	2007	David Relman	2000	Walter E. Stamm	1993	Floyd Denny
2013	Peter Hotez	2006	Wafaa El-Sadr	1999	Sharon L. Hillier	1992	Allan Brandt
2012	Elaine Larson	2005	Constance Benson	1998	Martin J. Blaser	1991	Theodore E. Woodward
2011	Larry Pickering	2004	Lucy Tompkins	1997	Judith Wasserheit		

Awards Presentation Schedule

IDSA Society Awards

IDSA Alexander Fleming Award for Lifetime Achievement

Richard Whitley, MD, FIDSA
Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

IDSA Society Citation

Louis Saravolatz, MD, FIDSA
Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center

IDSA Watanakunakorn Clinician Award

Barry Hartman, MD, FIDSA
Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center

IDSA D.A. Henderson Award

William Schaffner, MD, FIDSA, FSHEA
Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center

IDSA Clinical Teacher Award

Allan R. Tunkel, MD, FIDSA
Frank Berkowitz, MD, MPH
Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

IDSA Oswald Avery Award for Early Achievement

Susanna Naggie, MD, FIDSA
Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

IDSA Walter E. Stamm Mentor Award

Carol Kauffman, MD, FIDSA, FSHEA
Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

IDSA Clinical Practice Innovation Award

Javeed Siddiqui, MD, MPH
Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

SHEA Society Awards

SHEA Senior Scholar Award

David J. Weber, MD, MPH, FIDSA, FSHEA
Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

SHEA Advanced Practice Infection Preventionist Award

Joan Hebden, RN, MS, CIC
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA Antibiotic Stewardship Scholar Award

Deverick J. Anderson, MD, MPH, FIDSA, FSHEA
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA Mentor Scholar Award

Aaron Milstone, MD, MHS, FIDSA, FSHEA, FPIDS
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA Mid-Career Scholar Award

Anucha Apisarnthanarak, MD
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA Pediatric Scholar Award

Kristina A. Bryant, MD, FPIDS
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA Barry Farr Award

Amy J. Ray, MD, MPH
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA William Jarvis Award

Maria Souli, MD, PhD
Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

HIVMA Leadership Awards

HIVMA Clinical Educator Award

Rajesh T. Gandhi, MD, FIDSA
Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

HIVMA Research Award

Lisa B. Hightow-Weidman, MD, MPH
Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center

PIDS Society Awards


PIDS Distinguished Research Award

Carol J. Baker, MD, FIDSA, FPIDS
Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

IDSA Society Awards

Alexander Fleming Award for Lifetime Achievement

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center



Richard J. Whitley, MD,
FIDSA

Richard J. Whitley, MD, FIDSA, a pioneer in the development of antiviral therapies for infections in children and adults, is the recipient of IDSA's 2018 Alexander Fleming Award for Lifetime Achievement. This award recognizes a career that reflects major contributions to the acquisition and dissemination of knowledge about infectious diseases.

Dr. Whitley's work over more than 40 years has spanned from fundamental drug discovery through complex clinical trials that established the safety and efficacy of novel therapies for many previously untreatable viral infections. These include herpes simplex encephalitis, neonatal herpes, congenital cytomegalovirus, West Nile encephalitis, and influenza, among others. His efforts to define the pharmacokinetics of antiviral drugs for herpesvirus infections and their safety and efficacy in children, pregnant women, the immunocompromised, and older adults have enabled all patients to benefit from these therapies. Dr. Whitley was instrumental in the development of recommendations for the treatment of cytomegalovirus with ganciclovir and its derivatives, and following the 2009 H1N1 influenza outbreak, guidelines for the emergency use of oseltamivir in infants. His ongoing laboratory research focused on genetically engineered herpes viruses as oncolytic agents also holds promise for patients with otherwise fatal brain tumors.

A sought-after authority on viruses, biodefense, and emerging infections, Dr. Whitley has served on major national and international committees, including the Board of Scientific Counselors at the National Institute of Allergy and Infectious Diseases, among many others. The author of more than 400 publications, he is also responsible for the Collaborative Antiviral Study Group, based at the University of Alabama at Birmingham (UAB) and funded by the National Institutes of Health. This group has led multicenter trials of antiviral therapies for medically important diseases since the 1970s.

Dr. Whitley is a Distinguished Professor of Pediatrics, vice chair of the Department of Pediatrics, co-director of the Division of Pediatric Infectious Diseases, the Loeb Eminent Scholar Chair in Pediatrics, and professor of microbiology, medicine, and neurosurgery at UAB. After receiving his medical degree at George Washington University School of Medicine, he completed his pediatric internship, residency, and fellowship training at UAB before joining the faculty. An IDSA John F. Enders Lecturer in 2000, Dr. Whitley was president of IDSA from 2009 to 2010 and has been a strong supporter of the Society's mission for many years. The recipient of numerous honors and awards, he has served as an associate editor of *The Journal of Infectious Diseases* since 2004 and is a member of several other journal editorial boards.

Dr. Whitley's practice-changing work over four-plus decades has greatly improved how physicians diagnose and care for children and adults with once untreatable viral infections. The Society is proud to honor him with the 2018 Alexander Fleming Award for Lifetime Achievement.

IDSA Society Awards (continued)

IDSA Society Citation

Presented on Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center



Louis D. Saravolatz, MD,
FIDSA

Louis D. Saravolatz, MD, FIDSA, a widely respected clinician and researcher with a strong commitment to IDSA, is the recipient of the 2018 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

Dr. Saravolatz is chair of the Department of Medicine at St. John Hospital and Medical Center in Grosse Pointe Woods, Michigan, and a professor of medicine at Wayne State University School of Medicine in Detroit. He developed an extensive background in bacterial infections early in his career, including descriptions of early outbreaks of *Legionella*. In the early 1980s, he was among the first to document the emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) infection in the community. A decade later, Dr. Saravolatz was actively involved in National Institutes of Health committees that developed treatment strategies for HIV before modern antiretroviral therapy became available. The author of more than 200 publications and book chapters, he has continued to actively pursue research interests in infection control and novel antimicrobial agents for Gram-positive bacteria, including MRSA, vancomycin-intermediate *S. aureus*, vancomycin-resistant *S. aureus*, and daptomycin-resistant isolates.

One of the most respected ID physicians in the Detroit metropolitan area, Dr. Saravolatz has made substantial contributions to IDSA through his dedicated service on multiple committees. A member of the Publications Committee for more than five years (2010-2016), he served as its chair from 2013 to 2016, leading the committee's efforts to oversee the publication of the Society's scientific journals. In 2015, he was chair of the search committee for the editor-in-chief of *Clinical Infectious Diseases*. A former chair of the Society's Committee on Antimicrobial Usage and Clinical Trials (2000-2003) and chair of the ad hoc committee that reviewed the Joint Commission's sepsis guidelines in 2005, he has also been a member of the Fellows In-Training Examination Writing Committee (2006-2007) and the Regional Representative National Committee (2010-2012).

Dr. Saravolatz received his medical degree from the University of Michigan Medical School, followed by an internship and residency training at Henry Ford Hospital in Detroit, where he also completed his ID fellowship. Invited frequently to speak at regional, national, and international meetings and conferences, Dr. Saravolatz has served on numerous hospital, regional, and state committees. An active member of the Infectious Diseases Division who regularly rounds with house staff, he continues to attend on the consult service and mentors fellows and young faculty in their own research.

An accomplished physician and researcher, Dr. Saravolatz has contributed significantly to IDSA's mission, including through his extensive service on the Society's Publications Committee. IDSA is delighted to add the 2018 Society Citation to his long list of achievements.

continued on next page

IDSA Society Awards (continued)

IDSA Watanakunakorn Clinician Award

Presented on Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center



Barry J. Hartman, MD,
FIDSA

Barry J. Hartman, MD, FIDSA, a renowned clinician and teacher with a long history of service locally and nationally, is the recipient of IDSA's 2018 Watanakunakorn Clinician Award. Named to honor the memory of Chatrchai Watanakunakorn, this award is presented by the IDSA Foundation to recognize an IDSA member for outstanding achievement in the clinical practice of infectious diseases.

Dr. Hartman has earned the respect and admiration of several generations of students, residents, ID fellows, colleagues, and faculty throughout his career. Having transitioned to private practice in the late 1980s, he has remained closely affiliated with Weill Medical College of Cornell in New York City, where he is a clinical professor of medicine. He has delivered annual lectures to medical students on the clinical use of antibiotics, bacteremia, and sepsis for the past 20 years, in addition to presentations at various specialty and subspecialty conferences and ID continuing medical education courses. He has been a member of 30 different medical school committees, including search committees for the school's dean, the faculty promotions committee, and the general faculty council, which he also led as chair, all while maintaining his own private clinical practice.

Recognized by his institution's house staff in a survey identifying the most respected attending physicians, Dr. Hartman has

repeatedly been named among the Best Doctors in America and in New York. Sought after for his advice on the most challenging clinical cases, he is the ID physician that many colleagues would choose as their own. The author of more than 40 peer-reviewed publications and 12 book chapters, Dr. Hartman served on the panel that developed IDSA's 2004 practice guidelines for the management of bacterial meningitis and the 2008 management of encephalitis guidelines. He was a member of the IDSA Finance Committee and served as its chair. Active with the American Board of Internal Medicine, he has been a member of the self-evaluation program in infectious diseases and the subspecialty board. He has also served as a councilor of the Infectious Diseases Society of New York.

After obtaining his medical degree from M.S. Hershey Medical Center/Pennsylvania State University and completing his internship, residency, and ID fellowship training at New York Hospital (now New York Presbyterian Hospital-Weill Cornell Medical Center), Dr. Hartman joined the faculty at Cornell University Medical College. He also trained in the laboratory of Dr. Alexander Tomasz at Rockefeller University, where he conducted research on mechanisms of *S. aureus* resistance.

Truly a "doctor's doctor," Dr. Hartman is an esteemed clinician with an impressive record of dedicated service to patients, students, colleagues, and the ID specialty throughout his career. The Society is proud to recognize him with the 2018 Watanakunakorn Award.

IDSA Society Awards (continued)

IDSA D.A. Henderson Award

Presented on Thursday, October 5, at 4 p.m. in North Hall D, Moscone Center



William Schaffner, MD,
FIDSA, FSHEA

William Schaffner, MD, FIDSA, FSHEA, a peerless communicator and committed proponent of adult immunization, is the recipient of IDSA's 2018 D.A. Henderson Award for Outstanding Contributions to Public Health. Named to honor the memory of Dr. Henderson, who led the successful eradication of smallpox, this award recognizes a lifetime of achievement in public health.

Highly effective at melding curative and preventive medicine, Dr. Schaffner has advanced epidemiologic science, translated that science into national health policy, and eloquently communicated these developments and countless other infectious disease-related topics to the public throughout his career. He has served on the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices since 1982. During this unmatched length of service, he has provided an important and respected voice as the influential group has made recommendations about vaccine products and their use across the U.S. As a member of several organizations focused on immunization, he has been a tireless advocate for science-based evidence in debates fueled by vaccine skepticism, persistently providing both facts and reassurance.

Among Dr. Schaffner's more than 300 peer-reviewed publications are several with a significant impact on public health, including the first demonstration that vaccination could eliminate measles

from a state and an investigation of *Pseudomonas* and *Serratia* infections associated with defective bronchoscopes, which prompted a worldwide recall. Because of his unparalleled ability to distill topics like these and others to their essential points and convey them simply, he is the "go to" ID expert for many media outlets. Through these interactions, he has brought a greater understanding of infectious diseases and public health to the general public.

A graduate of Cornell University Medical College, Dr. Schaffner completed his internship, residency, and ID fellowship training at Vanderbilt University School of Medicine, where he is currently a professor of preventive medicine in the Department of Health Policy and a professor of medicine in the Division of Infectious Diseases. He joined the faculty there after serving as an Epidemic Intelligence Service officer with CDC. A past president of SHEA, he has served on the IDSA Board of Directors, including as secretary; received the IDSA Walter E. Stamm Mentor Award in 2011; and has been an IDSA Joseph E. Smadel Lecturer. An associate editor of *The Journal of Infectious Diseases* since 2003, he is also a past president of the National Foundation for Infectious Diseases, for which he currently serves as medical director.

Recognized as a premier ambassador for the field of ID and a dedicated advocate for adult immunization and evidence-based policies, Dr. Schaffner has advanced the nation's health through his research, teaching, mentorship, practice, and service. IDSA is pleased to recognize his outstanding contributions to public health with the 2018 D.A. Henderson Award.

continued on next page

IDSA Society Awards (continued)

IDSA Clinical Teacher Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center



Allan R. Tunkel, MD,
PhD, FIDSA

Allan R. Tunkel, MD, PhD, FIDSA, is one of two recipients of IDSA's 2018 Clinical Teacher Award. This award honors a career dedicated to teaching clinical infectious diseases to fellows, residents, and medical students and recognizes excellence as a clinician and motivation to teach the next generation of physicians.

An international expert in bacterial meningitis and other central nervous system infections, Dr. Tunkel has an

extensive background in medical education, administration, clinical care, and research. Currently a professor of medicine and medical science and associate dean for medical education at Brown University's Warren Alpert Medical School, he also held significant academic leadership positions at Drexel University College of Medicine and Monmouth Medical Center. Passionate about physician training and mentorship, he has received numerous honors and awards for teaching throughout his career, including six Golden Apple Awards, four Dean's Awards for Excellence in Clinical Teaching, the Christian R. and Mary F. Lindback Foundation Award for Distinguished Teaching at Drexel University, the Laureate Award from the Pennsylvania chapter of the American College of Physicians (ACP), and several awards for teaching excellence from internal medicine residents.

A leader in the development of unique and innovative medical education programs, Dr. Tunkel has authored more than 100 peer-reviewed publications and more than 150 book chapters,

including for prominent textbooks in the field. He is often asked by clinicians from around the world for advice on how to manage complex patients with central nervous system infections. A prominent authority in this area, he was the chair of three different panels that developed IDSA practice guidelines for bacterial meningitis, encephalitis, and healthcare-associated ventriculitis and meningitis. Listed as one of the Best Doctors in America, he has served multiple times on the writing committee for ACP's Medical Knowledge Self-Assessment Program, a highly regarded resource for internal medicine residents preparing for the board certification exam. A sought-after speaker, he has given several invited presentations at national and international conferences.


Dr. Tunkel earned a PhD in experimental pathology followed by a medical degree from the University of Medicine and Dentistry of New Jersey - New Jersey Medical School. He completed his residency and chief residency in internal medicine at the Hospital of the Medical College of Pennsylvania and a fellowship in infectious diseases at the University of Virginia Health Sciences Center. He has served on several IDSA committees, including the Society Awards Committee, the Nominations Committee, and the Education Committee.

Over the last three decades, Dr. Tunkel has contributed greatly to the education and training of medical students, residents, and fellows through his excellent teaching, clinical expertise, effective administrative leadership, and respected scholarship. IDSA is pleased to add the 2018 Clinical Teacher Award to his impressive record of achievements.

IDSA Society Awards (continued)

IDSA Clinical Teacher Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center



Frank E. Berkowitz,
MD, MPH

Frank E. Berkowitz, MD, MPH, is one of two recipients of IDSA's 2018 Clinical Teacher Award. This award honors a career dedicated to teaching clinical infectious diseases to fellows, residents, and medical students and recognizes excellence as a clinician and motivation to teach the next generation of physicians.

Dr. Berkowitz has served on the faculty of Emory University School of Medicine, where he is currently a professor of pediatrics, since 1988. Heavily involved in the education of hundreds of pediatricians and specialists during his tenure at Emory, he is widely regarded by students, residents, fellows, and colleagues for his astute clinical reasoning, the clarity of his teaching, and his unparalleled physical exam skills. Over the past three decades, these attributes have enriched pediatric grand rounds, ID educational seminars, pediatric infectious diseases case conferences, inpatient clinical service weeks, pediatric continuity clinics, and countless patient encounters at his institution. With specialty training not only in pediatric infectious diseases but also neurology and ophthalmology, Dr. Berkowitz brings these to bear in his clinical teaching as well.

The recipient of multiple honors for his teaching, Dr. Berkowitz has received the senior pediatric residents' annual teaching award 12 times while at Emory. In 2017, he was recognized as one of 41 top faculty educators from across his institution for Emory's Educator

Appreciation Day. His effective teaching styles range from bedside instruction to didactic lectures, including case studies and images collected from his own vast clinical experience, and even medically relevant poetry. No student leaves his team without having performed a Gram stain, and days on service with him often start in the microbiology lab. A supervisor of ID fellows on service and preceptor for the pediatric residency clinic, he also excels at educating patients and their families, using a series of diagrams he has created to help explain various infections.

Dr. Berkowitz earned his medical degree at the University of the Witwatersrand in Johannesburg, South Africa, followed by additional training in microbiology, neurology, pediatrics, and ophthalmology in South Africa. He completed his pediatric ID fellowship at the University of Colorado Health Sciences Center in Denver and also earned a master of public health degree from Emory. His publications include more than 50 articles, case reports, reviews, and case studies, in addition to two textbooks, *Practical Medical Microbiology for Clinicians*, which he co-authored, and *Case Studies in Pediatric Infectious Diseases*, both invaluable resources for clinicians. He has also contributed to the American Academy of Pediatrics' *Red Book*.

A master clinical educator and a consummate physician, Dr. Berkowitz has greatly impacted the careers of countless students, residents, and fellows with his passion for teaching. IDSA is pleased to recognize his achievements with the 2018 Clinical Teacher Award.

continued on next page

IDSA Society Awards (continued)

IDSA Oswald Avery Award for Early Achievement

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center



Susanna Naggie, MD,
MHS, FIDSA

Susanna Naggie, MD, MHS, FIDSA, whose novel research on the treatment of patients co-infected with HIV and hepatitis C virus (HCV) has advanced the field, is the recipient of IDSA's 2018 Oswald Avery Award for Early Achievement. This honor recognizes members of IDSA age 45 or younger who have demonstrated outstanding achievements in an area of infectious diseases.

Strongly committed to the care of patients living with HIV and viral hepatitis, Dr. Naggie's research has been dedicated to understanding the mechanisms of accelerated liver fibrogenesis in this population. Her impressive work has helped define the role of pharmacogenomics and mechanistic studies of HCV treatment response in these patients, including studies of single nucleotide polymorphisms in HCV therapy and associated liver disease. This research identified 16 genes that were expressed at higher levels in the unfavorable CT/TT genotype versus the favorable CC genotypes and biologically implicated innate immunity functions. Her group was the first to report that black patients who carried the favorable CC genotype had more immune dysregulation than non-black patients without the favorable genotype. This research has laid an important foundation for understanding the disparity in HCV treatment response in co-infected African Americans.

Currently an associate professor of medicine at Duke University School of Medicine, where she has been a member of the faculty since 2009, Dr. Naggie is medical director of the Department of Medicine's Clinical Research Unit and director of infectious diseases research at the Duke Clinical Research Institute. In addition to her own prolific research, she has served as the primary mentor for many trainees, including interns, residents, fellows, and junior faculty. She has demonstrated a strong interest in developing young trainees to pursue their own careers in research and academics by helping them gain important exposure to clinical trial design, operations, and leadership.

Dr. Naggie has served as a member and co-chair of the IDSA and American Association for the Study of Liver Diseases HCV guidance panel, as a member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and as a member or leader of several other notable national committees and groups. She has also served on the IDSA Clinical Affairs Committee, the **IDWeek** Program Committee, and the IDSA HCV Maintenance of Certification Development Panel. A graduate of Johns Hopkins University School of Medicine, Dr. Naggie completed her internship, residency, chief residency, and ID fellowship training at Duke, where she also earned a master of health sciences degree in clinical research.

For her important contributions to our understanding of the care of patients living with HIV and HCV, IDSA is proud to honor Dr. Naggie with the 2018 Oswald Avery Award for Early Achievement.

IDSA Society Awards (continued)

IDSA Walter E. Stamm Mentor Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center



Carol A. Kauffman, MD,
FIDSA, FSHEA

Carol A. Kauffman, MD, FIDSA, FSHEA, a dedicated mentor to countless trainees and colleagues during her career, is the recipient of IDSA's 2018 Walter E. Stamm Mentor Award. Named to honor the memory of a former IDSA president who was renowned for nurturing the careers of others, this award recognizes individuals who have served as exemplary mentors and who have been exceptional in guiding the professional growth of infectious diseases professionals.

Committed to equity and diversity, Dr. Kauffman has been an inspirational role model for trainees through her excellent patient care, inspirational teaching, innovative research, and participatory leadership. Professor of internal medicine at the University of Michigan Medical School since 1981 and chief of the Infectious Diseases Section of the Veterans Affairs Ann Arbor Healthcare System since 1977, she fosters an energetic, productive, close-knit team and has created a culture of support and encouragement that provides trainees with strong and enduring mentorship. A champion of inclusion, she has made mentoring a priority with a commitment to fostering the careers of women and encouraging them to seek and excel in leadership roles.

Bringing out the best in trainees and helping them maximize their potential, Dr. Kauffman maintains lifelong mentoring relationships, celebrating former trainees' successes, providing support during

adversity and disappointments, and serving as a valued sounding board. On a recent birthday, more than 80 of Dr. Kauffman's former colleagues and trainees travelled to San Diego to show their appreciation for the great impact she has had on their lives and to share stories of her ongoing mentorship throughout their careers, her advice on major career decisions, and her help with difficult cases. Many strive to emulate her mentorship style, seeking to be as kind, open, available, and influential in the lives of their trainees as Dr. Kauffman has been in their own.

An exceptional researcher whose interests include the diagnosis and treatment of fungal infections and infections in immunocompromised patients, Dr. Kauffman has published more than 300 peer-reviewed publications. The recipient of multiple awards for her teaching, including an IDSA Clinical Teacher Award in 2012, she has served on the IDSA Board of Directors, several Society committees and task forces, and multiple IDSA practice guideline panels. She earned her medical degree from the University of Michigan Medical School, completed an internship and residency at University of Michigan Medical Center, and completed fellowship training in infectious diseases at the University of Cincinnati Medical Center.

A tireless leader, physician, teacher, researcher, and role model with an immense capacity to mentor, Dr. Kauffman has had a tremendous and ongoing impact on the lives and careers of her mentees. IDSA is delighted to recognize her with the 2018 Walter E. Stamm Mentor Award.

continued on next page

IDSA Society Awards (continued)

Clinical Practice Innovation Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center



Javeed Siddiqui, MD,
MPH

Javeed Siddiqui, MD, MPH, a pioneer in the clinical application of telemedicine to infectious diseases, is the recipient of IDSA's 2018 Clinical Practice Innovation Award. This award recognizes members who devote the majority of their time to patient care and have, within the last five years, significantly advanced the clinical practice of infectious diseases by making innovations in clinical practice design or management, or by fostering change to better recognize the value of infectious diseases practice.

In less than a decade since co-founding TeleMed2U, a multi-specialty medical practice that is entirely telemedicine based, Dr. Siddiqui has become an authority on telemedicine and its application to the delivery of high quality ID clinical consultation and infection prevention and antimicrobial stewardship programs. His efforts have brought expert ID services to numerous hospitals and locations with no previous ID clinical presence. In 2011, Dr. Siddiqui and his practice deployed the first telemedicine-based infection preventionist program, followed by the first telemedicine-based stewardship program, which was recognized nationally by the Agency for Healthcare Research and Quality. Currently the chief medical officer at TeleMed2U in Roseville, California, he serves as the medical director of telemedicine-based stewardship programs at five hospitals in the state. His achievements have demonstrated the great potential of telemedicine at a time when the ID workforce faces challenges and the specialty's role in stewardship and infection prevention has never been more critical.

In addition to establishing his own clinical practice, Dr. Siddiqui has participated in more than 100 clinical research projects and been a co-investigator for telemedicine studies evaluating outcomes, economics, innovative applications, and new technology development. A member of IDSA's Clinical Affairs Committee since 2013 and chair of the Society's Workgroup on Telehealth since 2015, he has presented multiple times at IDWeek and the IDSA Clinical Fellows Meeting on the practical applications of telemedicine to ID, including how to establish a sustainable program. He has lectured at numerous conferences and workshops, and also serves as an advisor to the California Department of Public Health's Antimicrobial Stewardship Collaborative.

The recipient of a master of public health degree from Tulane University, Dr. Siddiqui earned his medical degree from the University of Missouri-Columbia, followed by an internship and residency at Santa Barbara Cottage Hospital. He completed his ID fellowship training at the University of California-Davis, where he also served as an associate clinical professor of medicine and associate medical director at the Center for Health and Technology.

Dr. Siddiqui's innovations have opened a crucial new avenue for ID physicians by allowing them to share their valuable expertise and deliver infection prevention and antimicrobial stewardship services to previously underserved hospitals and patients. The Society is delighted to recognize him with the 2018 Clinical Practice Innovation Award.

IDSA Education and Research Foundation Awards

Robert C. Moellering Trainee Travel Awards

The Robert C. Moellering Trainee Travel Award supports attendance at IDWeek for fellows-in-training who submit excellent research in the field of antibiotic resistance. Applicants must be IDSA members-in-training for 2018 and have an accepted abstract to IDWeek. Member donations to the IDSA Foundation directly support these awards.

Award Winners:

Thomas McConville, MD, Columbia University Medical Center

Michael Woodworth, MD, MSc, Emory University School of Medicine

Teppei Shimasaki, MD, MS, Rush University Medical Center

SHEA Society Awards

SHEA Senior Scholar Award

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center



David Jay Weber, MD,
MPH, FSHEA

David Jay Weber, MD, MPH, FSHEA, is the recipient of the 2018 SHEA Senior Scholar Award recognizing his work as a senior investigator in infection prevention and healthcare epidemiology over the course of his career. Dr. Weber received his Bachelor of Arts degree from Wesleyan University in 1973, his Medical Degree from the University of California San Diego in 1977, a master of public health degree from Harvard University in 1985, and completed his

medicine residency and infectious disease fellowship at the Massachusetts General Hospital in 1985. He is Board Certified in Internal Medicine, Infectious Disease, Critical Care Medicine, and Preventive Medicine.

Dr. Weber has been on the faculty of the University of North Carolina at Chapel Hill since 1985, where he is currently a Professor of Medicine and Pediatrics in the School of Medicine, and a Professor of Epidemiology in the Gillings School of Global Public Health. Dr. Weber serves as an Associate Chief Medical Officer for UNC Hospitals. He also serves as the Medical Director

of the Departments of Hospital Epidemiology (Infection Prevention) and Occupational Health for UNC Hospitals.

He is the Medical Director of the North Carolina Statewide Infection Control Program (SPICE), a co-chair of UNC Biomedical IRB, and serves as the UNC Principle Investigator on the CDC sponsored Duke-UNC Epicenter. Dr. Weber is an Associate Editor of *Infection Control Hospital Epidemiology*, the SHEA liaison to the Advisory Committee on Immunization Practices (ACIP), and is a member of the SHEA Board of Trustees. Dr. Weber has published more than 380 scientific papers in the peer-reviewed literature. His research interests include the epidemiology of healthcare-associated infections, disinfection and sterilization, new and emerging infectious diseases (novel influenza, SARS-coV, MERS-coV, Ebola), response to biothreats, nontuberculous mycobacteria, control of drug resistant pathogens, immunization practices (especially of healthcare personnel), zoonotic diseases, and epidemiology of tuberculosis.

SHEA is pleased to present Dr. Weber with the 2018 SHEA Senior Scholar Award for his ongoing career contributions to healthcare epidemiology and infection prevention.

SHEA Advanced Practice Infection Preventionist Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Joan Hebden, RN, MS, CIC

Joan Hebden, RN, MS, CIC, is the recipient of the 2018 SHEA Advanced Practice Infection Preventionist Award based on her career achievements in infection prevention. Ms. Hebden received her baccalaureate and master degrees from the University of Maryland School of Nursing. She is currently an independent infection prevention consultant and research coordinator. She served as the Director of Infection

Prevention and Control for 28 years at the University of Maryland Medical Center in Baltimore, Maryland. An accomplished practitioner, Ms. Hebden has presented at national epidemiology conferences, participated in research regarding the transmission

of multidrug-resistant bacteria, contributed chapters on infection control to nursing resource texts, and published in medical and infection control journals.

She is certified in infection control through the Certification Board of Infection Control and Epidemiology, is an active member of the Society for Healthcare Epidemiologists of America and the Association for Professionals in Infection Control, serves as a section editor and reviewer for the *American Journal of Infection Control*, and is a fellow of APIC.

For her years of dedication and overall contributions and commitment to excellence, SHEA is pleased to award Joan Hebden the 2018 Advanced Practice Infection Preventionist Award.

continued on next page

SHEA Society Awards (continued)

SHEA Antibiotic Stewardship Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Deverick ("Dev") J. Anderson, MD, MPH, FIDSA, FSHEA

SHEA is pleased to award **Deverick ("Dev") J. Anderson, MD, MPH, FIDSA, FSHEA**, the 2018 SHEA Antibiotic Stewardship Scholar Award for his contributions as an investigator and practitioner to antibiotic stewardship program and research. Dr. Anderson is an Associate Professor with tenure in the Division of Infectious Diseases and Department of Medicine at Duke University. He is currently Director of the Duke Center for Antimicrobial Stewardship and Infection Prevention.

With training in internal medicine, infectious diseases, and epidemiology, Dr. Anderson assesses medical problems at both the population and individual patient levels. Over the past decade, Dr. Anderson's work has led to improvements in the quality and safety of care in multiple areas of healthcare, including Duke University Hospital and more than 45 community hospitals in the southeastern U.S. through the Center's outreach networks, the

Duke Infection Control Outreach Network (DICON), and the Duke Antimicrobial Stewardship Outreach Network (DASON).

Dr. Anderson is recognized as an international expert in healthcare epidemiology and multidrug-resistant pathogens. He is currently a Fellow of the Infectious Diseases Society of America (IDSA) and a Fellow of the Society for Healthcare Epidemiology of America (SHEA). He is the Director of the Duke Program for Infection Prevention for the National Football League (NFL). Dr. Anderson has authored over 160 peer-reviewed articles related to quality of care, patient safety, healthcare epidemiology, antimicrobial stewardship, and multidrug-resistant pathogens. Dr. Anderson has received research funding from the NIH, AHRQ, and CDC and is currently the Principal Investigator of the Duke-UNC Prevention Epicenter Program. In addition, he is a member of the Steering Committee for the NIH's Antibacterial Resistance Leadership Group.

SHEA is pleased to recognize Dr. Anderson for his commitment to Antibiotic Stewardship with the 2018 SHEA Antibiotic Stewardship Scholar Award.

SHEA Mentor Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Aaron M. Milstone, MD, MHS, FIDSA, FSHEA, FPIDS

Aaron M. Milstone, MD, MHS, FIDSA, FSHEA, FPIDS, is this year's recipient for the 2018 SHEA Mentor Scholar Award for his commitment to mentoring fellows and junior faculty. Dr. Milstone is an Associate Professor of Pediatric Infectious Diseases and Epidemiology at Johns Hopkins University. He is Associate Hospital Epidemiologist at Johns Hopkins Hospital and the Pediatric Lead for Infection Prevention for Johns Hopkins Health System. He serves on multiple

national committees and writing groups guiding practices to prevent healthcare associated infections (HAIs) and emergence of antibiotic resistance. For more than 10 years, he has been working to advance the science of infection control through studies of the

prevalence and transmission of multidrug-resistant organisms (MDRO) and interventions to reduce MDRO spread and prevent healthcare-associated infections.

Dr. Milstone's research program is funded by NIH, CDC, and AHRQ. Recently, he has expanded his work in these areas to include low and middle-income countries in response to heightened need for and awareness of MRDO and HAI prevention in these locations. As a pediatrician, he advocates for unique approaches to infection prevention in children, to balance infection control and family-centered care. He has been an active member of SHEA advocating to advance science in infection control in a changing healthcare environment.

SHEA is pleased to recognize the achievements of Dr. Milstone with the 2018 SHEA Mentor Scholar Award.

SHEA Society Awards (continued)

SHEA Mid-Career Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Anucha Apisarnthanarak, MD

Anucha Apisarnthanarak, MD, is this year's recipient of the 2018 SHEA Mid-Career Scholar Award for his contributions during his career in infection prevention and healthcare epidemiology science and practice. Dr. Apisarnthanarak finished his Infectious Diseases fellowship training from Washington University School of Medicine, under the supervision of Professor Victoria Fraser, MD. He is currently the Professor in Infectious Diseases at Thammasat

University Hospital and also serves as Adjunct Visiting Professor at Washington University School of Medicine.

Over the past 15 years, he has been a strong contributor to the knowledge of Infection Prevention in resource-limited settings. He has co-authored over 240 peer-review publications and more than 20 book chapters and become one of the internationally renowned speakers from Asia for infection prevention and healthcare epidemiology. His major contributions include the characterization of human avian influenza (H5N1) including atypical avian influenza (H5N1), the control and prevention of the spread of healthcare associated infections in resource-limited settings, the emergence and control of drug-resistant bacterial and viral infections, outbreaks and hospital preparedness after major Thai

2011 floods, and most recently studies on the epidemiology and practice to prevent nosocomial infections on the national scale. Several of these efforts have contributed to many landmark studies for Asia Pacific and globally.

He was the recipient of the SHEA William Jarvis Award for a 2009 publication in *Infection Control and Hospital Epidemiology* which reported an association between an infection control bundle and reduced transmission of influenza-like illnesses in pre-school children. With continuous contribution in the field, Dr. Apisarnthanarak received the 2015 SHEA International Scholar Award and 2016 Distinguished Thai Academician Award from the Royal College of Physicians of Thailand. Dr. Apisarnthanarak also serves on the editorial board for key infectious diseases and infection control journals including *Clinical Infectious Diseases*, *Infection Control and Hospital Epidemiology*, *Journal of Hospital Infection* and *American Journal of Infection Control*. Recently, Dr. Apisarnthanarak served as a guest editor for *Clinical Infectious Diseases* Supplementary issue in 2017 titled "Advance in Infection Prevention in Asia Pacific," which represented the top-quality works on infection prevention in Asia Pacific.

SHEA is pleased to present Dr. Apisarnthanarak with this award for his career achievements to date and looks forward to his ongoing contributions to the global field.

SHEA Pediatric Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Kristina A. Bryant, MD, FPIDS

Kristina A. Bryant, MD, FPIDS, was selected as the 2018 SHEA Pediatric Scholar Award Recipient recognizing her contributions to the fields of pediatric infection prevention. Dr. Bryant is Professor of Pediatrics at the University of Louisville, Director of the Kosair Charities Fellowship in Pediatric Infectious Diseases, and Hospital Epidemiologist at Norton Children's Hospital. The majority of her professional activity is devoted to clinical service, education

of fellows and residents, and oversight of infection control and hospital epidemiology at Norton Children's Hospital. Dr. Bryant's research interests include vaccine clinical trials and prevention of healthcare-acquired infections. She is an active participant in national research collaboratives to study the epidemiology and prevention of HAIs and MDROs in children. Since December

2016, she has served as a member of the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Dr. Bryant has served on the PIDS Training Programs Committee since 2004 (and was chair or co-chair 2008-2017). She also served as the moderator or co-moderator of the annual Pediatric Fellows' Day Program held during IDWeek from 2008 to 2016. She is the President-elect of PIDS and currently serves as the PIDS liaison to the SHEA Board of Trustees. Actively involved in SHEA since 2000, Dr. Bryant has served as chair of the SHEA Guidelines Committee and SHEA External Affairs Committee, a member of the SHEA Pediatric Leadership Council steering committee, and is the Vice Chair representing SHEA on the IDWeek Planning Committee.

For her contributions to SHEA and pediatrics, we are pleased to present Dr. Bryant with the 2018 SHEA Pediatric Scholar Award.

continued on next page

SHEA Society Awards (continued)

SHEA Barry Farr Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Amy J. Ray, MD, MPH

The editors of *Infection Control and Hospital Epidemiology* (ICHE) selected the following manuscript to receive the Barry Farr Award for most outstanding domestic clinical study published in ICHE in 2017: “A Multicenter Randomized Trial to Determine the Effect of an Environmental Disinfection Intervention on the Incidence of Healthcare-Associated *Clostridium difficile* Infection.” ICHE (2017), 38(7): 777-783.

The study conducted a 12-month randomized trial in 7 intervention hospitals and 8 control hospitals to compare standard cleaning to enhanced cleaning that included monitoring of environmental services (EVS) personnel performance with feedback to EVS and infection control staff. The study assessed the thoroughness of cleaning based on fluorescent marker removal from high-touch surfaces and the effectiveness of

disinfection based on environmental cultures for *C. difficile*. Overall, the intervention resulted in significantly increased fluorescent marker removal in CDI and non-CDI rooms and decreased recovery of *C. difficile* from high-touch surfaces in CDI rooms. An environmental disinfection intervention improved the thoroughness and effectiveness of cleaning but did not reduce the incidence of healthcare-associated CDI. Thus, interventions that focus only on improving cleaning may not be sufficient to control healthcare-associated CDI.

Lead author Amy J. Ray, MD, MPH, has a dual appointment at both the Department of Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, both in Cleveland, Ohio. Additional authors include Abhishek Deshpande, Dennis Fertelli, Brett M. Sitzlar, Priyaleela Thota, Thriveen Sankar, Annette L. Jencson, Jennifer L. Cadnum, Robert A. Salata, Richard R. Watkins, Ajay K. Sethi, Philip C. Carling, Brigid M. Wilson, and Curtis J. Donskey.

SHEA William Jarvis Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center



Maria Souli, MD, PhD

The editors of *Infection Control and Hospital Epidemiology* (ICHE) selected the following manuscript to receive the William Jarvis Award for most outstanding international clinical study published in ICHE in 2017: “Reduction of Environmental Contamination With Multidrug-Resistant Bacteria by Copper-Alloy Coating of Surfaces in a Highly Endemic Setting.” ICHE (2017), 38(7): 765-771.

The study looked to evaluate the efficacy of copper-coating in reducing environmental colonization in an intensive-care unit (ICU) with multidrug-resistant-organism (MDRO) endemicity. The results showed that copper coating significantly reduced the percentage of colonized surfaces (55.6% vs 72.5%; $P<.0001$), the percentage of surfaces colonized by MDR gram-negative bacteria (13.8% vs 22.7%; $P=.003$) or by enterococci (4% vs 17%; $P=.014$), the total bioburden (2,858 vs 7,631 cfu/100 cm²; $P=.008$), and the bioburden of gram-negative isolates, specifically

(261 vs 1,266 cfu/100 cm²; $P=.049$). This effect was more pronounced when the ratio of coated surfaces around the patient was increased (phase 2b). Copper-coated items in an ICU setting with endemic high antimicrobial resistance reduced environmental colonization by MDROs.

The lead author was Maria Souli, MD, PhD, who practices in the 4th Department of Internal Medicine at the National and Kapodistrian University of Athens, School of Medicine, University General Hospital Attikon in Athens, Greece. Other authors were Anastasia Antoniadou, Ioannis Katsarolis, Irini Mavrou, Elisabeth Paramythiotou, Evangelos Papadomichelakis, Maria Drogari-Apiranthitou, Theofano Panagea, Helen Giamarellou, George Petrikkos, and Apostolos Armaganidis. SHEA is presenting the authors of this manuscript the 2018 William Jarvis Award based on the strength of the research performed. SHEA and ICHE do not endorse or recommend any commercial organizations, products, processes, or services. The views and opinions expressed in this paper do not necessarily state or reflect those of SHEA and may not be used for advertising or product endorsement purposes.

HIVMA Awards

HIVMA Clinical Educator Award

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center



Rajesh T. Gandhi, MD,
FIDSA

Research Clinical Core (CFAR). Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and

Rajesh T. Gandhi, MD, FIDSA, is a Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). Dr. Gandhi is the site leader of the MGH AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit and chair of the AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS

organizer of the HIV Online Provider Education (HOPE) program, an internet-based educational conference series for physicians and nurses caring for HIV-infected patients in resource-limited settings. He is also a Deputy Editor of *NEJM Journal Watch Infectious Diseases* and *NEJM Journal Watch HIV/AIDS*. Dr. Gandhi is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults. Dr. Gandhi graduated from Harvard Medical School, completed his medical residency and chief residency at Brigham and Women's Hospital, and his infectious diseases fellowship training at Johns Hopkins Hospital.

HIVMA Research Award

Presented on Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center



Lisa B. Hightow-Weidman, MD, MPH

at UNC-Chapel Hill. In 2004, she earned a Master's in Public Health in Epidemiology from the UNC-Chapel Hill School of Public Health. She has been directly involved with the management of HIV-infected and at-risk adolescents and adults at UNC-Chapel Hill since 2001. Dr. Hightow-Weidman is an expert on mhealth, social media and utilization and evaluation of technology-based

Lisa B. Hightow-Weidman, MD, MPH, is an Associate Professor of Medicine in the Departments of Infectious Diseases and Health Behavior, University of North Carolina-Chapel Hill. Dr. Hightow-Weidman completed her medical school training at the University of Virginia and became board certified in Internal Medicine in 2001 after completing three years residency training at Stanford University. She completed three years of fellowship training in Infectious Diseases

interventions to address the HIV Care Continuum for youth and young adults, particularly among young men who have sex with men (YMSM). She has published over 90 peer-reviewed articles on these topics. Her research interests include HIV prevention for YMSM using both the Internet and other mobile technologies, and interventions that incorporate game-based elements and social networking to change behaviors. She has developed technology-based interventions to address uptake and adherence to biomedical HIV prevention and treatment, as well as to increase HIV diagnosis, linkage, and retention in care for YMSM. She is the PI of iTech, The UNC/Emory Center for Innovative Technology Across the Prevention and Care Continuum. This grant, part of the Adolescent Trials Network for HIV Interventions (ATN), seeks to develop a technology center to address the domestic epidemic of HIV among at risk and HIV-infected youth. She has a proven track record of successful funding from the National Institutes of Health, HIV/AIDS Bureau, and the Centers for Disease Control and Prevention.

HIVMA Clinical Fellows



Amy Baca, MD

Amy Baca, MD, earned her medical degree at the University of New Mexico in 2015. She completed her residency in Internal Medicine-Primary Care at Highland Hospital in Oakland, California, in 2018. During residency she had a second continuity clinic in HIV primary care caring for vulnerable patients living with HIV. Working with a population that was disproportionately affected by complications of HIV/AIDS inspired

Dr. Baca to pursue training in HIV primary care under the guidance of mentors committed to working with underserved patients. Her primary clinical training site will be UCSF School of Medicine at San Francisco General Hospital and Susa Coffey, MD, will serve as her mentor.

Growing up in a low-income, single parent home, motivated Dr. Baca to work with underserved patients. During her childhood her uncle was diagnosed with HIV. He was a member of ACT-UP, and she watched the early AIDS epidemic unfold in his living room. Watching her beloved uncle live and ultimately succumb to the disease inspired her to pursue a career in HIV medicine. Witnessing the deleterious effects of stigma and poor access to care inspired her to be a patient advocate, and she was awarded the Woo Award for Patient Advocacy by her residency program.

“I was born and raised in northern New Mexico and my goal is to return home to practice outpatient HIV medicine. Many barriers make HIV care in New Mexico very challenging,” Dr. Baca said.

“HIV care is complicated by high rates of IV opiate abuse, poverty, minimal access to PrEP, and a shortage of qualified providers. As a person of Hispanic and Native American descent who grew up in a low-income family, I feel I am in a unique position to relate to this patient population and help overcome these barriers to care.”

Upon completion of her fellowship, Dr. Baca intends to practice outpatient HIV medicine in an underserved community and integrate hepatitis C treatment, addiction medicine, and transgender care into her practice.



Meghan Fibbi, DO,
MPH

Meghan Fibbi, DO, MPH, received her medical degree from the Philadelphia College of Osteopathic Medicine in 2015, and completed her residency in Family Medicine and Community Health at the University of Pennsylvania in 2018.

Dr. Fibbi is eager to further her training in HIV care this year through the HIVMA Clinical Fellowship at the University of Pennsylvania Department of Family Medicine and Community Health.

Her work will focus on the provision of comprehensive HIV and PrEP services, embedded in the primary care setting, to transgender/gender non-binary individuals and black MSM who have been most affected by the epidemic in Philadelphia.

“Since being identified as a transgender-competent provider in my health system, I have provided care for approximately two dozen transgender patients in my continuity clinic. A significant number of these patients are young adults living with HIV who have transitioned their care from the Children’s Hospital of Philadelphia to my Family Medicine resident clinic,” Dr. Fibbi said. “I believe that the HIVMA fellowship will add another layer of expertise to my training that would allow my clinic to function as a medical home for this population, eliminating the need for multiple sites of care that too often results in care lapses for those already struggling with housing insecurity, poverty, and a mistrust in the medical system.”

After her fellowship, Dr. Fibbi plans to use her skillset to continue to serve medically underserved urban populations including providing HIV primary care and to train Family Medicine residents with the goal of developing a primary care HIV fellowship at the University of Pennsylvania.

PIDS Society Awards

PIDS Distinguished Research Award

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center



Carol J. Baker, MD,
FIDSA, FPIDS

Carol J. Baker, MD, FIDSA, FPIDS, a Professor of Pediatrics at the University of Texas McGovern Medical School, has been selected as the 2018 recipient of the PIDS Distinguished Research Award. This award recognizes the outstanding investigative efforts of a Society member who, throughout his or her career, has made outstanding contributions to research with significant impact on the field of pediatric infectious diseases.

Dr. Baker's work has focused on all aspects of Group B streptococcal (GBS) infections, from the first description of early- and late-onset sepsis and meningitis in neonates and young infants to the discovery of critical epitopes in the capsular polysaccharides necessary for development of candidate conjugate vaccine candidates. Her policy work in the early 1990s led to the development of the first CDC recommendations for intrapartum chemoprophylaxis to prevent early-onset group B

streptococcal disease in neonates, a policy currently preventing more than 80% of infections. Her current research includes efforts to prevent infections in pregnant women and their young infants through maternal immunization.

Among numerous honors, Dr. Baker has received the Mentor Award (2008), Society Citation for outstanding achievements in the field of Infectious Disease (2011) and the Alexander Fleming Award for Lifetime Achievement (2016), each from the Infectious Diseases Society of America, and the Schneerson-Robbins Prize in Vaccinology (2018). Dr. Baker is a past secretary of PIDS, past president of IDSA, and a former chair of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, 2009-2012.

Carol Baker's contributions to our understanding, management, and prevention of Group B Streptococcal disease are unparalleled and are an inspiration to all our members. PIDS is proud to honor Dr. Baker with the Distinguished Research Award.

PIDS Society Awards

PIDS presents several Society Awards during their business meeting.

Antimicrobial Stewardship Fellowship Award

Maria de Lourdes Eguiguren Jimenez, MD
Sophie Katz, MD
Rebecca G. Same, MD

PIDS-St. Jude Children's Research Hospital Fellowship Award in Basic and Translational Science

Megan Culler Freeman, MD, PhD

PIDS Fellowship Award

Funded by the PIDS Foundation and the Quidel Corporation
Karen Ocwieja, MD, PhD

Stanley & Susan Plotkin and Sanofi Pasteur Fellowship Award

Jennifer Rathe, MD, PhD

PIDS Distinguished Physician Award, Young Investigator Award and other Society Awards will also be presented during the PIDS Business Meeting.

Abstract Awards

IDWeek Program Committee Choice Awards

This \$2,500 award recognizes up to four of the best abstracts overall. IDWeek's Program Committee selected the following recipients based on outstanding scientific research:

Alejandro Diaz, MD, Nationwide Children's Hospital, Columbus, OH - Presentation #118: "Nasopharyngeal (NP) Bacterial Detection in Infants with Respiratory Syncytial Virus (RSV) Infection: Impact on Clinical Outcomes" Session 31: Infant Viral Infections, Thursday, October 4, 2018, 8:45 - 10 a.m.

Kevin Kamis, MPH, Denver Public Health, Denver, CO - Presentation #859: "Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-In STD Clinic Appointments is a Safe, Feasible, and Effective Method to Engage Patients at Risk for HIV in PrEP Care" Session 85: Preventing and Identifying New HIV Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

Jennifer Manne-Goehler, MD, DSc, MSc, Beth Israel Deaconess Medical Center, Boston, MA - Presentation #875: "Sex Differences in Academic Achievement and Faculty Rank in Academic Infectious Diseases" Session 90: Featured Oral Abstract, Thursday, October 4, 2018, 4:05 - 4:20 p.m.

Chanu Rhee, MD, MPH, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA - Presentation #1659: "Variation in Identifying Sepsis and Organ Dysfunction Using Administrative versus Clinical Data and Impact on Hospital Outcome Comparisons" Session 174: SHEA Featured Oral Abstract, Friday, October 5, 2018, 3:55 - 4:10 p.m.

IDWeek Diagnostic Awards

The IDWeek Award for top abstracts submitted in diagnostics is intended to recognize the best abstract in the category of diagnostics. The IDWeek Program Committee selected the recipients based on outstanding scientific research in the field of diagnostics.

Tristan Clark, BM, MRCP, DTM&H, MD, University of Southampton, Southampton, United Kingdom - Presentation #1717: "The impact of routine molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis: results of a pragmatic randomised controlled trial (GastroPOC)" Session 199: Clinical Trials that May Change Your Practice, Saturday, October 6, 2018, 8:45 - 10 a.m.

Martin Hoenigl, MD, Medical University of Graz, Graz, Austria - Presentation #2567: "Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients receiving Mold-active Antifungals: Performance of Interleukins 6 and 8, Asp LFD,

and Aspergillus PCR in Same Day Blood and Bronchoalveolar Lavage Fluid Samples" Session 271: Novel Diagnostics for Fungi, Parasites, and CNS Infection, Saturday, October 6, 2018, 2 - 3:15 p.m.

Anne Piantadosi, MD, PhD, Massachusetts General Hospital, Boston, MA - Presentation #868: "Prospective pathogen detection in patients with central nervous system inflammation using metagenomic sequencing" Session 86: Pushing the Envelope in CNS Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

Abstract Awards (continued)

IDWeek Investigator Awards

The Investigator Awards are intended to recognize the work of investigators in practice for less than 15 years, whose submitted abstracts are accepted for presentation at IDWeek. The award consists of \$1,250, and selection was based on the quality of the scientific merit of the nominee's accepted abstract. Each IDWeek sponsoring society has chosen one outstanding abstract from a member in their specialty to highlight. Following are the awardees for IDWeek 2018:

SHEA Awardee: Robin Jump, MD, PhD, Case Western Reserve University School of Medicine, Cleveland, Ohio – Presentation 857: “A Tele-Antibiotic Stewardship Program Influences Antibiotic Use at 2 Rural Veterans Affairs Medical Centers” Session 84: Antimicrobial Stewardship: Better Prescribing, Better Outcomes, Thursday, October 4, 2018, 2 - 3:15 p.m.

PIDS Awardee: Larry Kociolek, MD, MSCI, Northwestern University Feinberg School of Medicine, Chicago, IL - Presentation #976: “Clostridium difficile colonization molecular epidemiology and anti-toxin serological responses in healthy infants: A prospective cohort study” Session 126: Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting, Friday, October 5, 2018, 10:30 - 11:45 a.m.

HIVMA Awardee: Sarah M. Labuda, MD, MPH, Tulane University School of Medicine, New Orleans, LA - Presentation #2571: “Higher Rates of Hospitalization and Infection-Related Hospitalization among HIV-Exposed Uninfected Infants Compared to HIV Unexposed Uninfected Infants in the U.S.” Session 272: Pediatric Viral Infections, Saturday, October 6, 2018, 2 - 3:15 p.m.

IDSA Awardee: Kyle J Popovich, MD, MS, FIDSA, Rush University Medical Center, Chicago, IL - Presentation #159: “Genomic Epidemiology of MRSA at Intake to a Large Inner-City Jail—Evidence for Community Transmission Networks?” Session 46: Healthcare Epidemiology: Special Populations, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

continued on next page

Abstract Awards (continued)

IDWeek International Investigator Awards

The IDWeek International Investigator Awards are intended to recognize and support the work of individuals outside the United States and Canada who are either currently in training or who have been in practice for five years or less, and have an abstract accepted for presentation at IDWeek. The grant selection was based on scientific merit of the submitted abstract, and presenting authors receive \$1,500. Following are the awardees for IDWeek 2018:

Carlos Correa-Martinez, MD, Institute of Medical Microbiology, University Hospital Münster, Muenster, Germany - Presentation #1987: "Validation of a MALDI-TOF MS-based direct-on-target microdroplet growth assay (DOT-MGA) for rapid detection of extended-spectrum beta-lactamase (ESBL) and AmpC in clinical Enterobacteriaceae isolates" Session 228: Diagnostics: Bacteria and Mycobacteria, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Hans De Graaf, BM, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, NH, United Kingdom - Presentation #167: "A Bordetella pertussis Human Challenge Model Induces Immunizing Colonization in the Absence of Symptoms" Session 47: Science Relevant to ID, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

Michal Meir, MD, The Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel - Presentation #787: "The addition of avibactam augments the activity of piperacillin against Mycobacterium abscessus in vitro, and is effective in treating M. abscessus infection in a Galleria mellonella in vivo model" Session 70: Tuberculosis and Other Mycobacterial Infections, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

Divyashree S, MD, MGM New Bombay Hospital, Navi Mumbai, India - Presentation #864: "Therapeutic Immunosuppression to Treat Rabies Encephalitis" Session 86: Pushing the Envelope in CNS Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

Okko Savonius, MD, Children's Hospital, Helsinki University Hospital, and the University of Helsinki, Helsinki, Finland - Presentation #867: "Upregulated Matrix Metalloproteinase-2 Relates to Milder Hearing Impairment in Bacterial Meningitis" Session 86: Pushing the Envelope in CNS Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

Robert Van De Peppel, MD, Leiden University Medical Center, Leiden, Netherlands - Presentation #968: "Managing Invasive Aspergillosis in the Era of Diagnostic PCR and Increasing Triazole Resistance: a Modelling Study of Different Strategies." Session 125: Fungal Infections, Friday, October 5, 2018, 10:30 - 11:45 a.m.

Each sponsoring society has chosen one outstanding abstract from a member in their specialty. These abstracts are recognized as the top submissions from international investigators, and the presenting authors have received an award in the amount of \$1,750. Following are the awardees for IDWeek 2018:

IDSA Awardee: Lucia Gallo Vaulet, Biochemist/PhD, Universidad de Buenos Aires, INFIBIOC. Instituto de Fisiopatología y Bioquímica Clínica., Buenos Aires, Argentina - Presentation #2056: "Trypanosoma cruzi DNA Detection by PCR in Dried Blood Spots Preserved in Filter Paper" Session 231: Diagnostics: Parasitology, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

PIDS Awardee: Nilson N. Mendes Neto, MD, University of California, Davis, Davis, CA - Presentation #693: "Congenital Zika Syndrome: Assessing the Fatality Rate Since the 2015 Zika Outbreak" Session 66: Public Health: Epidemiology and Outbreaks, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

SHEA Awardee: Olivia Smibert, Bachelor of Medicine, Bachelor of Surgery, Peter MacCallum Cancer Center, Melbourne, Australia - Presentation #1787: "The safety and efficacy of an oral penicillin rechallenge program in cancer patients – A pilot multicentre study" Session 217: Antimicrobial Stewardship: Impact of Allergy, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

HIVMA Awardee: Melanie Stecher, MSc. Public Health, University Hospital of Cologne, Cologne, Germany - Presentation #1767: "Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapy – Implications for Future HIV Cure Trials: a systematic review and meta-analysis" Session 214: Optimizing HIV Treatment, Saturday, October 6, 2018, 10:30 - 11:45 a.m.

Abstract Awards (continued)

Guerrant International Travel Grants

The Guerrant International Travel Grants are awarded to fund travel to **IDWeek** from low- and lower-middle income countries (based on the World Bank's definition). A limited number of grants up to \$1,600 are available to participants whose abstracts are accepted. The following are the recipients who have received this award for 2018:

Abera Balcha Bulti, MD, DTM&H, University of Gondar, College of Medicine and Health Sciences, Gondar, Ethiopia - Presentation #1776: "Establishing an Antimicrobial Stewardship Program in a Resource Limited Setting: Experience of an Ethiopian Hospital" Session 216: Antimicrobial Stewardship: Global Perspectives, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Iris Cazali, MD, Hospital Roosevelt, Guatemala, Guatemala - Presentation #2104: "Impact of a supervision and education directed bundle in Ventilator Associated Pneumonia (VAP) on a pediatric critical care unit of a teaching hospital." Session 234: Healthcare Epidemiology: Device-associated HAIs, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Arwa El Manakhly, PharmD, Dar Al Fouad Hospital, Cairo, Egypt - Presentation #2300: "Molecular Epidemiology of Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) Causing Central Line-Associated Bloodstream Infections (CLABSI) in 3 ICU Units in Egypt" Session 245: Molecular & Sequence Based Diagnostics, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Debdeep Mitra, MD, Dermatology, Army Hospital New Delhi, New Delhi, India - Presentation #811: "A Randomized Controlled Trial of Prednisolone vs Interleukin 17 A Inhibitor Secuinumab in the Management of Type 1 Leprosy Reaction in Leprosy Patients" Session 70: Tuberculosis and Other Mycobacterial Infections, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

Husain Poonawala, MBBS, National Institute for Research in Tuberculosis, Chennai, India - Presentation #760: "The Diversity of *Mycobacterium tuberculosis* in India is Underestimated and Underreported" Session 70: Tuberculosis and Other Mycobacterial Infections, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

Ubaldo Tamoufe, MPH, MS, Metabiota Cameroon, Yaoundé, Cameroon - Presentation #687: "Modeling the impact of introduction of influenza vaccination on ILI cumulative case count in Cameroon" Session 66: Public Health: Epidemiology and Outbreaks, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

continued on next page

Abstract Awards (continued)

Kass Awards

The Kass Awards were established to honor the achievements of Edward H. Kass, a past IDSA president and leader in infectious diseases research. Grants in the amount of \$750 are awarded to medical students, residents, or house officers who have demonstrated excellence in research in infectious diseases and allied fields. Following are the recipients of this award for 2018:

Sarah Baker, BSPH, MSc, Tulane University School of Medicine, New Orleans, LA - Presentation #168: "Intradermal immunization drives humoral and cellular immunity to the lung and protects against acute *P. aeruginosa* pneumonia" Session 47: Science Relevant to ID, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

Shahla Bari, MD, Morehouse School of Medicine, Atlanta, GA - Presentation #2241: "Outcomes of Program cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer" Session 240: HIV: Malignancy, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

James Cheaveau, MBBS, MRCP, DTMH, University of Calgary, Calgary, AB, Canada - Presentation #2564: "Clinical validation of a commercial LAMP test for ruling out malaria in returning travelers: A prospective diagnostic trial" Session 271: Novel Diagnostics for Fungi, Parasites, and CNS Infection, Saturday, October 6, 2018, 2 - 3:15 p.m.

Edward Cuaresma, MD, Columbia University Medical Center, New York, NY - Presentation #1772: "Vancomycin-Resistant Enterococcus Alters the Gastrointestinal Microbiome in Critically Ill Patients" Session 215: Translating Microbiome Science into Practice, Saturday, October 6, 2018, 10:30 - 11:45 a.m.

Kathryn Dalton, VMD, MPH, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD - Presentation #160: "Reduction in the Spread of Hospital-Associated Infections Among Pediatric Oncology Patients in an Animal-Assisted Intervention Program from a Canine Decolonization Procedure." Session 46: Healthcare Epidemiology: Special Populations, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

Yosefa Hefter, MD, Westchester Medical Center, Valhalla, NY - Presentation #1760: "Interferon Gamma Release Assay for Diagnosis of Lyme Disease" Session 211: Diagnostics Making a Difference, Saturday, October 6, 2018, 10:30 - 11:45 a.m.

Colm Kerr, MB, BCh, BAO, MRCPI, BSc, Microbiology, St. James' Hospital, Dublin, Ireland - Presentation #1903: "Cost Minimisation Analysis of a Preferred ARV Prescribing Pathway for Treatment-Naïve HIV-Positive Patients" Session 225: Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Thomas McHale, MD, MSc, University of Nebraska Medical Center, Omaha, NE - Presentation #158: "The Effect of Insurance Coverage on Appropriate Selection of Hospital Discharge Antibiotics for *Staphylococcus aureus* Bacteremia" Session 45: Cool Findings in Bacteremia and Endocarditis, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

Rebecca Slotkin, MD, Yale University, New Haven, CT - Presentation #2566: "Diagnosis of *Pneumocystis jirovecii* pneumonia in HIV-negative immunocompromised patients: Is the Gomori-methenamine silver stain of bronchoalveolar lavage fluid the gold standard or sub-standard?" Session 271: Novel Diagnostics for Fungi, Parasites, and CNS Infection, Saturday, October 6, 2018, 2 - 3:15 p.m.

Abstract Awards (continued)

IDWeek Trainee Awards

Each IDWeek partnering society has chosen one outstanding abstract from a member in their specialty. These abstracts are recognized as the top submissions from trainees, and the presenting author has received an award in the amount of \$1,250. Following are the awardees for IDWeek 2018:

PIDS Trainee: Rachel L. Epstein, MD, MA, Boston Medical Center, Boston, MA

HIVMA Trainee: Allison Glaser, MD, Icahn School of Medicine at Mount Sinai Hospital, New York, NY

SHEA Trainee: Michael Yarrington, MD, Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

IDSA Trainee: Yingda Xie, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

In addition to the above awards to trainees, IDWeek Trainee Awards are awarded to trainees who submitted excellent research. The IDWeek 2018 recipients are listed below:

Anum Abbas, MD, CHI Health Creighton University

Emily Abdoler, MD, University of California, San Francisco

Muhammad Bilal Abid, MD, MRCP, Medical College of Wisconsin

Henrietta Abodakpi, PharmD, University of Houston College of Pharmacy

Bahaa Abu Raya, MD, BC Children's Hospital, University of British Columbia

Anteneh Addisu, MD, PhD, University of South Florida Morsani College of Medicine

Ahmed Al Hammadi, MD, DTM, University of Texas Health Sciences Center at Houston

Muayad Alali, MD, University of Chicago/Comer Children Hospital

Owen Albin, MD, University of Michigan

William Alegria, PharmD, Michigan Medicine

Doaa Aljefri, PharmD, MSc, Northwestern Medicine

Abdullah Aljorayid, MD, Barns Jewish Hospital/Washington University in St.Louis

Safa Almarzoky Abuhussain, PharmD, Um-alQura University

Sarah Altamimi, MD, Henry Ford Hospital

Georgios Angelidakis, MD, The University of Texas MD Anderson Cancer Center

Tomefa E Asempa, PharmD, Hartford Hospital

Archana Asundi, MDCM, Boston University Medical Center

Sean Avedissian, PharmD, Midwestern University Chicago College of Pharmacy/Northwestern Memorial Hospital

Lindsay Avery, PharmD, Hartford Hospital

Ahmed Babiker, MBBS, University of Pittsburgh Medical Center

Javier Baez Presser, MD, University of Miami/Jackson Memorial Hospital

Archana Balamohan, MD, FAAP, Cohen Children's Medical Center

Marjorie Batista, MD, PhD, The University of Texas MD Anderson Cancer Center

Norman Beatty, MD, University of Arizona College of Medicine

Nika Bejou, PharmD, Yale New Haven Hospital

Ilan Berlinrut, MD, Northwell Health, North Shore University Hospital

Mahesh Bhatt, MBBS, University of Kentucky

Mark Biagi, PharmD, University of Illinois at Chicago, College of Pharmacy

Paul Blair, MD, MSPH, Johns Hopkins University School of Medicine

Ana C. Blanchard, MDCM, FRCPC, The Hospital for Sick Children

Jessica Boettcher, DO, University of Minnesota

Juri Boguniewicz, MD, Baylor College of Medicine and Texas Children's Hospital

Brian Bohn, PharmD, Cleveland Clinic

Tyler D. Bold, MD, PhD, Brigham and Women's Hospital/Harvard School of Public Health

Jeannette Bouchard, PharmD, UPMC Presbyterian Shadyside

Rachel S. Britt, PharmD, Beth Israel Deaconess Medical Center

Robert Brunner, DO, Allegheny Health Network

Gregory Buchek, MD, Brooke Army Medical Center

Maria X Bueno Rios, MD, Cleveland Clinic

Juan Calix, MD, PhD, Washington University School of Medicine

Chase Cannon, MD, University of Washington

Travis Carlson, PharmD, CHI St. Luke's Health - Baylor St. Luke's Medical Center

Amanda Casto, MD, PhD, Department of Medicine, University of Washington

Gaud Catho, MD, CHU Sainte-Justine, Université de Montréal

Kieran Chacko, BA, BS, Icahn School of Medicine at Mount Sinai

continued on next page

Abstract Awards (continued)

IDWeek Trainee Awards (continued)

Zohra Chaudhry, MD, Henry Ford Hospital

Matthew P. Cheng, MD, Brigham and Women's Hospital

Nicholas Cheronis, MD, MPH, Allegheny Health Network

Edna Cheung, PharmD, Michigan Medicine

Justine Choe, PharmD, University of Chicago Medicine

Emily Ciccone, MD, MHS, University of North Carolina

Erik Clarke, PhD, University of Pennsylvania School of Medicine

Meredith Clement, MD, Duke University Medical Center

Jennifer P. Collins, MD, MSc, Centers for Disease Control and Prevention

Allison Cormier, MD, University of Wisconsin School of Medicine and Public Health

Gabriela Corsi, MD, University of Texas

Ryan L. Crass, PharmD, University of Michigan

Caroline Cruce, PharmD, Midwestern University Chicago College of Pharmacy

Jaclyn Cusumano, PharmD, University of Rhode Island

Laura N. Cwengros, PharmD, Detroit Medical Center

Adam Dale, MBChB, BSc, MRCP, FRCPath, University of Southampton

Dima Dandachi, MD, Baylor College of Medicine

Shom Dasgupta-Tsinikas, MD, Harbor-UCLA Medical Center

Rupak Datta, MD, PhD, Yale School of Medicine

David De Gijssel, MD, MSc, Dartmouth-Hitchcock Medical Center

Coralee Del Valle Mojica, MD, MPH, Stanford University

Martha DesBiens, MD, Dartmouth Hitchcock Medical Center

Emma Dishner, MD, MPH, Baylor College of Medicine

David Dobrzynski, MD, Vanderbilt University Medical Center

Megan Donahue, MD, Walter Reed National Military Medical Center

Khalid M. Dousa, MD, FACP, CABIM, University Hospitals, Case Western Reserve University

Joshua Doyle, MD, PhD, Centers for Disease Control and Prevention

Kevin Dufour, MD, Université de Sherbrooke

Leona Ebara, MD, University of Chicago Medicine

Michael Edzards, MD, Children's National Medical Center

Lynn El Haddad, PhD, The University of Texas MD Anderson Cancer Center

Abdulrahman Elabor, MD, Temple University Hospital

Zerelda Esquer Garrigos, MD, Mayo Clinic

Evan Ewers, MD, Walter Reed National Military Medical Center

Farhan Fazal, MBBS, MD, All India Institute of Medical Science (AIIMS)

Priyanka Fernandes, MBBS, MPH, University of California Los Angeles

Madiha Fida, MD, Mayo Clinic

Sean Fitzwater, MD, MHS, University of California, Los Angeles

Molly Fleece, MD, University of Virginia

Kap Sum Foong, MD, Washington University in St. Louis

Catherine Foster, MD, Baylor College of Medicine and Texas Children's Hospital

Dustin Freshwater, PharmD, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Northeast Ohio VA Healthcare System (NOVAHS)

Gennifer Garmon, MD, Baylor Scott & White Memorial Hospital

Benjamin Gern, MD, Center for Infectious Disease Research

Jean Gibb, MD, University of California, Los Angeles

Christian Gill, PharmD, Henry Ford Hospital

Philip Goldstein, MD, The Ohio State University Wexner Medical Center

Robert Goldstein, MD, PhD, Massachusetts General Hospital

David Goodman-Meza, MD, MAS, University of California, Los Angeles

Ronnie Matthew Gravett, MD, University of Alabama at Birmingham

Megan Gray, MD, University of Virginia

Hind Hadid, MD, Henry Ford Health System

Manuela Haiduc, PharmD, Allegheny Health Network

Zeina Hajar, MD, Case Western Reserve University - University Hospitals Cleveland Medical Center

Ahmed Hamdi, MD, Mayo Clinic

Richard Hankins, MD, University of Nebraska Medical Center

Edwin Hayes, MD, University of South Carolina

Justin F Hayes, MD, University of Alabama at Birmingham

Shaina Hecht, MD, The Ohio State University and Nationwide Children's Hospital

Todd E. Hershberger, PharmD, Michigan Medicine

Matthew Hevey, MD, Washington University in St. Louis

Matthew Hitchcock, MD, MPH, Stanford University School of Medicine

Abstract Awards (continued)

IDWeek Trainee Awards (continued)

Hayley Hodgson, PharmD, Midwestern University, Chicago College of Pharmacy

Catherine Hogan, MD, MSc, Stanford University School of Medicine

Babak Hooshmand, MD, Saint John Hospital and Medical Center; Ascension

Courtney Horvat, PharmD, Aurora Health Care

Jeff Hosry, MD, The University of Texas MD Anderson Cancer Center

Joel Howard, MD, University of Utah

Michelle M. Hughes, PhD, MHS, Centers for Disease Control and Prevention

Ashley Husebye, MD, University of Minnesota

Claudia Ihm, MD, University of Utah

Hannah Imlay, MD, University of Washington

Marinela Ingilizova, MD, Drexel University College of Medicine

Sisham Ingnam, MD, The Ohio State University Wexner Medical Center

Ra'Ed Jabr, MBBchB, University of Kansas Medical Center

Paul Jacob, MD, MPH, Vanderbilt University

Niyati Jakharia, MD, University of Maryland Medical Center

Deeksha Jandhyala, MD, Mayo Clinic, Department of Infectious Diseases

Nathan Jansen, DO, San Antonio Military Medical Center

Teny Mathew John, MD, Cleveland Clinic

Milissa Jones, MD, Walter Reed National Military Medical Center

Su Jin Joo, MD, Emory University School of Medicine

Sarah Jorgensen, PharmD, BCPS, AAHIVP, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences

Christopher Kandel, MD, University of Toronto

Anubhav Kanwar, MD, Louis Stokes Cleveland VA Medical Center

Olga Kaplun, MD, Stony Brook University Hospital

Anthony Karabanow, MD, Tufts Medical Center

Manjiree Karandikar, MD, MBS, Boston Children's Hospital

Aspasia Katragkou, MD, PhD, Nationwide Children's Hospital

Sophie Katz, MD, Vanderbilt University Medical Center

Razieh Kebriaei, PhD, Wayne State University

Fareed Khawaja, MD, The University of Texas Health Science Center at Houston

Lilian Kibathi, PharmD, National Institutes of Health

James M. Kidd, PharmD, BCPS, Hartford Hospital

John Kiley, MD, San Antonio Military Medical Center

Maiko Kondo, MD, New York-Presbyterian Weill Cornell Medical Center

Angelica Kottkamp, MD, New York University School of Medicine

Natan Kraitman, MD, University of South Florida

Brandon Kulengowski, PharmD, MS, University of Kentucky, College of Pharmacy

Prathit Kulkarni, MD, The University of Texas MD Anderson Cancer Center

Bakri Kulla, MD, Eastern Virginia Medical School

Madan Kumar, DO, Childrens National Medical Center

Kevin Kuriakose, MD, Vanderbilt University Medical Center

Kathryn Lago, DO, San Antonio Military Medical Center

John Lam, MD, University of Calgary

Tyler Lambing, MD, University of Maryland

Mariana Lanata Piazzon, MD, Nationwide Children's Hospital

Derek Larson, DO, Naval Medical Center San Diego

Laurel Legenza, PharmD, MS, University of Wisconsin School of Pharmacy

Bethany Lehman, DO, Cleveland Clinic

Arnaud G L'Huillier, MD, University Health Network

Jiajun Liu, PharmD, Midwestern University/Northwestern Memorial Hospital

Santiago Lopez, MD, Children's Hospital of Pittsburgh of UPMC

Jessica Lum, MD, University of Colorado Hospital

Megan Luther, PharmD, University of Rhode Island

Derek MacFadden, MD, University of Toronto

Gregory Madden, MD, University of Virginia

Theresa Madigan, MD, Mayo Clinic

Stacey A. Maskarinec, MD, PhD, Duke University Medical Center

Michelle Matheu, MD, University of Texas Health at San Antonio

Susannah McKay, PhD, MPH, Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention

Megan McKenna, MD, Baylor College of Medicine

Nathan McLeod, MD, West Virginia University School of Medicine

continued on next page

Abstract Awards (continued)

IDWeek Trainee Awards (continued)

Tristan McPherson, MD, Columbia University Medical Center

Sonia Mehra, MD, University of Utah School of Medicine

Carlos Mejia, MD, Washington University School of Medicine

Nicholas J Mercurio, PharmD, Wayne State University

Jaime Eduardo Mogollon, MD, Montefiore Medical Center/
Albert Einstein College of Medicine

Elizabeth A Moulton, MD, PhD, Boston Children's Hospital

Mark Murphy, DO, Cincinnati Children's Hospital Medical
Center

Maria Nagori, MD, Cooper University Hospital

Julie Nahar, MD, University of Missouri Kansas City School of
Medicine

Nancy Nashid, MD, FRCPC, FAAP, The Hospital for Sick
Children

Margaret E. Newman, MD, The University of Chicago School of
Medicine

Jennifer O. Spicer, MD, MPH, Emory University School of
Medicine

Brigid O'Brien, DO, MS, Tulane University

Chikara Ogimi, MD, University of Washington

Jane O'Halloran, MD, PhD, Washington University School of
Medicine, Division of Infectious Diseases

Ana Paim, MD, Mayo Clinic

Ann Palmer, MD, University of Connecticut

Leo Parsons, DO, Detroit Medical Center

Ami Patel, MD, MPH, New York University School of Medicine/
NYU Langone Health

Corey Peak, ScD, MS, Centers for Disease Control and
Prevention

Dana Pepe, MD, MPH, Yale School of Medicine

Nitipong Permpalung, MD, MPH, Duke University Medical
Center

Whitney Perry, MD, Tufts Medical Center

Robert Pitts, MD, New York University

Heather Pomerantz, MD, San Antonio Military Medical Center

Haley Pritchard, MD, Baylor College of Medicine

Varvara Probst, MD, Vanderbilt University Medical Center

Laura Quilter, MD, MPH, Centers for Disease Control and
Prevention, Division of STD Prevention

Mohammad Ali Rai, MD, PhD, University of Cincinnati Medical
Center

Mohammed Raja, MD, University of Miami/Jackson Memorial
Hospital

Talha Riaz, MD, Medical University of South Carolina

Katherine Richardson, MD, Children's Mercy Hospital

Steven Richardson, PharmD, Cleveland Clinic

Alaina Ritter, MD, Massachusetts General Hospital

Makeda L. Robinson, MD, Stanford University

Ralph Rogers, MD, Warren Alpert Medical School of Brown
University

Frances Saccoccio, MD, PhD, Duke University Hospital

Najmus Sahar, MBBS, Wright State University Boonshoft School
of Medicine

Aki Sakurai, MD, The University of Texas MD Anderson Cancer
Center

Mohammed Samannodi, MD, University of Texas Health
Science Center at Houston, McGovern Medical School

Mindy Sampson, DO, University of South Florida

Terrel Sanders, MD, Naval Medical Center San Diego

Avnish Sandhu, DO, Wayne State University

Sarah Sansom, DO, Rush University Medical Center

Felicia Scaggs Huang, MD, Cincinnati Children's Hospital
Medical Center

Asher Schranz, MD, University of North Carolina

Jessica Seideman, MD, Duke Center for Antimicrobial
Stewardship and Infection Prevention

David P. Serota, MD, Emory University School of Medicine

Aditya Shah, MBBS, Mayo Clinic

Jacqueline Sherbuk, MD, University of Virginia

Hannah Shull, MD, David Geffen School of Medicine/University
of California, Los Angeles

Anna Sick-Samuels, MD, MPH, Johns Hopkins University
School of Medicine

Erik Skoglund, PharmD, University of Houston College of
Pharmacy

Jessica Smith, PharmD, Wake Forest Baptist Health

Matthew A. Spinelli, MD, University of California, San Francisco

Erica Stohs, MD, MPH, University of Washington

Nathan Summers, MD, Emory University School of Medicine

Zarchi Sumon, MD, University of Buffalo

Hiroyuki Suzuki, MD, University of Iowa Carver College of
Medicine

Abstract Awards (continued)

IDWeek Trainee Awards (continued)

Sadia Syed, MBBS, Mayo Clinic Rochester

Eugene M. Tan, MD, Mayo Clinic

Beth Thielen, MD, PhD, University of Minnesota

Melissa Tiyouh, MD, Drexel University College of Medicine

Mitsuru Toda, PhD, Centers for Disease Control and Prevention

Maria-Stephanie Tolg, PharmD, Providence Veterans Affairs Medical Center

Nicholas Turner, MD, Duke University Medical Center

Erlinda Rose Ulloa, MD, MSc, The Children's Hospital of Philadelphia

Robert Ulrich, MD, New York University School of Medicine

Amit Vahia, MD, MPH, Henry Ford Health System

Jose Carlo Valencia, MD, Division of Infectious Diseases, Mayo Clinic

Neethi Venkatappa, MD, Beaumont Hospital Royal Oak

Prakhar Vijayvargiya, MD, Mayo Clinic

Elizabeth Wang, MD, Baylor College of Medicine

Rachel Weihe, MD, University of Kansas Medical Center

Wesley Willeford, MD, University of Alabama at Birmingham

William R. Wilson, PharmD, University of Pittsburgh Medical Center

Rita Wilson Dib, MD, The University of Texas MD Anderson Cancer Center

Daniel Winetsky, MD, MS, Columbia University Medical Center

Rebeca Witherell, MD, Saint John Hospital and Medical Center; Ascension

Jacqueline Wong, MD, FRCPC, FAAP, The Hospital for Sick Children

Adrienne Workman, MD, University of Texas Southwestern

Joseph Yabes, MD, San Antonio Military Medical Center

Sanjay Yadava, MD, SUNY Upstate Medical Center

Masaki Yamada, MD, Children's Hospital of Pittsburgh of UPMC

Mohamad Yasmin, MD, Case Western Reserve University

Alexandra Yonts, MD, Children's National Medical Center

HoJoon You, MD, Albert Einstein Medical Center

Nabil Zeineddine, MD, Drexel University College of Medicine

Yanping Zhao, PhD, The University of Hong Kong

Shiwei Zhou, MD, University of Michigan

Matthew Ziegler, MD, Perelman School of Medicine, University of Pennsylvania

Jason Zucker, MD, Columbia University Medical Center

CME/CPE/MOC Credit Tracker

Use the CME/CPE/MOC Tracker below as a guide to track the sessions you've attended, then go to www.idweek.org to enter your sessions, complete a short evaluation for each session, and claim CME/CPE/MOC credit. In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session. IDSA, in conjunction with ProCE, Inc. will offer pharmacists continuing pharmacy education (CPE) credit for select sessions. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Program Number (for CPE credit)
	PW01	The Vincent T. Andriole ID Board Review Course (\$)	Maximum of 7.5 AMA PRA Category 1 Credits™	0221-9999-18-301-L01-P
	PW02	Best Practices for Antimicrobial Stewardship Programs (\$)	Maximum of 7.5 AMA PRA Category 1 Credits™	0221-9999-18-178-L01-P
	PW03	NIH Initiatives/Grant Writing Workshop	Maximum of 4 AMA PRA Category 1 Credits™	No CPE Credit
	PW06	TB Workshop (\$)	Maximum of 4 AMA PRA Category 1 Credits™	0221-9999-18-179-L01-P
	PW07	Hepatitis C Workshop	Maximum of 4 AMA PRA Category 1 Credits™	0221-9999-18-302-L01-P
	PW08	A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship	Maximum of 4 AMA PRA Category 1 Credits™	0221-9999-18-303-L01-P
	PW09	How to Use EBM/GRADE to Develop Guidelines	Maximum of 4 AMA PRA Category 1 Credits™	No CPE Credit
	PW10	Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Module: General ID 2018	Maximum of 15 AMA PRA Category 1 Credits™	No CPE Credit
	PW11	Medication Assisted Treatment Waiver Course	Maximum of 4 AMA PRA Category 1 Credits™	No CPE Credit
	1	Challenging Cases in Pediatric Infectious Diseases 	Maximum of 1.75 AMA PRA Category 1 Credits™	0221-9999-18-180-L01-P
	2	Late Breaker Ebola Update	Maximum of 1.75 AMA PRA Category 1 Credits™	No CPE Credit
	3	Machine Learning and Modeling in Infectious Diseases	Maximum of 1.75 AMA PRA Category 1 Credits™	0221-9999-18-181-L01-P
	4	RCT That Will Change Your Practice	Maximum of 1.75 AMA PRA Category 1 Credits™	0221-9999-18-182-L01-P
	5	Stewardship: Best Drivers of Change Debate	Maximum of 1.75 AMA PRA Category 1 Credits™	0221-9999-18-183-L04-P
	6	Update on Biofilm-Related Infections	Maximum of 1.75 AMA PRA Category 1 Credits™	0221-9999-18-304-L01-P
	7	What's Hot in ID + HIV	Maximum of 1.75 AMA PRA Category 1 Credits™	0221-9999-18-184-L02-P
	8	Opening Plenary	Maximum of 1.5 AMA PRA Category 1 Credits™	No CPE Credit
	11	Are You Ready? Outbreak Response Training	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	12	Disease Eradication Progress: Polio and Guinea Worm	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	13	Emerging Issues in the Diagnosis of STIs	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-185-L01-P
	14	How to Build Allergy Testing into Your Stewardship Program	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-187-L04-P
	15	NTM Infections: Challenges in Diagnosis and Management	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-188-L01-P
	16	Our Most Difficult HIV Cases (other than STIs)	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-189-L01-P
	17	Questions in Bacteremia	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-190-L01-P
	18	Respiratory Infections in Pregnant Women	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-191-L01-P
	19	Shall We Agree to Disagree: Management of Pediatric Acute Hematogenous Osteomyelitis 	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-186-L01-P
	20	Women in ID	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-305-L04-P
	21	"Brain on Fire": Challenging Cases in Infectious and Inflammatory Encephalitis 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-192-L01-P
	22	Case-Based Problems in Vaccines: Beyond the Guidelines 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-193-L04-P



Only sessions with this symbol are available for ABP MOC Points

CME/CPE/MOC Credit Tracker (continued)


Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Program Number (for CPE credit)
	23	Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-194-L01-P
	24	Can You Hear and See Me Now? ID Telehealth	Maximum of 1.25 AMA PRA Category 1 Credits™	No CPE Credit
	25	Combating Antimicrobial Resistance: Relevance of the One Health Concept	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-306-L04-P
	26	Just Your Average Day in a Pediatric Infectious Disease Clinic	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-307-L01-P
	27	Predict, Prevent, and Protect: Optimizing Transplant Outcomes 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-195-L01-P
	28	Still at Highest Risk: Innovative Approaches & Urgent Needs for Prevention and Care	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-196-L01-P
	29	What Are You Talking About? Communication Strategies for Stewardship Programs 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-197-L04-P
	34	Diagnostic Clinical Cases	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-198-L04-P
	35	STIs in the HIV Care Setting	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-203-L02-P
	36	Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-199-L04-P
	37	Hepatitis B: Current and Future Challenges in Treatment and Prevention	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-200-L01-P
	38	Hot Topics in Medical Education 2018 	Maximum of 1.25 AMA PRA Category 1 Credits™	No CPE Credit
	39	Hot Topics in Pediatric Infectious Diseases 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-201-L04-P
	40	Improving Healthcare-Associated Infection Metrics	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-202-L04-P
	41	New and Updated Guidelines	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-269-L01-P
	42	The Microbiome and Multidrug-Resistant Organisms	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-204-L01-P
	43	Tuberculosis: What's New in Diagnosis and Management	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-205-L01-P
	75	Clinical Controversies	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-309-L01-P
	76	Controversies in Infection Prevention	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-207-L04-P
	77	"Mano-a-Mano III": Controversies in Pediatric ID 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-308-L01-P
	78	Bread and Butter Transplant ID	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-206-L04-P
	80	Migration and Immigration: Global Diseases at Your Doorstep 	Maximum of 1.25 AMA PRA Category 1 Credits™	No CPE Credit
	81	New Developments on Picornaviruses 	Maximum of 1.5 AMA PRA Category 1 Credits™	No CPE Credit
	82	Novel Clinical Risks for Fungal Disease	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-209-L01-P
	83	The Human Microbiome in HIV	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-210-L02-P
	88	John F. Enders Lecture	Maximum of 0.25 AMA PRA Category 1 Credits™	0221-9999-18-310-L04-P
	91	Maxwell Finland Lecture 	Maximum of 0.25 AMA PRA Category 1 Credits™	0221-9999-18-211-L04-P
	93	Ask the Expert: Managing Invasive Fungal Infections	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-212-L01-P
	94	Challenging STIs in the HIV Infected Patient	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-213-L02-P
	95	Controversies in Sepsis (but not SIRS)	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-214-L04-P
	96	Designing a QI Project You Can Publish 	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-215-L04-P
	97	Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-216-L01-P
	98	ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit



Only sessions with this symbol are available for ABP MOC Points

continued on next page

CME/CPE/MOC Credit Tracker (continued)

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Program Number (for CPE credit)
	99	Microbiome Therapeutics	Maximum of 1 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-217-L01-P
	100	Mid-Career Challenges and Opportunities	Maximum of 1 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-311-L04-P
	101	Tropical Dermatology: Are You Ready for Jeopardy?	Maximum of 1 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-218-L01-P
	102	Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems	Maximum of 1 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-219-L04-P
	103	"Achy Breaky Heart": Challenging Cases in Cardiovascular Infections	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-220-L01-P
	104	A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	No CPE Credit
	105	Advances in RSV Prevention 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-221-L01-P
	106	Fungal MDR Outbreak: <i>Candida auris</i>	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-222-L01-P
	107	HIV State of the Art	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-223-L02-P
	108	Metagenomic-Based Infectious Disease Diagnostics	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-224-L04-P
	109	Pandemic Influenza	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-312-L01-P
	110	Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-225-L04-P
	111	Stewardship in Challenging Populations 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-226-L04-P
	116	Challenging Cases in Infectious Diseases	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-229-L01-P
	117	Big Beasts I	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-227-L01-P
	118	How to Treat Resistant Gram-Positive Infections	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-230-L01-P
	119	Infection Control and Antimicrobial Stewardship in Dialysis Facilities	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-231-L04-P
	120	Late Breaker Foodborne Illnesses	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	No CPE Credit
	121	Pathogen Interactions with the Microbiota	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-232-L01-P
	122	Strategies to Achieve HIV Remission	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-233-L02-P
	123	Time 101: Optimizing Meetings	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-234-L04-P
	129	Caroline B. Hall Lectureship 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-228-L01-P
	156	Challenging Cases in Transplant: When the ID Expert Says, "What?"	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-236-L01-P
	157	Challenging HIV Cases	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-237-L02-P
	158	Beyond the Big Beasts of Healthcare Epidemiology	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-235-L01-P
	159	Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-238-L01-P
	160	Leading Change	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-239-L04-P
	161	Pediatric Immunization: Perspectives From Both Sides of the Pond 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-240-L01-P
	162	T-Cell Biology: What the ID Physician Needs to Know	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-241-L04-P
	163	The ID Specialist and the Opioid Epidemic: What You Need to Know Now	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-242-L01-P
	164	Vaccines Against Herpesviruses 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-243-L01-P
	170	Diagnostic Updates: Clinical Mycology Update	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-245-L01-P
	171	ID Physicians in the Age of Value-Based Healthcare	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-313-L04-P
	172	My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> TM	0221-9999-18-246-L01-P



Only sessions with this symbol are available for ABP MOC Points

CME/CPE/MOC Credit Tracker (continued)





Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Program Number (for CPE credit)
	173	SHEA Lecture: A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology	Maximum of 1.25 AMA PRA Category 1 Credits™	No CPE Credit
	176	Influential Publications in Antimicrobial Stewardship from the Past Year	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-244-L04-P
	177	Stanley A. Plotkin Lectureship in Vaccinology	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-247-L04-P
	179	B-lactam / B-lactamase Inhibitor Combinations: Which one?	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-248-L01-P
	180	Clinical Teaching for the ID Provider	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	181	Creepy, Dreadful, Wonderful Parasites and Other Creatures	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-252-L01-P
	182	Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & “Aha” Moments	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-249-L01-P
	183	Diagnosis of Toxoplasmosis in Special Populations	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	184	Dollar Dollar Bills Y’All: Billing and Coding in ID	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	185	Educating Trainees about Stewardship	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-250-L04-P
	186	Emerging Drug Resistance in STIs	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-251-L01-P
	187	NHSN Update	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	188	Rapid Fire: Curbsides in Transplant ID	Maximum of 1 AMA PRA Category 1 Credits™	0221-9999-18-253-L01-P
	189	Updates from the Antibacterial Resistance Leadership Group	Maximum of 1 AMA PRA Category 1 Credits™	No CPE Credit
	190	Shots Across the Bow: Debates in Vaccinology 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-261-L01-P
	191	Big Beasts II	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-254-L01-P
	192	Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-255-L01-P
	193	ID Physicians and Addiction Medicine	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-256-L01-P
	194	Malignancies in Patients with HIV	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-257-L02-P
	195	Neonatal Infectious Disease: Chagas, Zika, and LCMV 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-258-L01-P
	196	Non-Zika Arboviruses in the Americas	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-259-L01-P
	197	Pediatric Infection Prevention: Small Patients, Big Challenges 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-260-L01-P
	198	The Future of Transplant ID: Novel Diagnostics and Therapeutics	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-262-L01-P
	203	Tropical Medicine Cases: Conundrums and Case Management	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-270-L01-P
	204	Advances in Transplantation for Patients with HIV	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-263-L02-P
	205	Changing Landscape of Rapid Diagnostic Tests and Their Impact	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-264-L04-P
	206	Controlling Antimicrobial Resistance Across Borders	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-265-L04-P
	207	Cool Ways to Discover Antibiotics	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-266-L04-P
	208	I’m Better than You and I Can Prove It: Quality Metrics for Clinical ID	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-267-L04-P
	209	Infections in Immunocompromised Hosts 	Maximum of 1.25 AMA PRA Category 1 Credits™	No CPE Credit
	210	Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-268-L01-P
	260	Advances in Epidemiology Research Methods 	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-271-L04-P
	261	Infection Prevention in Post-Acute Care: Controversies and Challenges	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-272-L01-P
	262	Intersection of Surgery and Pediatric Infectious Disease	Maximum of 1.25 AMA PRA Category 1 Credits™	0221-9999-18-314-L01-P



Only sessions with this symbol are available for ABP MOC Points

continued on next page

CME/CPE/MOC Credit Tracker (continued)

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Program Number (for CPE credit)
	263	Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children 	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-273-L01-P
	264	Pain Management and Mental Health in Patients with HIV	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-274-L02-P
	265	Strategy Trials: A New Paradigm in Infectious Diseases Research	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-275-L04-P
	266	Syphilis in the 21st Century	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-276-L01-P
	267	When Does PK/PD Matter for Patient Care?	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-277-L04-P
	268	When Transplant Tours the World	Maximum of 1.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-278-L01-P
	273	Joseph E. Smadel Lecture 	Maximum of 0.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-279-L04-P
	276	Edward H. Kass Lecture 	Maximum of 0.25 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-280-L02-P
	277	ID BugBowl	Maximum of 1 <i>AMA PRA Category 1 Credits</i> SM	No CPE Credit
	278	Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics	Maximum of 1 <i>AMA PRA Category 1 Credits</i> SM	No CPE Credit
	279	Red Book Update 	Maximum of 1 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-281-L04-P
	280	Tele-Antimicrobial Stewardship	Maximum of 1 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-315-L04-P
	281	Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections	Maximum of 1.5 <i>AMA PRA Category 1 Credits</i> SM	0221-9999-18-316-L01-P



IDWeek 2018 Program Tracks

Tuesday, October 2

8 a.m. - 5 p.m.

Pre-meeting Workshops

- ▶ PW01. The Vincent T. Andriole ID Board Review Course (\$) -W 2005-2020
- ▶ PW02. Best Practices for Antimicrobial Stewardship Programs (\$) -W 2009-2024

1 - 5:30 p.m.

- ▶ PW11. Medication Assisted Treatment Waiver Course (\$) -W 2014-2016

Wednesday, October 3

8 a.m. - 12 p.m.

Pre-meeting Workshops

- ▶ PW04. Fellows' Day Workshop (\$) -W 2006-2008
- ▶ PW06. TB Workshop (\$) -W 2001-2003
- ▶ PW07. Hepatitis C Workshop (\$) -S 156
- ▶ PW08. A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship (\$) -S 152-154
- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

8 a.m. - 12:30 p.m.

Pre-meeting Workshop

- ▶ PW10. Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: General ID (\$) -S 158

1:30 - 3:15 p.m.

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
- ▶ 4. RCT That Will Change Your Practice -N 25
- ▶ 6. Update on Biofilm-Related Infections -W 2014-2016
- ▶ 7. What's Hot in ID + HIV -N Hall D

Interactive Session

- ▶ 5. Stewardship: Best Drivers of Change Debate -N 24

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 11. Are You Ready? Outbreak Response Training -S 152-154
- ▶ 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
- ▶ 13. Emerging Issues in the Diagnosis of STIs -S 214-216
- ▶ 14. How to Build Allergy Testing into Your Stewardship Program -S 157
- ▶ 15. NTM Infections: Challenges in Diagnosis and Management -W 2001-2003
- ▶ 17. Questions in Bacteremia -W 2006-2008
- ▶ 18. Respiratory Infections in Pregnant Women -S 158
- ▶ 20. Women in ID -S 155

7:15 - 8:30 a.m.

Meet-the-Professor Session

- ▶ 92. Antimicrobial and Diagnostic Stewardship -S 206-208

8:45 - 10 a.m.

Interactive Sessions

- ▶ 21. "Brain on Fire": Challenging Cases in Infectious and Inflammatory Encephalitis -W 2005-2024
- ▶ 22. Case-Based Problems in Vaccines: Beyond the Guidelines -N 25
- ▶ 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D

Symposia

- ▶ 24. Can You Hear and See Me Now? ID Telehealth -S 206-208
- ▶ 25. Combating Antimicrobial Resistance: Relevance of the One Health Concept -W 2006-2008
- ▶ 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216
- ▶ 29. What Are You Talking About? Communication Strategies for Stewardship Programs -N 24

Oral Abstract Sessions

- ▶ 30. Healthcare Epidemiology: Hot Topics -S 157
- ▶ 32. Tuberculosis and other Mycobacterial Infections -W 2002
- ▶ 33. What's Hot in UTIs and STIs -S 158

10:30 - 11:45 a.m.

Interactive Session

- ▶ 34. Diagnostic Clinical Cases -W 2005-2024

Symposia

- ▶ 36. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship -N 24
 - ▶ 37. Hepatitis B: Current and Future Challenges in Treatment and Prevention -N 25
 - ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
 - ▶ 40. Improving Healthcare-Associated Infection Metrics -W 2006-2008
 - ▶ 41. New and Updated Guidelines -S 305-314
 - ▶ 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208
 - ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216
- Oral Abstract Sessions
- ▶ 44. Adult and Adolescent Vaccines -S 158
 - ▶ 45. Cool Findings in Bacteremia and Endocarditis -W 2002
 - ▶ 46. Healthcare Epidemiology: Special Populations -S 156
 - ▶ 47. Science Relevant to ID -S 157

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 49. Antimicrobial Stewardship: Interventions in Pediatric Populations -S Poster Hall
- ▶ 50. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record -S Poster Hall
- ▶ 51. Antimicrobial Stewardship: Interventions to Improve Outcomes -S Poster Hall
- ▶ 52. Antimicrobial Stewardship: Special Populations -S Poster Hall
- ▶ 54. Bone and Joint Infections -S Poster Hall
- ▶ 55. CNS Infections -S Poster Hall
- ▶ 56. Fungal Disease: Management and Outcomes -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall
- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

- ▶ 59. Healthcare Epidemiology: Updates in *C. difficile* -S Poster Hall
- ▶ 60. HIV: Antiretroviral Therapy -S Poster Hall
- ▶ 61. HIV: Linkage to Care and Viral Suppression in the Care Cascade -S Poster Hall
- ▶ 62. HIV: Management and Clinical Outcomes -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 64. Microbiome and Beyond -S Poster Hall
- ▶ 65. Pathogenesis and Immune Response -S Poster Hall
- ▶ 66. Public Health: Epidemiology and Outbreaks -S Poster Hall
- ▶ 67. Resistance Mechanisms: Gram-Negative -S Poster Hall
- ▶ 68. Resistance Mechanisms: Gram-Positive -S Poster Hall
- ▶ 69. Respiratory Infections: Viral -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Interactive Sessions

- ▶ 75. Clinical Controversies -W 2005-2024
- ▶ 76. Controversies in Infection Prevention -N 24

Symposia

- ▶ 78. Bread and Butter Transplant ID -N 25
- ▶ 79. Exploring the Antibiotic Pipeline 2018 -N Hall D
- ▶ 80. Migration and Immigration: Global Diseases at Your Doorstep -W 2006-2008
- ▶ 81. New Developments on Picornaviruses -S 214-216
- ▶ 82. Novel Clinical Risks for Fungal Disease -W 2014-2016

Oral Abstract Sessions

- ▶ 84. Antimicrobial Stewardship: Better Prescribing, Better Outcomes -S 156
- ▶ 85. Preventing and Identifying New HIV Infections -S 157
- ▶ 86. Pushing the Envelope in CNS Infections -S 158
- ▶ 87. Respiratory Infections: An Update -W 2002

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

Friday, October 5

7 - 9 a.m.

Meet-the-Professor Session

- ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 100. Mid-Career Challenges and Opportunities -S 158
- ▶ 101. Tropical Dermatology: Are You Ready for Jeopardy? -W 2014-2016
- ▶ 102. Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems -W 2006-2008
- ▶ 93. Ask the Expert: Managing Invasive Fungal Infections -W 2001-2003
- ▶ 95. Controversies in Sepsis (but not SIRS) -S 206-208
- ▶ 96. Designing a QI Project You Can Publish -S 157

- ▶ 97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era -S 214-216
- ▶ 98. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs -S 151-153
- ▶ 99. Microbiome Therapeutics -S 152-154

8:45 - 10 a.m.

Interactive Sessions

- ▶ 103. "Achy Breaky Heart": Challenging Cases in Cardiovascular Infections -W 2005-2024
- ▶ 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention -W 2006-2008

Symposia

- ▶ 105. Advances in RSV Prevention -N 24
 - ▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25
 - ▶ 108. Metagenomic-Based Infectious Disease Diagnostics -S 214-216
 - ▶ 109. Pandemic Influenza -S 305-314
 - ▶ 110. Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses -W 2014-2016
 - ▶ 111. Stewardship in Challenging Populations -S 206-208
- Oral Abstract Sessions
- ▶ 112. Bacterial Infections and Antimicrobial Stewardship -S 156
 - ▶ 113. Healthcare Epidemiology: Outbreaks! -S 158
 - ▶ 114. Hepatitis C: Epidemiology and Elimination -W 2002
 - ▶ 115. HIV-Related Comorbidities and Complications -S 157

10:30 - 11:45 a.m.

Interactive Session

- ▶ 116. Challenging Cases in Infectious Diseases -N Hall D

Symposia

- ▶ 117. Big Beasts I -W 2005-2024
 - ▶ 118. How to Treat Resistant Gram-Positive Infections -N 24
 - ▶ 119. Infection Control and Antimicrobial Stewardship in Dialysis Facilities -W 2006-2008
 - ▶ 120. Late Breaker Foodborne Illnesses -S 305-314
 - ▶ 121. Pathogen Interactions with the Microbiota -S 206-208
 - ▶ 122. Strategies to Achieve HIV Remission -N 25
 - ▶ 123. Time 101: Optimizing Meetings -S 155
- Oral Abstract Sessions
- ▶ 124. Adventures with Globally Acquired Infections -S 158
 - ▶ 125. Fungal Infections -W 2002
 - ▶ 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting -S 156
 - ▶ 127. Medical Education -S 157

10:45 - 11:45 a.m.

Named Lecture

- ▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 130. Adult and Pediatric Influenza Vaccine -S Poster Hall
- ▶ 131. Bacteremia and Endocarditis -S Poster Hall
- ▶ 132. Diarrhea Diagnostic Dilemmas -S Poster Hall
- ▶ 133. Enteric Infections -S Poster Hall
- ▶ 134. Fungi and Parasites in Immunocompromised Patients -S Poster Hall
- ▶ 135. Healthcare Epidemiology: Environmental and Occupational Health -S Poster Hall
- ▶ 136. Healthcare Epidemiology: MDR-Gram-Negative Infections -S Poster Hall

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

- ▶ 137. Healthcare Epidemiology: MSSA, MRSA and Other Gram-Positive Infections -S Poster Hall
- ▶ 138. Healthcare Epidemiology: Non-acute Care Settings -S Poster Hall
- ▶ 139. Healthcare Epidemiology: Outbreaks -S Poster Hall
- ▶ 140. HIV: Diagnosis and Screening -S Poster Hall
- ▶ 141. HIV: Molecular Epidemiology -S Poster Hall
- ▶ 142. HIV: Prevention -S Poster Hall
- ▶ 143. Medical Education -S Poster Hall
- ▶ 144. Novel Agents -S Poster Hall
- ▶ 145. PK/PD Studies -S Poster Hall
- ▶ 146. Pneumococcal Vaccines -S Poster Hall
- ▶ 147. Respiratory Infections: CAP -S Poster Hall
- ▶ 148. Respiratory Infections: Miscellaneous -S Poster Hall
- ▶ 149. Sexually Transmitted Infections -S Poster Hall
- ▶ 150. Urinary Tract Infection -S Poster Hall
- ▶ 151. Viruses and Bacteria in Immunocompromised Patients -S Poster Hall

2 - 3:15 p.m.

Interactive Session

- ▶ 156. Challenging Cases in Transplant: When the ID Expert Says, "What?" -S 206-208

Symposia

- ▶ 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
- ▶ 159. Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges -W 2006-2008
- ▶ 160. Leading Change -S 155
- ▶ 162. T-Cell Biology: What the ID Physician Needs to Know -N 24
- ▶ 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024
- ▶ 164. Vaccines Against Herpesviruses -S 305-314

Oral Abstract Sessions

- ▶ 165. Antibiotic Stewardship: Developing and Implementing Effective Programs -S 156
- ▶ 166. Changing Clinical Practice for Changing Times -S 157
- ▶ 167. Late Breaker Oral Abstracts -S 152-154
- ▶ 168. Novel Therapies for Superbugs -S 158
- ▶ 169. Respiratory and Gastroenteritis Viruses -W 2002

3:30 - 3:45 p.m.

Oral Abstract Session

- ▶ 178. PIDS Featured Oral Abstract -N 25

3:30 - 4:45 p.m.

Symposia

- ▶ 170. Diagnostic Updates: Clinical Mycology Update -N 24
- ▶ 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

3:55 - 4:10 p.m.

Oral Abstract Session

- ▶ 174. SHEA Featured Oral Abstract -N Hall D

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

4:20 - 4:45 p.m.

Symposium

- ▶ 176. Influential Publications in Antimicrobial Stewardship from the Past Year -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 179. B-lactam/ B-lactamase Inhibitor Combinations: Which one? -S 214-216
- ▶ 180. Clinical Teaching for the ID Provider -S 155
- ▶ 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures -S 151-153
- ▶ 182. Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & "Aha" Moments -W 2014-2016
- ▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- ▶ 184. Dollar Dollar Bills Y'All: Billing and Coding in ID -S 158
- ▶ 185. Educating Trainees about Stewardship -W 2001-2003
- ▶ 186. Emerging Drug Resistance in STIs -S 157
- ▶ 187. NHSN Update -S 156
- ▶ 188. Rapid Fire: Curbsides in Transplant ID -S 152-154
- ▶ 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Interactive Session

- ▶ 190. Shots Across the Bow: Debates in Vaccinology -N 24

Symposia

- ▶ 191. Big Beasts II -W 2005-2024
- ▶ 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs -S 305-314
- ▶ 193. ID Physicians and Addiction Medicine -N Hall D
- ▶ 196. Non-Zika Arboviruses in the Americas -N 25
- ▶ 197. Pediatric Infection Prevention: Small Patients, Big Challenges -W 2006-2008
- ▶ 198. The Future of Transplant ID: Novel Diagnostics and Therapeutics -S 214-216

Oral Abstract Sessions

- ▶ 199. Clinical Trials that May Change Your Practice -S 158
- ▶ 200. Public Health: Epidemiology and Outbreaks -S 157
- ▶ 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment -S 156
- ▶ 202. Transplant and Immunocompromised Hosts: Emerging Issues -W 2002

10:30 - 11:45 a.m.

Interactive Session

- ▶ 203. Tropical Medicine Cases: Conundrums and Case Management -S 305-314

Symposia

- ▶ 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208
- ▶ 206. Controlling Antimicrobial Resistance Across Borders -W 2005-2024
- ▶ 207. Cool Ways to Discover Antibiotics -N 25
- ▶ 208. I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID -W 2006-2008
- ▶ 209. Infections in Immunocompromised Hosts -S 214-216
- ▶ 210. Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future -N 24

Oral Abstract Sessions

- ▶ 211. Diagnostics Making a Difference -S 158
- ▶ 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts -S 157
- ▶ 213. Late Breaker Oral Abstracts -S 152-154
- ▶ 214. Optimizing HIV Treatment -S 156
- ▶ 215. Translating Microbiome Science into Practice -W 2002

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 216. Antimicrobial Stewardship: Global Perspectives -S Poster Hall
- ▶ 217. Antimicrobial Stewardship: Impact of Allergy -S Poster Hall
- ▶ 218. Antimicrobial Stewardship: Impact of New Diagnostics -S Poster Hall
- ▶ 219. Antimicrobial Stewardship: New Methods and Metrics -S Poster Hall
- ▶ 220. Antimicrobial Stewardship: Non-hospital Settings -S Poster Hall
- ▶ 221. Antimicrobial Stewardship: Outpatient Settings -S Poster Hall
- ▶ 222. Antimicrobial Stewardship: Potpourri -S Poster Hall
- ▶ 223. Antimicrobial Stewardship: Qualitative Research -S Poster Hall
- ▶ 224. Antiviral Therapies -S Poster Hall
- ▶ 225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis -S Poster Hall
- ▶ 226. Clinical Practice Issues: OPAT -S Poster Hall
- ▶ 227. Clinical Trials -S Poster Hall
- ▶ 228. Diagnostics: Bacteria and Mycobacteria -S Poster Hall
- ▶ 229. Diagnostics: Biomarkers and Novel Approaches -S Poster Hall
- ▶ 230. Diagnostics: Mycology -S Poster Hall
- ▶ 231. Diagnostics: Parasitology -S Poster Hall
- ▶ 232. Diagnostics: Resistance Testing -S Poster Hall
- ▶ 233. Diagnostics: Virology -S Poster Hall
- ▶ 234. Healthcare Epidemiology: Device-associated HAIs -S Poster Hall
- ▶ 235. Healthcare Epidemiology: Surgical Site Infections -S Poster Hall
- ▶ 236. Healthcare Epidemiology: Epidemiologic Methods -S Poster Hall
- ▶ 237. Healthcare Epidemiology: HAI Surveillance -S Poster Hall
- ▶ 238. Hepatitis A, B, and C -S Poster Hall
- ▶ 239. HIV and Viral Hepatitis Co-Infection -S Poster Hall
- ▶ 240. HIV: Malignancy -S Poster Hall
- ▶ 241. HIV: Metabolic, Cardiovascular, and Renal Complications -S Poster Hall
- ▶ 242. HIV: Opportunistic Infections and other Infectious Complications -S Poster Hall
- ▶ 243. HIV: Sexually Transmitted Infections -S Poster Hall
- ▶ 244. Miscellaneous Vaccines -S Poster Hall
- ▶ 245. Molecular & Sequence Based Diagnostics -S Poster Hall
- ▶ 249. Skin and Skin Structure Infection -S Poster Hall
- ▶ 250. Treatment of AMR Infections -S Poster Hall
- ▶ 251. Adolescent Vaccines -S Poster Hall
- ▶ 252. Vaccine Policy and Hesitancy -S Poster Hall
- ▶ 253. Vaccines for Herpes Zoster Virus -S Poster Hall
- ▶ 254. Vaccines for the Elderly and Immune Compromised -S Poster Hall
- ▶ 255. Virology Potpourri -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 260. Advances in Epidemiology Research Methods -N 24
 - ▶ 261. Infection Prevention in Post-Acute Care: Controversies and Challenges -S 206-208
 - ▶ 265. Strategy Trials: A New Paradigm in Infectious Diseases Research -W 2005-2024
 - ▶ 266. Syphilis in the 21st Century -N Hall D
 - ▶ 267. When Does PK/PD Matter for Patient Care? -S 305-314
 - ▶ 268. When Transplant Tours the World -N 25
- Oral Abstract Sessions
- ▶ 269. Flu and other Vaccines in Children -W 2002
 - ▶ 270. Genomics and Susceptibility of Superbugs -S 157
 - ▶ 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection -S 158

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposia

- ▶ 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics -W 2001-2003
- ▶ 280. Tele-Antimicrobial Stewardship -W 2014-2016

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Tuesday, October 2

8 a.m. - 5 p.m.

Pre-meeting Workshop

- ▶ PW02. Best Practices for Antimicrobial Stewardship Programs (\$) -W 2009-2024

Wednesday, October 3

8 a.m. - 12 p.m.

Pre-meeting Workshops

- ▶ PW06. TB Workshop (\$) -W 2001-2003
- ▶ PW08. A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship (\$) -S 152-154
- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

1:30 - 3:15 p.m.

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
- ▶ 7. What's Hot in ID + HIV -N Hall D

Interactive Session

- ▶ 5. Stewardship: Best Drivers of Change Debate -N 24

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 11. Are You Ready? Outbreak Response Training -S 152-154
- ▶ 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
- ▶ 13. Emerging Issues in the Diagnosis of STIs -S 214-216
- ▶ 14. How to Build Allergy Testing into Your Stewardship Program -S 157

7:15 - 8:30 a.m.

Meet-the-Professor Session

- ▶ 92. Antimicrobial and Diagnostic Stewardship -S 206-208

8:45 - 10 a.m.

Interactive Session

- ▶ 22. Case-Based Problems in Vaccines: Beyond the Guidelines -N 25

Symposia

- ▶ 25. Combating Antimicrobial Resistance: Relevance of the One Health Concept -W 2006-2008
- ▶ 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216
- ▶ 29. What Are You Talking About? Communication Strategies for Stewardship Programs -N 24

Oral Abstract Session

- ▶ 30. Healthcare Epidemiology: Hot Topics -S 157

10:30 - 11:45 a.m.

Interactive Session

- ▶ 34. Diagnostic Clinical Cases -W 2005-2024

Symposia

- ▶ 36. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship -N 24
- ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
- ▶ 39. Hot Topics in Pediatric Infectious Diseases -W 2001-2003
- ▶ 40. Improving Healthcare-Associated Infection Metrics -W 2006-2008
- ▶ 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208
- ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

Oral Abstract Session

- ▶ 46. Healthcare Epidemiology: Special Populations -S 156

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 49. Antimicrobial Stewardship: Interventions in Pediatric Populations -S Poster Hall
- ▶ 50. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record -S Poster Hall
- ▶ 51. Antimicrobial Stewardship: Interventions to Improve Outcomes -S Poster Hall
- ▶ 53. Pediatric Antimicrobial and Diagnostic Stewardship -S Poster Hall
- ▶ 56. Fungal Disease: Management and Outcomes -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall
- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 59. Healthcare Epidemiology: Updates in *C. difficile* -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 69. Respiratory Infections: Viral -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Interactive Sessions

- ▶ 75. Clinical Controversies -W 2005-2024
- ▶ 76. Controversies in Infection Prevention -N 24
- ▶ 77. "Mano-a-Mano III": Controversies in Pediatric ID -S 206-208

Symposium

- ▶ 82. Novel Clinical Risks for Fungal Disease -W 2014-2016

Oral Abstract Session

- ▶ 84. Antimicrobial Stewardship: Better Prescribing, Better Outcomes -S 156

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

W = West Hall N = North Hall S = South Hall

IDWeek 2018 Program Tracks (continued)

Friday, October 5

7 - 9 a.m.

- Meet-the-Professor Session
 ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

- Meet-the-Professor Sessions
 ▶ 100. Mid-Career Challenges and Opportunities -S 158
 ▶ 102. Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems -W 2006-2008
 ▶ 96. Designing a QI Project You Can Publish -S 157
 ▶ 98. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs -S 151-153

8:45 - 10 a.m.

- Interactive Session
 ▶ 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention -W 2006-2008

Symposia

- ▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25
 ▶ 109. Pandemic Influenza -S 305-314
 ▶ 111. Stewardship in Challenging Populations -S 206-208

Oral Abstract Sessions

- ▶ 112. Bacterial Infections and Antimicrobial Stewardship -S 156
 ▶ 113. Healthcare Epidemiology: Outbreaks! -S 158
 ▶ 114. Hepatitis C: Epidemiology and Elimination -W 2002
 ▶ 115. HIV-Related Comorbidities and Complications -S 157

10:30 - 11:45 a.m.

Symposia

- ▶ 119. Infection Control and Antimicrobial Stewardship in Dialysis Facilities -W 2006-2008
 ▶ 120. Late Breaker Foodborne Illnesses -S 305-314
 ▶ 123. Time 101: Optimizing Meetings -S 155

Oral Abstract Sessions

- ▶ 124. Adventures with Globally Acquired Infections -S 158
 ▶ 125. Fungal Infections -W 2002
 ▶ 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting -S 156

10:45 - 11:45 a.m.

Named Lecture

- ▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 132. Diarrhea Diagnostic Dilemmas -S Poster Hall
 ▶ 133. Enteric Infections -S Poster Hall
 ▶ 135. Healthcare Epidemiology: Environmental and Occupational Health -S Poster Hall
 ▶ 136. Healthcare Epidemiology: MDR-Gram-Negative Infections -S Poster Hall
 ▶ 137. Healthcare Epidemiology: MSSA, MRSA and Other Gram-Positive Infections -S Poster Hall
 ▶ 138. Healthcare Epidemiology: Non-acute Care Settings -S Poster Hall

- ▶ 139. Healthcare Epidemiology: Outbreaks -S Poster Hall
 ▶ 140. HIV: Diagnosis and Screening -S Poster Hall
 ▶ 141. HIV: Molecular Epidemiology -S Poster Hall
 ▶ 142. HIV: Prevention -S Poster Hall
 ▶ 143. Medical Education -S Poster Hall
 ▶ 145. PK/PD Studies -S Poster Hall
 ▶ 146. Pneumococcal Vaccines -S Poster Hall
 ▶ 147. Respiratory Infections: CAP -S Poster Hall
 ▶ 148. Respiratory Infections: Miscellaneous -S Poster Hall
 ▶ 150. Urinary Tract Infection -S Poster Hall
 ▶ 151. Viruses and Bacteria in Immunocompromised Patients -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
 ▶ 159. Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges -W 2006-2008
 ▶ 160. Leading Change -S 155
 ▶ 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024

Oral Abstract Sessions

- ▶ 167. Late Breaker Oral Abstracts -S 152-154
 ▶ 168. Novel Therapies for Superbugs -S 158
 ▶ 169. Respiratory and Gastroenteritis Viruses -W 2002

3:30 - 3:45 p.m.

Oral Abstract Session

- ▶ 178. PIDS Featured Oral Abstract -N 25

3:30 - 3:55 p.m.

Named Lecture

- ▶ 173. SHEA Lecture: A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology -N Hall D

3:30 - 4:45 p.m.

Symposia

- ▶ 170. Diagnostic Updates: Clinical Mycology Update -N 24
 ▶ 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

3:55 - 4:10 p.m.

Oral Abstract Session

- ▶ 174. SHEA Featured Oral Abstract -N Hall D

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

4:20 - 4:45 p.m.

Symposium

- ▶ 176. Influential Publications in Antimicrobial Stewardship from the Past Year -N Hall D

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 182. Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & “Aha” Moments -W 2014-2016
- ▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- ▶ 185. Educating Trainees about Stewardship -W 2001-2003
- ▶ 187. NHSN Update -S 156
- ▶ 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Symposia

- ▶ 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs -S 305-314
- ▶ 193. ID Physicians and Addiction Medicine -N Hall D
- ▶ 197. Pediatric Infection Prevention: Small Patients, Big Challenges -W 2006-2008

Oral Abstract Sessions

- ▶ 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment -S 156
- ▶ 202. Transplant and Immunocompromised Hosts: Emerging Issues -W 2002

10:30 - 11:45 a.m.

Symposia

- ▶ 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208
- ▶ 206. Controlling Antimicrobial Resistance Across Borders -W 2005-2024
- ▶ 208. I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID -W 2006-2008

Oral Abstract Sessions

- ▶ 211. Diagnostics Making a Difference -S 158
- ▶ 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts -S 157
- ▶ 213. Late Breaker Oral Abstracts -S 152-154

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 216. Antimicrobial Stewardship: Global Perspectives -S Poster Hall
- ▶ 218. Antimicrobial Stewardship: Impact of New Diagnostics -S Poster Hall
- ▶ 222. Antimicrobial Stewardship: Potpourri -S Poster Hall
- ▶ 224. Antiviral Therapies -S Poster Hall
- ▶ 229. Diagnostics: Biomarkers and Novel Approaches -S Poster Hall
- ▶ 230. Diagnostics: Mycology -S Poster Hall
- ▶ 232. Diagnostics: Resistance Testing -S Poster Hall
- ▶ 233. Diagnostics: Virology -S Poster Hall
- ▶ 234. Healthcare Epidemiology: Device-associated HAIs -S Poster Hall
- ▶ 235. Healthcare Epidemiology: Surgical Site Infections -S Poster Hall
- ▶ 236. Healthcare Epidemiology: Epidemiologic Methods -S Poster Hall

- ▶ 237. Healthcare Epidemiology: HAI Surveillance -S Poster Hall
- ▶ 238. Hepatitis A, B, and C -S Poster Hall
- ▶ 242. HIV: Opportunistic Infections and other Infectious Complications -S Poster Hall
- ▶ 243. HIV: Sexually Transmitted Infections -S Poster Hall
- ▶ 245. Molecular & Sequence Based Diagnostics -S Poster Hall
- ▶ 246. Pediatric Healthcare Associated Infections -S Poster Hall
- ▶ 247. Pediatric Bacterial Infections -S Poster Hall
- ▶ 248. Pediatric Viral Infections -S Poster Hall
- ▶ 249. Skin and Skin Structure Infection -S Poster Hall
- ▶ 250. Treatment of AMR Infections -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 260. Advances in Epidemiology Research Methods -N 24
- ▶ 261. Infection Prevention in Post-Acute Care: Controversies and Challenges -S 206-208
- ▶ 265. Strategy Trials: A New Paradigm in Infectious Diseases Research -W 2005-2024

Oral Abstract Sessions

- ▶ 269. Flu and other Vaccines in Children -W 2002
- ▶ 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection -S 158

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposia

- ▶ 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics -W 2001-2003
- ▶ 279. Red Book Update -W 2006-2008
- ▶ 280. Tele-Antimicrobial Stewardship -W 2014-2016

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Wednesday, October 3

8 a.m. - 12 p.m.

Pre-meeting Workshops

- ▶ PW06. TB Workshop (\$) -W 2001-2003
- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

1:30 - 3:15 p.m.

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 7. What's Hot in ID + HIV -N Hall D

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
- ▶ 13. Emerging Issues in the Diagnosis of STIs -S 214-216

8:45 - 10 a.m.

Interactive Session

- ▶ 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D

Symposia

- ▶ 24. Can You Hear and See Me Now? ID Telehealth -S 206-208
- ▶ 25. Combating Antimicrobial Resistance: Relevance of the One Health Concept -W 2006-2008

Oral Abstract Session

- ▶ 32. Tuberculosis and other Mycobacterial Infections -W 2002

10:30 - 11:45 a.m.

Interactive Session

- ▶ 34. Diagnostic Clinical Cases -W 2005-2024

Symposia

- ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
- ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 53. Pediatric Antimicrobial and Diagnostic Stewardship -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall
- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 79. Exploring the Antibiotic Pipeline 2018 -N Hall D
- ▶ 80. Migration and Immigration: Global Diseases at Your Doorstep -W 2006-2008
- ▶ 81. New Developments on Picornaviruses -S 214-216

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

Friday, October 5

7 - 9 a.m.

Meet-the-Professor Session

- ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 100. Mid-Career Challenges and Opportunities -S 158
- ▶ 101. Tropical Dermatology: Are You Ready for Jeopardy? -W 2014-2016
- ▶ 97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era -S 214-216

8:45 - 10 a.m.

Symposia

- ▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25
- ▶ 109. Pandemic Influenza -S 305-314

10:30 - 11:45 a.m.

Symposia

- ▶ 118. How to Treat Resistant Gram-Positive Infections -N 24
 - ▶ 120. Late Breaker Foodborne Illnesses -S 305-314
 - ▶ 123. Time 101: Optimizing Meetings -S 155
- Oral Abstract Session
- ▶ 124. Adventures with Globally Acquired Infections -S 158

10:45 - 11:45 a.m.

Named Lecture

- ▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 136. Healthcare Epidemiology: MDR-Gram-Negative Infections -S Poster Hall
- ▶ 143. Medical Education -S Poster Hall
- ▶ 148. Respiratory Infections: Miscellaneous -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 160. Leading Change -S 155
 - ▶ 161. Pediatric Immunization: Perspectives From Both Sides of the Pond -S 214-216
 - ▶ 164. Vaccines Against Herpesviruses -S 305-314
- Oral Abstract Session
- ▶ 167. Late Breaker Oral Abstracts -S 152-154

3:30 - 3:45 p.m.

Oral Abstract Session

- ▶ 178. PIDS Featured Oral Abstract -N 25

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

3:30 - 4:45 p.m.

Symposia

- ▶ 170. Diagnostic Updates: Clinical Mycology Update -N 24
- ▶ 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures -S 151-153
- ▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- ▶ 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Symposia

- ▶ 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs -S 305-314
- ▶ 196. Non-Zika Arboviruses in the Americas -N 25

10:30 - 11:45 a.m.

Interactive Session

- ▶ 203. Tropical Medicine Cases: Conundrums and Case Management -S 305-314

Symposia

- ▶ 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208
- ▶ 206. Controlling Antimicrobial Resistance Across Borders -W 2005-2024
- ▶ 210. Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future -N 24

Oral Abstract Session

- ▶ 213. Late Breaker Oral Abstracts -S 152-154

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 216. Antimicrobial Stewardship: Global Perspectives -S Poster Hall
- ▶ 238. Hepatitis A, B, and C -S Poster Hall
- ▶ 246. Pediatric Healthcare Associated Infections -S Poster Hall
- ▶ 247. Pediatric Bacterial Infections -S Poster Hall
- ▶ 248. Pediatric Viral Infections -S Poster Hall

2 - 3:15 p.m.

Symposium

- ▶ 268. When Transplant Tours the World -N 25

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposium

- ▶ 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics -W 2001-2003

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

W = West Hall N = North Hall S = South Hall

IDWeek 2018 Program Tracks (continued)

Tuesday, October 2

8 a.m. - 5 p.m.

Pre-meeting Workshop

- ▶ PW01. The Vincent T. Andriole ID Board Review Course (\$) -W 2005-2020

1 - 5:30 p.m.

- ▶ PW11. Medication Assisted Treatment Waiver Course (\$) -W 2014-2016

Wednesday, October 3

8 a.m. - 12 p.m.

Pre-meeting Workshops

- ▶ PW06. TB Workshop (\$) -W 2001-2003
- ▶ PW07. Hepatitis C Workshop (\$) -S 156
- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

1:30 - 3:15 p.m.

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 7. What's Hot in ID + HIV -N Hall D

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 13. Emerging Issues in the Diagnosis of STIs -S 214-216
- ▶ 16. Our Most Difficult HIV Cases (other than STIs) -S 156

8:45 - 10 a.m.

Symposium

- ▶ 28. Still at Highest Risk: Innovative Approaches & Urgent Needs for Prevention and Care -S 305-314

10:30 - 11:45 a.m.

Interactive Sessions

- ▶ 34. Diagnostic Clinical Cases -W 2005-2024
- ▶ 35. STIs in the HIV Care Setting -N Hall D

Symposia

- ▶ 37. Hepatitis B: Current and Future Challenges in Treatment and Prevention -N 25
- ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
- ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 56. Fungal Disease: Management and Outcomes -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall
- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 60. HIV: Antiretroviral Therapy -S Poster Hall

- ▶ 61. HIV: Linkage to Care and Viral Suppression in the Care Cascade -S Poster Hall
- ▶ 62. HIV: Management and Clinical Outcomes -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Symposium

- ▶ 83. The Human Microbiome in HIV -S 305-314
- Oral Abstract Session
- ▶ 85. Preventing and Identifying New HIV Infections -S 157

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

Friday, October 5

7 - 9 a.m.

Meet-the-Professor Session

- ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 100. Mid-Career Challenges and Opportunities -S 158
- ▶ 94. Challenging STIs in the HIV Infected Patient -S 156
- ▶ 97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era -S 214-216

8:45 - 10 a.m.

Symposium

- ▶ 107. HIV State of the Art -N Hall D

10:30 - 11:45 a.m.

Symposia

- ▶ 120. Late Breaker Foodborne Illnesses -S 305-314
- ▶ 122. Strategies to Achieve HIV Remission -N 25
- ▶ 123. Time 101: Optimizing Meetings -S 155

Oral Abstract Sessions

- ▶ 124. Adventures with Globally Acquired Infections -S 158
- ▶ 125. Fungal Infections -W 2002

10:45 - 11:45 a.m.

Named Lecture

- ▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 140. HIV: Diagnosis and Screening -S Poster Hall
- ▶ 141. HIV: Molecular Epidemiology -S Poster Hall
- ▶ 142. HIV: Prevention -S Poster Hall
- ▶ 143. Medical Education -S Poster Hall
- ▶ 149. Sexually Transmitted Infections -S Poster Hall

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

2 - 3:15 p.m.

Interactive Session

- ▶ 157. Challenging HIV Cases -N Hall D

Symposia

- ▶ 159. Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges -W 2006-2008
- ▶ 160. Leading Change -S 155
- ▶ 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024

Oral Abstract Session

- ▶ 167. Late Breaker Oral Abstracts -S 152-154

3:30 - 4:45 p.m.

Symposium

- ▶ 170. Diagnostic Updates: Clinical Mycology Update -N 24

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 180. Clinical Teaching for the ID Provider -S 155
- ▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- ▶ 186. Emerging Drug Resistance in STIs -S 157

8:45 - 10 a.m.

Symposium

- ▶ 194. Malignancies in Patients with HIV -S 206-208

10:30 - 11:45 a.m.

Symposia

- ▶ 204. Advances in Transplantation for Patients with HIV -W 2014-2016
- ▶ 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208

Oral Abstract Session

- ▶ 213. Late Breaker Oral Abstracts -S 152-154
- ▶ 214. Optimizing HIV Treatment -S 156

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis -S Poster Hall
- ▶ 238. Hepatitis A, B, and C -S Poster Hall
- ▶ 239. HIV and Viral Hepatitis Co-Infection -S Poster Hall
- ▶ 240. HIV: Malignancy -S Poster Hall
- ▶ 241. HIV: Metabolic, Cardiovascular, and Renal Complications -S Poster Hall
- ▶ 242. HIV: Opportunistic Infections and other Infectious Complications -S Poster Hall
- ▶ 243. HIV: Sexually Transmitted Infections -S Poster Hall
- ▶ 248. Pediatric Viral Infections -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 264. Pain Management and Mental Health in Patients with HIV -W 2014-2016

- ▶ 266. Syphilis in the 21st Century -N Hall D

Oral Abstract Session

- ▶ 269. Flu and other Vaccines in Children -W 2002

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposium

- ▶ 279. Red Book Update -W 2006-2008

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Wednesday, October 3

8 a.m. - 12 p.m.

Pre-meeting Workshop

- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

1:30 - 3:15 p.m.

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
- ▶ 6. Update on Biofilm-Related Infections -W 2014-2016
- ▶ 7. What's Hot in ID + HIV -N Hall D

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Session

- ▶ 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153

7:15 - 8:30 a.m.

Meet-the-Professor Session

- ▶ 92. Antimicrobial and Diagnostic Stewardship -S 206-208

8:45 - 10 a.m.

Oral Abstract Sessions

- ▶ 30. Healthcare Epidemiology: Hot Topics -S 157
- ▶ 31. Infant Viral Infections -S 156

10:30 - 11:45 a.m.

Symposia

- ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
- ▶ 39. Hot Topics in Pediatric Infectious Diseases -W 2001-2003
- ▶ 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208
- ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

Oral Abstract Session

- ▶ 46. Healthcare Epidemiology: Special Populations -S 156
- ▶ 47. Science Relevant to ID -S 157

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 49. Antimicrobial Stewardship: Interventions in Pediatric Populations -S Poster Hall
- ▶ 50. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record -S Poster Hall
- ▶ 51. Antimicrobial Stewardship: Interventions to Improve Outcomes -S Poster Hall
- ▶ 52. Antimicrobial Stewardship: Special Populations -S Poster Hall
- ▶ 53. Pediatric Antimicrobial and Diagnostic Stewardship -S Poster Hall
- ▶ 56. Fungal Disease: Management and Outcomes -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall

- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 59. Healthcare Epidemiology: Updates in *C. difficile* -S Poster Hall
- ▶ 61. HIV: Linkage to Care and Viral Suppression in the Care Cascade -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 64. Microbiome and Beyond -S Poster Hall
- ▶ 65. Pathogenesis and Immune Response -S Poster Hall
- ▶ 66. Public Health: Epidemiology and Outbreaks -S Poster Hall
- ▶ 67. Resistance Mechanisms: Gram-Negative -S Poster Hall
- ▶ 68. Resistance Mechanisms: Gram-Positive -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 79. Exploring the Antibiotic Pipeline 2018 -N Hall D
- ▶ 82. Novel Clinical Risks for Fungal Disease -W 2014-2016

Oral Abstract Sessions

- ▶ 84. Antimicrobial Stewardship: Better Prescribing, Better Outcomes -S 156
- ▶ 86. Pushing the Envelope in CNS Infections -S 158
- ▶ 87. Respiratory Infections: An Update -W 2002

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

Friday, October 5

7 - 9 a.m.

Meet-the-Professor Session

- ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 100. Mid-Career Challenges and Opportunities -S 158
- ▶ 102. Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems -W 2006-2008
- ▶ 93. Ask the Expert: Managing Invasive Fungal Infections -W 2001-2003

8:45 - 10 a.m.

Interactive Session

- ▶ 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention -W 2006-2008

Symposia

- ▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25
- ▶ 110. Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses -W 2014-2016

Oral Abstract Session

- ▶ 114. Hepatitis C: Epidemiology and Elimination -W 2002
- ▶ 115. HIV-Related Comorbidities and Complications -S 157

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

10:30 - 11:45 a.m.

Symposia

- 118. How to Treat Resistant Gram-Positive Infections -N 24
- 120. Late Breaker Foodborne Illnesses -S 305-314
- 121. Pathogen Interactions with the Microbiota -S 206-208
- 123. Time 101: Optimizing Meetings -S 155

Oral Abstract Sessions

- 124. Adventures with Globally Acquired Infections -S 158
- 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting -S 156

10:45 - 11:45 a.m.

Named Lecture

- 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- 131. Bacteremia and Endocarditis -S Poster Hall
- 137. Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections -S Poster Hall
- 138. Healthcare Epidemiology: Non-acute Care Settings -S Poster Hall
- 139. Healthcare Epidemiology: Outbreaks -S Poster Hall
- 141. HIV: Molecular Epidemiology -S Poster Hall
- 142. HIV: Prevention -S Poster Hall
- 143. Medical Education -S Poster Hall
- 144. Novel Agents -S Poster Hall
- 145. PK/PD Studies -S Poster Hall
- 146. Pneumococcal Vaccines -S Poster Hall
- 147. Respiratory Infections: CAP -S Poster Hall
- 150. Urinary Tract Infection -S Poster Hall
- 151. Viruses and Bacteria in Immunocompromised Patients -S Poster Hall

2 - 3:15 p.m.

Symposia

- 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
- 160. Leading Change -S 155
- 162. T-Cell Biology: What the ID Physician Needs to Know -N 24

Oral Abstract Sessions

- 165. Antibiotic Stewardship: Developing and Implementing Effective Programs -S 156
- 167. Late Breaker Oral Abstracts -S 152-154
- 168. Novel Therapies for Superbugs -S 158
- 169. Respiratory and Gastroenteritis Viruses -W 2002

3:30 - 3:45 p.m.

Oral Abstract Session

- 178. PIDS Featured Oral Abstract -N 25

3:45 - 4:45 p.m.

Named Lecture

- 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.

Awards Session

- 175. Awards Session -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Session

- 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Oral Abstract Sessions

- 199. Clinical Trials that May Change Your Practice -S 158
- 200. Public Health: Epidemiology and Outbreaks -S 157

10:30 - 11:45 a.m.

Symposium

- 207. Cool Ways to Discover Antibiotics -N 25

Oral Abstract Sessions

- 211. Diagnostics Making a Difference -S 158
- 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts -S 157
- 213. Late Breaker Oral Abstracts -S 152-154
- 215. Translating Microbiome Science into Practice -W 2002

12:30 - 1:45 p.m.

Poster Abstract Sessions

- 216. Antimicrobial Stewardship: Global Perspectives -S Poster Hall
- 217. Antimicrobial Stewardship: Impact of Allergy -S Poster Hall
- 218. Antimicrobial Stewardship: Impact of New Diagnostics -S Poster Hall
- 219. Antimicrobial Stewardship: New Methods and Metrics -S Poster Hall
- 220. Antimicrobial Stewardship: Non-hospital Settings -S Poster Hall
- 221. Antimicrobial Stewardship: Outpatient Settings -S Poster Hall
- 222. Antimicrobial Stewardship: Potpourri -S Poster Hall
- 223. Antimicrobial Stewardship: Qualitative Research -S Poster Hall
- 224. Antiviral Therapies -S Poster Hall
- 227. Clinical Trials -S Poster Hall
- 229. Diagnostics: Biomarkers and Novel Approaches -S Poster Hall
- 235. Healthcare Epidemiology: Surgical Site Infections -S Poster Hall
- 236. Healthcare Epidemiology: Epidemiologic Methods -S Poster Hall
- 237. Healthcare Epidemiology: HAI Surveillance -S Poster Hall
- 238. Hepatitis A, B, and C -S Poster Hall
- 244. Miscellaneous Vaccines -S Poster Hall
- 245. Molecular & Sequence Based Diagnostics -S Poster Hall
- 246. Pediatric Healthcare Associated Infections -S Poster Hall
- 247. Pediatric Bacterial Infections -S Poster Hall
- 248. Pediatric Viral Infections -S Poster Hall
- 254. Vaccines for the Elderly and Immune Compromised -S Poster Hall
- 255. Virology Potpourri -S Poster Hall

W = West Hall N = North Hall S = South Hall

IDWeek 2018 Program Tracks (continued)

2 - 3:15 p.m.

Symposia

- ▶ 260. Advances in Epidemiology Research Methods -N 24
 - ▶ 265. Strategy Trials: A New Paradigm in Infectious Diseases Research -W 2005-2024
 - ▶ 266. Syphilis in the 21st Century -N Hall D
 - ▶ 267. When Does PK/PD Matter for Patient Care? -S 305-314
- Oral Abstract Sessions
- ▶ 269. Flu and other Vaccines in Children -W 2002
 - ▶ 270. Genomics and Susceptibility of Superbugs -S 157
 - ▶ 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection -S 158

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

IDWeek 2018 Program Tracks (continued)

Tuesday, October 2

8 a.m. - 5 p.m.

Pre-meeting Workshop I

- ▶ PW02. Best Practices for Antimicrobial Stewardship Programs (\$) -W 2009-2024

Wednesday, October 3

7:45 a.m. - 12 p.m.

Pre-meeting Workshops

- ▶ PW05. Pediatric Fellows' Day (\$) -W 2002

8 a.m.-12 p.m.

Pre-meeting Workshops

- ▶ PW06. TB Workshop (\$) -W 2001-2003
- ▶ PW07. Hepatitis C Workshop (\$) -S 156
- ▶ PW08. A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship (\$) -S 152-154
- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

8 a.m.-12:30 p.m.

Pre-meeting Workshop

- ▶ PW10. Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: General ID (\$) -S 158

1:30 - 3:15 p.m.

Interactive Session

- ▶ 1. Challenging Cases in Pediatric Infectious Diseases -W 2005-2024

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
- ▶ 4. RCT That Will Change Your Practice -N 25
- ▶ 6. Update on Biofilm-Related Infections -W 2014-2016
- ▶ 7. What's Hot in ID + HIV -N Hall D

Interactive Session

- ▶ 5. Stewardship: Best Drivers of Change Debate -N 24

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space) -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 11. Are You Ready? Outbreak Response Training -S 152-154
- ▶ 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
- ▶ 13. Emerging Issues in the Diagnosis of STIs -S 214-216
- ▶ 14. How to Build Allergy Testing into Your Stewardship Program -S 157
- ▶ 15. NTM Infections: Challenges in Diagnosis and Management -W 2001-2003
- ▶ 17. Questions in Bacteremia -W 2006-2008
- ▶ 18. Respiratory Infections in Pregnant Women -S 158

- ▶ 19. Shall We Agree to Disagree: Management of Pediatric Acute Hematogenous Osteomyelitis -W 2014-2016

- ▶ 20. Women in ID -S 155

8:45 - 10 a.m.

Interactive Sessions

- ▶ 21. "Brain on Fire": Challenging Cases in Infectious and Inflammatory Encephalitis -W 2005-2024
- ▶ 22. Case-Based Problems in Vaccines: Beyond the Guidelines -N 25
- ▶ 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D

Symposia

- ▶ 24. Can You Hear and See Me Now? ID Telehealth -S 206-208
- ▶ 25. Combating Antimicrobial Resistance: Relevance of the One Health Concept -W 2006-2008
- ▶ 26. Just Your Average Day in a Pediatric Infectious Disease Clinic -W 2014-2016
- ▶ 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216
- ▶ 29. What Are You Talking About? Communication Strategies for Stewardship Programs -N 24

Oral Abstract Sessions

- ▶ 30. Healthcare Epidemiology: Hot Topics -S 157
- ▶ 31. Infant Viral Infections -S 156

10:30 - 11:45 a.m.

Interactive Session

- ▶ 34. Diagnostic Clinical Cases -W 2005-2024

Symposia

- ▶ 36. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship -N 24
- ▶ 37. Hepatitis B: Current and Future Challenges in Treatment and Prevention -N 25
- ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
- ▶ 39. Hot Topics in Pediatric Infectious Diseases -W 2001-2003
- ▶ 40. Improving Healthcare-Associated Infection Metrics -W 2006-2008
- ▶ 41. New and Updated Guidelines -S 305-314
- ▶ 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208
- ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

Oral Abstract Sessions

- ▶ 44. Adult and Adolescent Vaccines -S 158
- ▶ 46. Healthcare Epidemiology: Special Populations -S 156

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 49. Antimicrobial Stewardship: Interventions in Pediatric Populations -S Poster Hall
- ▶ 50. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record -S Poster Hall
- ▶ 51. Antimicrobial Stewardship: Interventions to Improve Outcomes -S Poster Hall
- ▶ 52. Antimicrobial Stewardship: Special Populations -S Poster Hall
- ▶ 53. Pediatric Antimicrobial and Diagnostic Stewardship -S Poster Hall
- ▶ 54. Bone and Joint Infections -S Poster Hall
- ▶ 55. CNS Infections -S Poster Hall
- ▶ 56. Fungal Disease: Management and Outcomes -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 59. Healthcare Epidemiology: Updates in *C. difficile* -S Poster Hall
- ▶ 60. HIV: Antiretroviral Therapy -S Poster Hall
- ▶ 61. HIV: Linkage to Care and Viral Suppression in the Care Cascade -S Poster Hall
- ▶ 62. HIV: Management and Clinical Outcomes -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 66. Public Health: Epidemiology and Outbreaks -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Interactive Sessions

- ▶ 75. Clinical Controversies -W 2005-2024
- ▶ 76. Controversies in Infection Prevention -N 24
- ▶ 77. "Mano-a-Mano III": Controversies in Pediatric ID -S 206-208

Symposia

- ▶ 78. Bread and Butter Transplant ID -N 25
- ▶ 79. Exploring the Antibiotic Pipeline 2018 -N Hall D
- ▶ 80. Migration and Immigration: Global Diseases at Your Doorstep -W 2006-2008
- ▶ 81. New Developments on Picornaviruses -S 214-216
- ▶ 82. Novel Clinical Risks for Fungal Disease -W 2014-2016
- ▶ 83. The Human Microbiome in HIV -S 305-314

Oral Abstract Sessions

- ▶ 84. Antimicrobial Stewardship: Better Prescribing, Better Outcomes -S 156
- ▶ 86. Pushing the Envelope in CNS Infections -S 158
- ▶ 87. Respiratory Infections: An Update -W 2002

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

Friday, October 5

7 - 9 a.m.

Meet-the-Professor Session

- ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 100. Mid-Career Challenges and Opportunities -S 158
- ▶ 101. Tropical Dermatology: Are You Ready for Jeopardy? -W 2014-2016
- ▶ 93. Ask the Expert: Managing Invasive Fungal Infections -W 2001-2003
- ▶ 95. Controversies in Sepsis (but not SIRS) -S 206-208
- ▶ 96. Designing a QI Project You Can Publish -S 157
- ▶ 97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era -S 214-216
- ▶ 98. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs -S 151-153
- ▶ 99. Microbiome Therapeutics -S 152-154

8:45 - 10 a.m.

Interactive Sessions

- ▶ 103. "Achy Breaky Heart": Challenging Cases in Cardiovascular Infections -W 2005-2024
- ▶ 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention -W 2006-2008

Symposia

- ▶ 105. Advances in RSV Prevention -N 24
- ▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25
- ▶ 107. HIV State of the Art -N Hall D
- ▶ 108. Metagenomic-Based Infectious Disease Diagnostics -S 214-216
- ▶ 109. Pandemic Influenza -S 305-314
- ▶ 110. Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses -W 2014-2016
- ▶ 111. Stewardship in Challenging Populations -S 206-208

Oral Abstract Sessions

- ▶ 112. Bacterial Infections and Antimicrobial Stewardship -S 156
- ▶ 113. Healthcare Epidemiology: Outbreaks! -S 158
- ▶ 114. Hepatitis C: Epidemiology and Elimination -W 2002

10:30 - 10:45 a.m.

Oral Abstract Session

- ▶ 128. PIDS Featured Oral Abstract Caroline B. Hall Lectureship -S 214-216

10:30 - 11:45 a.m.

Interactive Session

- ▶ 116. Challenging Cases in Infectious Diseases -N Hall D

Symposia

- ▶ 118. How to Treat Resistant Gram-Positive Infections -N 24
- ▶ 120. Late Breaker Foodborne Illnesses -S 305-314
- ▶ 121. Pathogen Interactions with the Microbiota -S 206-208
- ▶ 122. Strategies to Achieve HIV Remission -N 25
- ▶ 123. Time 101: Optimizing Meetings -S 155

Oral Abstract Sessions

- ▶ 124. Adventures with Globally Acquired Infections -S 158
- ▶ 125. Fungal Infections -W 2002
- ▶ 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting -S 156

10:45 - 11:45 a.m.

Named Lecture

- ▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 130. Adult and Pediatric Influenza Vaccine -S Poster Hall
- ▶ 131. Bacteremia and Endocarditis -S Poster Hall
- ▶ 132. Diarrhea Diagnostic Dilemmas -S Poster Hall
- ▶ 133. Enteric Infections -S Poster Hall
- ▶ 134. Fungi and Parasites in Immunocompromised Patients -S Poster Hall
- ▶ 135. Healthcare Epidemiology: Environmental and Occupational Health -S Poster Hall
- ▶ 136. Healthcare Epidemiology: MDR-Gram-Negative Infections -S Poster Hall
- ▶ 137. Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections -S Poster Hall
- ▶ 138. Healthcare Epidemiology: Non-acute Care Settings -S Poster Hall
- ▶ 139. Healthcare Epidemiology: Outbreaks! -S Poster Hall
- ▶ 140. HIV: Diagnosis and Screening -S Poster Hall

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

- ▶ 141. HIV: Molecular Epidemiology -S Poster Hall
- ▶ 142. HIV: Prevention -S Poster Hall
- ▶ 143. Medical Education -S Poster Hall
- ▶ 145. PK/PD Studies -S Poster Hall
- ▶ 146. Pneumococcal Vaccines -S Poster Hall
- ▶ 147. Respiratory Infections: CAP -S Poster Hall
- ▶ 148. Respiratory Infections: Miscellaneous -S Poster Hall
- ▶ 149. Sexually Transmitted Infections -S Poster Hall
- ▶ 150. Urinary Tract Infection -S Poster Hall
- ▶ 151. Viruses and Bacteria in Immunocompromised Patients -S Poster Hall

2 - 3:15 p.m.

Interactive Sessions

- ▶ 156. Challenging Cases in Transplant: When the ID Expert Says, "What?" -S 206-208
- ▶ 157. Challenging HIV Cases -N Hall D
- ▶ 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
- ▶ 160. Leading Change -S 155
- ▶ 161. Pediatric Immunization: Perspectives From Both Sides of the Pond -S 214-216
- ▶ 162. T-Cell Biology: What the ID Physician Needs to Know -N 24
- ▶ 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024
- ▶ 164. Vaccines Against Herpesviruses -S 305-314

Oral Abstract Sessions

- ▶ 166. Changing Clinical Practice for Changing Times -S 157
- ▶ 167. Late Breaker Oral Abstracts -S 152-154
- ▶ 168. Novel Therapies for Superbugs -S 158
- ▶ 169. Respiratory and Gastroenteritis Viruses -W 2002

3:30 - 4:45 p.m.

Symposia

- ▶ 170. Diagnostic Updates: Clinical Mycology Update -N 24
- ▶ 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 179. B-lactam/ B-lactamase Inhibitor Combinations: Which one? -S 214-216
- ▶ 180. Clinical Teaching for the ID Provider -S 155
- ▶ 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures -S 151-153
- ▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- ▶ 184. Dollar Dollar Bills Y'All: Billing and Coding in ID -S 158
- ▶ 185. Educating Trainees about Stewardship -W 2001-2003
- ▶ 186. Emerging Drug Resistance in STIs -S 157
- ▶ 187. NHSN Update -S 156
- ▶ 188. Rapid Fire: Curbsides in Transplant ID -S 152-154
- ▶ 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Interactive Session

- ▶ 190. Shots Across the Bow: Debates in Vaccinology -N 24
- Symposia
- ▶ 191. Big Beasts II -W 2005-2024
 - ▶ 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs -S 305-314
 - ▶ 193. ID Physicians and Addiction Medicine -N Hall D
 - ▶ 195. Neonatal Infectious Disease: Chagas, Zika, and LCMV -W 2014-2016
 - ▶ 196. Non-Zika Arboviruses in the Americas -N 25
 - ▶ 197. Pediatric Infection Prevention: Small Patients, Big Challenges -W 2006-2008
 - ▶ 198. The Future of Transplant ID: Novel Diagnostics and Therapeutics -S 214-216

Oral Abstract Sessions

- ▶ 199. Clinical Trials that May Change Your Practice -S 158
- ▶ 200. Public Health: Epidemiology and Outbreaks -S 157
- ▶ 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment -S 156
- ▶ 202. Transplant and Immunocompromised Hosts: Emerging Issues -W 2002

10:30 - 11:45 a.m.

Interactive Session

- ▶ 203. Tropical Medicine Cases: Conundrums and Case Management -S 305-314

Symposia

- ▶ 204. Advances in Transplantation for Patients with HIV -W 2014-2016
- ▶ 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208
- ▶ 206. Controlling Antimicrobial Resistance Across Borders -W 2005-2024
- ▶ 207. Cool Ways to Discover Antibiotics -N 25
- ▶ 208. I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID -W 2006-2008
- ▶ 209. Infections in Immunocompromised Hosts -S 214-216
- ▶ 210. Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future -N 24

Oral Abstract Sessions

- ▶ 211. Diagnostics Making a Difference -S 158
- ▶ 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts -S 157
- ▶ 213. Late Breaker Oral Abstracts -S 152-154
- ▶ 214. Optimizing HIV Treatment -S 156
- ▶ 215. Translating Microbiome Science into Practice -W 2002

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 217. Antimicrobial Stewardship: Impact of Allergy -S Poster Hall
- ▶ 218. Antimicrobial Stewardship: Impact of New Diagnostics -S Poster Hall
- ▶ 219. Antimicrobial Stewardship: New Methods and Metrics -S Poster Hall
- ▶ 220. Antimicrobial Stewardship: Non-hospital Settings -S Poster Hall
- ▶ 221. Antimicrobial Stewardship: Outpatient Settings -S Poster Hall
- ▶ 222. Antimicrobial Stewardship: Potpourri -S Poster Hall
- ▶ 224. Antiviral Therapies -S Poster Hall

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

- ▶ 225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis -S Poster Hall
- ▶ 226. Clinical Practice Issues: OPAT -S Poster Hall
- ▶ 227. Clinical Trials -S Poster Hall
- ▶ 228. Diagnostics: Bacteria and Mycobacteria -S Poster Hall
- ▶ 229. Diagnostics: Biomarkers and Novel Approaches -S Poster Hall
- ▶ 230. Diagnostics: Mycology -S Poster Hall
- ▶ 231. Diagnostics: Parasitology -S Poster Hall
- ▶ 232. Diagnostics: Resistance Testing -S Poster Hall
- ▶ 233. Diagnostics: Virology -S Poster Hall
- ▶ 234. Healthcare Epidemiology: Device-associated HAIs -S Poster Hall
- ▶ 235. Healthcare Epidemiology: Surgical Site Infections -S Poster Hall
- ▶ 236. Healthcare Epidemiology: Epidemiologic Methods -S Poster Hall
- ▶ 237. Healthcare Epidemiology: HAI Surveillance -S Poster Hall
- ▶ 238. Hepatitis A, B, and C -S Poster Hall
- ▶ 239. HIV and Viral Hepatitis Co-Infection -S Poster Hall
- ▶ 240. HIV: Malignancy -S Poster Hall
- ▶ 241. HIV: Metabolic, Cardiovascular, and Renal Complications -S Poster Hall
- ▶ 242. HIV: Opportunistic Infections and other Infectious Complications -S Poster Hall
- ▶ 243. HIV: Sexually Transmitted Infections -S Poster Hall
- ▶ 244. Miscellaneous Vaccines -S Poster Hall
- ▶ 245. Molecular & Sequence Based Diagnostics -S Poster Hall
- ▶ 246. Pediatric Healthcare Associated Infections -S Poster Hall
- ▶ 247. Pediatric Bacterial Infections -S Poster Hall
- ▶ 248. Pediatric Viral Infections -S Poster Hall
- ▶ 249. Skin and Skin Structure Infection -S Poster Hall
- ▶ 250. Treatment of AMR Infections -S Poster Hall
- ▶ 251. Adolescent Vaccines -S Poster Hall
- ▶ 252. Vaccine Policy and Hesitancy -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 260. Advances in Epidemiology Research Methods -N 24
- ▶ 261. Infection Prevention in Post-Acute Care: Controversies and Challenges -S 206-208
- ▶ 262. Intersection of Surgery and Pediatric Infectious Disease -S 214-216
- ▶ 263. Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children -W 2006-2008
- ▶ 265. Strategy Trials: A New Paradigm in Infectious Diseases Research -W 2005-2024
- ▶ 267. When Does PK/PD Matter for Patient Care? -S 305-314
- ▶ 268. When Transplant Tours the World -N 25

Oral Abstract Sessions

- ▶ 269. Flu and other Vaccines in Children -W 2002
- ▶ 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection -S 158
- ▶ 272. Pediatric Viral Infections -S 156

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposia

- ▶ 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics -W 2001-2003
- ▶ 279. Red Book Update -W 2006-2008
- ▶ 280. Tele-Antimicrobial Stewardship -W 2014-2016

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

IDWeek 2018 Program Tracks (continued)

Tuesday, October 2

1 - 5 p.m.

Pre-meeting Workshop

- ▶ PW03. NIH Initiatives/Grant Writing Workshop (\$) -W 2001-2003
- ▶ PW11. Medication Assisted Treatment Waiver Course (\$) -W 2014-2016

Wednesday, October 3

8 a.m.-12 p.m.

Pre-meeting Workshops

- ▶ PW04. Fellows' Day Workshop (\$) -W 2006-2008
- ▶ PW05. Pediatric Fellows' Day (\$) -W 2002
- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

1:30 - 3:15 p.m.

Interactive Session

- ▶ 1. Challenging Cases in Pediatric Infectious Diseases -W 2005-2024

- ▶ 5. Stewardship: Best Drivers of Change Debate -N 24

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
- ▶ 4. RCT That Will Change Your Practice -N 25
- ▶ 6. Update on Biofilm-Related Infections -W 2014-2016
- ▶ 7. What's Hot in ID + HIV -N Hall D

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 11. Are You Ready? Outbreak Response Training -S 152-154
- ▶ 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
- ▶ 13. Emerging Issues in the Diagnosis of STIs -S 214-216
- ▶ 14. How to Build Allergy Testing into Your Stewardship Program -S 157
- ▶ 15. NTM Infections: Challenges in Diagnosis and Management -W 2001-2003
- ▶ 16. Our Most Difficult HIV Cases (other than STIs) -S 156
- ▶ 17. Questions in Bacteremia -W 2006-2008
- ▶ 18. Respiratory Infections in Pregnant Women -S 158
- ▶ 19. Shall We Agree to Disagree: Management of Pediatric Acute Hematogenous Osteomyelitis -W 2014-2016
- ▶ 20. Women in ID -S 155

8:45 - 10 a.m.

Interactive Sessions

- ▶ 21. "Brain on Fire": Challenging Cases in Infectious and Inflammatory Encephalitis -W 2005-2024
- ▶ 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D

Symposia

- ▶ 24. Can You Hear and See Me Now? ID Telehealth -S 206-208
- ▶ 26. Just Your Average Day in a Pediatric Infectious Disease Clinic -W 2014-2016
- ▶ 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216
- ▶ 28. Still at Highest Risk: Innovative Approaches & Urgent Needs for Prevention and Care -S 305-314
- ▶ 29. What Are You Talking About? Communication Strategies for Stewardship Programs -N 24

10:30 - 11:45 a.m.

Interactive Sessions

- ▶ 34. Diagnostic Clinical Cases -W 2005-2024
- ▶ 35. STIs in the HIV Care Setting -N Hall D

Symposia

- ▶ 36. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship -N 24
- ▶ 38. Hot Topics in Medical Education 2018 -W 2014-2016
- ▶ 39. Hot Topics in Pediatric Infectious Diseases -W 2001-2003
- ▶ 40. Improving Healthcare-Associated Infection Metrics -W 2006-2008
- ▶ 41. New and Updated Guidelines -S 305-314
- ▶ 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208
- ▶ 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 54. Bone and Joint Infections -S Poster Hall
- ▶ 56. Fungal Disease: Management and Outcomes -S Poster Hall
- ▶ 57. Global Health and Travel Medicine -S Poster Hall
- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Interactive Sessions

- ▶ 75. Clinical Controversies -W 2005-2024
- ▶ 76. Controversies in Infection Prevention -N 24
- ▶ 77. "Mano-a-Mano III": Controversies in Pediatric ID -S 206-208

Symposia

- ▶ 78. Bread and Butter Transplant ID -N 25
- ▶ 79. Exploring the Antibiotic Pipeline 2018 -N Hall D
- ▶ 80. Migration and Immigration: Global Diseases at Your Doorstep -W 2006-2008
- ▶ 82. Novel Clinical Risks for Fungal Disease -W 2014-2016
- ▶ 83. The Human Microbiome in HIV -S 305-314

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Friday, October 5

7 - 9 a.m.

- Meet-the-Professor Session
▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

- Meet-the-Professor Sessions
▶ 101. Tropical Dermatology: Are You Ready for Jeopardy? -W 2014-2016
▶ 102. Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems -W 2006-2008
▶ 93. Ask the Expert: Managing Invasive Fungal Infections -W 2001-2003
▶ 94. Challenging STIs in the HIV Infected Patient -S 156
▶ 95. Controversies in Sepsis (but not SIRS) -S 206-208
▶ 96. Designing a QI Project You Can Publish -S 157
▶ 98. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs -S 151-153
▶ 99. Microbiome Therapeutics -S 152-154

8:45 - 10 a.m.

- Interactive Sessions
▶ 103. "Achy Breaky Heart": Challenging Cases in Cardiovascular Infections -W 2005-2024
▶ 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention -W 2006-2008

Symposia

- ▶ 105. Advances in RSV Prevention -N 24
▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25
▶ 107. HIV State of the Art -N Hall D
▶ 108. Metagenomic-Based Infectious Disease Diagnostics -S 214-216
▶ 110. Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses -W 2014-2016
▶ 111. Stewardship in Challenging Populations -S 206-208

10:30 - 11:45 a.m.

- Interactive Session
▶ 116. Challenging Cases in Infectious Diseases -N Hall D
- Symposia
▶ 117. Big Beasts I -W 2005-2024
▶ 118. How to Treat Resistant Gram-Positive Infections -N 24
▶ 119. Infection Control and Antimicrobial Stewardship in Dialysis Facilities -W 2006-2008
▶ 120. Late Breaker Foodborne Illnesses -S 305-314
▶ 121. Pathogen Interactions with the Microbiota -S 206-208
▶ 122. Strategies to Achieve HIV Remission -N 25
▶ 123. Time 101: Optimizing Meetings -S 155

10:45 - 11:45 a.m.

- Named Lecture
▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

- Poster Abstract Session
▶ 143. Medical Education -S Poster Hall

2 - 3:15 p.m.

- Interactive Sessions
▶ 156. Challenging Cases in Transplant: When the ID Expert Says, "What?" -S 206-208
▶ 157. Challenging HIV Cases -N Hall D

Symposia

- ▶ 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
▶ 159. Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges -W 2006-2008
▶ 160. Leading Change -S 155
▶ 161. Pediatric Immunization: Perspectives From Both Sides of the Pond -S 214-216
▶ 162. T-Cell Biology: What the ID Physician Needs to Know -N 24
▶ 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024

Oral Abstract Sessions

- ▶ 167. Late Breaker Oral Abstracts -S 152-154
▶ 169. Respiratory and Gastroenteritis Viruses -W 2002

3:30 - 4:45 p.m.

Symposia

- ▶ 170. Diagnostic Updates: Clinical Mycology Update -N 24
▶ 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

4:20 - 4:45 p.m.

Symposium

- ▶ 176. Influential Publications in Antimicrobial Stewardship from the Past Year -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures -S 151-153
▶ 182. Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & "Aha" Moments -W 2014-2016
▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
▶ 184. Dollar Dollar Bills Y'All: Billing and Coding in ID -S 158
▶ 185. Educating Trainees about Stewardship -W 2001-2003
▶ 186. Emerging Drug Resistance in STIs -S 157
▶ 187. NHSN Update -S 156
▶ 188. Rapid Fire: Curbsides in Transplant ID -S 152-154
▶ 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Symposia

- ▶ 191. Big Beasts II -W 2005-2024
▶ 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs -S 305-314
▶ 193. ID Physicians and Addiction Medicine -N Hall D
▶ 194. Malignancies in Patients with HIV -S 206-208
▶ 195. Neonatal Infectious Disease: Chagas, Zika, and LCMV -W 2014-2016
▶ 197. Pediatric Infection Prevention: Small Patients, Big Challenges -W 2006-2008
▶ 198. The Future of Transplant ID: Novel Diagnostics and Therapeutics -S 214-216

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Oral Abstract Sessions

- ▶ 199. Clinical Trials that May Change Your Practice -S 158
- ▶ 200. Public Health: Epidemiology and Outbreaks -S 157
- ▶ 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment -S 156
- ▶ 202. Transplant and Immunocompromised Hosts: Emerging Issues -W 2002

10:30 - 11:45 a.m.

Interactive Session

- ▶ 203. Tropical Medicine Cases: Conundrums and Case Management -S 305-314

Symposia

- ▶ 204. Advances in Transplantation for Patients with HIV -W 2014-2016
- ▶ 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208
- ▶ 207. Cool Ways to Discover Antibiotics -N 25
- ▶ 208. I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID -W 2006-2008
- ▶ 209. Infections in Immunocompromised Hosts -S 214-216
- ▶ 210. Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future -N 24

Oral Abstract Sessions

- ▶ 211. Diagnostics Making a Difference -S 158
- ▶ 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts -S 157
- ▶ 213. Late Breaker Oral Abstracts -S 152-154
- ▶ 214. Optimizing HIV Treatment -S 156
- ▶ 215. Translating Microbiome Science into Practice -W 2002

12:30 - 1:45 p.m.

Poster Abstract Session

- ▶ 248. Pediatric Viral Infections -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 260. Advances in Epidemiology Research Methods -N 24
- ▶ 261. Infection Prevention in Post-Acute Care: Controversies and Challenges -S 206-208
- ▶ 262. Intersection of Surgery and Pediatric Infectious Disease -S 214-216
- ▶ 263. Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children -W 2006-2008
- ▶ 264. Pain Management and Mental Health in Patients with HIV -W 2014-2016
- ▶ 265. Strategy Trials: A New Paradigm in Infectious Diseases Research -W 2005-2024
- ▶ 266. Syphilis in the 21st Century -N Hall D
- ▶ 267. When Does PK/PD Matter for Patient Care? -S 305-314
- ▶ 268. When Transplant Tours the World -N 25

Oral Abstract Sessions

- ▶ 269. Flu and other Vaccines in Children -W 2002
- ▶ 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection -S 158
- ▶ 272. Pediatric Viral Infections -S 156

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposia

- ▶ 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics -W 2001-2003
- ▶ 279. Red Book Update -W 2006-2008

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

Tuesday, October 2

8 a.m. - 5 p.m.

Pre-meeting Workshop

- ▶ PW01. The Vincent T. Andriole ID Board Review Course (\$) -W 2005-2020

Wednesday, October 3

8 a.m. - 12 p.m.

Pre-meeting Workshop

- ▶ PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

1:30 - 3:15 p.m.

Symposia

- ▶ 2. Late Breaker Ebola Update -S 305-314
- ▶ 7. What's Hot in ID + HIV -N Hall D

3:45 - 5:15 p.m.

Plenary Session

- ▶ 8. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space -N Hall D

5:30 - 6:30 p.m.

Posters in the Park

- ▶ Opening Reception and Posters in the Park -N Hall D Opening Reception Area

Thursday, October 4

8:45 - 10 a.m.

Symposium

- ▶ 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216

10:30 - 11:45 a.m.

Symposium

- ▶ 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 57. Global Health and Travel Medicine -S Poster Hall
- ▶ 58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall
- ▶ 63. Maternal-Child Infections -S Poster Hall
- ▶ 70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall

2 - 3:15 p.m.

Symposia

- ▶ 78. Bread and Butter Transplant ID -N 25
- ▶ 82. Novel Clinical Risks for Fungal Disease -W 2014-2016

3:30 - 3:55 p.m.

Named Lecture

- ▶ 88. John F. Enders Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 89. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 90. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 91. Maxwell Finland Lecture -N Hall D

Friday, October 5

7 - 9 a.m.

Meet-the-Professor Session

- ▶ 92b. Advocacy Session -S 155

7:15 - 8:15 a.m.

Meet-the-Professor Session

- ▶ 93. Ask the Expert: Managing Invasive Fungal Infections -W 2001-2003

8:45 - 10 a.m.

Symposium

- ▶ 106. Fungal MDR Outbreak: *Candida auris* -N 25

10:30 - 11:45 a.m.

Symposium

- ▶ 120. Late Breaker Foodborne Illnesses -S 305-314

10:45 - 11:45 a.m.

Named Lecture

- ▶ 129. Caroline B. Hall Lectureship -S 214-216

12:30 - 1:45 p.m.

Poster Abstract Sessions

- ▶ 134. Fungi and Parasites in Immunocompromised Patients -S Poster Hall
- ▶ 143. Medical Education -S Poster Hall

2 - 3:15 p.m.

Interactive Session

- ▶ 156. Challenging Cases in Transplant: When the ID Expert Says, "What?" -S 206-208

Oral Abstract Session

- ▶ 167. Late Breaker Oral Abstracts -S 152-154

3:45 - 4:45 p.m.

Named Lecture

- ▶ 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.

Awards Session

- ▶ 175. Awards Session -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- ▶ 188. Rapid Fire: Curbsides in Transplant ID -S 152-154
- ▶ 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.

Symposium

- ▶ 198. The Future of Transplant ID: Novel Diagnostics and Therapeutics -S 214-216

Oral Abstract Session

- ▶ 202. Transplant and Immunocompromised Hosts: Emerging Issues -W 2002

10:30 - 11:45 a.m.

Symposium

- ▶ 204. Advances in Transplantation for Patients with HIV -W 2014-2016

Oral Abstract Session

- ▶ 213. Late Breaker Oral Abstracts -S 152-154

W = West Hall

N = North Hall

S = South Hall

IDWeek 2018 Program Tracks (continued)

12:30 - 1:45 p.m.

Poster Abstract Session

- ▶ 248. Pediatric Viral Infections -S Poster Hall

2 - 3:15 p.m.

Symposium

- ▶ 268. When Transplant Tours the World -N 25

3:30 - 3:55 p.m.

Named Lecture

- ▶ 273. Joseph E. Smadel Lecture -N Hall D

3:55 - 4:05 p.m.

Awards Session

- ▶ 274. Awards Session -N Hall D

4:05 - 4:20 p.m.

Oral Abstract Session

- ▶ 275. Featured Oral Abstract -N Hall D

4:20 - 4:45 p.m.

Named Lecture

- ▶ 276. Edward H. Kass Lecture -N Hall D

5 - 6 p.m.

Interactive Session

- ▶ 277. ID BugBowl -N Hall D

Sunday, October 7

8 - 9 a.m.

Mini-Symposium

- ▶ 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics -W 2001-2003

9:15 - 10:45 a.m.

Plenary Session

- ▶ 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024



Scientific Sessions

Transplant ID / HIV-STD-TB / Adult ID

PW01. Pre-meeting Workshop

The Vincent T. Andriole ID Board Review Course (\$)

Tuesday, 8 a.m. - 5 p.m.


W 2005-2020

Objectives: At the conclusion of this session, participants will be able to:

- discuss and apply updated information on diagnosis and treatment of sexually transmitted infections
- assess and apply current trends in diagnosis and treatment of tuberculosis and other mycobacteria
- discuss and apply updated information on diagnosis and treatment of non-HIV/non-transplant viral syndromes
- discuss common parasitic disease infections including their diagnosis and treatment
- recognize and apply in diagnostic and therapeutic ways the epidemiologic, tempo, and sign/symptom features of important bacterial infections
- assess and apply components of effective infection control/prevention programs
- discuss the most common non-infectious causes of elevated temperature
- discuss the diagnosis and treatment of Rickettsial and other tick-borne diseases
- discuss and apply updated information on vaccination
- assess and apply current trends in HIV care
- assess and apply current trends in the diagnosis and treatment of transplant-associated infections
- identify and apply characteristic pharmacologic and clinical features of antimicrobial agents used in treating the spectrum of clinical infections

Intended Audience: clinicians, infectious diseases physicians

 Maximum of 7.50 hours of *AMA PRA Category 1 Credit™*

 ACPE 7.5 application-based contact hours of pharmacy CE; 0221-9999-18-301-L01-P

Pediatric ID / Epidemiology and Infection Control / Adult ID

PW02. Pre-meeting Workshop

Best Practices for Antimicrobial Stewardship Programs (\$)

Tuesday, 8 a.m. - 5 p.m.


W 2009-2024

Objectives: At the conclusion of this activity, participants should be able to:

- evaluate components of effective antimicrobial stewardship programs and implement interventions in their healthcare setting
- describe the strategies for the implementation process and the outcome measures
- apply antimicrobial stewardship interventions for unique populations and across healthcare settings
- critically assess available data, including pharmacy and microbiology data, needed to support antimicrobial stewardship in their institution

Intended Audience: clinicians, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, microbiologists, other: healthcare providers who wish to create, implement, or improve an antimicrobial stewardship program for their healthcare institution, pharmacists

 Maximum of 7.50 hours of *AMA PRA Category 1 Credit™*

 ACPE 7.5 knowledge-based contact hours of pharmacy CE; 0221-9999-18-178-L01-P

Trainee

PW03. Pre-meeting Workshop

NIH Initiatives/Grant Writing Workshop (\$)

Tuesday, 1 - 5 p.m.

W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:

- review NIH research training funding opportunities and identify how an applicant can decide which opportunity is best for them
- discuss the categories of grant mechanisms (what they are and which career stages they are intended to support) and test successful grantsmanship strategies
- determine how to set the best trajectory for a successful ID physician-scientist career and build best practices by refining career pathways and aligning training goals with those pathways

Intended Audience: fellows, medical students and residents, members-in-training

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID / HIV-STD-TB / Trainee

PW11. Pre-meeting Workshop

Medication Assisted Treatment Waiver Course (\$)


Tuesday, 1 - 5:30 p.m.

W 2014-2016

Objectives: Upon completion of the first 4 hours of training in-person and the second 4 hours of training online, the participants will be able to:

- have the training required to apply for a waiver to prescribe buprenorphine to their patients with opioid dependence (addiction)
- identify and assess patients who are appropriate for treatment with buprenorphine
- have the specific knowledge concerning the use of buprenorphine to manage opioid dependence in the outpatient setting
- discuss the psychiatric and medical comorbidities associated with opioid addiction

Intended Audience: clinicians, healthcare workers, HIV clinicians, HIV specialists, infection preventionists, infectious diseases physicians

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Scientific Sessions (continued)

Trainee / Adult ID

PW04. Pre-meeting Workshop

Fellows' Day Workshop (\$)

Co-organized with the IDSA ID Training Program Directors

Wednesday, 8 a.m. - 12 p.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- discuss challenging infectious disease cases and approaches to differential diagnosis
- describe career pathways in at least two different infectious disease fields
- develop an initial action plan in pursuit of a post-fellowship position

Intended Audience: fellows, medical students and residents, members-in-training

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID

PW05. Pre-meeting Workshop

Pediatric Fellows' Day (\$)

Co-organized with the PIDS Training Programs Committee

Wednesday, 7:45 a.m. - 12 p.m. W 2002

Objectives: At the conclusion of this session, participants will be able to:

- discuss challenging infectious disease cases and approaches to patient management
- summarize career opportunities and pathways to achieve professional goals
- review common questions and best practices for interviewing for your first job

Intended Audience: fellows, medical students and residents, members-in-training

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

PW06. Pre-meeting Workshop


TB Workshop (\$)


Wednesday, 8 a.m. - 12 p.m. W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:

- explain how a comprehensive approach using whole-genome sequencing can be developed, validated, and approved as a CLIA-compliant test for *Mycobacterium tuberculosis*
- evaluate psychosocial approaches to improve adherence to TB treatment
- translate such approaches into tangible changes in medical practice

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*

 ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-179-L01-P

Pediatric ID / HIV-STD-TB / Adult ID

PW07. Pre-meeting Workshop

Hepatitis C Workshop (\$)


Wednesday, 8 a.m. - 12 p.m. S 156

Objectives: At the conclusion of this session, participants will be able to:

- discuss how to design the treatment options for HCV patients according to their RAVS, treatment experience, HCV genotype, and disease stage
- compare methods for staging liver disease
- distinguish steatosis from steatohepatitis
- explain how to diagnose common liver diseases

Intended Audience: clinicians, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, pharmacists

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*

 ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-302-L01-P

Pediatric ID / Epidemiology and Infection Control / Adult ID

PW08. Pre-meeting Workshop

A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship (\$)


Wednesday, 8 a.m. - 12 p.m. S 152-154

Objectives: At the conclusion of this session, participants will be able to:

- describe a conceptual framework informed by the social sciences that can be applied to the work of improving patient safety and quality
- discuss an overview of the fields of medical sociology, behavioral economics and implementation science as they apply to antimicrobial stewardship and infection prevention
- describe a practical example of an antimicrobial stewardship intervention that utilizes evidence-based communication training
- explain what a social driver diagram is and how it can be practically applied to the everyday work of managing social barriers to change in implementing antimicrobial stewardship and infection prevention interventions

Intended Audience: clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases physicians, pharmacists

Scientific Sessions (continued)

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*
ACPE 4 knowledge-based contact hours of pharmacy CE;
0221-9999-18-303-L01-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB /
Global ID / Epidemiology and Infection Control / Adult ID


PW09. Pre-meeting Workshop How to Use EBM/GRADE to Develop Guidelines

Wednesday, 8 a.m. - 12 p.m. S 157

Objectives: At the conclusion of this session, participants will be able to:

- explain the guideline development process utilized by IDSA including: initiation of guidelines, scope, question formulation, searching for evidence, evidence synthesis, and recommendation development using Grading of Recommendation Assessment, Development and Evaluation framework (GRADE) methods
- discuss GRADE methods as a means to rate the quality/certainty of the underlying evidence and the grading of the strength and direction of recommendation

Intended Audience: clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, researchers, scientists, vaccinologists

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

Pediatric ID / Adult ID


PW10. Pre-meeting Workshop Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Module: General ID 2018 (\$)

Wednesday, 8 a.m. - 12:30 p.m. S 158

Objectives: At the conclusion of this activity, the learner will be able to:

- identify gaps in infectious diseases medical knowledge where further study is needed for board preparation and patient management
- improve competence in the area of infectious diseases medicine regarding diagnosis, treatments, and other aspects of patient management
- evaluate and revise patient management strategies
- improve clinical decision-making skills in infectious diseases medicine

Intended Audience: clinicians, infectious diseases pediatricians, infectious diseases physicians

 Maximum of 15 hours of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

CME and MOC credit may only be claimed here <http://idsa2.knowledgedirectweb.com>. Instructions will be provided during the workshop.

Trainee / Pediatric ID



1. Interactive Session Challenging Cases in Pediatric Infectious Diseases

Wednesday, 1:30 - 3:15 p.m. W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- discuss the clinical presentation and diagnostics of challenging cases in infectious diseases
- describe atypical presentations of certain infectious diseases
- discuss clinical presentations mimicking infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, medical students and residents, pharmacists

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*
 ACPE 1.75 application-based contact hours of pharmacy CE;
0221-9999-18-180-L01-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB /
Global ID / Epidemiology and Infection Control / Adult ID


2. Symposium Late Breaker Ebola Update

Wednesday, 1:30 - 3:15 p.m. S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- TBD

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

Pediatric ID / Trainee / Epidemiology and Infection Control /
Investigative ID / Adult ID

3. Symposium Machine Learning and Modeling in Infectious Diseases

Wednesday, 1:30 - 3:15 p.m. S 214-216


Objectives: At the conclusion of this session, participants will be able to:


- review the data on how the electronic medical record can be used to generate models that predict risk of healthcare-associated infections
- apply machine learning approaches to stratify patients who present with clinical manifestations of sepsis

Scientific Sessions (continued)

- discuss the impact data-driven approaches can have in the management of patients in the intensive care unit

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-181-L01-P

Pediatric ID / Trainee / Adult ID

4. Symposium

RCT That Will Change Your Practice


Wednesday, 1:30 - 3:15 p.m.


N 25

Objectives: At the conclusion of this session, participants will be able to:

- discuss recent data from randomized controlled trials in the area of antifungals
- discuss recent data from randomized controlled trials in the area of antivirals
- discuss recent data from randomized controlled trials in the area of antibacterials

Intended Audience: clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-182-L01-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

5. Interactive Session

Stewardship: Best Drivers of Change Debate


Wednesday, 1:30 - 3:15 p.m.


N 24

Objectives: At the conclusion of this session, participants will be able to:

- discuss the controversy surrounding the inclusion of the “end of life population” in antimicrobial stewardship programs
- debate the best outcome measures for antimicrobial stewardship programs: clinical outcomes vs. antibiotic use data
- discuss the advantages and disadvantages of including antifungals in an antimicrobial stewardship program

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-183-L04-P

Trainee / Investigative ID / Pediatric ID / Adult ID

6. Symposium

Update on Biofilm-Related Infections

Wednesday, 1:30 - 3:15 p.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- explain the role that biofilm plays in infectious diseases and certain hosts
- describe the impact that biofilm has on lung disease, particularly in cystic fibrosis
- discuss the challenges in diagnosing and assessing the impact of biofilm in implant related infections

Intended Audience: academicians, clinicians, fellows, infection preventionists, infectious diseases physicians, investigators, lab personnel, members-in-training, microbiologists, pharmacists, researchers, scientists

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-304-L01-P

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

7. Symposium

What's Hot in ID + HIV

Wednesday, 1:30 - 3:15 p.m.


N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- review what is new in the field of infectious diseases using basic and clinical science
- describe what is new in the field of clinical and epidemiological sciences in HIV
- review what is new in the field of basic science and pathogenesis of HIV infection

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.75 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-184-L02-P

Scientific Sessions (continued)

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

8. Plenary Session

Opening Plenary Session: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space


Wednesday, 3:45 - 5:15 p.m.

N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- TBD

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Posters in the Park

Opening Reception and Posters in the Park

Wednesday, 5:30 - 6:30 p.m. N Hall D Opening Reception Area

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

11. Meet-the-Professor Session

Are You Ready? Outbreak Response Training


Thursday, 7:15 - 8:15 a.m.

S 152-154

Objectives: At the conclusion of this session, participants will be able to:

- utilize tools developed as part of the SHEA/CDC Outbreak Response Training Program to respond to outbreaks in adult and pediatric healthcare facilities

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, public health practitioners, researchers

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Global ID / Epidemiology and Infection Control / Adult ID

12. Meet-the-Professor Session

Disease Eradication Progress: Polio and Guinea Worm


Thursday, 7:15 - 8:15 a.m.

S 151-153

Objectives: At the conclusion of this session, participants will be able to:

- review the practices of disease eradication, including the use of vaccines, water treatment, and prevention
- describe the progress of polio virus disease eradication
- summarize the progress of Guinea worm disease eradication
- discuss what other infectious diseases might be eradicated and the approach to doing so

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Trainee / Pediatric ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

13. Meet-the-Professor Session

Emerging Issues in the Diagnosis of STIs

Thursday, 7:15 - 8:15 a.m.


S 214-216

Objectives: At the conclusion of this session, attendees will be able to:

- discuss the prevalence and risks to health of bacterial vaginosis
- explain the clinical significance of *M. genitalium*
- list diagnostic testing approaches for bacterial vaginosis and *M. genitalium*

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-185-L01-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

14. Meet-the-Professor Session

How to Build Allergy Testing into Your Stewardship Program

Thursday, 7:15 - 8:15 a.m.

S 157

Objectives: At the conclusion of this session, participants will be able to:


- identify challenges in incorporating allergy testing into an antimicrobial stewardship program
- discuss practical examples of allergy testing in stewardship

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital

Scientific Sessions (continued)

epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, pharmacists, researchers

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 application-based contact hours of pharmacy CE; 0221-9999-18-187-L04-P

Trainee / Pediatric ID / Adult ID

15. Meet-the-Professor Session

NTM Infections: Challenges in Diagnosis and Management


Thursday, 7:15 - 8:15 a.m. W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:

- review the epidemiology of NTM infections
- discuss challenges in diagnosing clinical NTM infections
- review current management strategies and challenges in treating NTM infections

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, researchers

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-188-L01-P

HIV-STD-TB / Trainee

16. Meet-the-Professor Session

Our Most Difficult HIV Cases (other than STIs)


Thursday, 7:15 - 8:15 a.m. S 156

Objectives: At the conclusion of this session, participants will be able to:

- identify key aspects of managing antiretroviral therapy in HIV-infected patients who are treatment experienced and/or have co-occurring conditions
- evaluate different strategies and options in selecting an antiretroviral treatment regimen for HIV-infected patients

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-189-L01-P

Adult ID / Pediatric ID / Trainee

17. Meet-the-Professor Session

Questions in Bacteremia

Thursday, 7:15 - 8:15 a.m. W 2006-2008


Objectives: At the conclusion of this session, participants will be able to:

- discuss the current management of bacteremia

- explain recent advances in the diagnosis of bacteremia
- list outcomes in patients with bacteremia

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, researchers, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-190-L01-P

Trainee / Adult ID / Pediatric ID

18. Meet-the-Professor Session

Respiratory Infections in Pregnant Women


Thursday, 7:15 - 8:15 a.m. S 158

Objectives: At the conclusion of this session, participants will be able to:

- review the epidemiology, clinical presentation, and prevention of prevalent respiratory infections in pregnant women

Intended Audience: academicians, investigators, medical students and residents, members-in-training, vaccinologists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-191-L01-P

Trainee / Pediatric ID

19. Meet-the-Professor Session

Shall We Agree to Disagree: Management of Pediatric Acute Hematogenous Osteomyelitis


Thursday, 7:15 - 8:15 a.m. W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- explain the transition to oral antimicrobial therapy, including the criteria and whether the criteria differ for bacteremic patients
- discuss data for oral antimicrobial dosing, including the choice of agent and dosing intervals
- review intravenous therapy for bacteremic patients with MSSA
- describe the utility/yield and timing of bone aspirates for culture
- explain the use of inflammatory markers to guide management and therapy

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-186-L01-P

Scientific Sessions (continued)

Trainee / Pediatric ID / Adult ID

20. Meet-the-Professor Session

Women in ID

Thursday, 7:15 - 8:15 a.m.


S 155

Objectives: At the conclusion of this session, participants will be able to:

- discuss compensation disparities across gender in ID
- describe barriers to career enhancement across gender in ID
- identify strategies to enhance career success and satisfaction

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-305-L04-P

Investigative ID / Epidemiology and Infection Control / Adult ID

92. Meet-the-Professor Session

Antimicrobial and Diagnostic Stewardship

Co-organized with the Centers for Disease Control and Prevention

Thursday, 7:15 - 8:30 a.m.

S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- TBD

Intended Audience: academicians, clinicians, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Adult ID / Pediatric ID

21. Interactive Session

“Brain on Fire:” Challenging Cases in Infectious and Inflammatory Encephalitis

Thursday, 8:45 - 10 a.m.


W 2005-2024


Objectives: At the conclusion of this session, participants will be able to:

- list the common and rare causes of encephalitis
- describe the difference between infectious and autoimmune encephalitis
- interpret an MRI brain in the approach to encephalitis

- discuss the multidisciplinary management of patients with encephalitis

Intended Audience: academicians, clinicians, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-192-L01-P

Adult ID / Pediatric ID / Epidemiology and Infection Control

22. Interactive Session

Case-Based Problems in Vaccines: Beyond the Guidelines

Thursday, 8:45 - 10 a.m.


N 25

Objectives: At the conclusion of this session, participants will be able to:

- examine the current vaccine guidelines
- differentiate public health vaccine decisions versus personal health
- formulate vaccine decisions in unusual cases

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-193-L04-P

Global ID / Pediatric ID / Trainee / Adult ID

23. Interactive Session

Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium

Thursday, 8:45 - 10 a.m.

N Hall D


Objectives: At the conclusion of this session, participants will be able to:


- address the current challenges posed by the diagnosis of antimicrobial-resistant organisms in clinical settings
- review mechanisms of resistance and treatment options for carbapenem-resistant Enterobacteriaceae and multidrug-resistant *Pseudomonas aeruginosa*
- discuss the most important issues in the diagnosis and treatment of mold infections

Intended Audience: academicians, clinicians, fellows, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students

Scientific Sessions (continued)

and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-194-L01-P

Pediatric ID / Global ID / Adult ID / Trainee

24. Symposium

Can You Hear and See Me Now? ID Telehealth

IDSA Telehealth Committee

Thursday, 8:45 - 10 a.m.

S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- describe the current state of telemedicine in infectious disease practice
- discuss opportunities to improve patient care and programmatic interventions

Intended Audience: clinicians, hospital administrators, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Epidemiology and Infection Control / Global ID / Pediatric ID / Adult ID

25. Symposium

Combating Antimicrobial Resistance: Relevance of the One Health Concept

Thursday, 8:45 - 10 a.m.


W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- explain the importance of the work of the President's Advisory Council on Combating Antibiotic-Resistant Bacteria
- describe a gap in the U.S. system that can lead to the development of antibiotic-resistant bacteria
- discuss how a resistant organism or gene can spread through the environment

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-306-L04-P

Trainee / Pediatric ID

26. Symposium

Just Your Average Day in a Pediatric Infectious Disease Clinic


Thursday, 8:45 - 10 a.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- describe how to manage tired teenagers with post-infectious fatigue
- discuss the approach to a child with periodic fever
- describe how to manage a child with Lyme disease

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-307-L01-P

Transplant ID / Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

27. Symposium

Predict, Prevent, and Protect: Optimizing Transplant Outcomes

Thursday, 8:45 - 10 a.m.


S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- construct an infectious diseases approach to evaluating and readying the transplant candidate for transplantation
- discuss the complexities of infection control practices in the transplant population
- illustrate the importance and challenges of practicing antimicrobial stewardship in the transplant setting

Intended Audience: clinicians, epidemiologists, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-195-L01-P

HIV-STD-TB / Trainee

28. Symposium

Still at Highest Risk: Innovative Approaches & Urgent Needs for Prevention and Care

Thursday, 8:45 - 10 a.m.

S 305-314

Objectives: At the conclusion of this session, participants will be able to:


- apply strategies to improve HIV prevention and care for MSM and young African women
- assess the health care needs of transgender patients living with HIV
- describe approaches to improving health outcomes for adolescent patients at risk or living with HIV

Intended Audience: clinicians, fellows, HIV clinicians, HIV

Scientific Sessions (continued)

specialists, infectious diseases physicians, members-in-training, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-196-L01-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

29. Symposium

What Are You Talking About? Communication Strategies for Stewardship Programs


Thursday, 8:45 - 10 a.m. N 24

Objectives: At the conclusion of this session, participants will be able to:

- discuss strategies for communication in stewardship initiatives in the hospital setting
- assess stewardship communication practices in the emergency department and outpatient settings
- identify the role of social media-based communication strategies

Intended Audience: clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-197-L04-P

Investigative ID / Pediatric ID / Epidemiology and Infection Control / Adult ID

30. Oral Abstract Session

Healthcare Epidemiology: Hot Topics

Thursday, 8:45 - 10 a.m. S 157

Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Oral Abstract Sessions: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Investigative ID / Pediatric ID

31. Oral Abstract Session

Infant Viral Infections

Thursday, 8:45 - 10 a.m. S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

Global ID / Adult ID

32. Oral Abstract Session

Tuberculosis and other Mycobacterial Infections

Thursday, 8:45 - 10 a.m. W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID

33. Oral Abstract Session

What's Hot in UTIs and STIs

Thursday, 8:45 - 10 a.m. S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

34. Interactive Session

Diagnostic Clinical Cases


Thursday, 10:30 - 11:45 a.m. W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- explain the selection and interpretation of microbiologic testing to solve case-based diagnostic dilemmas in clinical infectious diseases
- describe the results of various tests to solve case-based diagnostic dilemmas in infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, public health practitioners, researchers

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-198-L04-P

HIV-STD-TB / Trainee

35. Interactive Session

STIs in the HIV Care Setting

Co-organized with the National Network of STD Clinical Prevention Training Centers

Thursday, 10:30 - 11:45 a.m. N Hall D

Objectives: At the conclusion of the session, participants will be able to:


- outline strategies for preventing, diagnosing, and managing common sexually transmitted infections in HIV care settings
- develop therapeutic approaches to managing syphilis, gonorrhea, nongonococcal urethritis trichomoniasis, and other infections in an era of increasing drug resistance and in the setting of drug allergies

Scientific Sessions (continued)

- review evidence-based treatment guidelines for managing STIs in HIV-infected persons

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-203-L02-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

36. Symposium

Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship


Thursday, 10:30 - 11:45 a.m.


N 24

Objectives: At the conclusion of this session, participants will be able to:

- describe concrete ways in which clinicians and antimicrobial stewardship teams can collaborate with microbiology laboratories to optimize test utilization and antimicrobial administration
- identify outcome measures that are appropriate for stewardship of laboratory tests
- define overuse, overdiagnosis, and overtreatment and apply these concepts to infectious diseases tests

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-199-L04-P

Pediatric ID / Adult ID / HIV-STD-TB

37. Symposium

Hepatitis B: Current and Future Challenges in Treatment and Prevention

Thursday, 10:30 - 11:45 a.m.


N 25


Objectives: At the conclusion of this session, participants will be able to:

- discuss current standard of care management and treatment of HBV infection
- review challenges of current HBV vaccine, approach to waning immunity and immunocompromised hosts, and investigational vaccines on the horizon
- discuss new approaches to HBV treatment and most recent developments in drug discovery

Intended Audience: academicians, clinicians, epidemiologists, fellows, HIV clinicians, HIV specialists, infectious diseases

pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-200-L01-P

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

38. Symposium

Hot Topics in Medical Education 2018

Co-organized with the IDSA Education Committee and Medical Education Workgroup

Thursday, 10:30 - 11:45 a.m.

W 2014-2016

Objectives: At the end of this session, participants will be able to:

- describe the ways in which the three domains of physician well-being—culture of wellness, efficiency of practice, and personal resilience—reciprocally influence one another
- name at least two strategies for enhancing trainee resilience
- describe strategies for supporting the development of skills associated with the promotion of trainee well-being
- identify at least one strategy to bring back to teaching and learning environments to enhance learner wellness
- define equity pedagogy and describe its principles
- describe the successes and failures of efforts to try to recruit a more diversified work force
- name existing challenges and barriers to the establishment of equity pedagogy
- describe at least one way to reduce disparities and incorporate principles of equity into teaching

Intended Audience: academicians, clinicians, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control

39. Symposium

Hot Topics in Pediatric Infectious Diseases

Thursday, 10:30 - 11:45 a.m.

W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:


- discuss the year's important clinical advances and biomedical discoveries that have the potential to impact clinical care
- describe the content of new scientific findings from experts in the field
- discuss strategies to apply new data to further discovery or clinical practices

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection

Scientific Sessions (continued)

preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-201-L04-P

Trainee / Epidemiology and Infection Control / Pediatric ID / Adult ID

40. Symposium

Improving Healthcare-Associated Infection Metrics


Thursday, 10:30 - 11:45 a.m. W 2006-2008

Objectives: At the end of this session, participants will be able to:

- explain how CMS selects HAI measures for quality reporting programs
- discuss methodology to improve risk adjustment of quality measures
- discuss improving metric communication and interpretation for patients and consumers

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-202-L04-P

Trainee / Pediatric ID / Adult ID

41. Symposium

New and Updated Guidelines

Co-organized with the IDSA Standards and Practice Guidelines Committee and Johns Hopkins University School of Medicine Division of Infectious Diseases


Thursday, 10:30 - 11:45 a.m. S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- discuss diagnostic approaches to Lyme disease and evidence-based therapeutics
- discriminate asymptomatic bacteriuria from other genitourinary infections and learn to facilitate indications for treatment and prevention of unnecessary treatment
- recognize appropriate patients for OPAT and employ effective programmatic strategies to achieve successful treatment and best safety measures

Intended Audience: academicians, clinicians, fellows, healthcare workers, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, public health practitioners, researchers

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-269-L01-P

Trainee / Transplant ID / Investigative ID / Pediatric ID / Epidemiology and Infection Control / Adult ID

42. Symposium


The Microbiome and MultiDrug-Resistant Organisms


Thursday, 10:30 - 11:45 a.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- review the data on the role the indigenous microbiota can play in resistance to colonization and disease to multidrug-resistant organisms
- analyze the evidence that analysis of the microbiome in an individual patient can provide guidance with formulating specific therapies
- discuss the impact that therapies that intentionally or unintentionally modify the microbiota can influence susceptibility to infection with MDROs

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-204-L01-P

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

43. Symposium

Tuberculosis: What's New in Diagnosis and Management

Thursday, 10:30 - 11:45 a.m. S 214-216

Objectives: At the conclusion of this session, participants will be able to:


- discuss the management of both HIV+ and HIV- persons with tuberculosis
- discuss the complications of tuberculosis therapy and drivers of multidrug-resistant *Mycobacterium tuberculosis*
- explain diagnostic modalities for tuberculosis, both latent and active forms

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-

Scientific Sessions (continued)

training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-205-L01-P

Pediatric ID / Adult ID

44. Oral Abstract Session

Adult and Adolescent Vaccines

Thursday, 10:30 - 11:45 a.m. S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID

45. Oral Abstract Session

Cool Findings in Bacteremia and Endocarditis

Thursday, 10:30 - 11:45 a.m. W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

46. Oral Abstract Session

Healthcare Epidemiology: Special Populations

Thursday, 10:30 - 11:45 a.m. S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

Investigative ID / Adult ID

47. Oral Abstract Session

Science Relevant to ID

Thursday, 10:30 - 11:45 a.m. S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

48. Oral Abstract Session

Late Breaker Oral Abstracts

Thursday, 10:30 - 11:45 a.m. S 151-153

No CME credit is offered for this session.

No CPE credit is offered for this session.

Poster Abstract Sessions

S Poster Hall

Thursday	10 a.m. - 6 p.m. 12:30 - 1:45 p.m. 12:30 - 1:45 p.m.	On Display Lunch in the Exhibit Hall Presenters at Posters
----------	--	--

49. **Antimicrobial Stewardship: Interventions in Pediatric Populations**
50. **Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record**
51. **Antimicrobial Stewardship: Interventions to Improve Outcomes**
52. **Antimicrobial Stewardship: Special Populations**
53. **Pediatric Antimicrobial and Diagnostic Stewardship**
54. **Bone and Joint Infections**
55. **CNS Infections**
56. **Fungal Disease: Management and Outcomes**
57. **Global Health and Travel Medicine**
58. **Healthcare Epidemiology: Advances in Hand Hygiene**
59. **Healthcare Epidemiology: Updates in *C. difficile***
60. **HIV: Antiretroviral Therapy**
61. **HIV: Linkage to Care and Viral Suppression in the Care Cascade**
62. **HIV: Management and Clinical Outcomes**
63. **Maternal-Child Infections**
64. **Microbiome and Beyond**
65. **Pathogenesis and Immune Response**
66. **Public Health: Epidemiology and Outbreaks**
67. **Resistance Mechanisms: Gram-Negative**
68. **Resistance Mechanisms: Gram-Positive**
69. **Respiratory Infections: Viral**
70. **Tuberculosis and Other Mycobacterial Infections**

No CME credit is offered for this session.

No CPE credit is offered for this session.

71. Poster Discussion Round

Clostridium difficile

Thursday, 12:30 - 1:45 p.m. S Poster Hall

Objectives for all IDWeek Poster Discussion Rounds: ALL IDWeek Poster Discussion Rounds objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Poster Discussion Rounds: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Scientific Sessions (continued)

72. Poster Discussion Round

Antiretroviral Therapy and Management

Thursday, 12:30 - 1:45 p.m.

S Poster Hall

No CME credit is offered for this session.

No CPE credit is offered for this session.

73. Poster Discussion Round

Antimicrobial Resistance

Thursday, 12:30 - 1:45 p.m.

S Poster Hall

No CME credit is offered for this session.

No CPE credit is offered for this session.

Epidemiology and Infection Control / Pediatric ID / Trainee / Adult ID

75. Interactive Session

Clinical Controversies


Thursday, 2 - 3:15 p.m.


W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- contrast the advantages and disadvantages of prescribing probiotics for all hospitalized patients who are taking antibiotics
- critically analyze available data suggesting that HIV persons with an undetectable viral load are not infectious to others
- define the risks and benefits of maintaining IV access after hospital discharge in persons known to use illicit IV drugs

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, medical students and residents, members-in-training

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-309-L01-P

Epidemiology and Infection Control / Trainee / Pediatric ID / Adult ID

76. Interactive Session

Controversies in Infection Prevention

Thursday, 2 - 3:15 p.m.


N 24

Objectives: At the conclusion of this session, participants will be able to:

- identify potential benefits and pitfalls of public reporting of healthcare-associated infections
- review different approaches to monitoring hand hygiene compliance

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-207-L04-P

Trainee / Pediatric ID / Epidemiology and Infection Control

77. Interactive Session

“Mano-a-Mano III”: Controversies in Pediatric ID

Thursday, 2 - 3:15 p.m.


S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- explain the differences between tuberculin skin test vs. IGRA in the initial evaluation of children for TB
- discuss the benefits of vancomycin for empiric therapy for meningitis
- describe associated benefits of respiratory viral panel testing

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-308-L01-P

Transplant ID / Trainee / Pediatric ID / Adult ID

78. Symposium

Bread and Butter Transplant ID


Thursday, 2 - 3:15 p.m.


N 25

Objectives: At the conclusion of this session, participants will be able to:

- review the importance of CMV infections in transplantation, providing an update on diagnosis and management
- discuss the implications of common respiratory viral infections in transplant recipients and management options
- explain how to generate a differential diagnosis for diarrhea in the transplant recipient and a thoughtful diagnostic and management approach

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-206-L04-P

Pediatric ID / Trainee / Global ID / Investigative ID / Adult ID

79. Symposium

Exploring the Antibiotic Pipeline 2018

Thursday, 2 - 3:15 p.m.

N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- review novel antibiotics in the pipeline including mechanism of action and clinical applications
- discuss the possible niche of novel therapies against antibiotic-resistant organisms

Scientific Sessions (continued)

- evaluate clinical and pre-clinic data of new antimicrobial molecules that are being developed

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Global ID / Adult ID

80. Symposium

Migration and Immigration: Global Diseases at Your Doorstep

Thursday, 2 - 3:15 p.m.

W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- identify diagnostic methods, clinical manifestations, and complications of Strongyloidiasis
- describe staging, treatment, and complications of echinococcal disease
- discuss diagnostic methods and treatment approaches to malaria in the U.S.

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Global ID / Pediatric ID / Adult ID

81. Symposium

New Developments on Picornaviruses

Thursday, 2 - 3:15 p.m.

S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- discuss updates in the epidemiology of picornaviruses
- review updates in laboratory methods for picornavirus infection
- describe childhood picornavirus illness

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, microbiologists, public health practitioners, scientists

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Investigative ID / Pediatric ID / Transplant ID / Trainee / Epidemiology and Infection Control / Adult ID

82. Symposium

Novel Clinical Risks for Fungal Disease


Thursday, 2 - 3:15 p.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- evaluate clinical risk for fungal disease with small molecule kinase inhibitors
- discuss the clinical risk for fungal disease with chimeric antigen receptor T cell therapy
- discuss fungal prophylaxis in high-risk groups
- explain the epidemiology of invasive fungal infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, members-in-training, microbiologists, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-209-L01-P

Trainee / HIV-STD-TB / Pediatric ID

83. Symposium

The Human Microbiome in HIV

Thursday, 2 - 3:15 p.m.


S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- review the metabolic effects of gut and immune modifications
- describe how the microbiome of the female genital tract interacts with HIV
- summarize the latest scientific findings on immunology in the rectal environment

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners, researchers

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-210-L02-P

Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

84. Oral Abstract Session

Antimicrobial Stewardship: Better Prescribing, Better Outcomes

Thursday, 2 - 3:15 p.m.

S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

Scientific Sessions (continued)

Adult ID / HIV-STD-TB

85. Oral Abstract Session Preventing and Identifying New HIV Infections

Thursday, 2 - 3:15 p.m. S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Investigative ID / Adult ID

86. Oral Abstract Session Pushing the Envelope in CNS Infections

Thursday, 2 - 3:15 p.m. S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Investigative ID / Adult ID

87. Oral Abstract Session Respiratory Infections: An Update

Thursday, 2 - 3:15 p.m. W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

88. Named Lecture John F. Enders Lecture


Thursday, 3:30 - 3:55 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- review the data on healthcare costs and physician's contributions to these costs
- provide a brief description of generic drugs and discuss issues and challenges in the use of some generic antimicrobial therapy
- discuss the question of whether use of generic antiretroviral therapy in the U.S. will help curb overall HIV costs

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 0.25 hours of *AMA PRA Category 1 Credit*[™]

 ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-310-L04-P

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

89. Awards Session Awards Session

Thursday, 3:55 - 4:05 p.m. N Hall D

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

90. Oral Abstract Session Featured Oral Abstract

Thursday, 4:05 - 4:20 p.m. N Hall D

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

91. Named Lecture Maxwell Finland Lecture


Thursday, 4:20 - 4:45 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- list reasons why antibiotic stewardship has become a national priority
- describe some of the factors that are promoting the uptake of antibiotic stewardship in hospitals
- summarize some of the key next steps for antibiotic stewardship in hospitals

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 0.25 hours of *AMA PRA Category 1 Credit*[™]

 ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-211-L04-P

Scientific Sessions (continued)

Business Meetings

SHEA's President's Reception & Business Meeting

Thursday, 6 - 7:30 p.m. Embarcadero Room, Parc 55 Hotel

No CME credit is offered for this session.

No CPE credit is offered for this session.

Business Meetings

PIDS Business Meeting

Thursday; 6 - 6:45 p.m. N 23

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

92b. Meet-the-Professor Session

Advancing ID and HIV Priorities: Making the Case to Policymakers

Friday, 7 - 9 a.m. S 155

Objectives: At the conclusion of this session, participants will be able to:

- identify opportunities for educating members of Congress and advocating for infectious disease and HIV policy priorities
- describe strategies for effectively communicating with policymakers to develop relationships with policymaker and their staff and to advance policy priorities
- describe the guidelines regarding advocacy and policy education by individuals who receive federal grant funding or work for a local or state health department or other agencies

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Investigative ID / Pediatric ID / Trainee / Adult ID

93. Meet-the-Professor Session


Ask the Expert: Managing Invasive Fungal Infections


Friday, 7:15 - 8:15 a.m. W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:

- discuss the management of invasive yeast and mold infections in transplant patients
- discuss contemporary anti-fungal agents and the use of diagnostic tests for fungal infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-212-L01-P

HIV-STD-TB / Trainee

94. Meet-the-Professor Session

Challenging STIs in the HIV Infected Patient


Friday, 7:15 - 8:15 a.m. S 156

Objectives: At the conclusion of this session, participants will be able to:

- identify key aspects of the medical evaluation, diagnosis, and treatment of STIs in patients with HIV
- evaluate different strategies and options in managing complicated STIs in patients with HIV

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, nurses, pharmacists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-213-L02-P

Pediatric ID / Trainee / Adult ID

95. Meet-the-Professor Session


Controversies in Sepsis (but not SIRS)


Friday, 7:15 - 8:15 a.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- describe the current use of sepsis criteria
- discuss the pros and cons of the sepsis definitions
- describe how the sepsis definition affects antimicrobial use

Intended Audience: clinicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-214-L04-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

96. Meet-the-Professor Session

Designing a QI Project You Can Publish

Friday, 7:15 - 8:15 a.m. S 157

Objectives: At the conclusion of this session, participants will be able to:


- explain how to design a quality improvement project

Scientific Sessions (continued)

- describe steps to plan for publication of a quality improvement project

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-215-L04-P

Pediatric ID / HIV-STD-TB / Global ID / Adult ID

97. Meet-the-Professor Session

Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era


Friday, 7:15 - 8:15 a.m. S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- discuss the recommendations for treatment of HCV using direct acting antiviral therapy
- describe the approach to treatment of HCV for special populations including patients with HIV-infection
- discuss testing required prior to HCV therapy

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-216-L01-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

98. Meet-the-Professor Session

ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs

Friday, 7:15 - 8:15 a.m. S 151-153

Objectives: At the conclusion of this session, participants will be able to:

- describe the various responsibilities for physicians entering into a role as medical director of infection prevention or an antibiotic stewardship program
- understand common challenges facing such physicians as they enter these roles and strategies to successfully overcome these barriers

Intended Audience: clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Pediatric ID / Trainee / Adult ID

99. Meet-the-Professor Session

Microbiome Therapeutics


Friday, 7:15 - 8:15 a.m. S 152-154

Objectives: At the conclusion of this session, participants will be able to:

- review the data on the use of fecal microbiota transplants in patients with infectious diseases
- discuss the development of novel therapies designed to modify the microbiome to improve human health

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-217-L01-P

Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

100. Meet-the-Professor Session

Mid-Career Challenges and Opportunities


Friday, 7:15 - 8:15 a.m. S 158

Objectives: At the conclusion of this session, participants will be able to:

- identify at least 3 challenges experienced in mid-career
- describe opportunities for mid-career physicians and pharmacists

Intended Audience: academicians, clinicians, epidemiologists, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, researchers, scientists, vaccinologists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-311-L04-P

Trainee / Pediatric ID / Global ID / Adult ID

101. Meet-the-Professor Session

Tropical Dermatology: Are You Ready for Jeopardy?

Friday, 7:15 - 8:15 a.m. W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:


- discuss differential diagnosis of skin lesions acquired during travel and residence in tropical areas
- identify and manage skin infections acquired in tropical regions

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists,

Scientific Sessions (continued)

hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-218-L01-P

Epidemiology and Infection Control / Investigative ID / Trainee / Adult ID

102. Meet-the-Professor Session

Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems


Friday, 7:15 - 8:15 a.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- describe how mathematical modeling can help inform the design and interpretation of studies to evaluate pathogen spread and strategies to prevent transmission
- discuss specific examples of how mathematical modeling can help guide concrete prevention strategies

Intended Audience: academicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-219-L04-P

Trainee / Adult ID / Pediatric ID

103. Interactive Session

“Achy Breaky Heart”: Challenging Cases in Cardiovascular Infections


Friday, 8:45 - 10 a.m. W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- describe the use of molecular diagnostic tests in endocarditis
- discuss the role of diagnostic imaging in endocarditis
- evaluate the role of surgical management in patients with endocarditis

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-220-L01-P

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

104. Interactive Session


A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention

Friday, 8:45 - 10 a.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- using case-based learning, understand the challenges with resolving infection control issues where guidance and prevention evidence may be lacking
- describe various approaches to complicated operational infection prevention problems

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Pediatric ID / Trainee / Adult ID

105. Symposium

Advances in RSV Prevention


Friday, 8:45 - 10 a.m. N 24

Objectives: At the conclusion of this session, participants will be able to:

- describe advances in RSV molecular virology
- describe advances in applications of RSV vaccines
- discuss approaches to RSV immunoprophylaxis

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, pharmacists, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-221-L01-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / Global ID / Epidemiology and Infection Control / Adult ID

106. Symposium

Fungal MDR Outbreak: *Candida auris*

Friday, 8:45 - 10 a.m. N 25


Objectives: At the conclusion of this session, participants will be able to:


- describe the epidemiology of the emerging yeast *C. auris*
- describe and compare the virulence characteristics of *C. auris* and other *Candida*
- identify opportunities for scientific and clinical studies on *C. auris*

Scientific Sessions (continued)

- describe the therapeutic challenges of managing patients with *C. auris*
- identify opportunities and challenges in infection control for fungi

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-222-L01-P

Trainee / HIV-STD-TB / Pediatric ID

107. Symposium HIV State of the Art

Friday, 8:45 - 10 a.m.


N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- review the status of long-acting antiretrovirals in HIV prevention and care
- identify new treatment approaches for highly treatment-experienced patients with HIV
- evaluate strategies for reducing inflammation in patients with HIV

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-223-L02-P

Pediatric ID / Trainee / Adult ID

108. Symposium Metagenomic-Based Infectious Disease Diagnostics

Friday, 8:45 - 10 a.m.

S 214-216


Objectives: At the conclusion of this session, participants will be able to:

- describe the principles, advantages, and limitations of metagenomic sequencing for the detection of infectious pathogens
- explain how next-generation sequencing (NGS) can be used to predict phenotypic bacterial resistance to antimicrobials
- describe the application of whole genome sequencing to the investigation and characterization of clinical bacterial outbreaks

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians,

investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-224-L04-P

Epidemiology and Infection Control / Global ID / Pediatric ID / Adult ID

109. Symposium Pandemic Influenza

Friday, 8:45 - 10 a.m.


S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- describe characteristics of an emerging novel influenza virus with pandemic potential
- identify treatment options for pandemic influenza
- describe two ways the global community can prepare for the next flu pandemic

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-312-L01-P

Adult ID / Investigative ID / Trainee / Pediatric ID

110. Symposium Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses


Friday, 8:45 - 10 a.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- describe the mechanism of adjuvants
- explain the risks and benefits of adjuvants
- identify which adjuvants are currently in use or will be used soon

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-225-L04-P

Scientific Sessions (continued)

Epidemiology and Infection Control / Pediatric ID / Trainee / Adult ID

111. Symposium Stewardship in Challenging Populations


Friday, 8:45 - 10 a.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- describe the use of antimicrobials in the neonatal, dental, and emergency department populations
- discuss antimicrobial stewardship interventions in these settings

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-226-L04-P

Pediatric ID / Epidemiology and Infection Control / Adult ID

112. Oral Abstract Session Bacterial Infections and Antimicrobial Stewardship

Friday, 8:45 - 10 a.m. S 156

Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Oral Abstract Sessions: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Epidemiology and Infection Control / Adult ID

113. Oral Abstract Session Healthcare Epidemiology: Outbreaks!

Friday, 8:45 - 10 a.m. S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

114. Oral Abstract Session Hepatitis C: Epidemiology and Elimination

Friday, 8:45 - 10 a.m. W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

115. Oral Abstract Session HIV-Related Comorbidities and Complications

Friday, 8:45 - 10 a.m. S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Adult ID / Pediatric ID

116. Interactive Session Challenging Cases in Infectious Diseases


Friday, 10:30 - 11:45 a.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- discuss the clinical presentation and diagnostics of challenging cases in infectious diseases
- describe atypical presentations of certain infectious diseases
- discuss clinical presentations mimicking infectious diseases

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, nurses, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-229-L01-P

Trainee / Adult ID

117. Symposium Big Beasts I


Friday, 10:30 - 11:45 a.m. W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- discuss the current clinical update on sino-facial infections
- discuss the current clinical update on infectious hepatitis
- discuss the current clinical update on intra-abdominal infections

Intended Audience: academicians, clinicians, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-227-L01-P

Scientific Sessions (continued)

Pediatric ID / Trainee / Global ID / Investigative ID / Adult ID

118. Symposium

How to Treat Resistant Gram-Positive Infections


Friday, 10:30 - 11:45 a.m. N 24

Objectives: At the conclusion of this session, participants will be able to:

- identify the most current approaches for the treatment of severe infections caused by multidrug-resistant *S. aureus*
- review the mechanisms of resistance and therapeutic options for vancomycin-resistant enterococci
- discuss the impact of resistance in the treatment of pneumococcal infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-230-L01-P

Epidemiology and Infection Control / Trainee / Adult ID

119. Symposium


Infection Control and Antimicrobial Stewardship in Dialysis Facilities


Friday, 10:30 - 11:45 a.m. W 2006-2008

Objectives:

- describe current approaches to antimicrobial stewardship in the dialysis population
- discuss the goals and accomplishments of the “Nephrologists Transforming Dialysis Safety” project
- identify HAI surveillance challenges in dialysis facilities and describe how surveillance can drive prevention

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-231-L04-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

120. Symposium


Late Breaker Foodborne Illnesses

Friday, 10:30 - 11:45 a.m. S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- TBD

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Investigative ID / Adult ID / Pediatric ID / Trainee

121. Symposium

Pathogen Interactions with the Microbiota


Friday, 10:30 - 11:45 a.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- list new research findings on how pathogens are modulated by the microbiota
- discuss how microbiota alter disease pathogenesis

Intended Audience: academicians, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, microbiologists, pharmacists, researchers, scientists

No CME credit is offered for this session.

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-232-L01-P

Pediatric ID / Adult ID / HIV-STD-TB / Trainee

122. Symposium

Strategies to Achieve HIV Remission


Friday, 10:30 - 11:45 a.m. N 25

Objectives: At the conclusion of this session, participants will be able to:

- review the relationship of acute HIV infection to developing an HIV cure
- describe bone marrow transplantation and other strategies to achieve a sterilizing cure for HIV
- summarize the state of research on HIV vaccine therapy to achieve HIV remission

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-233-L02-P

Scientific Sessions (continued)

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID /
Epidemiology and Infection Control / Adult ID

123. Symposium

Time 101: Optimizing Meetings


Co-organized by the IDSA Education Committee and IDSA
Medical Education Workgroup


Friday, 10:30 - 11:45 a.m. S 155

Objectives: At the end of this session, participants will be able to:

- describe appropriate reasons for setting up a meeting
- state key steps to effectively prepare for a meeting
- describe components of effectively running a meeting
- state key steps to effectively close and follow-up from a meeting
- apply skills to effectively run interactive, transformational events

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-18-234-L04-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB /
Global ID / Epidemiology and Infection Control / Adult ID

124. Oral Abstract Session

Adventures with Globally Acquired Infections

Friday, 10:30 - 11:45 a.m. S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology
and Infection Control / Adult ID

125. Oral Abstract Session

Fungal Infections

Friday, 10:30 - 11:45 a.m. W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Investigative ID / Epidemiology and Infection Control /
Adult ID

126. Oral Abstract Session

Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting

Friday, 10:30 - 11:45 a.m. S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID

127. Oral Abstract Session

Medical Education

Friday, 10:30 - 11:45 a.m. S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID

128. Oral Abstract Session

PIDS Featured Oral Abstract Caroline B. Hall Lecture

Friday, 10:30 - 10:45 a.m. S 214-216

No CME credit is offered for this session.

No CPE credit is offered for this session.

129. Named Lecture

Caroline B. Hall Lectureship


Friday, 10:45 - 11:45 a.m. S 214-216

Objectives: At the conclusion of the session, participants will be able to:

- describe challenges in the development of RSV vaccines
- identify types of RSV vaccines and mAbs currently in development and target populations for each product

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-18-228-L01-P

Poster Abstract Sessions

S Poster Hall

Friday	10 a.m. - 6 p.m. 12:30 - 1:45 p.m. 12:30 - 1:45 p.m.	On Display Lunch in the Exhibit Hall Presenters at Posters
--------	--	--

130. Adult and Pediatric Influenza Vaccine

131. Bacteremia and Endocarditis

132. Diarrhea Diagnostic Dilemmas

133. Enteric Infections

134. Fungi and Parasites in Immunocompromised Patients

135. Healthcare Epidemiology: Environmental and Occupational Health

136. Healthcare Epidemiology: MDR-Gram-Negative Infections

137. Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections

138. Healthcare Epidemiology: Non-acute Care Settings

139. Healthcare Epidemiology: Outbreaks

Scientific Sessions (continued)

- 140. **HIV: Diagnosis and Screening**
- 141. **HIV: Molecular Epidemiology**
- 142. **HIV: Prevention**
- 143. **Medical Education**
- 144. **Novel Agents**
- 145. **PK/PD Studies**
- 146. **Pneumococcal Vaccines**
- 147. **Respiratory Infections: CAP**
- 148. **Respiratory Infections: Miscellaneous**
- 149. **Sexually Transmitted Infections**
- 150. **Urinary Tract Infection**
- 151. **Viruses and Bacteria in Immunocompromised Patients**

152. Poster Discussion Round

Healthcare Epidemiology

Friday, 12:30 - 1:45 p.m.

S Poster Hall

Objectives for all IDWeek Poster Discussion Rounds: ALL IDWeek Poster Discussion Rounds objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Poster Discussion Rounds: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists
No CME credit is offered for this session.
No CPE credit is offered for this session.

153. Poster Discussion Round

PrEP

Friday, 12:30 - 1:45 p.m.

S Poster Hall

No CME credit is offered for this session.
No CPE credit is offered for this session.

154. Poster Discussion Round

Novel Agents

Friday, 12:30 - 1:45 p.m.

S Poster Hall

No CME credit is offered for this session.
No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Adult ID

156. Interactive Session

Challenging Cases in Transplant: When the ID Expert Says, "What?"

Co-organized with the American Society of Transplantation


Friday, 2 - 3:15 p.m.


S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- construct an approach to diagnosing and managing challenging infectious disease syndromes occurring in organ and stem cell transplant recipients

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-236-L01-P

Trainee / HIV-STD-TB / Pediatric ID

157. Interactive Session

Challenging HIV Cases

Friday, 2018: 2 - 3:15 p.m.


N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- identify complicating factors in HIV-infected patients
- apply strategies to address treatment complications in HIV-infected patients
- choose between different treatment strategies for managing HIV-infected patients

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-237-L02-P

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

158. Symposium

Beyond the Big Beasts of Healthcare Epidemiology

Friday, 2 - 3:15 p.m.


N 25

Objectives: At the conclusion of this session, participants will be able to:

- discuss the epidemiology and burden of several under-recognized healthcare-associated infections
- identify differences in surveillance definitions for these infections compared with those traditionally under infection prevention program surveillance
- describe potential interventions to prevent these infections

Intended Audience: clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-235-L01-P

Scientific Sessions (continued)

Epidemiology and Infection Control / HIV-STD-TB / Trainee / Adult ID

159. Symposium

Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges


Friday, 2 - 3:15 p.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- explain the principles for optimizing current blood culture technology
- describe the challenges and progress with direct from whole blood testing for detection of bacteremia
- discuss the clinical use and utility of sepsis biomarkers

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-238-L01-P

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

160. Symposium

Leading Change

Co-organized by the IDSA Education Committee and IDSA Medical Education Workgroup


Friday, 2 - 3:15 p.m. S 155

Objectives: At the conclusion of this session, participants will be able to

- identify initiatives that would significantly benefit from a thoughtful and deliberate change management process
- state the definition of change management
- describe Kotter's 8 stages of change
- apply Kotter's model to a change initiative
- explain how to facilitate change

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-239-L04-P

Trainee / Pediatric ID / Global ID

161. Symposium

Pediatric Immunization: Perspectives From Both Sides of the Pond


Co-organized with the European Society for Pediatric Infectious Diseases


Friday, 2 - 3:15 p.m. S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- discuss the differing recommendations for universal pediatric influenza immunization and selection of vaccination product in Europe and North America
- describe the North American and European perspectives on and experiences with effectiveness and safety of pediatric vaccine adjuvants
- outline strategies to increase uptake of pediatric immunization, especially influenza immunizations

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-240-L01-P

Trainee / Investigative ID / Pediatric ID / Adult ID

162. Symposium


T-Cell Biology: What the ID Physician Needs to Know


Friday, 2 - 3:15 p.m. N 24

Objectives: At the conclusion of this session, participants will be able to:

- review aspects of T-cell biology that increase understanding of immune responses to infection
- describe the current state of engineering of T cells for therapeutic use

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-241-L04-P

Scientific Sessions (continued)

Trainee / Pediatric ID / HIV-STD-TB / Epidemiology and Infection Control / Adult ID

163. Symposium

The ID Specialist and the Opioid Epidemic: What You Need to Know Now


Friday, 2 - 3:15 p.m.


W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- review strategies for successful treatment of chronic HCV among IDU in the context of elimination of HCV as a public health problem
- explain the key elements of a clinical practice-based model for delivering medication-assisted treatment for opiate use disorder by infectious disease specialists
- discuss the evidence base for supervised injection facilities for persons who inject drugs, including preventing infectious complications of IDU

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-242-L01-P

Global ID / Pediatric ID / Adult ID

164. Symposium

Vaccines Against Herpesviruses

Friday, 2 - 3:15 p.m.


S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- discuss progress in herpes simplex vaccines
- describe progress in cytomegalovirus vaccines
- discuss progress in varicella vaccines

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-243-L01-P

Adult ID / Investigative ID

165. Oral Abstract Session

Antibiotic Stewardship: Developing and Implementing Effective Programs

Friday, 2 - 3:15 p.m.

S 156

No CME credit is offered for this session.
No CPE credit is offered for this session.

Adult ID / Pediatric ID

166. Oral Abstract Session

Changing Clinical Practice for Changing Times

Friday, 2 - 3:15 p.m.

S 157

No CME credit is offered for this session.
No CPE credit is offered for this session.

167. Oral Abstract Session

Late Breaker Oral Abstract Session #1

Friday, 2 - 3:15 p.m.

S 152-154

No CME credit is offered for this session.
No CPE credit is offered for this session.

Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

168. Oral Abstract Session

Novel Therapies for Superbugs

Friday, 2 - 3:15 p.m.

S 158

No CME credit is offered for this session.
No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

169. Oral Abstract Session

Respiratory and Gastroenteritis Viruses

Friday, 2 - 3:15 p.m.

W 2002

No CME credit is offered for this session.
No CPE credit is offered for this session.

Trainee / Pediatric ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

170. Symposium

Diagnostic Updates: Clinical Mycology Update

Friday, 3:30 - 4:45 p.m.


N 24

Objectives: At the conclusion of this session, participants will be able to:

- explain the principles, advantages, and limitations of MALDI-TOF MS as a diagnostic tool for the identification of clinical fungal pathogens
- discuss methodologies, indications, interpretation, and predictive value of *in vitro* antifungal resistance testing
- understand laboratory diagnosis of emerging fungal pathogens

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-245-L01-P

Scientific Sessions (continued)

171. Symposium


ID Physicians in the Age of Value-Based Healthcare


Friday, 3:30 - 4:45 p.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- discuss macro-issues within the U.S. healthcare system that will influence the clinical practice of ID
- explain the body of literature that identifies the value that ID physicians play in the treatment of patients with severe infection
- describe how to deliver the value of ID message at the local level using resources provided by IDSA

Intended Audience: clinicians

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-313-L04-P

Trainee / Pediatric ID / Global ID / Epidemiology and Infection Control / Adult ID

172. Symposium


My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections

Friday, 3:30 - 4:45 p.m. S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- discuss the update on current zoonotic infections both in the U.S. and abroad
- explain the One Health approaches to combating zoonotic outbreaks

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, researchers

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-246-L01-P

Epidemiology and Infection Control

173. Named Lecture


SHEA Lecture: A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology

Friday, 3:30 - 3:55 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- describe recent advances, including disruptive innovations and cultural shifts in healthcare epidemiology
- compare and contrast challenges in healthcare epidemiology since these advances
- discuss the synergy of healthcare epidemiology with the quality improvement movement

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

174. Oral Abstract Session

SHEA Featured Oral Abstract

Friday, 3:55 - 4:10 p.m. N Hall D

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

175. Awards Session

Awards Session

Friday, 4:10 - 4:20 p.m. N Hall D

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Epidemiology and Infection Control / Adult ID

176. Symposium

Influential Publications in Antimicrobial Stewardship from the Past Year


Friday, 4:20 - 4:45 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- identify influential publications in antimicrobial stewardship from the past year
- identify influential publications in healthcare epidemiology from the past year

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Scientific Sessions (continued)

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-18-244-L04-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB /
Global ID / Epidemiology and Infection Control / Adult ID

177. Named Lecture



Stanley A. Plotkin Lectureship in Vaccinology

Friday, 3:45 - 4:45 p.m. N 25

Objectives: At the conclusion of this session, participants will be able to:

- discuss vaccine hesitancy in the broader context of human thought patterns and belief systems
- discuss how to engage stakeholders in developing strategies to improve immunization rates despite pervasive anti-vaccinationism

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
 ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-18-247-L04-P

178. Oral Abstract Session

PIDS Featured Oral Abstract

Friday, 3:30 - 3:45 p.m. N 25

No CME credit is offered for this session.

No CPE credit is offered for this session.

Business Meeting

Cocktails and Conversation with CDC Director Robert Redfield, MD, and an IDSA/HIVMA update: “Reflecting the New Face of ID”

Friday, 5 - 6 p.m. N Hall D

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID / Adult ID

179. Meet-the-Professor Session



B-lactam / B-lactamase Inhibitor Combinations: Which one?

Saturday, 7:15 - 8:15 a.m. S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- define the differences in activity between ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam
- define the correct role for each agent on the hospital formulary

Intended Audience: investigators, pharmacists, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
 ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-18-248-L01-P

Pediatric ID / Adult ID / HIV-STD-TB

180. Meet-the-Professor Session

Clinical Teaching for the ID Provider


Co-organized by the IDSA Education Committee and IDSA Medical Education Workgroup

Saturday, 7:15 - 8:15 a.m. S 155

Objectives: At the conclusion of this session, participants will be able to:

- describe the basic components of several evidence-based clinical teaching models
- apply these teaching models in their own clinical setting
- summarize current research on clinical teaching models
- set personal goals for applying the skills learned in this workshop to one's own practice setting, and review a tool designed to assess performance of new teaching skills

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

Trainee / Pediatric ID / Global ID / Adult ID

181. Meet-the-Professor Session



Creepy, Dreadful, Wonderful Parasites and Other Creatures

Saturday, 7:15 - 8:15 a.m. S 151-153

Objectives: At the conclusion of this session, participants will be able to:

- discuss different parasitic infections and infestations in a case-based format
- discuss management of parasitic infections and infestations in a case-based format

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
 ACPE 1 application-based contact hours of pharmacy CE;
0221-9999-18-252-L01-P

Scientific Sessions (continued)

Trainee / Epidemiology and Infection Control / Adult ID

182. Meet-the-Professor Session

Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & “Aha” Moments

Saturday, 7:15 - 8:15 a.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- discuss ways to improve the prevention and diagnosis of urinary tract infections
- explain the difference between asymptomatic bacteriuria urinary tract infection

Intended Audience: clinicians, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, nurses, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-249-L01-P

Transplant ID / Trainee / Pediatric ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

183. Meet-the-Professor Session

Diagnosis of Toxoplasmosis in Special Populations

Saturday, 7:15 - 8:15 a.m.

S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- describe optimal laboratory approaches to the diagnosis of toxoplasmosis in special patient populations, including test selection, interpretation and clinical implications in the diagnosis of congenital toxoplasmosis and the diagnosis of toxoplasmosis in the immunocompromised host

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Trainee / Pediatric ID / Adult ID

184. Meet-the-Professor Session

Dollar Dollar Bills Y'All: Billing and Coding in ID

Saturday, 7:15 - 8:15 a.m.


S 158

Objectives: At the conclusion of this session, participants will be able to:

- review optimal strategies for coding inpatient, outpatient, and non-face-to-face care

- facilitate discussion of new opportunities to employ advanced level practitioners or non-traditional settings such as nursing facilities, telemedicine, or other novel strategies to enhance revenues

Intended Audience: clinicians, HIV clinicians, hospital administrators, infectious diseases pediatricians, infectious diseases physicians

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

185. Meet-the-Professor Session

Educating Trainees about Stewardship

Co-organized with the IDSA Education Committee and Medical Education Workgroup


Saturday, 7:15 - 8:15 a.m.


W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:

- discuss the guidelines for educating trainees in antimicrobial stewardship
- describe behavioral interventions for improving antimicrobial use and stewardship among trainees

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-250-L04-P

Trainee / HIV-STD-TB / Pediatric ID / Adult ID

186. Meet-the-Professor Session

Emerging Drug Resistance in STIs


Saturday, 7:15 - 8:15 a.m.


S 157

Objectives: At the conclusion of this session, participants will be able to:

- discuss the current trends in drug resistance in STIs and propose management strategies

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases physicians, investigators, public health practitioners, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-251-L01-P

Scientific Sessions (continued)

Pediatric ID / Epidemiology and Infection Control / Adult ID / Trainee

187. Meet-the-Professor Session


NHSN Update

Saturday, 7:15 - 8:15 a.m. S 156

Objectives: At the conclusion of this session, participants will be able to:

- describe updates to the NHSN Patient Safety and Outpatient Procedure Components and NHSN data analytics
- identify answers to frequently asked questions about NHSN surveillance protocols and analysis

Intended Audience: epidemiologists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Adult ID

188. Meet-the-Professor Session


Rapid Fire: Curbsides in Transplant ID


Saturday, 7:15 - 8:15 a.m. S 152-154

Objectives: At the conclusion of this session, participants will be able to:

- identify common clinical dilemmas in transplant infectious diseases
- discuss management approaches in transplant infectious diseases
- evaluate nuances in the practice of transplant infectious diseases

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-253-L01-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / Global ID / Epidemiology and Infection Control / Adult ID

189. Meet-the-Professor Session

Updates from the Antibacterial Resistance Leadership Group


Saturday, 7:15 - 8:15 a.m. W 2002

Objectives: At the conclusion of this session, participants will be able to:

- define elements of a pragmatic clinical trial
- discuss how host gene expression-based diagnostics distinguish bacterial and viral infection

- describe three future challenges of antimicrobial drug resistance

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

Adult ID / Pediatric ID

190. Interactive Session

Shots Across the Bow: Debates in Vaccinology

Saturday, 8:45 - 10 a.m. N 24

Objectives: At the conclusion of this session, participants will be able to:

- explain the complexity of vaccine trials in pregnant women
- discuss the impact of 3 versus 4 pneumococcal vaccines in children in the U.S.
- describe the known immune responses to repeated influenza vaccination

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-261-L01-P

Trainee / Pediatric ID / Adult ID

191. Symposium

Big Beasts II


Saturday, 8:45 - 10 a.m. W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- explain how to diagnose and treat herpes simplex virus, *Klebsiella pneumoniae*, and *Cryptococcosis*
- asymptomatic bacteriuria from urinary tract infection

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-254-L01-P

Scientific Sessions (continued)

Trainee / Pediatric ID / Epidemiology and Infection Control / Global ID / Adult ID

192. Symposium

Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs


Saturday, 8:45 - 10 a.m. S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- discuss the status of global antimicrobial stewardship efforts
- discuss the World Health Organization's activities in tracking antimicrobial resistance and promoting antimicrobial stewardship in Eastern Europe
- describe the landscape of antimicrobial resistance and trends in South America

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-255-L01-P

Trainee / Epidemiology and Infection Control / Pediatric ID / Adult ID

193. Symposium

ID Physicians and Addiction Medicine


Saturday, 8:45 - 10 a.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- describe the status of the opioid epidemic, its impact on patients and as a driver of infectious diseases
- discuss how ID clinicians can integrate addiction medicine into ID practice
- describe how ID clinicians can overcome common challenges faced in the care of patients with substance dependence

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-256-L01-P

HIV-STD-TB / Trainee

194. Symposium

Malignancies in Patients with HIV


Saturday, 8:45 - 10 a.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- review the effects of smoking and lung cancer in patients with HIV
- identify key issues for treating lymphoma in patients with HIV
- describe the epidemiology and therapeutic approaches to malignancies in resource-limited settings

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-257-L02-P

Trainee / Pediatric ID

195. Symposium


Neonatal Infectious Disease: Chagas, Zika, and LCMV


Saturday, 8:45 - 10 a.m. W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- discuss the diagnosis and treatment of infants with congenital Chagas disease
- describe diagnostic testing and neurodevelopmental outcomes in infants with congenital Zika infection
- discuss the diagnosis and treatment of infants with congenital lymphocytic choriomeningitis virus (LCMV) infection

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-258-L01-P

Global ID / Pediatric ID / Adult ID

196. Symposium

Non-Zika Arboviruses in the Americas

Co-organized with the Panamerican Society of Infectious Diseases, Brazilian Society of Infectious Diseases

Saturday, 8:45 - 10 a.m. N 25


Objectives: At the conclusion of this session, participants will be able to:


- review the common and unusual presentations of infections caused by the Chikungunya virus

Scientific Sessions (continued)

- discuss the clinical presentation of dengue and controversies with the vaccine in the Americas
- assess the clinical impact of the yellow fever outbreak in Brazil

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-259-L01-P

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

197. Symposium

Pediatric Infection Prevention: Small Patients, Big Challenges


Saturday, 8:45 - 10 a.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- describe effective strategies for the prevention of mucosal barrier injury central line-associated bloodstream infections in children
- review infectious risks associated with animal-assisted therapy in pediatric healthcare facilities and offer practical solutions based on SHEA expert guidance
- discuss safe infant feeding practices in healthcare facilities with an emphasis on current challenges, including breast milk misadministrations

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-260-L01-P

Transplant ID / Trainee / Pediatric ID / Adult ID

198. Symposium


The Future of Transplant ID: Novel Diagnostics and Therapeutics


Saturday, 8:45 - 10 a.m. S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- evaluate new diagnostic tools and their applications in transplant infectious diseases
- review and categorize approaches to immunosuppressive therapy, emphasizing the relevance of each from an infectious diseases perspective
- discuss emerging transplant modalities and the implications for infectious diseases providers

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-262-L01-P

Trainee / Pediatric ID / Investigative ID / Adult ID

199. Oral Abstract Session

Clinical Trials that May Change Your Practice

Saturday, 8:45 - 10 a.m. S 158

Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Oral Abstract Sessions: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Adult ID

200. Oral Abstract Session

Public Health: Epidemiology and Outbreaks

Saturday, 8:45 - 10 a.m. S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

201. Oral Abstract Session

The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment

Saturday, 8:45 - 10 a.m. S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

202. Oral Abstract Session

Transplant and Immunocompromised Hosts: Emerging Issues

Saturday, 8:45 - 10 a.m. W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Scientific Sessions (continued)

Trainee / Pediatric ID / Global ID / Adult ID

203. Interactive Session

Tropical Medicine Cases: Conundrums and Case Management

Saturday, 10:30 - 11:45 a.m.

S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- discuss the work-up of a variety of tropical diseases in a case-based format
- discuss the management of a variety of tropical diseases in a case-based format

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-270-L01-P

Transplant ID / Pediatric ID / Trainee / HIV-STD-TB

204. Symposium

Advances in Transplantation for Patients with HIV


Saturday, 10:30 - 11:45 a.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- describe advances in transplantation for patients with HIV
- evaluate solid organ transplantation in patients with HIV
- summarize the latest approaches to bone marrow transplantation in patients with HIV

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-263-L02-P

Pediatric ID / Trainee / Global ID / HIV-STD-TB / Epidemiology and Infection Control / Adult ID

205. Symposium

Changing Landscape of Rapid Diagnostic Tests and Their Impact

Saturday, 10:30 - 11:45 a.m.

S 206-208


Objectives: At the conclusion of this session, participants will be able to:

- discuss the benefits and limitations of CIDTs
- explore the public health implications of CIDTs

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists,

infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-264-L04-P

Epidemiology and Infection Control / Global ID / Pediatric ID / Adult ID

206. Symposium

Controlling Antimicrobial Resistance Across Borders


Saturday, 10:30 - 11:45 a.m.


W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- describe local and regional experiences and approaches to controlling the spread of antimicrobial resistance
- identify public health challenges and opportunities for controlling the spread of resistance among states
- discuss examples of how antimicrobial resistance can be controlled across national borders

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-265-L04-P

Investigative ID / Pediatric ID / Trainee / Adult ID

207. Symposium

Cool Ways to Discover Antibiotics

Saturday, 10:30 - 11:45 a.m.


N 25

Objectives: At the conclusion of this session, participants will be able to:

- discuss novel and cutting-edge approaches to discover antibiotics
- evaluate chemical strategies to modify antibiotics and provide new structures with potential clinical utility
- discuss the discovery of antibiotics using a deep understanding of host-pathogen interactions

Intended Audience: academicians, clinicians, investigators, lab personnel, microbiologists, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-266-L04-P

Scientific Sessions (continued)

Epidemiology and Infection Control / Trainee / Pediatric ID / Adult ID

208. Symposium

I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID


Saturday, 10:30 - 11:45 a.m.


W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- describe the use of quality metrics that apply to specific infectious diseases
- discuss the role of metrics in improving the care of patients with infectious diseases

Intended Audience: clinicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-267-L04-P

Trainee / Pediatric ID / Adult ID

209. Symposium

Infections in Immunocompromised Hosts


Saturday, 10:30 - 11:45 a.m.

S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- describe the presentation and management of complicated pneumonia
- explain the different approaches to treat complicated appendicitis
- discuss the management and treatment of pediatric ventricular shunt infections

Intended Audience: clinicians, epidemiologists, fellows, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Trainee / Global ID / Pediatric ID / Adult ID

210. Symposium

Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future


Saturday, 10:30 - 11:45 a.m.


N 24

Objectives: At the conclusion of this session, participants will be able to:

- describe the history of the current influenza vaccine
- identify the strengths and weaknesses of the current influenza vaccine
- summarize the goals of universal immunization

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-268-L01-P

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

211. Oral Abstract Session

Diagnostics Making a Difference

Saturday, 10:30 - 11:45 a.m.

S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

212. Oral Abstract Session

Healthcare Epidemiology: You Can Try This at Home—Innovative Epi Abstracts

Saturday, 10:30 - 11:45 a.m.

S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / HIV-STD-TB / Adult ID

213. Oral Abstract Session

Late Breaker Oral Abstracts

Saturday, 10:30 - 11:45 a.m.

S 152-154

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

214. Oral Abstract Session

Optimizing HIV Treatment

Saturday, 10:30 - 11:45 a.m.

S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

215. Oral Abstract Session

Translating Microbiome Science into Practice

Saturday, 10:30 - 11:45 a.m.

W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Scientific Sessions (continued)

Poster Abstract Sessions	S Poster Hall
Saturday	10 a.m. - 6 p.m. 12:30 - 1:45 p.m. 12:30 - 1:45 p.m.
	On Display Lunch in the Exhibit Hall Presenters at Posters

216. Antimicrobial Stewardship: Global Perspectives
217. Antimicrobial Stewardship: Impact of Allergy
218. Antimicrobial Stewardship: Impact of New Diagnostics
219. Antimicrobial Stewardship: New Methods and Metrics
220. Antimicrobial Stewardship: Non-hospital Settings
221. Antimicrobial Stewardship: Outpatient Settings
222. Antimicrobial Stewardship: Potpourri
223. Antimicrobial Stewardship: Qualitative Research
224. Antiviral Therapies
225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis
226. Clinical Practice Issues: OPAT
227. Clinical Trials
228. Diagnostics: Bacteria and Mycobacteria
229. Diagnostics: Biomarkers and Novel Approaches
230. Diagnostics: Mycology
231. Diagnostics: Parasitology
232. Diagnostics: Resistance Testing
233. Diagnostics: Virology
234. Healthcare Epidemiology: Device-associated HAIs
235. Healthcare Epidemiology: Surgical Site Infections
236. Healthcare Epidemiology: Epidemiologic Methods
237. Healthcare Epidemiology: HAI Surveillance
238. Hepatitis A, B, and C
239. HIV and Viral Hepatitis Co-Infection
240. HIV: Malignancy
241. HIV: Metabolic, Cardiovascular, and Renal Complications
242. HIV: Opportunistic Infections and other Infectious Complications
243. HIV: Sexually Transmitted Infections
244. Miscellaneous Vaccines
245. Molecular & Sequence Based Diagnostics
246. Pediatric Healthcare-Associated Infections
247. Pediatric Bacterial Infections
248. Pediatric Viral Infections
249. Skin and Skin Structure Infection
250. Treatment of AMR Infections
251. Adolescent Vaccines
252. Vaccine Policy and Hesitancy
253. Vaccines for Herpes Zoster Virus
254. Vaccines for the Elderly and Immune Compromised
255. Virology Potpourri

256. Poster Discussion Round

Clinical Trials

Saturday, 12:30 - 1:45 p.m. S Poster Hall

Objectives for all IDWeek Poster Discussion Rounds: ALL IDWeek Poster Discussion Rounds objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Poster Discussion Rounds:

academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

257. Poster Discussion Round

Diagnostics

Saturday, 12:30 - 1:45 p.m. S Poster Hall

No CME credit is offered for this session.

No CPE credit is offered for this session.

258. Poster Discussion Round

Co-Morbidities and Metabolic Disorders

Saturday, 12:30 - 1:45 p.m. S Poster Hall

No CME credit is offered for this session.

No CPE credit is offered for this session.

259. Poster Discussion Round

Immunocompromised Hosts

Saturday, 12:30 - 1:45 p.m. S Poster Hall

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Epidemiology and Infection Control / Investigative ID / Adult ID

260. Symposium

Advances in Epidemiology Research Methods

Saturday, 2 - 3:15 p.m. N 24

Objectives: At the conclusion of this session, participants will be able to:

- discuss strategies for using implementation science
- describe the use of location mapping in infection prevention
- recognize novel sources of data for quality studies

Intended Audience: academicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-271-L04-P

Scientific Sessions (continued)

Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

261. Symposium

Infection Prevention in Post-Acute Care: Controversies and Challenges

Saturday, 2 - 3:15 p.m.


S 206-208

Objectives: At the conclusion of this session, participants will be able to:

- review implementation of contact precautions for multidrug-resistant organisms (MDROs) in long-term care settings, balancing risks and benefits
- discuss infection prevention challenges in long-term acute care hospitals (LTACHs)
- describe antibiotic stewardship interventions in long-term care settings

Intended Audience: clinicians, fellows, infection preventionists, medical students and residents, members-in-training, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-272-L01-P

Trainee / Pediatric ID

262. Symposium

Intersection of Surgery and Pediatric Infectious Disease


Saturday, 2 - 3:15 p.m.


S 214-216

Objectives: At the conclusion of this session, participants will be able to:

- describe the presentation and management of complicated pneumonia
- discuss the different approaches to treat complicated appendicitis
- discuss the management and treatment of pediatric ventricular shunt infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-314-L01-P

Trainee / Pediatric ID

263. Symposium

Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children

Saturday, 2 - 3:15 p.m.

W 2006-2008


Objectives: At the conclusion of this session, participants will be able to:


- evaluate the current status of community-acquired and healthcare-acquired gram-positive bacterial infections in

children and why these infections continue to be a threat to pediatric patients

- describe the evolution of resistance in gram-negative bacteria and how this emergence of multidrug-resistance is impacting children
- discuss the potential niches of newer antibiotic agents with enhanced gram-negative activity

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-273-L01-P

HIV-STD-TB / Trainee

264. Symposium

Pain Management and Mental Health in Patients with HIV

Saturday, 2 - 3:15 p.m.


W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- evaluate strategies for managing pain in patients with HIV
- identify approaches to treating opioid addiction in patients with HIV
- describe key considerations in monitoring and managing the mental health of aging patients with HIV

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-274-L02-P

Investigative ID / Pediatric ID / Trainee / Epidemiology and Infection Control / Adult ID

265. Symposium

Strategy Trials: A New Paradigm in Infectious Diseases Research

Saturday, 2 - 3:15 p.m.

W 2005-2024


Objectives: At the conclusion of this session, participants will be able to:


- explain the rationale for performing strategy trials in infectious diseases
- summarize data for two of the more common infections addressed by strategy

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab

Scientific Sessions (continued)

personnel, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-275-L04-P

Trainee / HIV-STD-TB / Investigative ID / Adult ID

266. Symposium Syphilis in the 21st Century


Saturday, 2 - 3:15 p.m.


N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- review the syphilis diagnostic and therapeutic pipeline
- describe the host-pathogen interactions in syphilis and their implications on vaccine development
- review the behavioral aspects associated with the current STI and syphilis epidemic

Intended Audience: academicians, clinicians, epidemiologists, fellows, HIV clinicians, HIV specialists, hospital epidemiologists, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, public health practitioners, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-276-L01-P

Trainee / Investigative ID / Pediatric ID / Adult ID

267. Symposium When Does PK/PD Matter for Patient Care?

Saturday, 2 - 3:15 p.m.


S 305-314

Objectives: At the conclusion of this session, participants will be able to:

- describe the clinical relevance of antibiotic pharmacokinetics
- explain when adjustment may be needed for optimal therapy
- discuss the literature exploring the impact of organ specific antibiotic pharmacokinetics

Intended Audience: academicians, clinicians, infectious diseases pediatricians, infectious diseases physicians, pharmacists, researchers, scientists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-277-L04-P

Transplant ID / Trainee / Pediatric ID / Global ID / Adult ID

268. Symposium When Transplant Tours the World

Saturday, 2 - 3:15 p.m.

N 25

Objectives: At the conclusion of this session, participants will be able to:


- discuss issues surrounding tuberculosis infection from

a transplant perspective, including infection prevention, identification, diagnosis, and treatment

- examine the infectious disease challenges that arise from transplant tourism
- review emerging arbovirus infections as they pertain to organ transplant donors and recipients

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

 Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-278-L01-P

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Epidemiology and Infection Control / Adult ID

269. Oral Abstract Session Flu and other Vaccines in Children

Saturday, 2 - 3:15 p.m.

W 2002

No CME credit is offered for this session.

No CPE credit is offered for this session.

Investigative ID / Adult ID

270. Oral Abstract Session Genomics and Susceptibility of Superbugs

Saturday, 2 - 3:15 p.m.

S 157

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

271. Oral Abstract Session Novel Diagnostics for Fungi, Parasites, and CNS Infection

Saturday, 2 - 3:15 p.m.

S 158

No CME credit is offered for this session.

No CPE credit is offered for this session.

Trainee / Pediatric ID

272. Oral Abstract Session Pediatric Viral Infections

Saturday, 2 - 3:15 p.m.

S 156

No CME credit is offered for this session.

No CPE credit is offered for this session.

Scientific Sessions (continued)

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

273. Named Lecture Joseph E. Smadel Lecture


Saturday, 3:30 - 3:55 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- describe the research potential of partnerships between academic and public health institutions
- discuss the impact of post-licensure studies on vaccine effectiveness

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 0.25 hours of *AMA PRA Category 1 Credit™*

 ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-279-L04-P

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

274. Awards Session Awards Session

Saturday, 3:55 - 4:05 p.m. N Hall D

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

275. Oral Abstract Session Featured Oral Abstract

Saturday, 4:05 - 4:20 p.m. N Hall D

No CME credit is offered for this session.

No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

276. Named Lecture Edward H. Kass Lecture


Saturday, 4:20 - 4:45 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- describe the evolution of opportunistic infections as a challenge to durable survival of patients with HIV
- discuss the broad range of skills that an ID practitioner has the opportunity to use to meet the challenges of infectious pathogens
- summarize the professional skills that are needed to be an effective ID practitioner

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 0.25 hours of *AMA PRA Category 1 Credit™*

 ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-280-L02-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID


277. Interactive Session ID BugBow!

Saturday, 5 - 6 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:

- TBD

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Scientific Sessions (continued)

Transplant ID / Pediatric ID / Trainee / Global ID / Epidemiology and Infection Control / Adult ID

278. Mini-Symposium


Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics

Sunday, 8 - 9 a.m. W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:

- explain how to use the 2017 Infectious Diseases Society of America guideline
- improve their approach to patients with potentially infectious causes of diarrhea

Intended Audience: clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, microbiologists, public health practitioners

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

Trainee / Pediatric ID / HIV-STD-TB / Epidemiology and Infection Control

279. Mini-Symposium

Red Book Update


Sunday, 8 - 9 a.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:

- discuss recent changes in recommendations in the Red Book: A Report of the AAP Committee on Infectious Diseases
- apply current recommendations in the administration of pediatric vaccines

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-281-L04-P

Epidemiology and Infection Control / Adult ID / Pediatric ID

280. Mini-Symposium

Tele-Antimicrobial Stewardship


Sunday, 8 - 9 a.m. W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:

- list and characterize the types of tele-antimicrobial stewardship programs that have been developed
- describe challenges and opportunities in the development of tele-antimicrobial stewardship programs

Intended Audience: clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians

 Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-315-L04-P

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

281. Plenary Session

Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections


Sunday, 9:15 - 10:45 a.m. W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:

- describe the rationale, opportunities, and challenges to the use of bacteriophages for the treatment of bacterial infections
- discuss how phage lysins work as therapeutic agents against antibiotic-resistant bacteria and their effectiveness

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

 ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-316-L04-P

Oral Abstract Sessions

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID

30. Oral Abstract Session

Healthcare Epidemiology: Hot Topics

Thursday, 8:45 - 10 a.m. S 157

- 109 Differences in Gram-Negative Antibiotic Susceptibility among Patients Receiving Fecal Microbiota Transplant for *Clostridioides difficile*
- 110 The Burden and Preventability of Sepsis-Associated Mortality in Six U.S. Acute Care Hospitals
- 111 Increasing Duration of Surgical Prophylaxis Increases Antimicrobial-Associated Adverse Events but Does Not Decrease Surgical Site Infections: An Opportunity for Stewardship
- 112 Sick Employee Online Log System for Tracking Employee Illnesses during the 2017-18 Influenza Season Provided Real-Time Surveillance and Early Detection of Influenza-Like Illnesses Among Employees
- 113 Accuracy of the NHSN Central Line-Associated Bloodstream Infection (CLABSI) Definition

Investigative ID / Pediatric ID

31. Oral Abstract Session

Infant Viral Infections

Thursday, 8:45 - 10 a.m. S 156

- 114 Birth Prevalence of Congenital Cytomegalovirus Infection and Language, Hearing, and Developmental Outcomes in a Cohort of HIV-Exposed, Uninfected Preschool Children
- 115 Results of a Targeted Neonatal Screening Program for Congenital Cytomegalovirus Infection in Montreal, Quebec
- 116 Role of Maternal Antibodies in Protection Against Postnatal Cytomegalovirus Acquisition
- 117 Effect of Nasopharyngeal Pneumococcal Carriage on RSV and hMPV Illness Severity in Infants in Nepal
- 118 Nasopharyngeal (NP) Bacterial Detection in Infants with Respiratory Syncytial Virus (RSV) Infection: Impact on Clinical Outcomes

Global ID / Adult ID

32. Oral Abstract Session

Tuberculosis and other Mycobacterial Infections

Thursday, 8:45 - 10 a.m. W 2002

- 119 Prospective Validation of a Three-Gene Signature for Tuberculosis Diagnosis, Predicting Progression, and Evaluating Treatment Response
- 120 A Randomized Double-Blind Trial Assessing the Efficacy of M72/AS01_E Vaccine Against Pulmonary Tuberculosis Disease in Adults with Latent *Mycobacterium tuberculosis* Infection

- 121 Improving Predictive Value of Phase 2a TB Drug Development Models through PET/CT Imaging (NexGen EBA)
- 122 All-cause Mortality Increased with Nontuberculous Mycobacterial Lung Disease in U.S. Medicare
- 123 Hansen's Disease and Complications Among Marshallese-Americans in Northwest Arkansas, 2003–2017

Adult ID

33. Oral Abstract Session

What's Hot in UTIs and STIs

Thursday, 8:45 - 10 a.m. S 158

- 124 Microbiological Outcomes with Plazomicin (PLZ) Versus Meropenem (MEM) in Patients (pts) with Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP) in the EPIC Study
- 125 eGISP: Enhanced Surveillance of *Neisseria gonorrhoeae* Antimicrobial Susceptibility in the United States
- 126 Robust and Persistent Vaginal Colonization with LACTIN-V Vaginal *Lactobacillus crispatus* Probiotic in a Double-Blind, Placebo Controlled (DBPC) Phase 2b Trial to Prevent Recurrent UTI (rUTI)
- 127 Urinary Tract Infection Incidence is Associated with Recent Environmental Temperatures
- 128 Sexually Transmitted Infections Among Adolescent Girls In Thika, Kenya

Adult ID / Pediatric ID

44. Oral Abstract Session

Adult and Adolescent Vaccines

Thursday, 10:30 - 11:45 a.m. S 158

- 149 Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
- 150 Relative Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017.
- 151 Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among U.S. Medicare Beneficiaries ≥ 65 Years Old
- 152 Protective Antibody Levels 7.5 Years after Primary Vaccination in Adolescence with a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical Findings
- 153 The Effect of Timing of Tetanus-Diphtheria and Pertussis Vaccine Administration in Pregnancy on the Avidity of Pertussis Antibodies

Oral Abstract Sessions (continued)

Adult ID

45. Oral Abstract Session

Cool Findings in Bacteremia and Endocarditis

Thursday, 10:30 - 11:45 a.m. W 2002

- 154 Diagnosis and Genotyping of *Coxiella burnetii* Causing Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement (PVR) Using Next-Generation Sequencing (NGS) of Plasma
- 155 Infective Endocarditis and Cardiac Valve Surgery During the Opioid Epidemic in North Carolina, 2007 to 2017
- 156 Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Infective Endocarditis (IE) Using the Karius Plasma Next Generation Sequencing (NGS) Test
- 157 Reducing Blood Culture Contamination Rates Through the Use of a Red Top Tube Discard
- 158 The Effect of Insurance Coverage on Appropriate Selection of Hospital Discharge Antibiotics for *Staphylococcus aureus* Bacteremia

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID

46. Oral Abstract Session

Healthcare Epidemiology: Special Populations

Thursday, 10:30 - 11:45 a.m. S 156

- 159 Genomic Epidemiology of MRSA at Intake to a Large Inner-City Jail—Evidence for Community Transmission Networks?
- 160 Reduction in the Spread of Hospital-Associated Infections Among Pediatric Oncology Patients in an Animal-Assisted Intervention Program from a Canine Decolonization Procedure
- 161 Prevalence and Risk Factors for *Candida auris* Colonization Among Patients in a Long Term Acute Care Hospital—New Jersey, 2017
- 162 Association between Antibiotic Use and Multidrug-Resistant Organism Detection in Advanced Cancer Patients on Palliative Chemotherapy
- 163 Development of an Electronic Flagging Tool for Identifying Cardiac Device Infections: Insights from the VA CART Program

Adult ID / Investigative ID

47. Oral Abstract Session

Science Relevant to ID

Thursday, 10:30 - 11:45 a.m. S 157

- 164 Reporting the High-Resolution Structure of the Enterococcal Ribosome—A New Template for Antibiotic Discovery
- 165 *Mycobacterium Tuberculosis* Produces Molecules that Trigger Nociceptive Neurons to Activate Cough
- 166 TGF β Restricts T Cell IFN γ Production in Pulmonary Tuberculous Granulomas

- 167 A *Bordetella pertussis* Human Challenge Model Induces Immunizing Colonization in the Absence of Symptoms
- 168 Intradermal Immunization Drives Humoral and Cellular Immunity to the Lung and Protects Against Acute *P. aeruginosa* Pneumonia

48. Oral Abstract Session

Late Breaker Oral Abstracts

Thursday, 10:30 - 11:45 a.m. S 151-153

See meeting app.

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID

84. Oral Abstract Session

Antimicrobial Stewardship: Better Prescribing, Better Outcomes

Thursday, 2 - 3:15 p.m. S 156

- 854 The Impact of the CMS SEP-1 Core Measure on Antimicrobial Utilization: A Multicenter Interrupted Time-Series (ITS) Analysis
- 855 Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern U.S. Hospitals
- 856 Impact of Early Discontinuation of Antimicrobial Therapy on Survival in Culture-Negative Clinically Suspected Serious Infection: An Electronic Health Record-Based Analysis from 111 U.S. Hospitals
- 857 A Tele-Antibiotic Stewardship Program Influences Antibiotic Use at 2 Rural Veterans Affairs Medical Centers
- 858 Preoperative “Dirty” Urinalysis Leads to Antibiotic Use Without Benefit

Adult ID / HIV-STD-TB

85. Oral Abstract Session

Preventing and Identifying New HIV Infections

Thursday, 2 - 3:15 p.m. S 157

- 859 Same-day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-In STD Clinic Appointments is a Safe, Feasible, and Effective Method to Engage Patients at Risk for HIV in PrEP Care
- 860 Immediate Access to Post-Exposure Prophylaxis (PEP) through a 24/7 New York City PEP Hotline

Oral Abstract Sessions (continued)

- 861 Health Disparities in HIV and Pregnancy
862 Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters
863 Increasing PrEP Uptake: A Diffusion-Based Network Intervention for HIV Prevention Among Young Black Men Who Have Sex with Men

Adult ID / Investigative ID / Pediatric ID

86. Oral Abstract Session

Pushing the Envelope in CNS Infections

Thursday, 2 - 3:15 p.m. S 158

- 864 Therapeutic Immunosuppression to Treat Rabies Encephalitis
865 *Acanthamoeba* Disease Associated with the Practice of Nasal Rinsing in Immunocompromised Patients
866 Increased Diagnosis of Varicella Zoster Virus Infection of the Central Nervous System with the BioFire FilmArray Meningitis/Encephalitis Panel
867 Upregulated Matrix Metalloproteinase-2 Relates to Milder Hearing Impairment in Bacterial Meningitis
868 Prospective Pathogen Detection in Patients with Central Nervous System Inflammation Using Metagenomic Sequencing

Pediatric ID / Investigative ID / Adult ID

87. Oral Abstract Session

Respiratory Infections: An Update

Thursday, 2 - 3:15 p.m. W 2002

- 869 Evaluation of Broad-Spectrum Antibiotic De-Escalation in Patients with Healthcare-Associated Pneumonia (HCAP) and No Microbiological Diagnosis
870 Incidence and Temporality of Influenza-Related Parotitis—Arkansas, 2016–17
871 Symptomatic Respiratory Syncytial Virus and Adenovirus Upper Respiratory Tract Infections Increase the Risk of Invasive Aspergillosis after Allogeneic Hematopoietic Cell Transplantation
872 PROPHEC: Predicting Pneumonia in Hospitalized Patients in the ICU—A Model and Scoring System
873 Using the Host Immune Response to Identify Viral-Bacterial Coinfection in Children with *Respiratory syncytial virus* Infection

Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID

90. Oral Abstract Session

Featured Oral Abstract

Thursday, 4:05 - 4:20 p.m. N Hall D

- 875 Sex Differences in Academic Achievement and Faculty Rank in Academic Infectious Diseases

Pediatric ID / Epidemiology and Infection Control

112. Oral Abstract Session

Bacterial Infections and Antimicrobial Stewardship

Friday, 8:45 - 10 a.m. S 156

- 918 Typhoid Fever in the U.S. Pediatric Population, 1999-2015, and the Potential Benefits of New Vaccines
919 Clinical and Microbiologic Characteristics Associated with Long Term Orthopedic Complications Following *Staphylococcus aureus* Acute Hematogenous Osteoarticular Infections in Children
920 A Sharp Fall in Antibiotic Use in Infants is Correlated with a Population-Wide Reduction in Asthma Incidence for Children Under Five
921 Antibiotic Prescribing for Children in Family Medicine Clinics within a Practice Research Network
922 Barriers to Pediatric Staff Nurse Participation in Antimicrobial Stewardship Programs (ASP) Linked to Organizational Culture

Adult ID / Epidemiology and Infection Control / Pediatric ID

113. Oral Abstract Session

Healthcare Epidemiology: Outbreaks!

Friday, 8:45 - 10 a.m. S 158

- 923 Rapid Emergence of *Candida auris* in the Chicago Region
924 Incidence of Symptomatic and Asymptomatic Influenza Among Healthcare Workers: A Multicenter Prospective Cohort Study
925 Healthcare-Associated Legionnaires' Disease, California, 2015-2017
926 Outbreak of Invasive Nontuberculous *Mycobacterium* (NTM) Infections Associated with a Pediatric Dental Practice
927 Tap Water Avoidance Decreases Rates of Nontuberculous *Mycobacteria* in Intensive Care Units

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID

114. Oral Abstract Session

Hepatitis C: Epidemiology and Elimination

Friday, 8:45 - 10 a.m. W 2002

- 928 Major Decrease in Prevalence of Hepatitis C Viremia in Key Populations Following the 2nd Year of Treatment as Prevention for Hepatitis C (TraP HepC) Program in Iceland
929 Hepatitis C Virus in Women of Child-Bearing Age, Pregnant Women, and Young Children
930 HCV Treatment is Associated with a Reduced Risk of Cardiovascular Disease Events: Results from ERCHIVES
931 Telemedicine for the Treatment of Hepatitis C: A Systematic Review and Meta-Analysis
932 Universal Hepatitis C Virus Screening in a Tennessee Tertiary Care Emergency Department

Oral Abstract Sessions (continued)

Adult ID / Epidemiology and Infection Control / Investigative ID

115. Oral Abstract Session

HIV-Related Comorbidities and Complications

Friday, 8:45 - 10 a.m. S 157

- 933 Serum Albumin is Associated with Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection
- 934 Incidence of Skin and Soft Tissue Infection in People Living with HIV in a Large Urban Public Health Care System in Houston, Texas, 2009-2014
- 935 Repeat Pregnancies Among Women Living with HIV: Evaluating Temporal Changes in HIV Disease Status and Exploring the Association Between Preterm Birth and Protease Inhibitor Use in Pregnancy
- 936 Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
- 937 Virally Suppressed PLH Switching from Abacavir to Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID

124. Oral Abstract Session

Adventures with Globally Acquired Infections

Friday, 10:30 - 11:45 a.m. S 158

- 962 Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
- 963 Whole Blood Transcriptome Analysis Reveals Differences in Erythropoiesis and Neurologically Relevant Pathways between Cerebral Malaria and Severe Malarial Anemia
- 964 Impact of Doxycycline as Malaria Prophylaxis on Risk of Influenza Like Illness among International Travelers
- 965 Applying Clinical Prediction Tools to Patients with Lassa Fever
- 966 Infectious Diseases among U.S. Resident Student Travelers after Return to the United States: A GeoSentinel Analysis, 2007-2017

Adult ID / Epidemiology and Infection Control / HIV-STD-TB / Pediatric ID

125. Oral Abstract Session

Fungal Infections

Friday, 10:30 - 11:45 a.m. W 2002

- 967 Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis
- 968 Managing Invasive Aspergillosis in the Era of Diagnostic PCR and Increasing Triazole Resistance: A Modelling Study of Different Strategies
- 969 GRP78 and Integrin $\beta 1/\alpha 3$ Play Disparate Roles in Epithelium Invasion During Mucormycosis

- 970 Emerging Pathogen *Candida auris* Evades Neutrophil Attack
- 971 Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID

126. Oral Abstract Session

Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting

Friday, 10:30 - 11:45 a.m. S 156

- 972 Asymptomatic Carriage of *Clostridiodes difficile* and Risk of Subsequent Infection
- 973 Inter-Facility Patient Sharing and *Clostridium difficile* Incidence in the Ontario Hospital Network: A 13-Year Longitudinal Cohort Study of 116 Hospitals
- 974 Impact of Mandatory Infectious Disease (ID) Specialist Approval on Hospital-Onset *Clostridium difficile* (HO-CDI) Testing and Infection Rates: Results of a Pilot Study
- 975 *Clostridium difficile* Infection and Antibiotic Prescription Rates in the Community: Explaining the Gender Gap
- 976 *Clostridium difficile* Colonization, Molecular Epidemiology, and Anti-Toxin Serological Responses in Healthy Infants: A Prospective Cohort Study

Adult ID

127. Oral Abstract Session

Medical Education

Friday, 10:30 - 11:45 a.m. S 157

- 977 An Innovative 3-Year Medical Student Spiral Curriculum in Antimicrobial Stewardship and Infectious Diseases
- 978 Assessing the Impact of a Mobile Device-Based Clinical Decision Support Tool on Guideline Adherence and Mental Workload
- 979 Standardizing Medical Student Learning for Infectious Diseases Consult Electives: Prioritizing Content
- 980 Using Videoconferencing with the Clinical Microbiology Lab to Enhance Medical Student Learning during Clinical Rotations
- 981 A Comprehensive Survey of Infectious Diseases Curriculum among United States Pharmacy Schools

Pediatric ID

128. Oral Abstract Session

PIDS Featured Oral Abstract Caroline B. Hall Lecture

Friday, 10:30 - 10:45 a.m. S 214-216

- 982 Summer Outbreak of Severe RSV-B Disease, Minnesota, 2017

Oral Abstract Sessions (continued)

Adult ID / Investigative ID

165. Oral Abstract Session

Antibiotic Stewardship: Developing and Implementing Effective Programs

Friday, 2 - 3:15 p.m. S 156

- 1629** Targeted Antimicrobial Use Admission Provides an Actionable Denominator for Antimicrobial Stewardship Programs Evaluating Inpatient Length of Therapy
- 1630** Antibiotics Prescribed for Infection Prophylaxis Prior to Dental Procedures Are Frequently Unnecessary in the United States
- 1631** Made to Measure: Development of a Scoring Tool to Customize Antimicrobial Stewardship Goals across a Large Health-System
- 1632** Non-Visit-Based and Non-Infection-Related Ambulatory Antibiotic Prescribing
- 1633** A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection in Adults and Children in Emergency Department and Urgent Care Settings (MITIGATE Trial)

Adult ID / Pediatric ID

166. Oral Abstract Session

Changing Clinical Practice for Changing Times

Friday, 2 - 3:15 p.m. S 157

- 1634** A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
- 1635** Do Persons with Opioid Use Disorder and Injection-Related Infections Really Need Prolonged Hospitalizations to Complete Intravenous Antibiotic Therapy?
- 1636** Variation in Clinical Practice Patterns among Infectious Diseases Faculty at a Large Academic Institution
- 1637** Improving Transitions of Care in the Division of Infectious Diseases
- 1638** Tele-Infectious Disease Consultation Produces Equivalent Outcomes as In-Person Consultation

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

167. Oral Abstract Session

Late Breaker Oral Abstracts

Friday, 2 - 3:15 p.m. S 152-154

See meeting app.

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID

168. Oral Abstract Session

Novel Therapies for Superbugs

Friday, 2 - 3:15 p.m. S 158

- 1639** Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole Resistant *Aspergillus fumigatus* Strains
- 1640** Towards New Anti-Biofilm Therapies: High Mobility Group Box 1 (HMGB1) Protein and its Structural Variants Can Be Used to Disrupt Bacterial Biofilms (BBs)
- 1641** Treatment of Recurrent *Clostridium difficile* Infection with SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
- 1642** Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data
- 1643** Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID / Trainee

169. Oral Abstract Session

Respiratory and Gastroenteritis Viruses

Friday, 2 - 3:15 p.m. W 2002

- 1644** A Potent Broadly Neutralizing Antibody Isolated from Human Memory B-Cells Binding to Conserved Site IV on the RSV F Protein
- 1645** Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time, and Influenza Type B Virus Infection (CAPSTONE-1 Study)
- 1646** Combined Resistance Analyses from Phase 2b Studies of Presatovir Treatment in RSV-Infected Adults
- 1647** Real-Time Metagenomic Sequencing Reveals Discrete Transmission Clusters within a Hospital-Associated Norovirus Outbreak
- 1648** Incidence of Norovirus and Rotavirus from Multisite Active Surveillance in Veteran's Affairs Hospitals, December 2016–February 2018: Results from the SUPERNOVA Network

Epidemiology and Infection Control / Adult ID

174. Oral Abstract Session

SHEA Featured Oral Abstract

Friday, 3:55 - 4:10 p.m. N Hall D

- 1659** Variation in Identifying Sepsis and Organ Dysfunction Using Administrative versus Clinical Data and Impact on Hospital Outcome Comparisons

Oral Abstract Sessions (continued)

Adult ID / Epidemiology and Infection Control / Global ID / Investigative ID

178. Oral Abstract Session PIDS Featured Oral Abstract

Friday, 3:30 - 3:45 p.m. N 25

- 1663** Marked Improvement in Pandemic H1N1 Component Shedding and Immunogenicity in 2017-18 Russian-Backbone Live Attenuated Influenza Vaccine (LAIV) in Gambian Children

Pediatric ID / Investigative ID / Adult ID / Trainee

199. Oral Abstract Session Clinical Trials that May Change Your Practice

Saturday, 8:45 - 10 a.m. S 158

- 1715** A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Immunocompromised (IC) Patients with Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO)
- 1716** Results of the Respiratory Protection Effectiveness Clinical Trial (ResPECT)
- 1717** The Impact of Routine Molecular Point-Of-Care Testing for Gastrointestinal Pathogens in Adults Hospitalized With Suspected Gastroenteritis: Results of a Pragmatic Randomised Controlled Trial (GastroPOC)
- 1718** Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
- 1719** Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial

Adult ID / Investigative ID / Pediatric ID / Trainee

200. Oral Abstract Session Public Health: Epidemiology and Outbreaks

Saturday, 8:45 - 10 a.m. S 157

- 1720** Regional Differences in Trends of Hospitalizations Associated with Tick-Borne Diseases in the United States, 2009-2014
- 1721** An Outbreak of Botulism Associated with Nacho Cheese Sauce from a Gas Station in California
- 1722** The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Emerging Risk Factor for Candidemia
- 1723** Mumps Attack Rates Following Administration of a Third Dose of MMR Vaccine To School-Aged Children, Arkansas, 2016 - 2017
- 1724** Characteristics of the Ongoing Measles Outbreak in Greece in the Context of the Recent European-Wide Epidemic and Public Health Measures

Adult ID / Epidemiology and Infection Control / Pediatric ID / Trainee

201. Oral Abstract Session The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment

Saturday, 8:45 - 10 a.m. S 156

- 1725** Addressing Presenteeism: Variability in Facility Healthcare Personnel Work Restriction Policy Monitoring and Enforcement
- 1726** A Random Forest Prediction Model Accurately Identifies Periods at Increased Risk for Positive Legionella Cultures in a Hospital Water Distribution System
- 1727** Sustained Antimicrobial Activity of a Novel Disinfectant Against Healthcare Pathogens
- 1728** Effectiveness and Healthcare Personnel (HCP) Perceptions of a Multi-Site Personal Protective Equipment (PPE) Free Zone Intervention
- 1729** Effect of Glove Disinfection on Bacterial Contamination of Healthcare Worker Hands

Adult ID / Epidemiology and Infection Control / Pediatric ID / Trainee / Transplant ID

202. Oral Abstract Session Transplant and Immunocompromised Hosts: Emerging Issues

Saturday, 8:45 - 10 a.m. W 2002

- 1730** Outcomes of Patients with Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-Blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
- 1731** Disseminated Metacestode Infection Due to an Unknown *Versteria* Species
- 1732** Adenovirus Load Dynamics Are Consistently Correlated with Risk of Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients: Findings from the Landmark AdVance Study
- 1733** 10 Years of DTAC Experience with Donor-Derived Cryptococcus Transmission in Solid Organ Transplantation in the U.S.
- 1734** Cytokine Levels In Bronchoalveolar Lavage Fluid of Rhinovirus Infected Hematopoietic Cell Transplant Recipients: Associations with Mortality

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID / Trainee

211. Oral Abstract Session Diagnostics Making a Difference

Saturday, 10:30 - 11:45 a.m. S 158

- 1756** Prediction of Bloodstream Infection Prior to Onset of Symptoms by Plasma Metagenomic Sequencing in Pediatric Patients with Relapsed or Refractory Malignancy (PRESEQ)

Oral Abstract Sessions (continued)

- 1757** Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to Assess Antibiotic Therapy Guided by Rapid Molecular Diagnostics (RMD) in Bloodstream Infection (BSI) Caused by *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*)
- 1758** Impact of Accelerate Pheno™ Rapid Blood Culture Detection System on Laboratory and Clinical Outcomes in Bacteremic Patients
- 1759** High Proportion of Discordant Results in Culture-Independent Diagnostic Tests (CIDT) for Shiga Toxin, Foodborne Disease Active Surveillance Network (FoodNet), 2012–2017
- 1760** Interferon Gamma Release Assay for Diagnosis of Lyme Disease

Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID / Trainee

212. Oral Abstract Session

Healthcare Epidemiology: You Can Try This at Home—Innovative Epi Abstracts

Saturday, 10:30 - 11:45 a.m. S 157

- 1761** Effect of Carbapenem-Resistant Enterobacteriaceae (CRE) Surveillance Case Definition Change on CRE Epidemiology - Selected U.S. Sites, 2015-2016
- 1762** The Adjusted Ranking Metric (ARM) and its Use in Composite Measures for HAI Prevention in the National Healthcare Safety Network (NHSN)
- 1763** Estimating Median Survival Time to Central Line-Associated Bloodstream Infection (CLABSI) among Patients in Intensive Care Units Reported to National Healthcare Safety Network (NHSN)
- 1764** The Gut: A Veiled Reservoir for Multidrug-Resistant Organisms (MDROs) below the Tip of the Iceberg
- 1765** Use of a Natural Language Processing-Based Informatics Pipeline for Infectious Disease Syndrome Surveillance

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

213. Oral Abstract Session

Late Breaker Oral Abstracts

Saturday, 10:30 - 11:45 a.m. S 152-154

See meeting app.

Adult ID / HIV-STD-TB / Pediatric ID / Trainee

214. Oral Abstract Session

Optimizing HIV Treatment

Saturday, 10:30 - 11:45 a.m. S 156

- 1766** Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy among Highly Treatment-Experienced Individuals
- 1767** Structured Treatment Interruptions in HIV-Infected Patients Receiving Antiretroviral Therapy—Implications for Future HIV Cure Trials: A Systematic Review and Meta-Analysis
- 1768** Efficacy and Safety of Switching from Boosted-Protease Inhibitors (bPI) plus Emtricitabine/Tenofovir Disoproxil Fumarate (E/TDF) Regimens to the Once Daily (OD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/E/TAF) in Virologically-Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial
- 1769** Viral Suppression among Participants of the Patient-Centered HIV Care Model Project—a Collaboration between Community-Based Pharmacists and HIV Clinical Providers
- 1770** The Association of Unmet Needs with Subsequent Retention in Care and HIV Suppression among Hospitalized Patients with HIV Who Are Out of Care

Adult ID / Investigative ID / Pediatric ID / Trainee

215. Oral Abstract Session

Translating Microbiome Science into Practice

Saturday, 10:30 - 11:45 a.m. W 2002

- 1771** Gut Resistome Changes in Response to Prophylactic Antibiotic Administration during Chemotherapy in Children with Acute Lymphoblastic Leukemia
- 1772** *Vancomycin-Resistant Enterococcus* Alters the Gastrointestinal Microbiome in Critically Ill Patients
- 1773** Impact of Antibiotics Used to Treat Community Acquired Pneumonia on the Gut Microbiome and Resistome in Healthy Volunteers
- 1774** Ridinilazole (RDZ) for *Clostridium difficile* infection (CDI): Correlation of *In Vitro* Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
- 1775** Microbiome-Based Classifiers Accurately Differentiate Infectious Diarrhea from Functional Gastrointestinal Disorders and Provide Population-Scale Confidence Measures of Fecal Microbiota Restoration in Recurrent *C. Difficile* Infection

Oral Abstract Sessions (continued)

Adult ID / Epidemiology and Infection Control / HIV-STD-TB /
Investigative ID / Pediatric ID / Trainee

269. Oral Abstract Session Flu and other Vaccines in Children

Saturday, 2 - 3:15 p.m. W 2002

- 2553** Individual Patient-Level Data Meta-Analysis of Live Attenuated and Inactivated Influenza Vaccine Effectiveness among U.S. Children, 2013-14 through 2015-16
- 2554** Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
- 2555** Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children after 13-Valent Pneumococcal Conjugate Vaccination
- 2556** Retrospective Evaluation of Mismatch from Egg-Based Isolation of Influenza Strains Compared to Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness
- 2557** A Model to Estimate the Potential Impact of Immunizations on Respiratory Syncytial Virus (RSV) Disease Burden among Infants in the United States

Adult ID / Investigative ID

270. Oral Abstract Session Genomics and Susceptibility of Superbugs

Saturday, 2 - 3:15 p.m. S 157

- 2558** Predicting β -Lactam Resistance Using Whole Genome Sequencing (WGS) in *Klebsiella pneumoniae*: The Challenge of β -lactam Inhibitors
- 2559** Incidence and Clinical Impact of Discordant Genotypic and Phenotypic Categorization of Methicillin Susceptibility in *Staphylococcus aureus* Bacteremia
- 2560** Multispecies Outbreak of KPC-2 Producing *Enterobacteriaceae* in a Chilean Pediatric Hospital
- 2561** Using Whole Genome Sequencing to Assess the Emergence of Antibiotic Resistance during Treatment of *Enterococcus faecium* and *Enterococcus faecalis* Bacteremia at Mount Sinai Hospital
- 2562** Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics-Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data

Adult ID / Epidemiology and Infection Control / Investigative ID /
Pediatric ID / Trainee

271. Oral Abstract Session Novel Diagnostics for Fungi, Parasites, and CNS Infection

Saturday, 2 - 3:15 p.m. S 158

- 2563** Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Meningitis and Encephalitis
- 2564** Clinical Validation of a Commercial LAMP Test for Ruling Out Malaria in Returning Travelers: A Prospective Diagnostic Trial

- 2565** A Novel Prognostic Gene Set for the Prediction of Severe Dengue
- 2566** Diagnosis of *Pneumocystis jirovecii* pneumonia in HIV-Negative Immunocompromised Patients: Is the Gomori-Methenamine Silver Stain of Bronchoalveolar Lavage Fluid the Gold Standard or Sub-Standard?
- 2567** Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients Receiving Mold-Active Antifungals: Performance of Interleukins 6 and 8, *Asp* LFD, and *Aspergillus* PCR in Same-Day Blood and Bronchoalveolar Lavage Fluid Samples

Pediatric ID / Trainee

272. Oral Abstract Session Pediatric Viral Infections

Saturday, 2 - 3:15 p.m. S 156

- 2568** Variability in Pediatric Antibiotic Prescribing for Upper Respiratory Illnesses by Provider Specialty
- 2569** High Incidence of Enterovirus, HHV6, Parechovirus, and Adenovirus Blood Viremia in Children 0 to 3 Years Old Presenting with Fever without Source
- 2570** HCV Screening Practices among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers in the U.S.
- 2571** Higher Rates of Hospitalization and Infection-Related Hospitalization among HIV-Exposed Uninfected Infants Compared to HIV Unexposed Uninfected Infants in the U.S.
- 2572** Decreased T-Cell Response, but Appropriate Antibody Production to Tetanus Vaccine among HIV-Exposed Uninfected Infants in Botswana

Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB /
Investigative ID / Pediatric ID / Trainee / Transplant ID

275. Oral Abstract Session Featured Oral Abstract

Saturday, 4:05 - 4:20 p.m. N Hall D

See meeting app.

Poster Abstract Sessions

49. Poster Abstract Session

Antimicrobial Stewardship: Interventions in Pediatric Populations

Thursday, 12:30 - 1:45 p.m.

- 169 Targets for Optimizing Oral Antibiotic Prescriptions for Pediatric Outpatients in Japan
- 170 Characterization of Appropriate Antibiotic Prescribing for Pediatric Respiratory Tract Infections: Setting the Stage for Stewardship
- 171 Impact of Limiting Antimicrobial Indication Options in a Pediatric Electronic Health Record
- 172 Antimicrobial Stewardship in High Risk Pediatric Patients
- 173 Nationwide Outpatient Oral Antimicrobial Utilization by Children in Japan
- 174 Treatment of Tracheitis and Antimicrobial Stewardship Interventions
- 175 Implementation of Clinical Practice Guidelines for Care of Neonates with Necrotizing Enterocolitis Reduces Broad Spectrum Antibiotic Use in the Neonatal Intensive Care Unit
- 176 Comparison of Prescribing Practices for Community-Acquired Pneumonia (CAP) among Outpatient versus Emergency Department Settings

50. Poster Abstract Session

Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record

Thursday, 12:30 - 1:45 p.m.

- 177 Use of Electronic Best Practice Alert (BPA) to Reduce Inappropriate Testing for *Clostridium difficile* infection (CDI) at a Tertiary Care Center
- 178 Impact of a Best Practice Alert Linking *Clostridium difficile* Infection Test Results to a Severity-Based Treatment Order Set
- 179 A Passive, Prescriber-Directed, Electronic Alert Plus Prescriber Education Decreased Antibiotic Prescribing for Ambulatory Adults with Acute, Uncomplicated Bronchitis in a Large Integrated Health System
- 180 Best Practice Advisory Decreases Inpatient Urine Culture Orders
- 181 Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated with Antibiotic Orders
- 182 Successes of a System-Directed and Multi-Faceted Inpatient Antimicrobial Stewardship Program in a Large, Integrated Delivery Organization
- 183 Alerting and Education via the Electronic Health Record (EHR) Decreases Inappropriate Fluoroquinolone Prescribing in the Emergency Department of a Large Integrated Hospital Network
- 184 Implementation and Evaluation of an Electronic Antimicrobial Prior Authorization Approval Process at a Large Academic Medical Center
- 185 Implementation of a Clinical Decision Support System (CDSS) for Ordering Antimicrobials in a Veterans Affairs Medical Center (VAMC): Results from a Pilot Quality Improvement (QI) Project

- 186 Effective Antimicrobial Stewardship Strategies (ARIES): Cluster-Randomized Trial of a Clinical Decision Support System to Supplement Antibiotic Prospective Review and Feedback
- 187 Comparison of Active versus Passive Strategies in Improving Compliance to Antimicrobial Stewardship Interventions
- 188 A Novel Inpatient Antibiotic Stewardship Assistance Program (ASAP) using Real-Time Electronic Health Record Data, Prediction Modeling, and Epidemiologic Data to Provide Personalized Empiric Antibiotic Recommendations
- 189 Evaluating the Impact of Mandatory Indications on Antibiotic Utilization: A Retrospective Study
- 190 Promise and Pitfalls: Analyzing the Accuracy and Perceptions of Documenting Antibiotic Indication during Order Entry
- 191 Accuracy of Clinical Indications for Use When Ordering Antibiotics for Cystitis in Community Hospitals
- 192 More Low-Hanging Fruit: Antibiotic Chelation Drug Interactions
- 193 Duration of Antimicrobial Therapy: The Impact of Defaults
- 194 Mandatory Antimicrobial Duration at the Time of Computerized Physician Order Entry: What's the Harm?

51. Poster Abstract Session

Antimicrobial Stewardship: Interventions to Improve Outcomes

Thursday, 12:30 - 1:45 p.m.

- 195 The Effect of Two Antibiotic Stewardship Interventions in a Telemedicine Practice
- 196 Public Health Can Play a Role Implementing a Successful Outpatient Antimicrobial Stewardship in Primary and Urgent Care
- 197 Implementation of a Prospective, Pharmacist-Led Methicillin-Resistant *Staphylococcus aureus* Nasal PCR Screening Pilot Protocol to Reduce Overutilization of Vancomycin
- 198 Pharmacist-Led Antimicrobial Prompting during Interdisciplinary Team Rounds as a Novel Antimicrobial Stewardship Intervention
- 199 The Urgent Need for Urgent Care Antimicrobial Stewardship: Evaluating Prescribing and Patient Outcomes Associated with a Pharmacist-Led Stewardship Program
- 200 Pharmacist Prescribing and Care for Patients with Uncomplicated Urinary Tract Infections in the Community: Antimicrobial Utilization and Stewardship Results of the R_xOUTMAP Study
- 201 Outcomes of an Antibiotic Stewardship Team at an Academic Medical Center: 11 Years of Experience
- 202 Implementation and Three-Year Results of Antimicrobial Stewardship Program in a Three Hospital Community Health System
- 203 Impact of an Infectious Diseases Fellow-Led Antimicrobial Stewardship Initiative in a Medical/Surgical ICU

Poster Abstract Sessions (continued)

- 204** Impact of Education and Data Feedback Interventions on Outpatient Prescribing for Urinary Tract Infections
- 205** Reduction of Antibiotic Prescribing within a Veterans Affairs Emergency Department through Peer Comparison
- 206** Respiratory Viral Testing is Associated with Lower Frequency of Antibiotic Prescribing for Acute Upper Respiratory Infections at a Large Ambulatory Cancer Center
- 207** Impact of Educational Interventions on Antibiotic Prescribing for Acute Upper Respiratory Tract Infections in the Ambulatory Care Setting
- 208** Trends in Antibiotic Prescribing for Acute Respiratory Tract Infections and Implementation of a Provider-Directed Intervention within the Veterans Affairs Healthcare System (VA)
- 209** Impact of a Risk-Based CAP Prescribing Guideline Paired with Antimicrobial Stewardship to Improve Antibiotic Prescribing for Patients at Low Risk for Drug-Resistant Pathogens
- 210** Improved Antimicrobial Utilization in the Emergency Department: Impact of a Point of Care Polymerase Chain Reaction Test for the Rapid Detection of Influenza
- 211** Does Pharmacist-Driven Methicillin-Resistant *Staphylococcus aureus* PCR Nasal Screening Decrease Time to De-Escalation of MRSA Coverage in Patients with Pneumonia?
- 212** Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Initiative on Pneumonia Treatment at an Academic Teaching Hospital
- 213** Multi-centered Evaluation of an Acute Respiratory Tract Infection Audit-Feedback Intervention: Impact on Antibiotic Prescribing Rates and Patient Outcomes
- 214** Antimicrobial Usage and Outcomes Following Laboratory Suppression of Antimicrobial Susceptibility Results for *Pseudomonas aeruginosa* in Sputum Cultures
- 215** Unintended Consequences of Fluoroquinolone Stewardship: Impact on Overall Antimicrobial Use Data and Implications for Benchmarking
- 216** Step-Down Therapy with Oral Fluoroquinolones vs. Oral Beta-Lactams for Hospitalized Adult Patients with Community-Acquired Pneumonia: A Multi-Hospital Cohort Study
- 217** Bang for the Buck: Lessons Learned from an Ambulatory Stewardship Pilot to Reduce Excess Antibiotic Prescribing for Adult Upper Respiratory Infections
- 218** IV to PO Conversion of Antimicrobials: Small Intervention, Big Impact
- 220** Taking Off with Antimicrobial Intervention Rounds (AIR): Successes of a Pilot Stewardship Service at a Tertiary-Care VA Medical Center
- 221** Save the Quinolones! Impact of a Non-Restrictive Fluoroquinolone Reduction Initiative on Antibiotic Resistance at an Urban Teaching Hospital
- 222** The Impact of Education and Prospective Audit and Feedback on Reducing Ciprofloxacin Utilization at a Small Community Academic Hospital
- 223** Impact of Different Stewardship Strategies Applied to a Single Antibiotic Over Time
- 224** Cost Analysis of a Significant Decrease in Vancomycin Use as a Result of an Antimicrobial Stewardship Intervention
- 225** Antimicrobial Stewardship Program Interventions Targeting Intravenous Vancomycin Use at a Community Hospital Improves Prescribing and Safety
- 226** An Emergency Department Antimicrobial Stewardship Intervention to Improve Antibiotic Selection and Duration for Skin and Soft Tissue Infections in Adult and Pediatric Outpatients
- 227** Provider Education Paired with Peer Comparison Demonstrates Sustained Reduction in Overall Antibiotic Prescribing within a Veterans Affairs Primary Care System
- 228** Impact of Early Alert to Antimicrobial Stewardship Interventions with the Prospective Audit and Feedback Strategy
- 229** The Role of Antimicrobial Stewardship Program on Appropriate Use, Dose, and Duration of Vancomycin Treatment
- 230** Characterization of Antibiotic Timeout Program Strategies Across the United States
- 231** Facilitating the Everyday Steward: Impact of Mandatory Antimicrobial Indication/Duration and a 48-Hour Timeout
- 232** Do Antibiotic Timeouts Improve Antibiotic Utilization?
- 233** Evaluation of an Antimicrobial Timeout on Antimicrobial Utilization at a Large Health System
- 234** Improving Antimicrobial Prescribing and Rate of Infectious Diseases Consult Utilizing a Best-Practice Alert and Targeted Education for *Staphylococcus Aureus* Bacteremia
- 235** If Symptoms Aren't Described, Antibiotics Aren't Prescribed: Implementation of a Multifaceted Toolkit Targeting Overtreatment of Asymptomatic Bacteriuria across a Large Health System
- 236** The Impact of Earlier Intervention by an Antimicrobial Stewardship Team on Appropriate Antimicrobial Therapy for Specific Antimicrobial Agents
- 237** Antibiotic Assessment at Discharge-Room for Stewardship Intervention
- 238** Sharing Unit-Specific Stewardship Metrics with Front-Line Providers to Improve Antibiotic Prescribing
- 239** Implementation of a Vertical Antimicrobial Stewardship Intervention for Patients Colonized with *Clostridium difficile*
- 240** Estimated Clinical and Economic Impact Through Use of an Initial Specimen Diversion Device to Reduce Blood Culture Contamination: A Cost-Benefit Analysis
- 241** Reducing Fluoroquinolone Use Through Implementation of a Urinary Tract Infection (UTI) Treatment Pathway and Healthcare Provider Education: A Pre- and Post-Intervention Study
- 242** Evaluating the Effectiveness of Antimicrobial Restriction at an Academic Medical Center
- 243** Prioritization of Antibiotic Administration for STAT Orders in the Septic Patient: A Retrospective Analysis
- 244** Impact of Antibiotic Susceptibility Reporting on Broad-Spectrum Antibiotic Use in *Serratia* and *Morganella* Bacteremia

Poster Abstract Sessions (continued)

52. Poster Abstract Session

Antimicrobial Stewardship: Special Populations

Thursday, 12:30 - 1:45 p.m.

- 245 Elimination of Routine Urinalysis Before Elective Orthopedic Surgery Reduces Antibiotic Utilization Without Impacting Catheter-Associated Urinary Tract Infection or Surgical Site Infection Rates
- 246 Antimicrobial Stewardship Program (ASP) Efforts to Reduce Antimicrobial Usage in Geriatric Patients without Affecting Outcomes
- 247 Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria
- 248 Antimicrobial Therapy for Suspected Urinary Tract Infection in Advanced Cancer Patients Transitioning to Comfort Measures
- 249 Frequency of Antimicrobial Complications Following Initiation of Palliative Chemotherapy in Advanced Cancer Patients
- 250 Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
- 251 Overuse of Antimicrobials in the End-of-Life Care: Factors Influencing Physicians' Prescribing Behaviors in Treating Patients with an Advanced Stage of Illnesses in the Robust Era of Antimicrobial Stewardship
- 252 Relative Use of Carbapenems in Immunocompromised Patients
- 253 Febrile Neutropenia Antibiotic De-Escalation Study in Acute Myeloid Leukemia Patients with Prolonged Neutropenia
- 254 Antimicrobial Use in Hospitalized Older Patients with Advanced Cancer
- 255 Evaluation of Antibiotic Prescribing at University-Affiliated Dental Clinics
- 256 A Cross-Disciplinary Educational Approach: Antibiotic Prescribing Practices and the Use of Prophylactic Antibiotics Prior to Dental Procedures

53. Poster Abstract Session

Pediatric Antimicrobial and Diagnostic Stewardship

Thursday, 12:30 - 1:45 p.m.

- 257 A Whole of Country Analysis of Antimicrobial Stewardship Resources, Activities, and Barriers for Children in Hospitals in Australia
- 258 Variation in Antibiotic Use Among Neonates Hospitalized in United States Academically Affiliated Centers
- 259 A Retrospective Cross-Sectional Comparison of the Neonatal Gut Microbiota after Antimicrobial Exposure: Implications for Stewardship
- 260 Effect of Antibiotic Indications on Clinician Documentation and Pharmacy Workflow in Hospitalized Children
- 261 Alternative Antibiotic Prescribing for Community Acquired Pneumonia (CAP) in Pediatric Patients in Relation to Allergy Status

- 262 Pediatric Antibiotic Use in the Duke Antimicrobial Stewardship Outreach Network
- 263 Effect of Microbiologic Data on Prospective Audit and Feedback Recommendations
- 264 Simple and Feasible NICU Antimicrobial Stewardship Program in a Japanese Community Hospital
- 265 Identification of Solid Organ Transplant Antimicrobial Stewardship Opportunities in Pediatric Liver Transplant Patients
- 266 Implementation and Evaluation of a Pharmacist-Managed Pediatric Vancomycin Protocol
- 267 Viral Respiratory Infections in Children with Neuromuscular Disease and Chronic Lung Disease Hospitalized in the Pediatric Intensive Care Unit and Associated Antibiotic Use
- 268 Cardiothoracic Surgery Antimicrobial Prophylaxis in Pediatric Patients: Reducing Antimicrobial Exposure
- 269 De-Labeling of Allergies to Beta-Lactam Antibiotics (De-LABEL) Program—Development and Pilot of An Inpatient Pediatric Program
- 270 Prevalence and Impact of β -Lactam Allergies at a Canadian Pediatric Center
- 271 Diagnosis and Management of Polymicrobial Bloodstream Infections with Multiplex PCR in Hospitalized Children
- 272 Impact of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) on Time to Optimal Antimicrobial Therapy in Pediatric Patients with Positive Blood Cultures at Children's Cancer Hospital-Egypt (CCEH-57357)
- 273 Effects of a Rapid Meningitis/Encephalitis Panel on Antimicrobial Use and Clinical Outcomes in Children
- 274 Diagnostic Stewardship for Positive Endotracheal Cultures in a Pediatric Intensive Care Unit (PICU)—Reassessing the Role of Neutrophil Quantification in Clinician Decision-Making
- 275 Evaluation of Vancomycin Prescribing Quality in Hospitalized Pediatric Patients
- 276 Vancomycin Utilization in a Neonatal Intensive Care Unit
- 277 Assessment of a Pharmacist-Driven Voriconazole Clinical Practice Guideline in a Children's Hospital
- 278 Developing a Logistic Regression Model to Aid Clinicians to Evaluate Outpatients and Predict Odds of Hospital Transfer in a Nicaraguan Pediatric Population: Comparison of Epidemiological Models to Predict Hospitalization with a Focus on Antimicrobial Stewardship
- 279 A Decision Tree Using Clinical Characteristics to Predict a Hospitalized Child's Risk of a Multidrug-Resistant Gram-Negative Bloodstream Infection
- 280 The Impact of a Revised Neutropenic Fever Guideline on Vancomycin-Resistant *Enterococcus* Rates in Pediatric Oncology Patients
- 281 Cefdinir Prescribing Increased in Low-Income Children in Kentucky from 2012-2016
- 282 Adherence to Acute Otitis Media Guidelines in Pediatricians' Offices, Urgent Care Centers, and a Pediatric Emergency Department

Poster Abstract Sessions (continued)

- 283** Antibiotic Utilization for Pneumonia and other Respiratory Infections in Pediatricians' Offices, Urgent Care Centers, and a Pediatric Emergency Department
- 284** Antibiotic Usage in the First Year of Life in Hiv-Exposed, Uninfected Infants in Malawi: Results from the Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study

54. Poster Abstract Session

Bone and Joint Infections

Thursday, 12:30 - 1:45 p.m.

- 285** Challenging the Dogmas of Outpatient Parenteral Antimicrobial Therapy Through a Randomized Controlled Trial
- 286** Rapid, One-Tier Diagnosis for Lyme Arthritis
- 287** The Attributable Mortality of Prosthetic Joint Infection after Primary Hip and Knee Arthroplasty among Medicare Beneficiaries, 2005—2012
- 288** Expediting Discharge in Acute Bacterial Skin and Skin Structure Infections: A Clinical and Economic Comparison between Vancomycin and Oritavancin
- 289** International Validation of a Methicillin-Resistant *Staphylococcus aureus* (MRSA) Risk Assessment Tool for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 290** Safety and Effectiveness of Oral Sodium Fusidate (Fusidic Acid) as Chronic Antibiotic Suppressive Therapy in Patients with Staphylococcal Bone or Joint Infections
- 291** Effect of Previous Antibiotic Exposure on the Yield of Bone Biopsy Culture in Patients with Osteomyelitis
- 292** Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multidrug-Resistant *Pseudomonas aeruginosa*
- 293** Concurrent Atlantoaxial Septic Arthritis and Septic Thrombosis of the Ophthalmic Vein due to *Staphylococcus aureus*: A Case Report and Review of the Literature
- 294** Spondylodiscitis after Spine Surgery: Microbiology, Clinical Findings, Outcome, and Comparison with Spontaneous Spondylodiscitis
- 295** Outcomes of Orthopedic Hardware-Related Osteomyelitis Treated Via a County Hospital Outpatient Parenteral Antimicrobial Therapy (OPAT) Program
- 296** Outcomes from a Novel Transition-of-Care OPAT Service Targeting Orthopedic Device-Related Infections
- 297** Risk Factors for Infections in Open Fractures
- 298** Vertebral Osteomyelitis due to *Candida*: Increasing Incidence in Appalachia
- 299** Tolerance and Serum Concentration of Cefepime Used Subcutaneously (SC) in the Management of Bone and Joint Infections
- 300** Armed to the Teeth—Human Bite Associated Septic Arthritis
- 301** The Use of Multiplex Touchdown PCR to Genotype *Cutibacterium* (*Propionibacterium*) *Acnes* Isolated from Periprosthetic Shoulder Infections
- 302** Role of Inflammatory Markers in Diagnosing Diabetic Foot Infection: A Meta-Analysis

- 303** Clinical Characteristics and Outcomes of Patients Naïve Septic Arthritis caused by Methicillin-Resistant *Staphylococcus aureus*
- 304** Comparison of Short and Long Courses of Antibiotics in Patients with Prosthetic Joint Infection: A Systemic Review and Meta-Analysis
- 305** Enterobacteriaceae Native Joint Septic Arthritis
- 306** Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
- 307** Evaluation of the Diagnostic Approach to Native Spondylodiskitis
- 308** Identification of Prosthetic Hip and Knee Joint Infections in Administrative Databases
- 309** The Infected Spacer: The Impact of Spacer Exchanges and Debridements on Two-Stage Exchange Arthroplasty Outcomes
- 310** Assessment of MSIS Diagnostic Criteria as Predictors of Treatment Success in Total Knee Arthroplasty (TKA) Infections Treated with Two-Stage Exchange
- 311** Low Rate of Microbiologic Relapse in Two-Stage Exchange for Knee Prosthetic Joint Infections
- 312** Comparison of Short Course and Long Course of Antibiotics in Patients with Osteomyelitis: A Systemic Review and Meta-Analysis
- 313** Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
- 314** Discordant Microbiology Cultures from Paired Osteomyelitis Bone Specimens Should Question the Current Approach To Evaluation
- 315** Oral versus Intravenous Antibiotic Treatment for Gram-Positive Prosthetic Joint Infections: A Retrospective Study
- 316** Joint Initiative between Infectious Diseases and Podiatry in Outpatient Settings Improves Diabetic Foot Infection Patients' Compliance and Outcomes
- 317** Risk Factors for Fungal Prosthetic Joint Infections (PJIs)
- 318** Treatment Outcomes of Prosthetic Joint Infections: An Internal Assessment of Adherence to Best Practice Guidelines
- 319** Is Chronic Vertebral Disk Infection with Low Virulence Bacteria a Common Cause of Back Pain?
- 320** Variation in Use of Chronic Antibiotic Suppression (CAS) for Treatment of *Staphylococcus aureus* Prosthetic Joint Infection (PJI)
- 321** Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection
- 322** Joint Spacer Retention, Antimicrobial Suppression, and Risk of Reinfection

55. Poster Abstract Session

CNS Infections

Thursday, 12:30 - 1:45 p.m.

- 323** Childhood Outcomes Following Parechovirus Central Nervous System Infection in Young Infants at a U.S. Children's Hospital

Poster Abstract Sessions (continued)

- 324** Lack of Accuracy of the International Classification of Disease, Ninth (ICD-9) Codes in Identifying Patients with Encephalitis
- 325** Neurosyphilis Management in the Post-Procaïne Penicillin Era
- 326** Malaria vs. Bacterial Meningitis in Children with Spinal Tap in the Luanda Children's Hospital, Angola
- 327** Comparison of Clinical Outcome, Causative Serotypes, and Antimicrobial Susceptibilities between Pneumococcal Meningitis and Pneumococcal Bacteremic Pneumonia in Adult Patients in the Republic of Korea
- 328** National Expertise Group to Improve Management of Complex Encephalitis Cases
- 329** Impact of the Biofire® FilmArray (FA) Meningitis/Encephalitis (ME) Panel in Colombia
- 330** Head and Spine Injuries Increase Risk of *Streptococcus pneumoniae* Meningitis in Adults
- 331** Vascular Complications among Children and Adolescents with Acute Complicated Sinusitis
- 332** Phaeohyphomycosis Due to *Scopulariopsis Brumptii* in a Hematopoietic Stem Cell Transplant (HSCT) Recipient
- 333** Meningitis in Well-Appearing Febrile Infants Aged 1-90 Days
- 334** Implementation of FilmArray Meningitis/Encephalitis Panel at a Tertiary Medical Center
- 335** Missed and Delayed Diagnosis of Herpes Simplex Encephalitis in Inpatient and Ambulatory Care Settings
- 336** Characteristics of Acute Bacterial Meningitis and Predictors of Mortality
- 337** The Use of Adjunctive Steroids in 438 Adults with Herpes Simplex Virus Encephalitis
- 338** The Use of Multiplex PCR Panel in the Diagnosis of Meningitis in Children
- 339** An Unusual Complication after Dental Procedure Prophylaxis
- 340** Clinical Use of a Multiplex PCR Meningitis/Encephalitis Panel at an Urban Tertiary Care Center
- 341** Characteristics, Risk Factors, and Outcomes of Encephalitis in Older Adults
- 342** Time to Antimicrobial De-Escalation/Discontinuation after Implementation of Cerebrospinal Fluid Polymerase Chain Reaction Tool
- 343** Compliance to Standard of Care in the Diagnosis and Management of Suspected Encephalitis
- 344** Post Malaria Neurological Syndrome: A Rare Complication of Malaria
- 345** Diagnosis of Acute Bacterial Meningitis by Polymerase Chain Reaction vis-a-vis Conventional Culture Method
- 346** Prognostic Factors in Adults with Encephalitis: An Analysis of 340 Cases
- 347** *Capnocytophaga canimorsus* Meningitis: Diagnosis Using Polymerase Chain Reaction Testing and Systematic Review of the Literature
- 348** *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Enterobacteriaceae* as Leading Causes of Bacterial Meningitis in Infants Younger than Three Months Old in a Mexican Hospital: Six Years of Active Surveillance
- 349** Retrospective Descriptive Analysis of West Nile Neuroinvasive Disease in Northwest Louisiana
- 350** Epidemiology of Bacterial Meningitis in Pediatric Population after the Introduction of Pneumococcal Conjugated Vaccine in Costa Rica
- 351** It's Not Always Tuberculosis: Cytomegalovirus Polyradiculopathy and Encephalitis in Two Filipino Men with Advanced HIV Infection
- 352** Towards Earlier Diagnosis of Transmissible Spongiform Encephalopathies (TSEs): A Case Series, Including One Associated with Squirrel Brain Consumption
- 353** HSV Induced Anti-NMDAR Encephalitis

56. Poster Abstract Session

Fungal Disease: Management and Outcomes

Thursday, 12:30 - 1:45 p.m.

- 354** Evidence of Aspergillosis among Patients with Influenza-Associated Hospitalizations—United States, 2005–2017
- 355** Invasive Pulmonary Aspergillosis (IPA) Complicating Respiratory Viral Infections in Patients with Hematological Malignancies
- 356** Bronchoalveolar Lavage Fluid Cytology by GMS Stain for the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies: Analysis of 67 Episodes
- 357** Aspergillus Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program using Azole Prophylaxis
- 358** Comparison of Voriconazole (VORI), Isavuconazole (ISAV) and Posaconazole (POSA) in the Initial Treatment of Patients with Invasive Aspergillosis (IA)
- 359** Baseline Serum *Aspergillus* Galactomannan Index among *Aspergillus* Species in Hematologic Malignancies Patients with Invasive Pulmonary Aspergillosis
- 360** Breakthrough Invasive Pulmonary Aspergillosis during Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single Center Experience
- 361** Changing Epidemiology of *Blastomyces Dermatitidis* Infection in Quebec, Canada: A Retrospective Multicenter Study
- 362** Species Distribution and Trends of Invasive Candidiasis in the United States, 2009-2015, Using a Large Electronic Medical Record Database
- 363** National Burden of Candidemia, United States, 2017
- 364** The Capital District of New York State, Likely a New Blastomycosis Endemic Region
- 365** Candida Bloodstream Infections in a Tertiary Care Hospital in Costa Rica, Five-Year Experience
- 366** Impact of Obesity in Patients with Candida Bloodstream Infections
- 367** Influence of Body Weight and Outcomes in Candidemia
- 368** Community-Onset Candidemia: Trends Over Seven Years
- 369** Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis
- 370** Efficacy of Cochleated Amphotericin B (C-AMB) in Mouse Models of Oropharyngeal and Vulvovaginal Candidiasis

Poster Abstract Sessions (continued)

- 371** Risk Factors for Non-Albicans Candidal Vulvovaginitis
- 372** Attributable Mortality of Candidemia after Introduction of Echinocandins
- 373** Impact of Concurrent Renal Replacement Therapy on Treatment Outcomes of Candidemia in Adults
- 374** Candidemia Management and Associated Clinical Outcomes in Hospitalized Patients: An Opportunity for Antifungal Stewardship
- 375** Tolerability of Anidulafungin for Candidemia in Patients with Hepatic or Renal Dysfunction
- 376** Predictive Model for Fluconazole Resistance in Patient with Candida Bloodstream Infection
- 377** High Resistance and Mortality Rates in Patients with Ventricular Assist Device (VAD) Associated Candidemia: A Need for Alternative Antifungal Strategies
- 378** *Candida auris* Fungemia: Risk Factors and Outcome
- 379** Pediatric Bloodstream Infections by *Candida auris* in Colombia: Clinical Characteristics and Outcomes of 34 Cases
- 380** *Drosophila melanogaster* as a Facile Model for Large-Scale Studies of Virulence Mechanisms and Antifungal Drug Efficacy in *Candida auris* Candidiasis
- 381** Morphologic Changes Associated with Echinocandin Tolerance Enhance Immuno-evasion of *C. glabrata* (Cg)
- 382** Virulence in *Candida glabrata* is Not Attenuated by FKS Mutations but Associated with the Frequency of Cells with Distinct Morphology
- 383** An Increased Rate of *Candida parapsilosis* Infective Endocarditis is Associated with Injection Drug Use
- 384** Findings From a *Candida auris* Admission Screening Pilot in New York State
- 385** The Value Added from *Candida auris* Point Prevalence and Environmental Studies in New York State
- 386** A Reexamination of Disseminated Coccidioidomycosis: The Natural History in the Pre-Antifungal Era
- 387** Coccidioidomycosis In Children Younger than Two Years of Age: A Retrospective Review
- 388** New Observations in Coccidioidomycosis Serology
- 389** Pediatric Musculoskeletal Coccidioidomycosis In Central California: Single Center Experience
- 390** Sociodemographic Factors Associated with Patients Hospitalized for Coccidioidomycosis in California and Arizona, State Inpatient Database 2005-2011
- 391** Evaluation of 2nd Generation Triazoles in the Treatment of Refractory Coccidioidomycosis
- 392** Evaluation of the Long-Term Tolerability and Efficacy of Fluconazole in Patients with Coccidioidomycosis
- 393** Isavuconazole in the Treatment of Coccidioidal Meningitis
- 394** Outcomes in Patients with Disseminated Non-Central Nervous System Cryptococcus
- 395** Missed Opportunities for Diagnosis of Cryptococcal Disease in Patients from Florida
- 396** Clinical Features of Proven and Probable Cases of Histoplasmosis and the Role of Urinary Histoplasma Antigen Testing: A Case Series from India
- 397** Long-term Mortality of HIV Patients Following Cryptococcal Infection
- 398** Review of Mucormycosis Cases at the University of Colorado Hospital from 2012-2018 and Evaluation of Risk Factors and Appropriateness of Antifungal Prophylaxis
- 399** Multi-Centre Observational Study on Epidemiology, Treatment, and Outcome of Mucormycosis in India
- 400** The Frequency and Clinical Characteristics of Positive Galactomannan Assay Results in Patients with Mucormycosis
- 401** *Pneumocystis jirovecii* Pneumonia in Renal Transplant Recipients after a 6-Month Trimethoprim-Sulfamethoxazole Prophylaxis: A Case-Control Study
- 402** Breakthrough *Pneumocystis jirovecii* Pneumonia among Cancer Patients: Opportunity for Antimicrobial Stewardship?
- 403** Prognostic Factors in 260 Adults with Invasive Scedosporiosis from Literature and FungiScope™
- 404** Tinea Capitis: Are Epidemiologic Shifts Associated with Distinct Clinical Presentations?
- 405** Outbreak of Prototheca Wickerhamii Algaemia in a Tertiary Care Chemoradiation Oncology Unit
- 406** Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients with Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT)
- 407** Changes in the Utilization Patterns of Antifungal Agents, Medical Cost, and Clinical Outcomes of Candidemia by Healthcare Benefit Expansion to Include Newer Antifungal Agents
- 408** Invasive Fungal Petrositis and Carotiditis (IFPAC) Syndrome in Immunocompromised Hosts: An Unrecognized, Often Catastrophic Invasive Fungal Disease (IFD)
- 409** Changing Epidemiology of Fungal Bloodstream Infections in a Tertiary Care Center in India
- 410** Impact of Pediatric Antifungal Adverse Drug Reactions on Prescribing Practices
- 411** Tolerability of Isavuconazole after Posaconazole Toxicity in Leukemia Patients
- 412** Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis with Continuous Micafungin Compared to Posaconazole with Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A Six-Year Cohort-Analysis
- 413** Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals
- 414** Diagnostic Usefulness of Differential Time to Positivity (DTP) in Neutropenic Cancer Patients with Suspected Catheter-Related Candidemia (CRC)
- 415** Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
- 416** Culture-Documented Invasive Mold Infections (cIMIs) at MD Anderson Cancer Center (MDACC) in Houston, TX, Pre- and Post-Hurricane Harvey
- 417** Clinical Mycology in Latin America and the Caribbean: Diagnostic Capabilities and Antifungal Therapy

Poster Abstract Sessions (continued)

- 418** Evaluation of β -D-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
- 419** Diagnostic Performance of Immunohistochemistry Test to Differentiate Aspergillosis from Mucormycosis with Formalin-fixed Tissue Specimens
- 420** A Rapid PCR Assay Detects Fungemia due to Mixed *Candida* Species that is Missed by the Clinical Microbiology Laboratory

57. Poster Abstract Session

Global Health and Travel Medicine

Thursday, 12:30 - 1:45 p.m.

- 421** Babesiosis: Retrospective Review of 38 Cases from Upper Midwest
- 422** Brucellosis Regimens Comparison in a Saudi Tertiary Academic Medical Center
- 423** Ten-Year Experience of *Burkholderia pseudomallei* Infections in a Singapore Tertiary Hospital
- 424** Southern Arizona Town: Homes Colonized by Kissing Bugs. Is Chagas Disease Being Transmitted?
- 425** Chikungunya in Solid Organ Transplant Recipients, a Case Series and Literature Review
- 426** Post-Chikungunya Chronic Disease and its Impact on Quality of Life, Depression, Anxiety, Fatigue, and Sleep Quality: Results from a 2-Year Follow-Up Comparative Study of 62 Patients in La Virginia, Risaralda, Colombia
- 427** Symptoms Associated with Fasciola Hepatica Infection: A Community Based Study in Cusco, Peru
- 428** Mobile Phone Access and Comfort: Implications for HIV and Tuberculosis Care in India and South Africa
- 429** Delayed Diagnosis of Leprosy in a Non-Endemic Area: Lessons from a Retrospective Case Series
- 430** The First Case Reports of Leptospirosis and Melioidosis in the Aftermath of Hurricanes Irma and Maria—Saint Thomas/Saint John District, U.S. Virgin Islands, September-October 2017
- 431** Enhanced Malaria Surveillance in Greece, 2009-2017
- 432** Hold That Buzz: Timely Malaria Medication Access in New Orleans, LA
- 433** Impact of Malaria Prophylaxis on Risk of Travelers' Diarrhea among International Travelers
- 434** Neurocysticercosis in Houston
- 435** Serological Cross-Reactivity between *Rickettsia japonica* and *Orientia tsutsugamushi*, and among *Orientia tsutsugamushi* Serotypes
- 436** A Survey of Schistosomiasis and Strongyloidiasis among Eritrean Immigrants to Israel
- 437** Spatial Distribution of Schistosomiasis after Repeated Praziquantel Treatments in a Rural Community in Brazil
- 438** Finding Toxocara Eggs in Park Soil from Montgomery County, Pennsylvania
- 439** Impact of Pre-Travel Consultation on Clinical Management and Outcomes of Traveler's Diarrhea
- 440** The Masqueraders Presenting a Multi-System Disease: Unusual and Atypical Clinical Features of Scrub Typhus in Fukushima, Japan

- 442** The Results of a Primary Care-Based Screening Program for *Trypanosoma cruzi* in East Boston, MA
- 443** West Nile Virus in Humans in Greece, 2010-2017
- 444** Zika Testing in a Large Academic Center during a Continental U.S. Outbreak
- 445** Cross-Reactivity between Zika and Dengue Virus: A Cross-Sectional Analysis in Rio Grande do Norte, Brazil
- 446** Leveraging Partnerships to Care for Babies Born to Mothers after Maternal Zika Infection - U.S. Virgin Islands (USVI)
- 447** Infant Microcephaly during the Zika Virus Epidemic in Dominican Republic, 2016-2017
- 448** Can Electronic Clinical Notes Identify Travelers with Zika?
- 449** Post-Hurricane Maria Surveillance for Infectious Diseases in the Veterans Affairs San Juan Medical Center, Puerto Rico
- 450** Using Geographical Information Systems to Interpret the Efficacy of Mass Drug Administration for Soil-Transmitted Helminthiasis in Rural Madagascar
- 451** High Frequency of MultiDrug-Resistant Organisms (MDRO) at University Teaching Hospital (UTH), Lusaka, Zambia
- 452** Spectrum of Respiratory Pathogens Detected by Multiplex PCR in a Study of Respiratory Tract Infections Among Travelers
- 453** Understanding Travel Medicine Provider's Risk Assessment of Travel-Associated Diseases
- 454** Barriers and Facilitators to Control of Hospital-Acquired Infections in Jimma, Ethiopia
- 455** Epidemiological Surveillance in Points of Care for Refugees/Migrants: the 2016-2017 Experience in Greece
- 456** Discrepant Trip Experiences Among Travelers Attending a Tertiary Care Center Family Travel Medicine Clinic

58. Poster Abstract Session

Healthcare Epidemiology: Advances in Hand Hygiene

Thursday, 12:30 - 1:45 p.m.

- 457** Relationship Between Healthcare Worker (HCW) Perception of Safety and Rates of Healthcare Associated Infections (HAI) and Hand Hygiene (HH) Compliance
- 458** Using a Humanoid Robot to Improve Hand Hygiene Compliance
- 459** Patient-Based Surveys to Better Understand Patients' Perceptions of Healthcare Providers' Hand Hygiene Practices and If Patient Responses Validate Secret Observers' Hand Hygiene Compliance Reporting
- 460** Teaching an Old Dog New Tricks—Environmental Cleaning Services Not So Set in Their Ways That They Can't Be Taught Better Hand Hygiene Practices
- 461** Electronic Hand Hygiene Compliance Monitoring Systems: Not All Are Created Equal

Poster Abstract Sessions (continued)

- 462** "All Eyes on You": A Covert Observational Study on Contact Precaution Compliance in Six Hospitals at the Detroit Medical Center
- 463** Healthcare Workers' Perceptions Regarding the Use of an Electronic Hand Hygiene Monitoring System at a VA Hospital
- 464** The Efficacy of Alcohol-Based Wipes, Gel, Foam, and Spray Compared to Liquid Soap in Eliminating Transient Hand Bacteria
- 465** Microbial Removal Efficacy of a Novel Non-Antimicrobial Hand Soap
- 59. Poster Abstract Session**
Healthcare Epidemiology: Updates in *C. difficile*
Thursday, 12:30 - 1:45 p.m.
- 466** Use of Administrative Data to Characterize *Clostridium difficile* Infections (CDI) Reported by California Hospitals to the California Department of Public Health (CDPH) via the National Healthcare Safety Network (NHSN): 2014–2015
- 467** Investigation of a *Clostridium difficile* Infection (CDI) Outbreak in a Community Teaching Hospital
- 468** Diagnosis of Clinical *Clostridium Difficile* Infection: An Unmet Challenge
- 469** Validation and Characterization of Community-Acquired *Clostridium difficile* Infections from the Quebec *Clostridium difficile* Infection Surveillance Program (QCISP)
- 470** Concomitant Antibiotic Use and Death among a National Cohort of Veterans with *Clostridium difficile* Infection (CDI)
- 471** Prevalence and Characteristics of *Clostridioides difficile* Infection in Bangladesh
- 472** Prevalence, Risk Factors, and Outcome of Postoperative *Clostridium difficile* Infection After Orthopedic Surgery
- 473** Molecular Typing of *Clostridium difficile*: Concordance between PCR-Ribotyping and Multilocus Sequence Typing (MLST)
- 474** Temporal Trends of Inpatient *C. difficile* Infections within the Veterans Affairs Hospitals: A Bioinformatics Analysis of Nationwide Metadata from the Past Decade
- 475** Burden of *Clostridium difficile* Infection in South Carolina: A Population-Based Study
- 476** Comparison of Community-Associated *Clostridium difficile* Infections with other Reportable Enteric Pathogens, Minnesota, 2016
- 477** Trends in the Incidence of Community-Associated and Healthcare-Associated *Clostridium difficile* Infections in Quebec over a 7-Year Period (2008-2015)
- 478** Improving Acid Suppression Therapy to Reduce Hospital-Onset *C. difficile* Infection (HO-CDI): Impact of a Novel Analytic Application
- 479** Trends in *C. difficile* Incidence, Mortality, and NAP1/027 Strain in the Population of Monroe County, NY
- 480** Reduction in *Clostridium difficile* Infection Rates Following a Prevention Collaborative in Orange County, CA, 2014-2017
- 481** Implementation of a Prospective, Pharmacist-Driven *Clostridium difficile* PCR Pre-Authorization Process to Optimize Appropriate Testing
- 482** Association between Socioeconomic Status Factors and Incidence of Community-Associated *Clostridium difficile* Infection Utilizing Factor Analysis—United States, 2014–2015
- 483** Clinical Characteristics of Military Trauma Patients with *Clostridium difficile* Infections
- 484** A Severity Score for Predicting In-Hospital Death in Patients with *Clostridium difficile* Infection: A Hospital-Based Cohort Study
- 485** On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired *Clostridium difficile* Infection (CDI)
- 486** Endemic Corridors: A Useful Tool for the Approach of *Clostridium difficile*. A 5-Year Epidemiologic Surveillance Program in a Teaching Hospital of a Middle-Income Country
- 487** Severity and Clinical Outcomes of *Clostridium difficile* Infection Based on Toxin B Assay Results
- 488** Oral Vancomycin plus Intravenous Metronidazole for Severe *Clostridium difficile* Infection in Critically Ill Patients
- 489** Validation of the SHEA/IDSA Severity Criteria to Predict Poor Outcomes among Inpatients and outpatients with *Clostridium difficile* Infection
- 490** Comparison of *Clostridium difficile* Infection Outcomes by Diagnostic Testing Method
- 491** Clinical Manifestations and Outcomes of *Clostridium difficile* Infection in Long Term Care Patients: An 8-Year Retrospective Cohort Study
- 492** Long Term Outcomes of *Clostridium difficile* Infection among Medicare Beneficiaries
- 493** Development of a Simple *Clostridium difficile* Infection Clinical Risk Prediction Tool for Medical Inpatients
- 494** Use of a Clinical Prediction Tool to Predict *Clostridium difficile* Infection
- 495** Predictors of *C. difficile* Infection and Impact of Primary Prophylaxis among Asymptomatic *C. difficile* Colonized Patients: A Cross Sectional Study
- 496** Secondary Prophylaxis for *Clostridium difficile* infection—A Physician Practice Assessment
- 497** Identification of Patients at Risk of *Clostridium difficile* Infection for Enrollment in Vaccine Clinical Trials
- 498** Molecular Epidemiology of *C. difficile* within a Community Hospital: A Pilot for a Regional Survey
- 499** Determining Risk of *Clostridium difficile* Using Electronic Health Record (EHR) Data
- 500** Efficacy of 30-Day Fidaxomicin for Treatment of Acute *Clostridium difficile* Infection with History of Multiple Recurrences
- 501** Evaluation of Bezlotoxumab in Prevention of Recurrent *C. difficile* Infection: A Multicenter Single Arm Study in Outpatient Infusion Centers
- 502** Enhanced Sporulation and Vancomycin Resistance Associated with *Clostridium difficile* from Recurrent Infections

Poster Abstract Sessions (continued)

- 503** Risk and Timing of *Clostridium difficile* Infection Relapse after Antibiotic Exposure
- 504** Change in *Clostridium difficile* Strain Type Distribution after Implementation of Diagnostic Stewardship
- 505** Bezlotoxumab Reduces Recurrence of *Clostridium difficile* Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
- 506** The Impact of Bowel Management System (BMS) on the Incidence of Hospital-Onset (HO) *Clostridium difficile* Infection Laboratory-ID Events despite Diagnostic Stewardship
- 507** Degree of Concordance of *Clostridium difficile* Strains in Adults with Community-Associated *Clostridium difficile* Infection and Infants with *Clostridium difficile* Colonization.
- 508** High Rates of Cure and Long-Term Symptom Resolution with Both Capsule and Lower Gastrointestinal Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection
- 509** Spatio-Temporal Clustering of CDI Cases at the University of Iowa Hospitals and Clinics
- 510** First Environmental Investigation of Toxigenic *Clostridium difficile* Strains in Texas Hospitals
- 511** What is the Current State of Patient Education after *Clostridium difficile* Infection?
- 512** Tracking the Use of Soap and Sanitizer for Hand Hygiene after Caring for *Clostridium difficile* Patients
- 513** Effectiveness of Pulsed Xenon Ultraviolet Light Disinfection System to Decrease *Clostridium difficile* Infections at the South Texas Veterans Health Care System
- 514** The Effect of Probiotics on the Incidence of *Clostridium difficile*
- 515** Estimating the Effect of Proton Pump Inhibitor Stewardship in Reducing *Clostridium difficile* Transmission
- 516** Implementation of a Probiotic for the Primary Prevention of Hospital-Onset *Clostridium difficile* Infection
- 517** Impact of Doxycycline in place of Azithromycin for Community Acquired Pneumonia on *Clostridium difficile* Infections
- 518** Modeling the Potential Impact of Administering Vaccines against *Clostridium difficile* Infection to Individuals in Healthcare Facilities
- 519** Longer Length of Antibiotic Therapy for Community-Acquired Pneumonia and Risk of *Clostridium difficile* Infection
- 520** Reducing Inappropriate *Clostridium difficile* Testing by Empowering Nurses
- 521** *Clostridium difficile* Timeout: A Nurse—Driven Protocol to Optimize Testing Stewardship
- 522** Impact of a Multicomponent Intervention Bundle on Healthcare Facility-Onset *Clostridium difficile* Rates
- 523** Use of Whole-Genome Sequencing to Guide a *C. difficile* Diagnostic Stewardship Program
- 524** The Journey to Implement a Computerized Clinical Decision Support (CDS) Tool to Improve Testing for *Clostridium difficile* Infection (CDI)
- 525** The Impact of Switching to Molecular Testing on *Clostridium difficile* Infection Rates: Large-Scale Assessment Using an Interrupted Time Series Poisson Regression Approach
- 526** An EMR-Based Diagnostic Stewardship Intervention for GI mPCR Aimed at Reducing Inappropriate *C. difficile* Tests
- 527** New Robust Antimicrobial Stewardship Program (ASP) Results in Reduction of *Clostridium difficile* 30-Day Readmission
- 528** Lab Stewardship for *Clostridium difficile* Testing Improves Appropriate Testing While Decreases Unnecessary Testing and Saves Laboratory Resources While Dramatically Helping to Reduce *C diff* Standardized Infection Ratios (SIR)
- 529** Overdiagnosis of *Clostridioides difficile* with a Multiplex PCR Panel
- 530** The Perfect Storm for Improved Standardized Infection Ratio (SIR)—Recognizing More Community Onset *Clostridium difficile* (*C diff*) Infections Increases the Expected Number of *C diff* Cases While Also Helping to Decrease the Actual Observed Number of Hospital Onset *C diff* Cases
- 531** Reducing Inappropriate Hospital-Acquired *Clostridium difficile* Diagnoses
- 532** Recurrent *C. difficile* in Children: Not Easy to Cure
- 533** Scaling Pediatric Access to Fecal Microbiota Transplantation in the United States: A Time-Series Geospatial Analysis
- 534** *Clostridium difficile* Reduction: An Agent-Based Simulation Modeling Approach to Evaluating Intervention Comparative Effectiveness at Pediatric Hospitals
- 535** Transmission of *Clostridium Difficile* from Patients ≤ 2 Years of Age in a Pediatric Oncology Setting
- 536** *Clostridium difficile* Colonization in the First Year of Life
- 537** Engaging the Bedside Nurse in Reducing *Clostridium difficile* Infection Through an Innovative Patient Care Rounding Program

60. Poster Abstract Session

HIV: Antiretroviral Therapy

Thursday, 12:30 - 1:45 p.m.

- 538** Integrase Inhibitor-Based HAART is Associated with Greater BMI Gains in Blacks, Hispanics, and Women
- 539** GS-CA2: A Novel, Potent, and Selective First-In-Class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans
- 540** Investigating the Mechanism of a Unique Human Immunodeficiency Virus-1 (HIV-1) Entry Inhibitor, MF275
- 541** Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4⁺ Count, and WHO Clinical Staging
- 542** Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates

Poster Abstract Sessions (continued)

- 543** An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
- 544** Pharmacokinetic Profile of ibalizumab from a Phase 3 Trial
- 545** Rational Design of Doravirine (DOR): A Review of Development from Bench to Patients (pts)
- 546** No Difference in MK-8591 and Doravirine Pharmacokinetics after Co-Administration
- 547** Results of Patient-Reported Outcome Data from the Phase III BRIGHT Study of Fostemsavir
- 548** Antiretroviral Therapy Regimen Characteristics within an Urban, Safety-Net Clinic in the United States
- 549** Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
- 550** Adherence and Persistency with Modern Single vs Multi-Tablet Antiretroviral (ARV) Regimens in 1st treatment of HIV in Clinical Practice
- 551** MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
- 552** Evaluation of Relationships between *UGT1A1* Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics among HIV-infected subjects in the LATTE-2 Study
- 553** A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
- 554** Does Protease Inhibitor (PI) Monotherapy Select Primary PI Resistance?
- 555** Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
- 556** Factors Associated with Integrase Strand Transfer Inhibitor Use between 2008- 2015
- 557** Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV Infected Patients
- 558** Genotype-Guided versus Standard First-line Antiretroviral Regimen for Treatment Naïve HIV-infected Patients in Thailand: A Prospective Randomized Controlled Trial
- 559** Efficacy and Tolerability of Integrase Inhibitors—Experiences from a Nationwide Real-life Cohort
- 560** Immune Recovery of Acute HIV Treated Patients is Characterized by an Increase in Immune Senescence
- 564** Higher “No Show” Rates Are Associated with Lower Rates of Retention in HIV Care and Viral Suppression
- 565** Implementing HIV Rapid Entry in a Community Infectious Disease Practice
- 566** Earlier Linkage and ART Initiation Via Fast Track Referral System for New HIV Patients Leads to Stronger Engagement and Better Outcomes
- 567** Stigma, Secrecy, and Spirituality: An Exploratory Study of How Sociocultural Practices and Perceptions Influence Care Engagement among HIV-Positive Adults in Akwatia, Ghana
- 568** The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
- 569** Pre-Tained: Early Intervention for HIV Patients at High Risk of Becoming Un-retained
- 570** The Effects of Loss of Control, Social Support, and Stigma on the HIV Care Continuum in the Aging HIV-Infected Population
- 571** In a Well Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes are No Longer Observed
- 572** Cascade of HIV Care of Newly-Diagnosed Citizens in Israel 2011-2015: A Population-Based Cohort Study
- 573** Are Facility-Based HIV Interventions in Low, Middle, and High-Income Countries Achieving UNAIDS 90-90-90 Targets? Results from a Systematic Review (2007-2017)
- 574** Late Diagnosis of HIV in South Carolina: Prevalence, Cause, and Consequences
- 575** Older HIV-infected Adults are Twice More Likely to Present Late to Care
- 576** Continuing Disparities in Virologic Control for People Living with HIV (PLWH) Receiving Care at a Large, Urban, Safety-Net Clinic
- 577** Barriers to Transitions of Care in the Detroit Young HIV Population
- 578** Virtual vs. True: Identifying Out-of-Care HIV Patients at Lower Risk for Poor Health Outcomes
- 579** Acceptability of Home-Based Medical Assessment to Facilitate Re-Engagement of HIV-Positive Out-Of-Care Persons into Clinical Care, New York City

61. Poster Abstract Session

HIV: Linkage to Care and Viral Suppression in the Care Cascade

Thursday, 12:30 - 1:45 p.m.

- 561** Co-Occurring Psychosocial Barriers to Viral Suppression Among Men Who Have Sex with Men (MSM) in India
- 562** Management and Outcomes of Patients with Acute HIV Infection in an Expanded Testing and Linkage to Care Program
- 563** Not Your Parent's Epidemic: New HIV Diagnoses and the New Patient Cascade of Care in the Bronx, NY

62. Poster Abstract Session

HIV: Management and Clinical Outcomes

Thursday, 12:30 - 1:45 p.m.

- 580** Key Factors for Treatment Changes within One Year after Starting ART in the German ClinSurv Cohort; between 2005 and 2014
- 581** Do Comorbidities and Polypharmacy Lead to Virologic Failure in All Populations Living with HIV?
- 582** Strengthening HIV Care and Treatment in the RoC Military
- 583** Demographic Factors and Clinical Outcomes Associated with Mental Health Medication Use in People Living with HIV
- 584** Investigation of the Association between Neurocognitive Function and Depression in HIV Infection
- 585** Hospitalization Rates and Diagnoses Vary by Age Group among Persons with HIV (PWH) in 2014-2015

Poster Abstract Sessions (continued)

- 586** The Aging Epidemic: Virologic Control, Immunologic Recovery, Treatment Regimens, and Clinical Outcomes among Older Adults Living with HIV in Washington, DC
- 587** HIV Care Outcomes among PWID in San Francisco, 2009-2015
- 588** Retrospective Analysis of Clinical Characteristics and Treatment Patterns Among HIV Patients with Commercial and Medicare Advantage Health Insurance in the U.S.
- 589** Assessment of an Antiretroviral Therapy Policy in Patients with Human Immunodeficiency Virus at a Large Academic Medical Center
- 590** Tackling HIV/AIDS in Brooklyn, NY, Within a Network of Federally Qualified Health Centers
- 591** Impact of an Antimicrobial Stewardship (ASP) Initiative Evaluating Antiretroviral Regimens for HIV-Positive Patients
- 592** Determining the Impact of an Antiretroviral Stewardship Team on the Care of HIV-Infected Patients Admitted to an Academic Research Institution
- 593** A Nationwide Assessment of Predictive Factors for Provision of Continuity of Care Resources for HIV-Positive Detainees in ICE Health Service Corps-staffed Facilities, 2015 and 2017
- 594** The Prevention and Management of HIV: Online Education as a Tool to Improve Knowledge and Confidence among HIV/ID Specialists
- 595** Changes in Ryan White Clinic Referral Patterns among HIV-infected Patients following Implementation of the Affordable Care Act
- 596** Case Study of Motivational Interviewing Intervention in Patients Non-Adherent to Antiretroviral Therapy
- 597** Pharmacist-Led Interventions for Inpatient HIV-Related Medication Errors
- 598** Choosing Wisely with CD4 Counts: When Less is More
- 599** Expanding HIV Training in Internal Medicine Residency Program: A Prospect to Meet the HIV Workforce Demand
- 600** To Study the Status of HIV Disclosure in Children and Adolescents
- 601** Prescription Drug Misuse in an HIV-Infected U.S. Military Cohort
- 602** Factors Associated with Erectile Dysfunction Diagnosis in HIV-Infected Individuals: A Case-control Study
- 603** Multi-Morbidity and Impaired CD4/CD8 ratios in Older Adults with well controlled HIV
- 604** Impact of Substance and Alcohol Abuse on Smoking-Related Behaviors When Using a Smoking Cessation Decisional Algorithm Among People Living with HIV (PLWH)
- 605** Loneliness among Older Adults Living with HIV: A Study and Online Community

63. Poster Abstract Session

Maternal-Child Infections

Thursday, 12:30 - 1:45 p.m.

- 606** Risk Factors for Congenital Infection in the United States: Analysis of the Kids' Inpatient Database (KID)

- 607** Group B *Streptococcus* Resistance to Clindamycin: Regional Antibiogram Surveillance in Los Angeles County
- 608** The Effect of Prenatal Screening for *Chlamydia trachomatis* (CT) on Chlamydial Conjunctivitis in Infants
- 609** Acute Kidney Injury during Treatment with Intravenous Acyclovir (AKITA) for Suspected Neonatal Herpes Simplex Virus Infection
- 610** Barriers and Facilitators to Uptake of Male Partner Attendance for HIV VCT During Prenatal Care in Brazil
- 611** Placental Pathology and Neonatal Outcomes in Pregnancies of Perinatally versus Non Perinatally HIV Infected Women
- 612** Increase in Perinatal HIV Infection in North Florida - Missed Opportunities to Prevent Maternal to Child Transmission in Rural Areas
- 613** Transmission of Influenza Virus in Mother and Infant Transmission Events in Nepal

64. Poster Abstract Session

Microbiome and Beyond

Thursday, 12:30 - 1:45 p.m.

- 614** Modeling Changes in Gastrointestinal and Respiratory Tract Bacterial Community Diversity Attributable to Common Antibiotic Exposures During Long-Term Acute Care
- 615** Can We Restore the Lung Microbiome with Fecal Microbiota Transplant (FMT)?
- 616** Vancomycin is Frequently Administered to Hematopoietic Cell Transplant Recipients Without a Provider Documented Indication and Correlates with Microbiome Disruption and Adverse Events
- 617** Characterization and Development of the Infant Gut Virome: A STORK Study
- 618** Do Clinical Factors Affect Microbial Engraftment After Fecal Microbiota Transplantation in Recurrent *Clostridium difficile* Infection?
- 619** Intestinal Microbiome Changes Associated with Immune Status and *Clostridium difficile* Colonization in Hospitalized Children
- 620** Oral Beta-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance from IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis
- 621** Treatment of Recurrent *Clostridium difficile* Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose Dependent Manner
- 622** Increased IgA Coating of Gut Microbes After Administration of Killed, Whole-Cell Oral Cholera Vaccine
- 623** Dynamic Nature of the Gut Resistome Among Infants in Singapore
- 624** Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation

Poster Abstract Sessions (continued)

65. Poster Abstract Session

Pathogenesis and Immune Response

Thursday, 12:30 - 1:45 p.m.

- 625 Metabolic Interactions Drive *Staphylococcus aureus* Adaptation to the Skin
- 626 An Inexpensive Quantitative Method for Testing Anti-Fungal Drug Activity Using the Invertebrate *Caenorhabditis elegans*
- 627 Differences In *C. difficile* Toxin A Binding In Humans: Adults Versus Infants
- 628 Short-Term Water-Pipe (Shisha) Smoke Exposure Worsens Lung Inflammation in Mice Infected with Respiratory Syncytial Virus
- 629 Blood Transcriptome Variations Predict Infection and Rejection in the Older Kidney Transplant Recipient
- 630 Identification of a Depressed Mucosal Immune Environment in HIV Infection
- 631 Markers of Immune Response in Patients with Acute, Chronic, and Fatal Infection with Chikungunya Virus in Colombia during the 2015 Epidemic
- 632 Recurrent Pneumococcal Meningitis in Adults
- 633 HIV-1 Vpu Immune Correlates in a Narrow-Source Infection Cohort: Impact of ADCC and KIR-Associated Pressure
- 634 Transcriptional Stimulation of Antiviral Response Components by the Structural and Accessory *Human Coronavirus OC43* Proteins
- 635 In HIV Infected Patients Killing of Latently HIV-Infected CD4 T Cells by Autologous CD8 T Cells is Modulated by Nef
- 636 The Hepcidin-25 and Iron Kinetics during the Acute Phase of Systemic Infection
- 637 Beta-lactam (BL) Antibiotics Promote an IL-1 β Response in Patients with *Staphylococcus aureus* Bacteremia (SaB)
- 638 CMV-Specific T Cell Immune Responses in Older Versus Younger Kidney Transplant Recipients
- 639 Indoleamine 2,3 Dioxygenase, Age, and Chronic Immune Activation in HIV Patients
- 640 Prospective Association of Serum Vitamin D level with Sepsis-Mortality in Postmenopausal Women: Results from the Women's Health Initiative
- 641 Development of Structural Epitope Targeting During B cell ontogeny by Exploration of Relatives of Gp41 Structural Epitope Binding Antibody 6F5
- 642 B and T cell Responses to Pneumococcal Polysaccharide and Protein Vaccine Antigens in Recently-Diagnosed HIV-1-Infected Patients
- 643 Coronary Artery Aneurysms are Found on Blindly Read Echocardiograms from Febrile Patients with and without Kawasaki Disease
- 644 How Antibody Isotype Affects Anti-Capsular Antibody Protection Against Carbapenem-Resistant *Klebsiella pneumoniae* Infection
- 645 Mucosal Associated Invariant T cells in renal tissue from patients with Recurrent Urinary Tract Infections
- 646 Activated Macrophages as Pathogenesis Factors in Ebola Virus Disease in Humans

- 647 Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3
- 648 Urinary Tract-Associated *Escherichia coli* Bacteraemia Strains are Genetically More Virulent than Those Originating from Non-Urinary and Neutropaenic Infective Foci
- 649 The Clinical Significance of Sequence Type 17 of Vancomycin-Resistant *Enterococcus faecium*
- 650 Genomic Analysis of Shiga Toxin-Producing *Escherichia coli* from Symptomatic Patients and Asymptomatic Carriers
- 651 Non-Encapsulation of Pneumococci as a Potential Evasion Mechanism from Vaccines
- 652 What's Blood Got to Do with It? Genetic Susceptibility to Norovirus and Rotavirus Infection: Results from the SUPERNOVA Network
- 653 To Treat or Not to Treat *Corynebacterium striatum*? That is the Question
- 654 Biofilm Forming Methicillin-Resistant *Staphylococcus aureus* Induces Renal Deterioration and Severe Virulence in a Mouse Bacteraemic Model
- 655 Antimicrobial Susceptibility and Prevalence of Extra-intestinal Enterotoxigenic *Bacteroides fragilis* Among a 5-year Collection of Isolates Causing Sepsis in Kuwait
- 656 *E. coli* Clone Sharing and Persistence within Households (HHs) in Relation to Fluoroquinolone (FQ) Resistance and ST131 Status
- 657 Epstein-Barr Virus Genetic Diversity in Blood versus Saliva Samples from Patients with Infectious Mononucleosis

66. Poster Abstract Session

Public Health: Epidemiology and Outbreaks

Thursday, 12:30 - 1:45 p.m.

- 658 Trends in Mumps Cases and Incidence, United States, January 2016–April 2018
- 659 Mumps Outbreak in a High School: Uptake and Parental Perceptions of 3rd Dose MMR Recommendations, Dallas County, TX, 2017
- 660 Are U.S. Clinicians Thinking Measles in the Post-Elimination Era? Surveillance for Measles-Like Illness in a Commercially Insured U.S. Population
- 661 Surveillance of Rabies Prophylactic Treatments after Exposure to Animals: 5 years Experience
- 662 Tick Borne Associated Thrombocytopenia Among United States Veterans in Long Island, NY
- 663 Characteristics, Treatment Patterns, and Outcomes of Outpatients with Rickettsial Diseases in a Large, Commercially Insured Population—United States, 2005–2016
- 664 Factors Associated with the Need for ICU Care Among Patients with Human Ehrlichiosis
- 665 Key Clinical and Laboratory Features in Early Diagnosis of Ehrlichiosis in an Endemic Area of Long Island, NY
- 666 Human Granulocytic Anaplasmosis and Ehrlichiosis Presenting to an Upstate New York Emergency Department
- 667 An Emerging Tick-Borne Disease in Long Island, NY: Relapsing Fever Caused by *Borrelia miyamotoi*

Poster Abstract Sessions (continued)

- 668** Clinical Spectrum of Powassan Virus Infection in Patients Presenting with Suspected Acute Tick-borne Illness from a Lyme-endemic Focus in the Midwest
- 669** Changing Epidemiology of Murine Typhus in Texas
- 670** Estimating *Bordetella pertussis* Seroprevalence in Persons Aged 10-25 Years in Mexico Using the 2012 National Health and Nutrition Survey (ENSANUT)—Challenges and Lessons Learned
- 671** Increased Disease Severity and Larger Household Size among Hispanic Infants with Pertussis—Chicago, IL, 2010-2016
- 672** The Impact on Humans of Treating Dogs with Amoxicillin/Clavulanate
- 673** Syphilis Outbreak in Women Who Have Sex with Men in Japan: A Case-Control Study in Tokyo, 2017-2018
- 674** Epidemiology of Diphtheria and Antimicrobial Resistance Among Diphtheria Cases, Bijapur district, Karnataka, India, 2012 to 2015
- 675** Current Physician Knowledge, Attitudes, and Clinical Practice regarding Legionnaires' Disease in the Aftermath of the Flint Water Crisis in Genesee County, MI
- 676** A Retrospective Forensic Review of Sudden Unexpected Infectious Deaths
- 677** Using a Multisectoral One Health Approach to Prioritize Zoonotic Diseases in the U.S.
- 678** Outbreak of Shiga Toxin-Producing *Escherichia coli* Infections at Marine Corps Recruit Depot (MCRD), San Diego and Camp Pendleton, CA, October–November, 2017
- 679** Mass-Scale Post-Hurricane Sheltering of Evacuees from Hurricane Harvey: Infectious Disease Surveillance and Prevention—Dallas County, TX, 2017
- 680** “There’s More to This than Meets the Eye”: Opportunities for Infection Prevention in Optometry Clinics
- 681** Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States (U.S.) Hospitals, 2010-2015
- 682** The Changing Epidemiology of Bacterial Meningitis During 2015-2017 in Turkey: A Hospital-Based Prospective Surveillance Study
- 683** Cost Calculator for Mass Vaccination Response to a U.S. College Campus Outbreak of Serogroup B Meningococcal Disease
- 684** Risk Stacking for Pneumococcal Disease in Costa Rica
- 685** Correlation between Hospitalized Influenza and Group A Streptococcus Infections in Minnesota, 2010 – 2016
- 686** Use of an Influenza-like Illness School Absenteeism Monitoring System to Identify Seasonal Influenza Outbreaks in the Community: ORCHARDS (Wisconsin, September 2014—June 2017)
- 687** Modeling the Impact of Introduction of Influenza Vaccination on ILI Cumulative Case Count in Cameroon
- 688** Impact of Expanded Influenza Post-Exposure Prophylaxis on Health Care Worker Absenteeism at a Tertiary Care Center during the 2017–2018 Season
- 689** Narcolepsy During the 2009–2010 H1N1 Pandemic
- 690** Bacterial Coinfections Among Adults Hospitalized with Community-Associated Influenza, 2016-2017
- 691** Real-Time Local Influenza Forecasting using Smartphone-Connected Thermometer Readings
- 692** Effects of Regional Climatic Variability on West Nile Virus Outbreaks in the United States
- 693** Congenital Zika Syndrome: Assessing the Fatality Rate Since the 2015 Zika Outbreak
- 694** The CAGE Study: Prevalence of Acute Gastroenteritis and Enteric Virus Infection in the Community

67. Poster Abstract Session

Resistance Mechanisms: Gram-Negative

Thursday, 12:30 - 1:45 p.m.

- 695** Regional and Longitudinal Mapping of *Escherichia coli* Antibiotic Susceptibility
- 696** Mechanism of Ceficerocol High MIC Mutants Obtained in Non-Clinical FoR Studies
- 697** *Pseudomonas aeruginosa* PcrV and Psl, the Molecular Targets of Bispecific Monoclonal Antibody MEDI3902, are Conserved Among Diverse Hospital Isolates Collected from an International Surveillance Study
- 698** Nacubactam Inhibits Class A and C β -lactamases
- 699** Relationship between *Klebsiella pneumoniae* Antimicrobial Resistance and Biofilm Formation
- 700** Identification and Whole Genome Sequencing (WGS) of Meropenem-Vaborbactam (MV) Resistant *Klebsiella pneumoniae* (MVRKP) Among Patients without Prior Exposure to MV: Collateral Damage
- 701** Rapid Detection of Antimicrobial Resistance Determinants with the BioFire® System
- 702** Zinc Blockade of SOS Response Inhibits Horizontal Transfer of Antibiotic Resistance Genes in Enteric Bacteria
- 703** Mechanisms of High-Level Ceftolozane/Tazobactam (CT) Resistance against *Pseudomonas aeruginosa* and Synergy between CT and tobramycin (TOB)
- 704** *Klebsiella pneumoniae* Carbapenemase and Verona Integron-Encoded Metallo-Beta-Lactamase among Carbapenem-Resistant Enterobacteriaceae in Kentucky
- 705** Four Superbugs Isolated from a Single Patient in the United States: *E. coli* (EC) and *K. pneumoniae* (KP) harboring NDM-5, *P. aeruginosa* (PA) Harboring NDM-1 and *Candida auris*
- 706** Ceftazidime-avibactam (CZA) and Meropenem (MER) are Synergistic and Bactericidal against Genetically-Diverse KPC-Producing *Klebsiella pneumoniae* (Kp)
- 707** Clarifying the Role of CrrB in Polymyxin Resistant *Klebsiella pneumoniae* Clinical Isolates Utilizing a Novel CRISPR-Cas9 System
- 708** Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients
- 709** Activity of Key β -Lactam Agents against Gram-Negative Bacilli from ICU Patients with Lower Respiratory Tract Infections – SMART United States 2015-2017

Poster Abstract Sessions (continued)

68. Poster Abstract Session

Resistance Mechanisms: Gram-Positive

Thursday, 12:30 - 1:45 p.m.

- 710 Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in *Clostridioides difficile*
- 711 Molecular Epidemiology of Daptomycin Non-Susceptibility in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia
- 712 Identification of a Novel Tedizolid Resistance Mutation in *rpoB* of Methicillin-Resistant *Staphylococcus aureus*
- 713 Vancomycin Heteroresistance in Coagulase Negative Staphylococci (CoNS) Causing Central Line Associated Bloodstream Infection (CLABSI) in Pediatric Patients with Leukemia

69. Poster Abstract Session

Respiratory Infections: Viral

Thursday, 12:30 - 1:45 p.m.

- 714 Predictors of Influenza-Associated Hospitalization and Pneumonia in a Pediatric Population in Bangkok, Thailand
- 715 Increase in Reported Respiratory Syncytial Virus Cases among Adults in the Minneapolis-St. Paul Metropolitan Area, 2014-2018
- 716 Molecular Epidemiology of Respiratory Syncytial Virus in Children and Adults in Seattle, WA
- 717 Cumulative Incidence of Asthma/Wheezing among Neonates/Infants/Toddlers Clinically Diagnosed with Respiratory Syncytial Virus Infection in the United States: A Retrospective Database Analysis
- 718 Viral Coinfection and Nasal Cytokines in Children with Acute Bacterial Sinusitis (ABS)
- 719 The Respiratory Pathogen Panel and Antibiotic Utilization in the Emergency Department
- 720 Respiratory and Non-Respiratory Complications among Patients Hospitalized with Influenza, FluSurv-NET, 2016-17
- 721 Clinical Respiratory Syndromes and Association with Influenza Clinical Diagnostic Testing and Antiviral Treatment among Children Hospitalized with Acute Respiratory Illness, 2015-2016
- 722 Normal Clinical Signs and Duration of Antibiotics in Hospitalized Patients with Pneumonia
- 723 Validation of a Wild-Type Influenza A/Texas-like H3N2 Human Challenge Model with Comparison to the Validated A(H1N1)pdm09 Model
- 724 Neurologic Complications in Hospitalized Pediatric Patients with Influenza Infection - A Multicenter Retrospective Study in Korea
- 725 Clinical Outcomes of Elderly Individuals Presenting with Acute Respiratory Infections
- 726 Viral Genomic Load, Cytokine Profiles and Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants

- 727 Evaluation of Antibiotic Prescribing Practices for Upper Respiratory Infections in the Adult and Pediatric Emergency Departments
- 728 Regional Validation of Distinct RSV Seasonality Thresholds for Antigen and PCR Testing
- 729 Improved Detection of Adenovirus with the FilmArray Respiratory Panel 2 Panel in a Pediatric Population
- 730 Hospital Readmissions following Laboratory-confirmed Influenza
- 731 Investigating Clinical Factors Contributing to Continued Antibiotic Therapy in Patients with Viral Upper Respiratory Tract Infections
- 732 Description of Diagnoses and Antibiotic Management of Otitis Media and Otitis Externa in Adults
- 733 Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults
- 734 Post-Exposure Management of *Influenza* in Roommates at a Tertiary Care Cancer Center
- 735 Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in U.S. Preterm Infants Born at 29-34 Weeks Gestation: 2014-2016
- 736 Incidence and Etiology of Community-Acquired Pneumonia Requiring Hospitalization among American Indian/Alaskan Native Adults
- 737 The Prevalence of Diagnosed Chronic Lung Disease in U.S. Infants by Gestational Age: Implications for RSV Policy
- 738 Role of Respiratory Syncytial Virus and *Mycoplasma pneumoniae* in Pediatric Community-Acquired Lower Respiratory Tract Infections
- 739 Middle East Respiratory Syndrome Coronavirus Infection Profile in Qatar: A 7-year retrospective study
- 740 Impact of the 2014 American Academy of Pediatrics Guidance on Respiratory Syncytial Virus Hospitalization Rates for Preterm Infants <29 Weeks Gestational Age at Birth: 2012-2016
- 741 Impact of Adenovirus Co-Detections on Illness Severity
- 742 "Troponin Leaks" in Patients with Acute Respiratory Viral Infections Enrolled in SUPERNOVA: A Marker of Worse Clinical Outcomes
- 743 Severity and Costs of Respiratory Syncytial Virus and Bronchiolitis Hospitalization in Commercially Insured Preterm and Term Infants Before and After the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis
- 744 Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine and Influenza Vaccine against Pneumococcal Pneumonia among Elderly Patients Aged 65 Years and Older in The Republic of Korea: A Case-Control Study
- 745 Surveillance for Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus Infections During 2016-2017 and 2017-2018, United States
- 746 Characteristics of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Adults—United States, 2014-2017
- 747 Antibiotic Therapy for Community-Acquired Pneumonia: A Systematic Review and Network Meta-Analysis of Randomized Trials

Poster Abstract Sessions (continued)

- 748** The Impact of a Positive Respiratory Viral Panel among Hospitalized Adult Patients with Negative Rapid Influenza Testing at an Academic Tertiary Care Facility: A Matched Cohort Study
- 749** Healthcare Utilization After Hospitalization for Respiratory Syncytial Virus or Unspecified Bronchiolitis in the First Year of Life
- 750** Respiratory Virus Infections and Airflow Obstruction after Allogeneic Hematopoietic Cell Transplantation
- 751** Acute Respiratory Illness Hospitalizations Among Young Children—Multi-Center Viral Surveillance Network, United States, 2015–2016

70. Poster Abstract Session

Tuberculosis and Other Mycobacterial Infections

Thursday, 12:30 - 1:45 p.m.

- 752** Geographic Analysis of Latent Tuberculosis Screening: A Health System Approach
- 753** Screening for Latent *Mycobacterium tuberculosis* Infection (LTBI): A Clinical Conundrum of Public Health Concern
- 754** Prevalence of Latent Tuberculosis Infection among Health Care Workers at a Tertiary Care University Hospital
- 755** Clinical Adherence to Latent Tuberculosis Screening Recommendations in Adults with Inflammatory Bowel Disease (IBD) Prior to Biologic Therapy
- 756** Targeting the Birth-Cohort of the Pre-Antibiotic Era; A Proposal to Screen for Tuberculosis in Seniors in Arkansas
- 757** Community Prevalence of Bacteriologically Confirmed Pulmonary Tuberculosis: A Seven-Year Retrospective Study
- 758** Tuberculosis Recurrence in New York City: A Retrospective Study
- 759** Molecular Characterization and Epidemiology of Multidrug-Resistant *Mycobacterium tuberculosis* (MDR-TB) and Identification of Possible Cases of Local Transmission of MDR-TB in Kuwait
- 760** The Diversity of *Mycobacterium tuberculosis* in India is Underestimated and Underreported
- 761** Age Related Incidence of TB Infection Supporting Efficacy of BCG Vaccination
- 762** Sex Differences in The Epidemiology of Tuberculosis in Tunisia
- 763** Risk Factors for Homeless Status and Mortality among Homeless TB Cases in Texas, 2010-2017
- 764** Impact of Diabetes Mellitus on the Presentation and Response to Treatment of Adults with Pulmonary Tuberculosis in Qatar
- 765** Tuberculosis and Diabetes Mellitus among Prison Inmates in Peru: Results of a National Survey, 2016
- 766** Migration Flows and Increase of Extrapulmonary Tuberculosis in a Low Prevalence Setting: A Retrospective Analysis in Two Italian Centers
- 767** A Seven-Year Retrospective Study of Pediatric tuberculosis in a Third Level Hospital in Mexico City
- 768** Epidemiological and Clinical Profile of Miliary Tuberculosis in Southern Tunisia
- 769** An Outbreak of Multidrug-Resistant Tuberculosis, Minnesota, 2016–2017
- 770** Multidrug-Resistant Tuberculosis Cases in Arkansas in 2017: A Tale of Two Threats
- 771** Drug Resistance Tuberculosis (DR-TB), Comorbidities, and Risk Factors Identified in a Prospective Multicenter Cohort Study in Indonesia
- 772** Factors Associated with Healthcare Delay of Active Pulmonary Tuberculosis after Hospitalization
- 773** Statins Decrease the Risk of Active tuberculosis: A Propensity Score-Matched Analysis
- 774** Extrapulmonary Tuberculosis: Impact of Early Diagnosis and Treatment on Mortality
- 775** An Epidemiological Analysis of Patients with Multidrug-Resistant Tuberculosis among Tibetan Refugees in India
- 776** Tuberculosis Screening among People Living with HIV in Arkansas: A Ryan White Program Evaluation
- 777** Ten-Year Experience of Tertiary Hospital Regarding Epidemiology, Diagnostic Method, and Drug Resistance of Tuberculosis - Jeddah, Saudi Arabia
- 778** Trend of tuberculosis Meningitis and Associated Mortality in Texas, 2010-2017, a Large Population-Based Analysis
- 779** *Mycobacterium tuberculosis* Prosthetic Joint Infections: A Case Series and Literature Review
- 780** Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare, 2008-2015
- 781** *Non Tuberculous Mycobacterium*: Often a Missed Entity
- 782** Risk Factors, Clinical Characteristic, and Treatment Outcomes for Nontuberculous Mycobacterial Disease in Mexico
- 783** Characterization of Non-tuberculous Mycobacteria Isolates in a National Mycobacterial Laboratory in Panama: 2012 - 2015
- 784** The Changing Epidemiology of Disseminated *Mycobacterium avium* Complex in the U.S.
- 785** Treatment of *Mycobacterium immunogenum* Skin and Soft Tissue Infections: A Case in a Peritoneal Dialysis Patient
- 786** Ceftaroline and Avibactam? Is This a Potential Combination for *Mycobacterium abscessus* Infection?
- 787** The Addition of Avibactam Augments the Activity of Piperacillin against *Mycobacterium abscessus in vitro*, and is Effective in Treating *M. abscessus* Infection in a *Galleria mellonella in vivo* Model
- 788** Therapeutic Drug Monitoring for Pyrazinamide during Tuberculosis Treatment: What is the Diagnostic Accuracy?
- 789** Comparison of Interferon-Gamma Release Assays (IGRAs) for Diagnosis of Latent or Active Tuberculosis in Cancer Patients
- 790** The Efficacy of the Interferon-Gamma Releasing Assay-Based Isoniazid Treatment for Preventing Active tuberculosis in Kidney Transplant Recipients: A Quasi-Experimental Study
- 791** Hyponatremia Incidence and its Association with Mortality in Patients with Tuberculosis

Poster Abstract Sessions (continued)

- 792** Number and Volume of Cavitory Lesions on Chest Computed Tomography Associated with Prolonged Time to Culture Conversion in Drug-Susceptible Pulmonary Tuberculosis
- 793** Diagnostic Accuracy of Single versus Multiple Gene Xpert for Discontinuation of Airborne Infection Isolation in Suspected Pulmonary Tuberculosis Patients at a U.S. Safety-Net Hospital
- 794** Infectivity of Smear Positive Pulmonary TB after Two Weeks of Rifampicin Based Anti-Tuberculous Therapy
- 795** Review of Treatment of Latent Tuberculosis Infection at VA Portland Health Care System
- 796** Treatment of Latent Tuberculosis Infection in a Refugee Population
- 797** Tuberculosis Treatment: Combined Forms vs Dissociated Forms
- 798** The Role of Whole Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated with Para-Amino Salicylic Acid and its Analogue
- 799** Genetic Diversity of *Mycobacterium tuberculosis* Strains Causing Drug Resistant tuberculosis in Central Region of Mozambique. The Whole Genome Sequencing
- 800** Drug Resistant TB: An Experience from Qatar
- 801** Emergence of Multidrug-Resistance Tuberculosis during the Treatment Course of Pan-Susceptible TB: A Case Series
- 802** Use of N-acetylcysteine for Prevention and Treatment of Isoniazid Induced Liver Injury during Treatment of Mycobacterial Infections
- 803** Overcoming β -lactam Resistance in *Mycobacterium abscessus*
- 804** Impact of Azithromycin Prophylaxis in Lung Transplant Recipients on the Risk of Nontuberculous Mycobacterial Infections
- 805** Amikacin Liposome Inhalation Suspension (ALIS) Add-On Therapy for Refractory *Mycobacterium avium* Complex (MAC) Lung Disease: Effect of *In Vitro* Amikacin Susceptibility on Sputum Culture Conversion
- 806** 2013-2015 Nationwide Tuberculosis Contact Investigation in Childcare Centers and Schools in Korea
- 807** A Risk-Stratified Approach to Healthcare-Associated Tuberculosis Exposures Following the "Stone in the Pond" Principle
- 808** Perinatal Depression among HIV and TB Infected and Uninfected Women in an Urban Slum in India: Prevalence and Associated Birth Outcomes
- 809** Osteitis Caused by Bacillus Calmette-Guerin Tokyo 172 Strain in Immunocompetent Patients
- 810** Diagnosis of BCG Aortitis by Plasma Metagenomic Sequencing
- 811** A Randomized Controlled Trial of Prednisolone vs Interleukin 17 A Inhibitor Secuinumab in the Management of Type 1 Leprosy Reaction in Leprosy Patients
- 812** Case Control Trial to Evaluate the Cytokine Response to the Use of Capsule Thalidomide in Erythema Nodosum Leprosum in Leprosy Patients
- 813** Combination of N-acetyl-cysteine with Clarithromycin against *Mycobacterium avium* infection

130. Poster Abstract Session Adult and Pediatric Influenza Vaccine

Friday, 12:30 - 1:45 p.m.

- 984** Maternal and Infant Factors Influencing Influenza Vaccination among Young Children Born in Colorado from 2008 to 2016
- 985** Safety of Guidelines Recommending LAIV for Routine Use in Children and Adolescents with Asthma
- 986** Evaluation of Moderate-to-Severe Influenza Disease in Children 6 months to 8 years of age in Colorado
- 987** Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study
- 988** Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, U.S. Flu VE Network, 2010-2018
- 989** Clinical Effectiveness of High-Dose Trivalent versus Quadrivalent Influenza Vaccination among Veterans Health Administration Patients
- 990** Impact of Influenza Vaccination Setting on Timing of Vaccination in a National Sample of Influenza-Vaccinated Adults
- 991** Randomized Trial of High Dose, Adjuvanted, and Standard Inactivated Influenza Vaccine Immune Response Against Egg- and Cell-propagated Vaccine Strains in Older Adults, 2016-2017 Season
- 992** 2016/2017 Influenza Burden of Disease and End-of-Season Influenza Vaccine Effectiveness (VE) Estimates for Preventing Influenza-Related Hospitalization Among Canadian Adults: An Analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network
- 993** Combining Key Residues of the Russian and U.S. Live-Attenuated Influenza Viruses for a More Attenuated Virus
- 994** AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
- 995** Effectiveness of Influenza Vaccine for Prevention of Influenza-Associated Hospitalizations among High-Risk Adults in the U.S., 2015 – 2016
- 996** A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in U.S. Nursing Homes
- 997** Protection of Unvaccinated Individuals by Influenza Vaccine Coverage of Household Contacts

131. Poster Abstract Session Bacteremia and Endocarditis

Friday, 12:30 - 1:45 p.m.

- 998** Misclassification of Community and Hospital Onset Bloodstream Infections Using Laboratory-Identified Events

Poster Abstract Sessions (continued)

- 999** Ongoing Burden of *Streptococcus pneumoniae* Sepsis in Children after Introduction of Pneumococcal Conjugate Vaccines
- 1000** Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
- 1001** Evaluation of the Clinical Efficacy and Safety of Oral Antibiotic Therapy for *Streptococcus* spp. Bloodstream Infections
- 1002** Epidemiology of Pneumococcal Bacteremia in a Large Tertiary Center
- 1003** Clinical Implications of Emerging Nonvaccine-Serotype Invasive Pneumococcal Disease among Adults in The Republic of Korea in the Era of Protein Conjugated Pneumococcal Vaccine
- 1004** Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017)
- 1005** HIV-Associated Bloodstream Infection (BSI): Trends Over Seven Years
- 1006** Demographic, Clinical, Microbiological Characteristics and Outcome of Patients Admitted to the Emek Medical Center with Bloodstream Infection Acquired in LTCF: A 5 Years Surveillance
- 1007** Etiology of Sepsis; a Systematic Review of Emergency Department Sepsis
- 1008** Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients with Bloodstream Infections
- 1009** VENOUS 1: A Prospective Multicenter Cohort Study of Enterococcal Bacteremia
- 1010** Effectiveness of Oral Antibiotics for Definitive Therapy of Gram-positive Bloodstream Infections
- 1011** Sepsis and Secondary Hemophagocytic Lymphohistiocytosis
- 1012** Group B Streptococcus Bacteremia in Non-Pregnant Adults in a Tertiary Care Hospital between 2008 and 2017 in Korea
- 1013** If Blood Cultures Were Not Done Before Starting Antibiotics, Is It of Any Value to Obtain Them Later?
- 1014** Microbiology and Outcome of Bloodstream Infections in Children with Intestinal Failure
- 1015** Enhanced Detection of Bloodstream Pathogens from Positive Blood Culture Specimens with an Improved Multiplex PCR Molecular Diagnostic System
- 1016** Bloodstream Infection Survey in High-Risk Oncology Patients (Bishop) with Fever and Neutropenia (FN): Predictors for Morbidity and Mortality
- 1017** Impact of Enterococcal Bloodstream Infection on Mortality in Patients with Acute Myelogenous Leukemia
- 1018** Prevalence of Bacteremia/Fungemia and Pneumonia in Remission Induction Chemotherapy for Adult Acute Myeloid Leukemia from 1987 to 2005: Japan Adult Leukemia Study Group (JALSG)
- 1019** Treatment Outcomes for *Enterococcus faecium* Bacteremia in Solid Organ Transplant Patients: Implications for Daptomycin
- 1020** Injection Drug Use-Associated *Staphylococcus aureus* Bacteremia in a Large Urban Hospital in Atlanta, GA
- 1021** Repeat Infective Endocarditis (rIE) in Persons Who Inject Drugs (PWID)
- 1022** Rising Rates of Injection Drug Use Associated Infective Endocarditis in Virginia with Missed Opportunities for Injection Drug Use Disorder Treatment Referral: A Retrospective Cohort Study
- 1023** A Controlled-Release Prescription Oral Opioid can Prolong *S. aureus* Survival in Injection Drug Preparation Equipment and Potentially Increase Bacteremia Risk
- 1024** First Episode Infective Endocarditis in Persons Who Inject Drugs (PWIDs); a Retrospective Cohort Study
- 1025** Microbial Epidemiology of Infectious Endocarditis in the Intravenous Drug Abuse Population: A Retrospective Study in East Tennessee
- 1026** Trends in Infective Endocarditis During the Substance Use Disorder Epidemic at an Academic Medical Center
- 1027** Outpatient Parenteral Antimicrobial Therapy (OPAT) in Injection Drug Users (IDUs): Is It Safe?
- 1028** Synergizing Infectious Diseases and Substance Use Treatment to Improve the Outcomes of Endocarditis in People who Inject Drugs at a Large Academic Hospital
- 1029** Outcome of Candida Graft Vascular Infection: Results from a Prospective Cohort
- 1030** Risk Predictive Model for Candida Endocarditis in Patients with Candidemia: A 12-year Experience in a Single Tertiary Care Hospital
- 1031** Nationwide Temporal Trends of Candidemia Incidence over 18 Years within the Veteran Health Administration System
- 1032** A Case Series of *Clostridium septicum* Aortitis
- 1033** Thinking Outside the Bowel - *Clostridium difficile* Bacteremia Case Series
- 1034** "Four-Leaf Clover Sign" as a Rapid Identification of Coagulase Negative Staphylococci Species by Gram Stain of Blood Culture
- 1035** Differentiation between True Infection and Contamination of Coagulase-Negative Staphylococci by Developing a Prediction Rule
- 1036** Whole Genome Sequencing Analysis of a Large Cohort of *Staphylococcus epidermidis* Blood Culture Positive Isolates from a Multicenter Clinical Trial
- 1037** Effect of Oral Step-Down Therapy on Readmission Rates in *Escherichia coli* Bacteremia
- 1038** *Edwardsiella tarda* Bacteremia: Epidemiology, Clinical Features, and Outcomes
- 1039** Surveillance Blood Cultures Associated With Decreased Mortality in Gram-Negative Bacteremia
- 1040** Comparative Characteristics of Patients with Pseudomonas Bacteremia Receiving Intravenous Only versus Intravenous Followed by Oral Therapy
- 1041** How Do Healthcare Providers Approach Empiric Beta-lactam (BL) Treatment of Bloodstream Infections (BSI) Caused by Gram-Negative Rods (GNRs)? Analysis of *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*) BSI from the Veterans Health Administration (VHA)

Poster Abstract Sessions (continued)

- 1042** *Stenotrophomans maltophilia* Bacteremia, a 10-Year Tertiary Center Experience
- 1043** Evaluation of Early Clinical Failure Criteria for Gram-Negative Bloodstream Infections
- 1044** Aztreonam (AZT) versus Cephalosporin (CEP) Therapy for the Treatment of Gram-Negative Bacteremia
- 1045** A Multicenter Propensity Score-Adjusted Retrospective Study for Comparison of the Outcome of Treatment with Third-Generation Cephalosporin versus Broad-Spectrum Antibiotics for Enterobacter Bacteremia
- 1046** Clinical and Microbiological Characteristics of Patients with Septicemia Caused by IMP-1-Producing Enterobacteriaceae in a Tertiary Hospital in Japan
- 1047** Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* Isolates Collected from Bloodstream Infections in the United States from 2015-2017
- 1048** Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort
- 1049** Outcome and Impact of Empirical Antimicrobial Treatment in Bacteraemia with Bacteroides Species; A Retrospective Cohort Study in a Region of Southern Sweden
- 1050** Oral Antibiotics for the Treatment of Gram-negative Bloodstream Infections: Prescribing Practices and Outcomes at a Large Academic Medical Center
- 1051** Increased Mortality In Bacteremia by *Enterobacter* Species with Discordant Imipenem and Ertapenem Susceptibilities
- 1052** Do Healthcare Providers De-Escalate Beta-lactam (BL) Antibiotic Therapy Based on Results of Antibiotic Susceptibility Testing (AST)? Analysis of Bloodstream Infections (BSI) Caused by *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*) from the Veterans Health Administration (VHA)
- 1053** Biofilm Production and Clinical Characteristics of *S. maltophilia* Causing Persistent or Relapsing Bacteremia
- 1054** Biofilm Formation Among *Escherichia coli* Bloodstream Infection Isolates is Associated with Source of Bacteremia and Bacterial Sequence Type
- 1055** Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β -lactamase- Producing *Enterobacteriaceae* Bacteremia
- 1056** Predicting Central Nervous System Complications in *Staphylococcus aureus* Bacteremia using Clinical Scoring System
- 1057** Treatment Efficacy of Ceftriaxone versus Cefazolin for Methicillin-Susceptible *Staphylococcus Aureus* Infections
- 1058** Prognostic Biomarkers for Persistent Bacteremia and Mortality in Complicated *S. aureus* Bloodstream Infection
- 1059** *Staphylococcus aureus* Bacteremia Treatment: Results from Pilot Surveillance in Four U.S. States
- 1060** Risk Factors for Recurrent *Staphylococcus aureus* Bacteremia
- 1061** Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant *Staphylococcus aureus* Bacteremia
- 1062** Daptomycin/Ceftaroline in Combination versus Vancomycin for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia
- 1063** Impact of Rapid Organism Identification and a Standardized Algorithm on Antimicrobial Therapy in Patients with Bacteremia
- 1064** Clinical Outcomes of Daptomycin in Combination with Ceftaroline or Anti-Staphylococcal Penicillins for Patients with Persistent MRSA Bacteremia
- 1065** Evaluation of a *Staphylococcus aureus* Bacteremia Treatment Checklist
- 1066** Adjuvant β -lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia: Does β -lactam Class Matter?
- 1067** Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive *Staphylococcus aureus* Bacteremia
- 1068** Evaluation of Cefazolin versus Anti-Staphylococcal Penicillins for the Treatment of Methicillin-Susceptible *Staphylococcus aureus* Bloodstream Infections in Acutely-III Adult Patients: Results of a Systematic Review and Meta-Analysis
- 1069** Predictive Factors for Metastatic Infection in Patients with Bacteremia Caused by *Staphylococcus aureus*
- 1070** Epidemiological and Clinical Features of Pantone-Valentone Leukocidin Positive *Staphylococcus aureus* bacteremia: A Case-Control Study
- 1071** Impact of Standard versus Prolonged Courses of Antibiotics for the Treatment of Uncomplicated *Staphylococcus aureus* Bacteremia (SAB) in Patients with Hematologic Malignancies
- 1072** Streamlining to Oral Beta-Lactam versus Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
- 1073** Predictors of Vancomycin Switch or Escalation in Patients with Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection
- 1074** Management and Outcomes of Infective Endocarditis due to Nutritionally Variant Streptococci
- 1075** A Retrospective Comparison of Native Valve Endocarditis and Prosthetic Valve Endocarditis in a Large Tertiary Care Teaching Hospital from 2007-2015
- 1076** What is the Positivity Delay of Blood Cultures in Infective Endocarditis?
- 1077** Heart Transplantation as Salvage Treatment for Intractable Infective Endocarditis
- 1078** Use of PCR/Electrospray Ionization Mass Spectrometry for Rapid Identification and Antibiotic Treatment Adaptation in Patients Suffering from Infective Endocarditis
- 1079** When Does a Trans-Esophageal Echocardiogram (TEE) Change Management of *Staphylococcus aureus* Bacteremia (SAB)?
- 1080** Time to Blood Culture Positivity in *Staphylococcus aureus* Bacteremia is Associated with the Risk of Infectious Endocarditis
- 1081** Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers

Poster Abstract Sessions (continued)

- 1082** Meta-Analysis of Survival Outcomes in People who Inject Drugs after Cardiac Surgery for Infective Endocarditis
- 1083** Long-Term Prognosis of 448 Infectious Endocarditis followed by an Endocarditis Team
- 1084** *Nocardia cyriacigeorgica* Endocarditis
- 1085** Enterococcal Cardiac Implantable Electronic Device (CIED) Infections: Clinical Features and Outcomes
- 1086** Impact of Systematic Thoraco-Abdomino-Pelvic CT Scan on the Diagnosis of Infective Endocarditis
- 1087** Aortic Graft Infections Caused by *Propionibacterium acnes* at the Minneapolis Veterans Affairs Health Care System (MVAHCS) 2007 – 2017

132. Poster Abstract Session

Diarrhea Diagnostic Dilemmas

Friday, 12:30 - 1:45 p.m.

- 1088** Ultrasensitive Detection of *C. difficile* Toxins in Stool Using Single Molecule Counting Technology: A Multicenter Study for Evaluation of Clinical Performance
- 1089** Analytical Performance of an Ultrasensitive Immunoassay for Detection of *Clostridium difficile* Toxins in Stool
- 1090** Patient Outcomes with Prevented versus Negative *Clostridium difficile* Tests Using Computerized Clinical Decision Support (CCDS)
- 1091** Algorithmic Release of *Clostridium difficile* PCR Results from a Multiplex Gastrointestinal (GI) Panel in Children < 3 years old
- 1092** Tuning Down *Clostridioides difficile* PCR Sensitivity Reduces Treatment for *C. difficile* Infection in Toxin-Negative Patients with No Increase in Adverse Outcomes
- 1093** Single Molecule Counting Technology for Ultrasensitive Quantification of *Clostridium difficile* Toxins A and B
- 1094** Performance of Toxin Enzyme Immunoassays and PCR Cycle Threshold for Differentiating *Clostridium difficile* Infection from Colonization in Children with Diarrhea
- 1095** The Value of Hardwiring Diagnostic Stewardship in the Electronic Health Record: Electronic Ordering Restrictions for PCR-Based Rapid Diagnostic Testing of Diarrheal Illnesses

133. Poster Abstract Session

Enteric Infections

Friday, 12:30 - 1:45 p.m.

- 1096** Effect of Diarrheal Illness During Pregnancy on Adverse Birth Outcomes in Nepal
- 1097** Is Early Bisphosphonate Treatment Safe or Effective for Pyogenic Vertebral Osteomyelitis with Osteoporosis?
- 1098** Clinical Features and Outcomes of United States Marine Corps Recruits Hospitalized with Shiga Toxin-Producing *Escherichia coli* Infection and Hemolytic-Uremic Syndrome
- 1099** Antibiotic Prescriptions for Acute Gastroenteritis during Office and Emergency Department Visits—United States, 2006–2015

- 1100** Characterization of Enteropathogenic *Escherichia coli* (EPEC) in Cancer Patients with Diarrhea
- 1101** Comparison of Clinical Characteristics and Demographics of GII.4 versus other GII Noroviruses associated with Sporadic Acute Gastroenteritis in Children in Nashville, TN, 2012-2015
- 1102** Food Insecurity and Reported History of Cholera in Haitian Households: An Analysis of the 2012 Demographic and Health Survey (DHS)
- 1104** Deployment-Associated Infectious Gastroenteritis and Associations with Irritable Bowel Syndrome, Post-Traumatic Stress Disorder, and Combat Stress: A Retrospective Cohort Study Among Deployed United States Military Personnel
- 1105** Vibriocidal Titer Variation and Likelihood of Protection in Children Compared to Adults in a Cholera Endemic Area
- 1106** Infectious Etiologies of Acute Gastroenteritis in Children during the First 100 Days Post-Allogeneic Hematopoietic Cell Transplant
- 1107** The MAAGE Study: Health Care Utilization for the Treatment of Medically-Attended Acute Gastroenteritis
- 1108** Diagnostic Yield of the BioFire® FilmArray Gastrointestinal Panel in Hospitalized Children at an Academic Children's Center
- 1109** Factors Impacting the Decision to Order Stool Diagnostic Testing in Patients with Acute Gastroenteritis Among Primary Care Providers
- 1110** A Multicenter Evaluation of Outcomes Associated with Oral Vancomycin Dose in Patients with *Clostridium difficile* Infection
- 1112** Detection of Enteric Viruses in Children with Acute Gastroenteritis
- 1113** Real Time Evolution of Extensively Drug Resistant *Vibrio cholerae*
- 1114** Utility of a Bedside Diagnostic Testing Algorithm to Screen for Hospital-Onset *Clostridium Difficile* Infection
- 1115** Use of a Fluoroquinolone (FQ) versus a Non-Fluoroquinolone (Non-FQ) Based Antibiotic Regimen in the Treatment of Acute, Uncomplicated Diverticulitis
- 1116** Comparison of Short-Course versus Prolonged-Course Antimicrobial Therapy in the Management of Intra-Abdominal Infections
- 1117** Avascular Necrosis of the Femoral Head as a Sequela of Shiga Toxin-Producing *Escherichia coli* (STEC) Infection
- 1118** Viral Species Richness and Composition in Young Children with Loose or Watery Stool in Ethiopia
- 1119** Risk Factors for *Clostridium difficile* Acquisition and Persistence among Guatemalan Children
- 1120** *Clostridium difficile* Infection Risk Factors, Severity, and Outcomes in Patients Infected with NAP1/027 Strain in a Non-Epidemic Setting
- 1121** Epidemiology and Risks for Infection following Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy at an Australian Centre

Poster Abstract Sessions (continued)

- 1122** Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients with recurrent *Clostridium difficile* infection (CDI)
- 1123** Individual and Household Risk Factors for Symptomatic Cholera Infection: A Systematic Review and Meta-Analysis
- 1124** Effects of Co-infection on the Severity, Response to Treatment, and Duration of Hospital Stay in Patients with *Clostridium difficile* Infection
- 1125** Reduced Time to Pathogen Identification and Antibiotic Prescription using Multiplex Molecular Testing for Gastrointestinal Infections
- 1126** Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
- 1127** Genomic Analysis of Biofilm-Forming Enteroinvasive *E. coli* Emergent Pathogen

134. Poster Abstract Session

Fungi and Parasites in Immunocompromised Patients

Friday, 12:30 - 1:45 p.m.

- 1128** Utility of Anaerobic and Fungal Blood Cultures in the Pediatric Oncologic Population
- 1129** Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
- 1130** Low Risk of *Pneumocystis jirovecii* Pneumonia in Patients with Waldenstrom's Macroglobulinemia on Ibrutinib
- 1131** Characteristics and Risk Factors for Mortality in Hematologic Patients with Invasive Non-*Aspergillus* Mold Infections: A Single Center 7-Year Cohort Study
- 1132** Pneumocystis Infection in Children: National Trends and Characteristics in the United States, 1997-2012
- 1133** Epidemiology of Invasive Fungal Infections in Lung Transplant Recipients: Harnessing Data Mining Tools to Build a Comprehensive Database
- 1134** Novel T2Candida Panel Assay Compared to Blood Cultures for Detection of Candidemia in Transplant and Non-Transplant Patients
- 1135** Strongyloides Stercoralis Serology in Transplant Patients: to Test or Not?
- 1136** Universal Prophylaxis for Prevention of Invasive *Aspergillus* in Lung Transplant Recipients
- 1137** Implementation of Universal Screening for Strongyloidiasis Among Solid Organ and Hematopoietic Stem Cell Transplantation Candidates in a Non-endemic Area
- 1138** Retrospective Cohort Analysis of Amphotericin B Nephrotoxicity in Kidney Transplant Recipients
- 1139** Novel Formulation SUBA-Itraconazole Prophylaxis in Patients with Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow Up Survival Data
- 1140** GATA2 Mutations are Frequently Identified among Patients with Myeloid Malignancies who Develop Invasive *Aspergillus*

135. Poster Abstract Session

Healthcare Epidemiology: Environmental and Occupational Health

Friday, 12:30 - 1:45 p.m.

- 1141** Microbial Assessment of Healthcare-Associated Pathogens on Various Environmental Sites in Patient Rooms after Terminal Room Disinfection
- 1142** Use of DNA Markers to Assess the Potential for Pathogen Transmission from Physicians' White Coats
- 1143** Epidemiologic Characteristics of Outbreaks Associated with the Healthcare Environment
- 1144** Modern Problem, Medieval Cure – Resistant *Aeromonas* in Medicinal Leeches
- 1145** Sparring with Spores: Ultrasounds as a Vector for Pathogen Transmission in the Intensive Care Unit
- 1146** Effectiveness of Ultraviolet Irradiation on *Candida auris*: A Laboratory Study
- 1147** Pseudo-Outbreak of *Clostridium parapatrificum* Related to Anaerobic Tent Contamination
- 1148** Reduction of Blood Culture Contamination Rates by an Altered Sampling Protocol: Single Center, Prospective, Randomized, Controlled, Open Label Trial
- 1149** Environmental Disinfection with Photocatalyst as an Adjunctive Measure to Control Multidrug-Resistant Organisms Transmission: A Prospective Cohort Study in High Incidence Setting
- 1150** Cleaning High Touch Surfaces of Patients' Rooms: Make it Easier, and it Simply Gets Cleaner
- 1151** A Safer, More Effective Method for Cleaning and Disinfecting GI Endoscopic Procedure Rooms
- 1152** Leveraging Human Factors Engineering to Optimize Low Level Disinfection of Bedside Medical Tools
- 1153** UV-C Technology is an Effective Adjunct to Terminal Cleaning in Environmental Pathogen Reduction in a Tertiary Pediatric Hospital
- 1154** Comparison of Five Testing Modalities for the Assessment of Patient Environment Cleanliness
- 1155** Excessive Movement, Unnecessary Contamination: *Clostridium difficile* Patients in the Hospital
- 1156** Observation of Stethoscope Sanitation Practices in an Emergency Department Setting
- 1157** Optimal Isolation Periods Based on Time Interval to Elimination of Scabies after Topical Agent in the Real Clinical Practice
- 1158** Needlestick Injuries and Other Potential Exposures to Bloodborne Pathogens Among Police Officers in a City Police Department, 2011–2016
- 1159** Influenza Symptoms in Vaccinated Healthcare Workers in an H3N2-Dominant Season
- 1160** Infrequency of Respirator Change Following Annual Respiratory Fit Testing at an Academic Medical Center
- 1161** Infection Control after Debridement of *Brucella melitensis* Hardware Infection

Poster Abstract Sessions (continued)

136. Poster Abstract Session

Healthcare Epidemiology: MDR-Gram Negative Infections

Friday, 12:30 - 1:45 p.m.

- 1162** Epidemiology of Carbapenem-Resistant *Pseudomonas aeruginosa* Identified through the Emerging Infections Program (EIP), United States, 2016–2017
- 1163** Impact of Difficult-to-Treat Resistance on Survival in Gram-Negative Bacteremia: A Risk-Adjusted Analysis Using Electronic Health Record–Based Clinical Data from 140 U.S. Hospitals
- 1164** County-Level Geographic Distribution of Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae across Outpatient Settings of the Veterans Health Administration, 2000–2017
- 1165** Comparing Patient Risk Factors, Sequence Type, and Resistance Loci Identification Approaches for Predicting Antibiotic Resistance in *Escherichia coli* Bloodstream Infections
- 1166** Development of a Bedside Tool to Predict the Probability of Drug-Resistant Pathogens among an Adult Population with Gram-Negative Infections
- 1167** Trends in Multidrug-Resistant Gonorrhea, Gonococcal Isolate Surveillance Project, United States, 1987–2016
- 1168** Role of Extended-Spectrum Cephalosporin-Resistance in Recurrent Enterobacteriaceae Urinary Tract Infections
- 1169** Surveillance of Antibiotic-Resistant Bacteria Reported among Healthcare-Associated Infections, California, 2011–2017
- 1170** Applying Machine Learning Algorithms to Predict Multidrug-Resistant Bacterial Infections from Prior Drug Exposure
- 1171** Impact on Mortality, Length of stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized with Carbapenemase-producing Enterobacteriaceae
- 1172** Travel-Associated Multidrug-Resistant Organism Acquisition and Risk Factors among U.S. Military Personnel
- 1173** A Cluster of Carbapenemase-Producing *Acinetobacter baumannii*
- 1174** Epidemiology of Carbapenem-Resistant Enterobacteriaceae, a 5-year Experience at a Tertiary Care Hospital
- 1175** Clinical and Microbiological Features of *Klebsiella pneumoniae* Liver Abscess Caused by Multidrug-Resistant Strains
- 1176** Risk Factors for ESBL *Enterobacteriaceae* Colonization Identified by Universal Admission Screening in a London Teaching Hospital
- 1177** Carbapenemase-Producing Carbapenem-Resistant Organism Colonization Screening Surveys—Maryland, April 2017–April 2018
- 1178** A Multicenter Prospective Study of Clinical and Molecular Epidemiological Analysis of Carbapenem-Resistant *Enterobacteriaceae* (CRE) and Carbapenemase-Producing *Enterobacteriaceae* (CPE) in Japan
- 1179** Incidence of Bacteremia and Bacteriuria with Antibiotic-resistant *Enterobacteriaceae* after Transrectal Ultrasound-Guided Biopsy of the Prostate (TRUSBP)
- 1180** Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- 1181** Use of the Combination Antibiogram in the Era of MDR Gram Negative Pathogens
- 1182** Risk Factors for the Acquisition of IMP-Type Carbapenemase-Producing Carbapenem-Resistant *Enterobacteriaceae* in Japan: A Matched Case-Control Study
- 1183** Epidemiological, Clinical, and Microbiological Characteristics of Carbapenemase-Producing Enterobacteriaceae Bloodstream Infection in Republic of Korea
- 1184** Resistance Patterns and Susceptibility Analysis of *Klebsiella pneumoniae* Infections in Service Members Who Sustained Trauma in Iraq and Afghanistan
- 1185** Impact of Bloodstream Infections Caused by Multidrug-Resistant Organisms on Performance Status: A KARS-Net Study
- 1186** Prevalence of Carbapenemase-Producing *Enterobacteriaceae* (CPE) in Hospital Drains in Southern Ontario
- 1187** Retrospective and Prospective Analysis of *Acinetobacter* Modern-Day Clinical Isolates in a Large Midwest Hospital System
- 1188** Could Chlorhexidine (CHX) bathing decrease the incidence of Carbapenem-resistant Enterobacteriaceae (CRE) bacteremia in previously Colonized CRE Hematopoietic Stem Cell Transplant recipients (HSCT)?
- 1189** A Comprehensive Characterization of the Emerging Carbapenem-Resistant *Klebsiella pneumoniae* Clinical Isolates from a Public Hospital in Lima, Peru
- 1190** Reduction of Carbapenem-Resistant Enterobacteria (CRE) infections and Total Polymyxin B Use Due to a Comprehensive Infection Control strategy in Colombia
- 1191** Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in U.S. Hospitals, 2010–2015
- 1192** Identification of a Novel *Enterobacter cloacae* Isolate Producing an IMP-13 Metallo-Beta-Lactamase
- 1193** Comparison of the Clinical Outcomes of Patients with IMP-Type Carbapenemase-Producing Carbapenem-resistant *Enterobacteriaceae* and Carbapenem-Sensitive *Enterobacteriaceae* in Japan
- 1194** Carbapenem-Resistant Enterobacteriaceae in Kentucky - Initial Six Months of Mechanism Testing
- 1195** Where You Live Matters: United States Region as a Significant Predictor of Mortality for ESBL Infection Based on a Descriptive Study using NIS Database
- 1196** *Serratia marcescens* Strains Carrying *bla^{KPC-2}* and *bla^{KPC-3}* Carbapenemase Associated with Chronic Mechanical Ventilation
- 1197** Microbiological Surveillance of Duodenoscopes Before and After High-Level Disinfection Following Endoscopic Retrograde Cholangiopancreatography (ERCP)

Poster Abstract Sessions (continued)

- 1198** Clinical Characteristics and Outcomes of *Klebsiella pneumoniae* Infections in Service Members Who Sustained Trauma in Iraq and Afghanistan
- 1199** Epidemiology of Carbapenem Resistant *Klebsiella pneumoniae*: A Comparative Study between Facilities in the United States and the Dominican Republic
- 1200** Molecular Epidemiology of Cephalosporinases and Extended Spectrum Beta-lactamases (ESBLs) in *Proteus mirabilis* Isolates from Croatia: Following the Spread of Resistance Determinants between Long-Term Care Facilities and the Community
- 1201** A Prolonged Multispecies Outbreak of Carbapenemase-Producing Enterobacteriaceae Due to Transmissible Plasmid with Carbapenemase Gene
- 1202** Multimodal Sequencing of a Clonal Case Cluster of Carbapenem-Resistant *Citrobacter* Reveals Unexpectedly Rapid Dynamics of KPC3-Containing Plasmids
- 1203** Molecular Screening for Multidrug-Resistance Genes in Hospitalized Veterans
- 1204** The MDR Upon Admission Score for Shortening Time to Initiation of Appropriate Antimicrobial Therapy in the Era of Widespread Resistance to Antimicrobials
- 1205** Emergence of Carbapenemase Producing *Enterobacteriaceae* in South Central Ontario, Canada
- 1206** Risk Factors of Antibiotic Resistance in *E. coli* Isolated from the MAL-ED Birth Cohort Study in Rural Tanzania
- 1207** Acquisition and Quantification of Antimicrobial Resistance Genes in the Gut Microbiome of Ugandan Women Exposed to Small-Scale Chicken Farming
- 1215** Geographic Distribution of *Staphylococcus aureus* with Reduced Sensitivity and Resistance to Vancomycin in the Dominican Republic
- 1216** Cost-Effectiveness of Penicillin Skin Allergy Testing in Methicillin-Sensitive *Staphylococcus aureus* (MSSA) Bacteremia
- 1217** *Staphylococcus* Protein A (spa) Typing Demonstrates Genetic Heterogeneity of Methicillin-Susceptible *Staphylococcus aureus* (MSSA) in a Neonatal Intensive Care Unit (NICU)
- 1218** Retapamulin as a Potential Decolonizing Agent: Activity against Mupirocin-Resistant Strains from Pediatric Patients with Methicillin-Resistant *Staphylococcus aureus* infection
- 1219** Increasing Methicillin Resistance of *Staphylococcus lugdunensis* in a Tertiary Care Community Hospital in Japan
- 1220** Impact of Mandatory Infectious Diseases Consultation on the Use of Core Measures and Mortality in *Staphylococcus aureus* Bacteremia (SAB) at an Academic Medical Center
- 1221** Genetic Characteristics of Healthcare-Associated Methicillin-Resistant *Staphylococcus aureus* (HA-MRSA) Belonging to Clonal Complex 5 (CC5) in Latin America
- 1222** Risk Factors and Outcomes for Daptomycin Non-Susceptible Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections
- 1223** Increasing Incidence of Methicillin-Resistant *Staphylococcus aureus* in Greenland
- 1224** Drug-Resistance Dynamics of *Staphylococcus aureus* at a Tertiary Hospital, Beijing, China, 2013-2017
- 1225** High Rate of Linezolid (LZD) Non-Susceptibility (LNS) among Enteric Vancomycin-Resistant Enterococci (VRE) Recovered from Hospitalized Patients Actively Screened for VRE Rectal Colonization (VREC)
- 1226** Can Universal Decolonization Obviate the Need for Screening and Contact Precautions for Carriers of Methicillin-Resistant *Staphylococcus aureus* in a Medical Intensive Care Unit with MRSA Endemicity? An Interrupted Time Series Study
- 1227** Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant *Staphylococcus aureus* Bacteremia
- 1228** Incidence of *Staphylococcus aureus* Infection after Elective Surgeries among Adults in U.S. Hospitals
- 1229** Prevalence and Acquisition of MRSA in Females During Incarceration at a Large Inner-City Jail
- 1230** Epidemiology and Risk Factors for Recurrent Invasive Methicillin-Resistant *Staphylococcus aureus* Infection—9 U.S. States, 2006–2013
- 1231** Patient-Level Factors Associated with Vancomycin-Resistant Enterococci Transmission to Healthcare Workers' Gowns or Gloves
- 1232** Phylogenomics of *Enterococcus faecium* from South America: Revisiting Worldwide VRE Population Structure
- 1233** An Automated e-mail Notification System to Infectious Disease Specialists and Effect on the Management of *Staphylococcal aureus* Bacteremia in a Community Hospital setting

Poster Abstract Sessions (continued)

- 1234** Racial Disparities in Invasive *Staphylococcus aureus* (ISA) Disease in Metropolitan Atlanta, a Population-Based Assessment, 2016
- 1235** Transmission of Genetically Related, Multidrug-Resistant, and Invasive Vancomycin-Resistant Enterococci (VRE) between Patients and Rooms on the Stem Cell Transplant (SCT) and Leukemia (LKM) Units

138. Poster Abstract Session

Healthcare Epidemiology: Non-acute Care Settings

Friday, 12:30 - 1:45 p.m.

- 1236** Infection Control Risk Mitigation and Implementation of Best Practice Recommendations in Long-term Care Facilities
- 1237** New York State Outpatient Regional Antibigram for Urinary Pathogens: Have We Reached a Post Antibiotic Era for the Treatment of UTIs?
- 1238** A National Comparison of Antibigrams Between Veterans Affairs Long-Term Care Facilities and Affiliated Hospitals
- 1239** Frequently Identified Infection Control Gaps in Outpatient Hemodialysis Centers
- 1240** Antibiotic Prescribing in U.S. Nursing Homes Using National Pharmacy Transaction Data
- 1241** Surveillance for Viral Respiratory Infections in Pediatric Chronic Care Facilities
- 1242** Quantitative Analysis of Microbial Burden on LTCF Environmental Surfaces
- 1243** Comparative Analysis of Antimicrobial Related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
- 1244** Evaluation of Antibiotic Prescribing Practices for Geriatric Patients in the Outpatient Setting in a Veterans Affairs Hospital: Identification of Stewardship Targets
- 1245** Infection Prevention and Control (IP&C) and Antibiotic Stewardship (AS) Practices in Pediatric Long-term Care Facilities
- 1246** *Acinetobacter baumannii* in the Post-Acute Care Setting: Prevalence and Resistance Rates in Patients, Health Care Personnel, and The Environment
- 1247** Genomic Epidemiology of MRSA During Incarceration at a Large Inner-City Jail

139. Poster Abstract Session

Healthcare Epidemiology: Outbreaks

Friday, 12:30 - 1:45 p.m.

- 1248** Genomic Sequencing and Clinical Data Integration for Next-Generation Infection Prevention
- 1249** Emergence of Diverse Carbapenem-Resistant Enterobacteriaceae (CRE) in the Dominican Republic
- 1250** Prevalence and Risk Factors for Acquiring Carbapenem-Resistant *Enterobacteriaceae* in an Intensive Care Unit at a Tertiary Hospital
- 1251** Contaminated Sinks May be an Environmental Source for Serial Transmission of Carbapenem-Resistant *Enterobacteriaceae* (CRE) to ICU Patients

- 1252** A Challenging *Burkholderia (Bu)* Outbreak Investigation Across Multiple Units at an Academic Medical Center from 6/2017-2/2018
- 1253** Healthcare-Associated Transmission of *Burkholderia cepacia* complex Associated with Extrinsically Contaminated Nasal Spray
- 1254** Outbreak of *Mycobacterium chelonae* Skin Infections Associated with Human Chorionic Gonadotropin Injections at Weight Loss Clinics
- 1255** First Outbreak Due to Vancomycin Resistant *Enterococcus* Epidemic Clone ST796 in Europe
- 1256** New Acquisitions of ET-12 *Burkholderia Cenocepacia* in Adults With Cystic Fibrosis: Role of Whole Genome Sequencing in Outbreak Investigation
- 1257** Assessing Risk Factors for an Outbreak of *Burkholderia cenocepacia* in Non-Cystic Fibrosis (CF) Patients
- 1258** The Eyes Have It: Investigating a Cluster of Non-lactose Fermenting Gram-Negative Bacilli from Donor Corneal Rim Tissue
- 1259** The Local Hospital Milieu and Healthcare-Associated VRE Acquisition
- 1260** Decreasing Hospital-Acquired Bloodstream Infections through Self-Investigation by Hospital Wards
- 1261** Utility of a Multiplex Molecular Gastrointestinal Panel in Rapid Identification and Control of a Norovirus Outbreak in a Pediatric Tertiary Care Centre
- 1262** Investigation and Mitigation of a Multi-Species Outbreak of Invasive Fungal Infections on Two Oncology Wards
- 1263** Managing an Influenza Outbreak Which Spilled Over to an Acute Care Hospital from a Behavioral Health Unit
- 1264** Healthcare Acquired Influenza in Critical Ill Patients
- 1265** Application of the ALERT Influenza Trigger for Enhanced Prevention Activities
- 1266** Multifaceted Infection Control Strategies to Control Multidrug-resistant *Acinetobacter baumannii* in Adult Intensive Care Unit in a Tertiary Hospital in Eastern Region, Saudi Arabia
- 1267** Nonventilator Hospital Acquired Pneumonia (NV-HAP) Prevention Initiative in Colombia - Bogotá
- 1268** Transmissibility of *Candida auris* by Type of Inpatient Healthcare Facility

140. Poster Abstract Session

HIV: Diagnosis and Screening

Friday, 12:30 - 1:45 p.m.

- 1269** HIV Testing in a Large Community Health Center Serving a Multi-Cultural Population: A Qualitative Study of Providers
- 1270** Are HIV-Related Diagnostics Excessively Ordered? A Pilot Intervention Study to Improve Test Use in the Inpatient Setting
- 1271** Prevalence and Factors Associated with HIV Testing Among Sexually Experienced 18-49-Year-Old Hong Kong Residents
- 1272** A Routine, HIV and HCV Testing and Treatment Program in a Large, Multi-Campus Emergency Department Finds High Prevalence of Acute HIV and Chronic Hepatitis C

Poster Abstract Sessions (continued)

- 1273** Routine Opt-Out HIV Screening and Detection of HIV Infection Among Emergency Department Patients
- 1274** Universal HIV and HCV Screening in San Diego Emergency Departments: Implications for other Settings with a High Density of free of charge HIV Screening Programs
- 1275** Will an App-Optimized HIV Self-Testing Strategy Work for South Africans? Results from a Large Cohort Study
- 1276** Human Immunodeficiency Virus (HIV) Diagnostic Limbo: a Retrospective Review of Discordant HIV Test Results in a Large, Academic Health Center Over a 10-Year Period to Guide Clinicians in Distinguishing False Positive versus Acute HIV Infection
- 1277** Universal Screening is Key: Identifying Gaps in Adolescent HIV Infection Diagnosis at Local Pediatric Health System as Compared to Regional Adult Hospital
- 1278** Comparing Rates of Routine HIV and HCV Screening to Estimate the Impact of Consent on Identifying Patients with Undiagnosed HIV
- 1279** Prevalence of HIV Among the Youth Aged 15-24 In Nigeria - A Need to Increase Access for Young Adolescents To HIV Counseling And Testing

141. Poster Abstract Session

HIV: Molecular Epidemiology

Friday, 12:30 - 1:45 p.m.

- 1280** Geospatial Spread of HIV in the Cologne-Bonn Region, Germany, From 2001-2016
- 1281** Emergence of a B/F1 HIV Recombinant in the Philippines: A Potentially New Circulating Recombinant Form
- 1282** Detection of HIV Transmitted Drug Resistance by Next-Generation Sequencing in a CRF01_AE Predominant Epidemic
- 1283** Pre Treatment HIV-1 Drug Resistance in Transmission Clusters of the Cologne-Bonn Region, Germany
- 1284** Study of Single Nucleotide Polymorphisms Associated with HIV-1 Set-Point Viral Load in Antiretroviral Therapy-Naïve HIV-Positive Participants of the START Study

142. Poster Abstract Session

HIV: Prevention

Friday, 12:30 - 1:45 p.m.

- 1285** Impact of an Educational Program on Knowledge, Attitude, and Practice to Prevent HIV Infection among HIV-Negative Heterosexual Partners of HIV-Infected Patients
- 1286** Evaluating Strategies to Reduce Risk of HIV Infection in the U.S. Blood Supply
- 1287** Seizing Opportunities for Intervention: Changing HIV Knowledge among Men Who Have Sex with Men and Transgender Women Attending Trusted Community Centers in Nigeria
- 1288** Adolescents' Knowledge and Acceptance of Pre-Exposure Prophylaxis (PrEP) in the Capital District Region of NY

- 1289** Knowledge, Attitudes and Barriers of Pre-Exposure Prophylaxis for HIV Infection Among Resident Physicians in Rural, Eastern North Carolina
- 1290** A Model for "At-Distance" PrEP Navigation: Acceptability and Early Insights
- 1291** Assessing Uptake of HIV Pre-Exposure Prophylaxis (PrEP) Among High Risk Demographics in a Community-based Clinic in Brooklyn
- 1292** HIV Pre-Exposure Prophylaxis (PrEP) Implementation at Silom Community Clinic in Bangkok, Thailand, 2016-2018
- 1293** The Next Step in PrEP: Evaluating Outcomes of a Pharmacist-Run HIV Pre-Exposure Prophylaxis (PrEP) Clinic
- 1294** Acceptability and Feasibility of a Pharmacist-Led Pre-exposure Prophylaxis Program in the Midwestern United States
- 1295** Advancing the PrEP Continuum: A Novel Collaboration between a Public Health Department and a Federally Qualified Health Care Center in the Southern United States
- 1296** Potential Use of Sexually Transmitted Infection (STI) Testing for Expanding HIV Pre-Exposure Prophylaxis (PrEP) at an Urban Hospital Center
- 1297** Characteristics for PrEP Uptake, Retention, and Discontinuation: Data from the ANCHOR Study
- 1298** Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
- 1299** Iowa TelePrEP: Preliminary Experience with a Public Health-Partnered, Telemedical PrEP Delivery Model in a Rural State
- 1300** Young Heterosexual Men in Rural South Africa Want Access to PrEP
- 1301** Evaluation of the Rates of HIV Post-Exposure Prophylaxis Completion After the Implementation of an Automated Referral System in the Emergency Department

143. Poster Abstract Session

Medical Education

Friday, 12:30 - 1:45 p.m.

- 1302** Antibiotic Prescribing Knowledge: A Brief Survey of Providers and Staff at an Ambulatory Cancer Center during Antibiotic Awareness Week 2017
- 1303** Provider Knowledge and Attitudes Towards Antibiotic Prescribing and Antibiotic Stewardship in Outpatient Rural Clinics
- 1304** From Information Bolus to Continuous Infusion: Resident Knowledge and Satisfaction with an "Antibiotic of the Month" Educational Initiative at an Academic Children's Hospital
- 1305** Application of Standard Antibiotic Use Criteria to Evaluate Inpatient Antibiotic Use
- 1306** Antimicrobial Resistance Knowledge, Attitudes, and Perceptions Among Medical Students in Southern India

Poster Abstract Sessions (continued)

- 1307** Emerging Treatments in Ongoing Battle Against Community-Acquired Bacterial Pneumonia (CABP): The Positive Impact of Online Education
- 1308** Predictors of Career Interest in Infectious Diseases among U.S. Pharmacy Students
- 1309** The Impact of Clinical Practice Guideline Using Educational Intervention for Improvement of Diabetic Foot Infections Treatment Outcomes
- 1310** Improving Infectious Disease Electronic Medical Records Documentation – A Quality Improvement Study in an Academic Teaching Hospital
- 1311** Incorporating an “Escape Room” Game Design in Infectious Diseases Instruction
- 1312** Division Divided: Using Debate as an Educational Tool to Teach Evidence-Based Clinical Decision-Making
- 1313** Does Time Fly When Having Fun? A Study Assessing the Relationship Between Estimated Time on Task and Enjoyment of Infectious Diseases Serious Games
- 1314** From Book to Bedside: Theoretical and Applied Knowledge on the Topic of Healthcare-Associated Infections in Second-Year Nursing Students from a Croatian University
- 1315** Mind the Gap: Medical Trainees Require Training in Hepatitis C, Drug Use, and Mental Health to Help Address the Opioid Crisis
- 1316** An Integrative Approach to Teaching History of Medicine in Medical School
- 1317** Online Simulation-Based Education to Improve Primary Care Providers’ Knowledge about Best Practices in HIV Preexposure Prophylaxis Care
- 1318** Are we PrEPared? Awareness and Prescribing Patterns of HIV Pre-Exposure Prophylaxis (PrEP) by Internal Medicine Resident Physicians at an Academic Medical Center
- 1319** Examining PrEP Knowledge and Prescribing Likelihood Among Medical Residents Before and After PrEP Education
- 1320** Continuing Education Improves HIV Screening and Use of PrEP in High-Risk Patients
- 1321** The UNZA/UMB MMed ID Collaboration: Training and Retaining HIV Specialist Physicians in Zambia
- 1322** Impact of Hospital Medicine on Trends in Infectious Diseases and Other Subspecialty Fellowship Applications
- 1323** Implementation and Effectiveness of the Asia Pacific HIV Practice Course: Building Capacity of Healthcare Workers in the Region
- 1324** Development of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection
- 1325** HIV, Aging, and Comorbid Conditions: Case-Based, Online Education Improves HIV/ID Specialists’ Management Strategies
- 1326** Inter-Professional Education and Training to Build Capacity Among Healthcare Workers in Singapore
- 1327** Educational Intervention to Improve Communication with Patients Who Have Opioid Use Disorder
- 1328** Medical Education in an Epidemic: Historical Lessons from the Early Days of HIV in America (1982-1986)
- 1329** Beyond Reporting: Using an Accreditation Council for Graduate Medical Education (ACGME) Milestone-Linked Evaluation System to Improve Clinical Infectious Diseases Rotations for Baylor College of Medicine Internal Medicine (BCM IM) Residents
- 1330** Diagnosis and Management of NTM Lung Disease: Effect of Online Educational Interventions on Infectious Disease Specialist Knowledge
- 1331** Learning Experiences Within Infectious Diseases Pharmacy Residency Programs Demonstrate High Degrees of Consistency
- 1332** West Coast Transplant ID Conferences, A Model for Building Community in ID Disciplines?
- 1333** Developing an Educational Tool to Improve Housestaff Knowledge, Attitudes, and Behavior in Managing Common Infectious Diseases

144. Poster Abstract Session

Novel Agents

Friday, 12:30 - 1:45 p.m.

- 1334** Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support APX001 Dose Selection
- 1335** Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
- 1336** Assessment of the *In Vivo* Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant *Acinetobacter baumannii* (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
- 1337** SYN-004 (ribaxamase) Protects the Gut Microbiome of Patients Treated with Ceftriaxone from Disruption and Reduces the Emergence of Antimicrobial Resistance
- 1338** A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Iclaprim Versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections
- 1339** Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) versus Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients (Pts) with Imipenem-Nonsusceptible (NS) Bacterial Infections
- 1340** Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
- 1341** ASN100-Mediated Neutralization of *Staphylococcus aureus* Cytotoxicity against Bacterial Isolates Collected from Mechanically Ventilated Patients
- 1342** Comparison of Lysin CF-301 (Exebacase) Activity Against *S. aureus* Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
- 1343** Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model

Poster Abstract Sessions (continued)

- 1344** Ridinilazole (RDZ) for *Clostridium difficile* Infection (CDI): Impact of Diagnostic Method on Outcomes from a Phase 2 Clinical Trial
- 1345** Comparative Activity of Plazomicin and Other Aminoglycosides against *Enterobacteriaceae* Isolates from Various Infection Sources from Hospitalized Patients in the United States
- 1346** The Tetrazole VT-1598 is Efficacious in a Murine Model of Invasive Aspergillosis with a PK/PD Expected of a Mold-Active CYP51 Inhibitor
- 1347** Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
- 1348** *In vitro* Activity of Plazomicin, a Next-Generation Aminoglycoside, against Carbapenemase-Producing *Klebsiella pneumoniae*
- 1349** Global Surveillance of Cefiderocol against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
- 1350** Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
- 1351** *In vitro* Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, Against *Enterobacteriaceae* with Defined Extended-Spectrum β -lactamases and Carbapenemases
- 1352** A Computational Approach for Exploring the Binding Mechanism of Chebulinic acid on Herpes Simplex Virus-2 and its Implication on Chikungunya and Dengue
- 1353** *In Vitro* Activity of Lefamulin (LEF) against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data from the United States
- 1354** Novel Formulation SUBA-Itraconazole in Fed and Fasted Healthy Volunteers: Expanding the Clinical Utility of the Established Mold Active Agent
- 1355** Global Activity of Imipenem-Relebactam and Comparators against Clinical Gram-Negative Pathogens – SMART 2017
- 1356** Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid
- 1357** A Combination of Itraconazole and Amiodarone is Highly Effective against *Trypanosoma cruzi* Infection of Human Stem Cell Derived Cardiomyocytes
- 1358** *In vitro* activity of Ceftazidime-Avibactam and Comparator Agents against *Pseudomonas aeruginosa* Causing Intra-Abdominal, Lower Respiratory, and Urinary Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012-2016
- 1359** Activity of Meropenem/Nacubactam Combination against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017
- 1360** Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of *Enterobacteriaceae* Including Resistant Phenotypes
- 1361** Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for *Clostridium difficile* Infection (CDI): From Animal Models to Patients
- 1362** A Novel Intravesical Antimicrobial for CAUTIs
- 1363** Sulopenem Activity against *Enterobacteriaceae* Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection
- 1364** Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSEI Clinical Trials
- 1365** *In Vitro* Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results from Asia-Pacific (APAC) and Latin America (LA)
- 1366** *In Vitro* and *In Vitro* Activity of Cefiderocol against *Stenotrophomonas maltophilia* Clinical Isolates
- 1367** Clinical Cure in Secondary Efficacy Populations in Patients with Complicated Urinary Tract Infection Treated with ZTI-01 (fosfomycin for injection): Findings from the ZEUS Trial
- 1368** Assessment of the *In Vivo* Efficacy of Human-simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination against β -lactamase-Producing *Enterobacteriaceae* in Neutropenic Lung Infection Model
- 1369** Combined Analysis of the *In Vitro* Activity of Ridinilazole (RDZ) Against More than 500 *Clostridium difficile* (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
- 1370** Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug-Resistant *K. pneumoniae* and *P. aeruginosa*
- 1371** Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully Synthetic Tetracycline, in a Phase 1 Study
- 1372** *In Vitro* Activity of Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations against Carbapenem-Non-Susceptible *Enterobacteriaceae* Isolates by Phenotype Collected in Latin America from 2014-2017 as part of the INFORM Surveillance Program
- 1373** Activity of Ceftriaxone-Sulbactam-EDTA against Multidrug-Resistant *A. baumannii*, *P. aeruginosa*, and *Enterobacteriaceae* Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
- 1374** Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
- 1375** *In vitro* Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
- 1376** Antifungal Activity of Cerium Nitrate against Fungal Isolates Associated with Combat-Related Injuries Including Burns
- 1377** Omadacycline *In Vitro* Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
- 1378** Evaluation of the *in vitro* Activity of Meropenem-Vaborbactam against Carbapenem-Resistant *Enterobacteriaceae*, Including Isolates Resistant to Ceftazidime-Avibactam

Poster Abstract Sessions (continued)

145. Poster Abstract Session

PK/PD Studies

Friday, 12:30 - 1:45 p.m.

- 1379** Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)
- 1380** Effect of Absolute Body Weight on Clinical Outcomes of Obese Patients Treated with Cefepime
- 1381** Impact of Total Body Weight on Efficacy of Ceftriaxone in Obese Patients
- 1382** Acute Kidney Injury with Piperacillin-Tazobactam and Vancomycin in the Intensive Care Unit
- 1383** *In vivo* Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, against *E. coli* (EC) and *K. pneumoniae* (KPN) in the Murine Neutropenic Thigh Model
- 1384** RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
- 1385** Efficacy of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo- β -lactamase producing-Enterobacteriaceae (MBL)
- 1386** Efficacy of Repeat Dosing of Oral Fosfomycin in a Dynamic Bladder Infection *In Vitro* Model
- 1387** Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects
- 1388** Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model
- 1389** Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against *S. aureus* (SA) and *S. pneumoniae* (SPN)
- 1390** Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of *Candida*
- 1391** Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A systematic Review and Meta-analysis of observational studies
- 1392** Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
- 1393** A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem
- 1394** A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
- 1395** Defining the Magnitude of AUC:MIC Driver for Efficacy of the β -lactamase Inhibitor VNRX-5133 when combined with Cefepime against KPC- and VIM/NDM-Producing Enterobacteriaceae and *P. aeruginosa*
- 1396** Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 months - <18 years by Physiologically Based Pharmacokinetic Modeling
- 1397** Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) against Methicillin-Resistant *Staphylococcus Aureus* (MRSA) in Neutropenic (I-) vs Immunocompetent (I+) Murine Models of Pneumonia
- 1398** β -lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model
- 1399** Efficacy of Daptomycin Combination with β -lactams for Daptomycin Resistant *Enterococcus faecium* Harboring LiaSR Substitutions
- 1400** Mass Balance, Metabolism, and Excretion of [14 C]-Plazomicin in Healthy Human Subjects
- 1401** A Randomized, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects
- 1402** Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
- 1403** Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against *Streptococcus mitis-oralis* Group in an *In vitro* Model of Simulated Endocardial Vegetations (SEVs)
- 1404** A Pharmacokinetic Study on CMS and Colistin and its Impact on Clinical Cure and Acute Kidney Injury in Critically Ill Patients with Normal Renal Function from South India
- 1405** Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination against Serine β -lactamase-Producing Gram-Negative Bacteria in the Neutropenic Murine Thigh Infection Model
- 1406** Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling with Bayesian Estimation in Children in the Pediatric Intensive Care Unit
- 1407** Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
- 1408** Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
- 1409** Evaluation of Alternative Piperacillin-Tazobactam Dosing Strategies against ESBL-Producing Enterobacteriaceae using a Hollowfiber Infection Model
- 1410** Novel Framework to Compare the Effectiveness of Tazobactam, Relebactam, and Avibactam against Extended-Spectrum β -lactamase-Producing Enterobacteriaceae
- 1411** Tecioplanin (TEI) vs Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
- 1412** Caspofungin and Anidulafungin Behave as Fungistatic Agents Against *Candida auris*

Poster Abstract Sessions (continued)

- 1413** A Phase IIa Efficacy, Safety, Tolerability, and Pharmacokinetic (PK) Study of Encapsulated Amphotericin B in Patients with Mucocutaneous (Esophageal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies
- 1414** Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in *Klebsiella aerogenes*
- 1415** Implementation and Validation of a Vancomycin AUC/MIC Calculator and Dosing Protocol at a Large Community Hospital
- 1416** Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Interpatient Variability or Compound Instability?
- 1417** Evaluating the Dissonance between C_{max} and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against *Pseudomonas aeruginosa* (PA) as a Case Study
- 1418** Pharmacokinetics (PK) and Toxicity of Intravenous Amikacin (AMK) Dosed Three Times a Week (TIW) for Treatment of Disseminated *Mycobacterium abscessus* Infection in Children
- 1419** 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury
- 1420** Case Report: Ganciclovir Subtherapeutic Dosing in a Pediatric Patient on Extracorporeal Membrane Oxygenation
- 1421** IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects
- 1422** Comparative Monte Carlo Analysis of Aztreonam-Avibactam vs Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Pathogens
- 1423** Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia
- 1424** Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults with Presumed or Documented Staphylococcal Infections
- 1425** Population Pharmacokinetic Analysis of Ciprofloxacin and Levofloxacin in Critically Ill Trauma, Surgical, and Burn Patients
- 1429** Emergence of Multidrug-Resistant Serotype 24 among Children under 2 years old with Invasive Pneumococcal Disease after the Introduction of PCV13 in Argentina
- 1430** Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
- 1431** Dynamics of Antibiotic Prescription Rate Following Pneumococcal Conjugate Vaccine (PCV) Implementation in Children <2 Years Old: Comparison between High and Low Prescribing Clinics in Two Different Ethnic Groups
- 1432** County-Wide Pediatric IPD Experience Following Prevnar 13 Implementation
- 1433** Association between Impact of Pneumococcal Conjugate Vaccines (PCVs) on Acute Respiratory Infections Rates and Impact on Antibiotic Consumption Rates in Young Children
- 1434** Cost-Effectiveness of Sequential Vaccination with the 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) Followed by the 23 Valent Polysaccharide Vaccine (Ppv23) in the Netherlands
- 1435** The Cost-Effectiveness of Vaccinating with an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
- 1436** Risk Factors for Invasive Pneumococcal Disease in Adults ≥ 65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
- 1437** Family Duty and Safety Linked to Overcoming Attitudinal Barriers to Adult Pneumococcal Vaccination in Disparate Populations
- 1438** Uptake of 13-Valent Pneumococcal Conjugate Vaccine in High-Risk Adults Aged 19-64 Years: A Kaplan-Meier Approach
- 1439** The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in the Netherlands
- 1440** Potential Impact of Routine Use of 13-valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
- 1441** Doses of 13-valent Conjugated Pneumococcal Vaccine (PCV13) for Patients with Multiple Myeloma (MM)
- 1442** Pneumonia Hospitalizations Averted with 13-valent Pneumococcal Conjugate Vaccination of Adults Aged 18-64 Years with Diabetes in the United States
- 1443** Serotypes 8 and 3 are the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2015-2017)
- 1444** Trends in Antimicrobial Non-susceptibility of PCV13-type *Streptococcus pneumoniae* Pneumonia in Adults in the United States during 2009-2017
- 1445** Impact of 10-valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns among Children Aged <5 Years and Adults with HIV Infection, Kenya 2009-2013
- 1446** Correlation between Adult Invasive and Non-Invasive *Streptococcus pneumoniae* Disease in 13-valent Pneumococcal Conjugate Vaccine Serotypes in the United States

146. Poster Abstract Session

Pneumococcal Vaccines

Friday, 12:30 - 1:45 p.m.

- 1426** Impact of Routine Pediatric PCV13 on the Incidence and Severity of Invasive Pneumococcal Disease in Adults in Ontario, Canada
- 1427** A Dynamic Modelling Study of the Effect of Introducing a New Higher Valent Pneumococcal Conjugate Vaccine in a Pediatric Population in the United States
- 1428** Modeling Reductions in Antibiotic Prescriptions Due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination

Poster Abstract Sessions (continued)

147. Poster Abstract Session

Respiratory Infections: CAP

Friday, 12:30 - 1:45 p.m.

- 1447 Molecular Epidemiology, Serotype Distribution, Antimicrobial Sensitivity, and Clinical Findings of Adult Pneumococcal Pneumonia Patients in Japan; Hospital-Based Study
- 1448 Impact of Mental Illness on Outcomes of Outpatients with Community-Acquired Pneumonia
- 1449 Comparison of Emergency Department versus Inpatient Pediatric Treatment for Empiric Community-Acquired Pneumonia in Infants and Children over 3 months of age
- 1450 Clinical Characteristics of Patients with Community-Acquired Pneumonia due to *Moraxella catarrhalis* in Adults: a Retrospective Single Center Study in Okinawa Miyako Island in Japan
- 1451 Predictive Values of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Nasal Swab PCR Assay for MRSA Pneumonia
- 1452 Non-Invasive Pneumococcal Pneumonia in Adults in Portugal: Continued Decline of pcv13 Serotypes (2015-2017)
- 1453 Ninety-One Day Quality of Life Post-Pneumonia Diagnosis in Adult Patients in Japan
- 1454 Beta-Hemolytic Non-Group A *Streptococcus* Pharyngitis in Children
- 1456 Biomarkers in Different Etiologies of Pneumonia in Pediatrics in Indonesia
- 1457 *Escherichia Coli* Community-Acquired Pneumonia
- 1458 A Single Center Quasi-Experimental Study to Evaluate the Impact of Utilizing Rapid Diagnostic Technology to Detect Methicillin-Resistant *Staphylococcus aureus* in Respiratory Culture Samples
- 1459 The Scope of *Mycoplasma Pneumoniae* Pneumonia Diagnosed by Multiplex Polymerase Chain Reaction Respiratory Viral Panel in Pediatric Patients in Hawaii
- 1460 Community-Acquired Bacteremic Pneumonia in Post-Pneumococcal Vaccination Era in a Pediatric Hospital
- 1461 Non-Invasive Pneumococcal Pneumonia in the United States, 2013–2014
- 1462 Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
- 1463 Comparative Evaluation of Adverse Tendon Events between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin among Veterans Affairs Patients with Community-Acquired Bacterial Pneumonia
- 1464 The Clinical Features of Pneumonia Caused by *Legionella pneumophila* vs. *Streptococcus pneumoniae*: A Retrospective Study
- 1465 Discovering Outpatient Stewardship Targets: An Evaluation of Community-Acquired Pneumonia in the Outpatient Setting

- 1466 Adherence to Empiric Treatment Recommended by IDSA/ PIDS Pediatric Community-Acquired Pneumonia (CAP) Guidelines According to Immunization Status
- 1467 Clinical Significance of Microbiologic Treatment Failure following Clinical Cure of Pneumonia
- 1468 PCV13 Serotype Trends Over Time in Pneumococcal Community-Acquired Pneumonia: Which Method(s) Work Best?
- 1469 Microbial Etiology of Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
- 1470 Neurocognitively-Acting Potentially Inappropriate Medications, Alcohol, and Community-Acquired Pneumonia among Patients with and without HIV

148. Poster Abstract Session

Respiratory Infections: Miscellaneous

Friday, 12:30 - 1:45 p.m.

- 1471 Case Report: Andes Virus Hantavirus Pulmonary Syndrome in a Traveler Returning to the United States
- 1472 Antibiotic De-Escalation Compared with Continued Empirical Treatment in Non-Ventilated Hospital-Acquired Pneumonia
- 1474 Etiology of Pulmonary Granulomas: How Common is Unsuspected Infection?
- 1475 Etiology and Outcome of Fever and Respiratory Distress in Adult Patients Presenting to Medical Emergency in a Tertiary Care Hospital in North India
- 1476 Objective Surveillance Definitions for Hospital-Acquired Pneumonia in Non-Ventilated Patients
- 1477 MUCOVIB Project: Concordance Between Upper and Lower Airway Microbiota in Children with Cystic Fibrosis
- 1478 A Retrospective Review of *Pseudomonas aeruginosa* Infection in a Quarternary Intensive Care Unit: Epidemiology, Outcomes, and Antimicrobial Susceptibilities: 2013-2016
- 1479 Evaluating the Impact of Procalcitonin on Antibiotic Utilization in Chronic Obstructive Pulmonary Disease Exacerbations
- 1480 Impact of a Guidance Document, Order Set Changes and Physician Education on Antibiotic Prescribing in Acute Exacerbation of COPD
- 1481 Clinical Outcomes of *Escherichia coli* Infections in Cystic Fibrosis (CF) Patients
- 1482 Changing Patterns of HIV-TB Coinfection Among Patients in a Public Health Department Ambulatory Care Setting; A 5-year Experience from a U.S. Metropolitan Area
- 1483 Pleural Empyema Caused by *Stenotrophomonas maltophilia* in A National Cohort of Hospitalized Veterans
- 1484 Impact of Combination versus Monotherapy on Clinical Outcomes Associated with *Stenotrophomonas maltophilia* Pneumonia
- 1485 Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Patients with Pneumonia in U.S. Medical Centers

Poster Abstract Sessions (continued)

- 1486** Missed and Delayed Diagnosis of *Pneumocystis* Pneumonia in HIV and non-HIV-Infected Individuals
- 1487** Variability of *Pneumocystis jirovecii* Prophylaxis Use Among Pediatric Solid Organ Transplant Providers
- 1488** Invasive Pulmonary Aspergillosis in Patients with Solid Tumors: Risk Factors and Predictors of Clinical Outcomes

149. Poster Abstract Session Sexually Transmitted Infections

Friday, 12:30 - 1:45 p.m.

- 1489** Trends in Antimicrobial Resistance in *N. gonorrhoeae* Isolated in Korea during 2015 to 2017
- 1490** Lymphogranuloma Venereum: Correct Diagnosis Makes all the Difference
- 1491** *Mycoplasma genitalium*: A Concordance Study in Heterosexual Partnerships at Risk for Chlamydial Infection
- 1492** Chlamydia, Gonorrhea, Syphilis, and HIV Screening among Men Presenting with STI-related Complaints at a Community Based Emergency Department in Columbus, Ohio: A 5-Year Retrospective Study
- 1493** Effect of HIV Status on Early Syphilis Treatment Response in the Era of Combination Antiretroviral Therapy
- 1494** Vaginal pH: Associations with *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and *Trichomonas vaginalis*
- 1495** Incidence of Sexually Transmitted Infections (STIs) in Patients on Pre-exposure Prophylaxis (PrEP)
- 1496** Anorectal *Mycoplasma genitalium* is Common among Nigerian MSM and Associated with HIV
- 1497** Evidence-Based Care for Sexually Transmitted Infections: Missed Opportunities in an Academic Medical Center
- 1498** Sexually Transmitted Infections among Persons Living with HIV Infection and Receiving Care in the District of Columbia: Time with Viral Load above 1500 as Proxy for Risk of Transmission
- 1499** Gonorrhea and Chlamydia Infections in the Department of Veterans Affairs (VA), 2013-2017
- 1500** At Risk Drinking is Common among HIV infected Department of Defense (DoD) Beneficiaries but was not Associated with Prevalent GC/CT Infections

150. Poster Abstract Session Urinary Tract Infection

Friday, 12:30 - 1:45 p.m.

- 1501** Comparative Effectiveness of Antibiotic Therapy for the Outpatient Treatment of Urinary Tract Infections Among Otherwise Healthy, Premenopausal Women
- 1502** Identifying Risk Factors for Recurrent Urinary Tract Infections among Female Outpatients
- 1503** No Benefit to Treating Male UTI for Longer than 7 Days: An Outpatient Database Study
- 1504** Patient Demographics and Comorbidity Profiles Associated with Hospitalized Patients Admitted with Resistant vs. Susceptible Urinary Tract Infections (UTI): A Multicenter Analysis

- 1505** Predictive Value of Early Post-Transplant Bacteriuria on Rates of Recurrent Urinary Tract Infections in the First Year After Renal Transplantation
- 1506** Association of Antibiotic Treatment Duration with First Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients
- 1507** Evaluating the Effects of a "Urinalysis to Reflex Culture" Process Change in the Emergency Department (ED) at a Veterans Affairs (VA) Hospital
- 1508** Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
- 1509** Clinical Significance of *Staphylococcus aureus* Bacteriuria
- 1510** Treatment of Asymptomatic Bacteriuria prior to Transcatheter Aortic Valve Replacement
- 1511** Utility of Clinical Scoring Models in Predicting Community Acquired Urinary Tract Infections with Extended-Spectrum β -lactamase-Producing *Escherichia coli* in a General Hospital in Mexico City
- 1512** Variation in Outpatient Urine Testing Practices for Uncomplicated Urinary Tract Infections
- 1513** A New Method for Rapid Phenotypic Antimicrobial Susceptibility Testing Directly from Patient Samples
- 1514** Clinical Decision-Making in Suspected Urinary Tract Infection in Hospitalized Patients: Which Factors Lead to Treatment, and How Would Reflex Urine Cultures Impact Diagnosis?
- 1515** Patient-Based Stratification of Weighted-Incidence Syndromic Antibiogram (WISCA) for Empiric Antibiotic Prescribing
- 1516** Evaluating Appropriate Antimicrobial Selection and Duration of Therapy for Urinary Tract Infections in Outpatient Clinics
- 1517** Evaluation of Antibiotic Prescribing Practices for Lower Urinary Tract Infections in the Emergency Department
- 1518** Assessment of Antibiotic Prescribing in the Outpatient Setting for Uncomplicated Urinary Tract Infection in Pediatrics (UTIP Trial) with a Review of Local *E. coli* Susceptibilities
- 1519** Management and Outcomes of Children with Extended-Spectrum Cephalosporin-Resistant Urinary Tract Infections (ESC-R UTIs)
- 1520** Determining the Management of Children with Acute UTI/Pyelonephritis Who Do Not Fit Current Management Recommendations
- 1521** Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
- 1522** Initial Clinical Response of Children with Extended-Spectrum Cephalosporin-Resistant Urinary Tract Infections (ESC-R UTI's) Started on Discordant Antibiotics
- 1523** Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program
- 1524** Are Providers Shifting from NTF to Fosfomycin for Inpatient UTI? Big Data Reveals Small Shifts
- 1525** Evaluation of Clinical Outcomes with Fosfomycin for *E. coli* and non-*E. coli* Enterobacteriaceae Urinary Tract Infections

Poster Abstract Sessions (continued)

- 1526** Oral Fosfomycin Use for Urinary Tract Infections and its Clinical Impact on Hospital Stay
- 1527** The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
- 1528** A Real World Perspective on Treatment of CRE UTIs with Oral Agents
- 1529** Suprapubic Catheter Placement Improves Antimicrobial Stewardship in a Veterans Affairs Long-Term Care Facility
- 1530** De-Implementation Strategy to Reduce the Inappropriate Use of Urinary and Intravenous CATHeters: The RICAT-Study
- 151. Poster Abstract Session**
Viruses and Bacteria in Immunocompromised Patients
Friday, 12:30 - 1:45 p.m.
- 1531** A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients
- 1532** Increased Risk of Bacterial, Fungal, and Other Viral Infections During CMV Infection: Decreased Cytokine Production in Response to Toll-Like Receptor Ligands
- 1533** The Use of QuantiFERON®-CMV Gamma Interferon-releasing Assay as a Diagnostic Stewardship Tool Following Kidney Transplantation
- 1534** Prevalence and Outcome of Neutropenic Enterocolitis Among Pediatric Acute Myeloid Leukemia Patients: A Developing Country Experience
- 1535** Utility of CT Abdomen in Evaluation of Neutropenic Fever in Patients with Hematological Malignancies
- 1536** Donor Derived *Mycobacterium tuberculosis* Infection after Solid-Organ Transplantation: A Comprehensive Review
- 1537** Reactivation of Latent Cytomegalovirus Infection in Patients with Rheumatologic Disease: A Case-Control Study
- 1538** High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopoietic Cell Transplant Recipients
- 1539** Diagnosis of *Yersinia enterocolitica* in Cancer Patients with Diarrhea in the Era of Molecular Diagnostics for Gastrointestinal Infections
- 1540** Left Ventricular Assist Device Driveline Infections: Relapsed Infections and Minimum Inhibitory Concentration Changes
- 1541** Infectious Complications in Adult Patients with Hemophagocytic Lymphohistiocytosis: A Single Center Experience
- 1542** Infectious Complications in Patients (Pt) following Umbilical Cord Blood Transplant (UCBT) for Hematologic Malignancy
- 1543** The More Resistant, the More Fatal: Results of 414 Bacteremia Episodes in Febrile Neutropenic Patients
- 1544** Kinetics of BK Virus in Urine Associated with BKV DNAemia and BKVAN in Pediatric Kidney Transplantation
- 1545** Gram-Negative Bacteremia in Neutropenic Patients: Risk Factors for Mortality in the Era of Multiresistance
- 1546** Incidence of Carbapenemase-Producing *Klebsiella pneumoniae* Colonization in Hematopoietic Stem Cell Transplant Recipients in King Chulalongkorn Memorial Hospital (KCMH), Thailand
- 1547** BK Virus Reactivation in Solitary Heart Transplant Recipients: Prevalence and Relationship to Kidney Dysfunction
- 1548** Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
- 1549** Development and Validation of a Cycle-Specific Risk Score for Febrile Neutropenia after Chemotherapy in Patients with Cancer: The ^{CSR}FENCE Score
- 1550** Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
- 1551** The Impact of Recurrent CMV Disease on Long-Term Survival in Solid Organ Transplant Recipients
- 1552** Absolute Lymphocyte Threshold: A Simple Readily Available Tool to Predict Risk of Cytomegalovirus Infection after Transplantation
- 1553** Infectious Complications Following Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiency Diseases
- 1554** Reactivation of Varicella Zoster Virus in Solid Organ Transplant Recipients: Identification of Risk Factors Using Data Mining Tools
- 1555** A New Perspective about Disseminated Adenovirus Infection and its Outcomes in Pediatric Solid Organ Transplantation
- 1556** Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies
- 1557** Acyclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients
- 1558** Commensal *Neisseria* Species as a Cause of Disease in Patients Taking Eculizumab
- 1559** Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Bloodstream Infections
- 1560** Clinical Presentation of BK Virus-Associated Hemorrhagic Cystitis (HC) after Hematopoietic Cell Transplantation (HCT)
- 1561** Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
- 1562** Impact of Skin Biopsy on Diagnosing Infections and Changing Treatment in Cancer Patients with New Skin Rash
- 1563** Relationship of Cumulative Viral Burden of Adenovirus with Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Early Adenovirus Viremia
- 1564** Lower Rates of Epstein-Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
- 1565** Lymphocyte Subsets as Predictors of Cytomegalovirus Infection after Transplantation
- 1566** Is Primary CMV Infection Post-Transplant Influenced by Circadian Rhythms?

Poster Abstract Sessions (continued)

- 1567** Predicting Mortality among Immunocompromised Patients Who Present with Infection
- 1568** Implementation of a Standard Diet Regimen for Neutropenic High Risk Cancer Patients: Effects on Incidence of Infections, Foodborne Diseases, and Outcome
- 1569** Incidence, Risk Factors, and Impact of Antiviral Prophylaxis Duration on Cytomegalovirus [CMV] Disease in High-Risk Donor Seropositive/Recipient Seronegative [D+R-] Orthotopic Heart Transplant Recipients [OHTR]
- 1570** Infectious Disease (ID) Complications in Immunocompromised (IC) Patients with Cancer Post-Hurricane Harvey at a Comprehensive Cancer Center in 2017
- 1571** Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis among CMV Serology Mismatched (Donor+/Recipient-) Lung Transplant Recipients
- 1572** Conjugate Pneumococcal Vaccination Reduces Invasive Pneumococcal Disease Post Haematopoietic Stem Cell Transplant
- 1573** Discrepancies Between Premortem and Postmortem Diagnoses of Infectious Diseases Found on Autopsy in Hematopoietic Cell Transplantation Recipients at a High-volume Academic Transplant Center
- 1574** Cancer Chemotherapy May Induce Acquisition of Antibiotic Resistance Genes in Antibiotic- Naïve Cancer Patients
- 1575** Clinical Validation of a Novel ELISpot-Based *in vitro* Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients
- 1576** Risk of Clinical Tuberculosis (TB) among Patients with Latent TB Infection (LTBI) who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT)
- 1577** Evaluation of a Routine Screening Program with Tuberculin Skin Testing on Rates of Detection of Latent Tuberculosis Infection and Prevention of Active tuberculosis in Patients with Multiple Myeloma at a Canadian Cancer Center
- 1578** Back to Bactrim – Utilizing Preferred Prophylaxis Strategies in Immunocompromised Hosts via a Trimethoprim-Sulfamethoxazole Rechallenge Program
- 1579** Evaluation of MATCH: An Electronic Individual Patient-Focused Management System Aimed at Preventing Cytomegalovirus Disease Following Solid Organ Transplantation
- 1580** Characteristics of Early vs. Late Onset Post-Transplant Lymphoproliferative Disorder after Liver Transplant - A Descriptive Study of the United Network of Organ Sharing (UNOS) Database
- 1581** Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin
- 1582** Is Antibiotic Prophylaxis Needed for All Acute Variceal Bleeds in Decompensated Cirrhosis? A Retrospective Pilot Study
- 1583** The Utility of the Immunodeficiency Scoring Index (ISI) to Predict Outcomes of Coronavirus (HCoV) Infections in Hematopoietic Cell Transplant (HCT) Recipients
- 1584** Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next Generation Sequencing
- 1585** Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Correlation between Initial Empiric Antibiotic Regimen Correlation and Susceptibility Patterns
- 1586** Prevalence and Significance of Pre-Transplant BK Viremia and Viruria in Deceased and Living Kidney Donors and Kidney Transplant Recipients
- 1587** Analysis of Breakthrough Bloodstream Infections in Left Ventricular Assist Device Recipients Managed with Chronic Antimicrobial Suppressive Therapy
- 1588** Clinical Prediction Tool for Extended-Spectrum Beta Lactamase-Producing *Enterobacteriaceae* as the Etiology of Bacteremia in Solid Organ Transplant Recipients
- 1589** Increased Detection of Diarrheal Pathogens in Hematopoietic Stem Cell Transplant Recipients using a Multiplexed PCR Panel
- 1590** A Hybrid CMV Prevention Strategy is Effective in Preventing CMV Disease Outcomes in Pediatric Solid Organ Transplant Patients
- 1591** Infectious Outcomes of Levofloxacin Prophylaxis in Obese versus Non-Obese Patients with Hematologic Malignancies
- 1592** Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
- 1593** Recurrence of *Clostridium difficile* Infection in Multiple Myeloma patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole versus No Prophylaxis
- 1594** Evaluating Clinical Outcomes of an Alternative Cefepime Dosing Regimen as Empiric Antibiotic Therapy in Hospitalized Adults with Febrile Neutropenia
- 1595** Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy
- 1596** Thinking Locally: Can Unit-Specific Methicillin-Resistant *Staphylococcus aureus* Screening Augment Stewardship Interventions for Febrile Neutropenia?
- 1597** Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
- 1598** Oral Step Down Therapy with Levofloxacin for Low Risk Febrile Neutropenia in Children
- 1599** Rejection Outcomes in Lung Transplant Recipients Post Respiratory Syncytial Virus Infections
- 1600** An Optimal Respiratory Syncytial Virus (RSV) Treatment in Lung Transplant Recipients: Oral Ribavirin, Inhaled Ribavirin, or Conservative Approach
- 1601** Effect of Preemptive Rituximab Therapy on Epstein-Barr Reactivation in Allogeneic Hematopoietic Stem Cell Pediatric Transplants
- 1602** *Clostridium difficile* Infection as a Predictor of Acute Graft versus Host Disease among Allogeneic Stem Cell Transplant Recipients
- 1603** Our Experience with *M. marinum* cutaneous Infections in Three Patients Receiving Anti TNF α

Poster Abstract Sessions (continued)

216. Poster Abstract Session

Antimicrobial Stewardship: Global Perspectives

Saturday, 12:30 - 1:45 p.m.

- 1776 Establishing an Antimicrobial Stewardship Program in a Resource Limited Setting: Experience of an Ethiopian Hospital
- 1777 Implementation of an Antimicrobial Stewardship Program (ASP) at the Princess Margaret Hospital, Nassau, Bahamas
- 1778 Exploring Bacterial Resistance in Northern Oman, a Stewardship Initiative to Improve Antibiotic Prescription
- 1779 Defining Antimicrobial Use and Resistance in a Teaching Hospital in the Dominican Republic: Key First Steps for Development of Antimicrobial Stewardship in a Resource Limited Setting
- 1780 Results of a Successful Implementation of an Antimicrobial Stewardship Program in a Public Hospital in São Paulo, Brazil
- 1781 Impact of an Antimicrobial Stewardship Intervention in India: Evaluation of Post Prescription Review and Feedback as a Method of Promoting Optimal Antimicrobial Use
- 1782 Guideline-Discordant Carbapenem Prescribing Policies at a Large, Urban Hospital in Manila, Philippines
- 1783 Implementation of New Strategy for Real Time Antimicrobial Stewardship (ASP) in a Secondary Healthcare Hospital in Mexico City
- 1784 Impact of a Novel Multidisciplinary Anti-Tubercular Stewardship Program in a Tertiary Care Center in India
- 1785 Regional Variation of Antimicrobial Use in Japan from 2013 to 2016

217. Poster Abstract Session

Antimicrobial Stewardship: Impact of Allergy

Saturday, 12:30 - 1:45 p.m.

- 1786 Safety, Efficacy, and Clinical Impact of Penicillin Allergy Skin Testing in Immunocompromised Cancer Patients at a Comprehensive Cancer Center
- 1787 The Safety and Efficacy of an Oral Penicillin Rechallenge Program in Cancer Patients – A Pilot Multicentre Study
- 1788 Cost-Effectiveness of Penicillin Skin Testing among Patients with Methicillin Sensitive *Staphylococcus aureus* bacteremia and Reported Penicillin Allergy
- 1789 Inpatient Penicillin Skin Testing: Outcomes from a Propensity-Matched Case-control Study
- 1790 Clinical and Economic Outcome Evaluation with Penicillin Skin Testing as an Antimicrobial Stewardship Initiative in a Not-for-Profit Community Health System
- 1791 The Impact of a Beta-lactam Allergy Assessment on Aztreonam Utilization within a Healthcare System
- 1792 Assessing Outcomes of Antimicrobial Stewardship Interventions along with a Hospital-Wide Beta-Lactam Allergy Guideline through Aztreonam Use: A 5-Year Observation

- 1793 Description of a Pharmacist-Managed Penicillin Allergy Skin Testing (PAST) Service at a Community Teaching Hospital
- 1794 Impact of a Pharmacist-Driven Detailed Penicillin Allergy Interview
- 1795 Safety Outcomes of the Use of Beta-Lactam Therapy in Patients with Documented Beta-Lactam Allergy
- 1796 Inappropriate Aztreonam Usage Identified as an Opportunity to Reduce Pharmaceutical Expenditures

218. Poster Abstract Session

Antimicrobial Stewardship: Impact of New Diagnostics

Saturday, 12:30 - 1:45 p.m.

- 1797 Combining Rapid Diagnostics with Pharmacy Resident-Led Antimicrobial Stewardship to Optimize Outcomes for Bacteremia with Methicillin-Resistant *S. aureus* (MRSA-B), Methicillin-Susceptible *S. aureus* (MSSA-B), and Coagulase-Negative *Staphylococcus* (CoNS) at Yale New Haven Hospital (YNHH)
- 1798 Phenotypic and Genotypic Impact of Antibiotic Stewardship Intervention on Daptomycin-nonsusceptible *Enterococcus faecium* (DNSE) Clinical Isolates
- 1799 Impact of Real-Time Electronic Notifications to Pharmacists of Rapid Diagnostic Blood Culture Results
- 1800 Clinical Impact of Real-Time Predictive Model to Facilitate Antibiotic Prescribing in Gram-Negative Bacteremia
- 1801 Impact of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) on Clinical Outcomes in Patients with Gram-Positive Blood Cultures in a Diverse, Multicenter Healthcare System with a Central Laboratory
- 1802 Evaluation of Clinical Pharmacists use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
- 1803 Clinical Impact of Rapid Blood Culture Diagnostics Differs by Time of Day and Gram Stain Type: Lessons from Implementation of Verigene® Blood Culture Testing in a Children's Hospital
- 1804 Impact of Susceptibility Testing Method on Antibiotic Selection for Methicillin-Resistant *Staphylococcus Aureus* (MRSA) Bacteremia
- 1805 Impact of Antimicrobial Stewardship Interventions Using Rapid Molecular Testing on the Appropriate Use of Antiviral Therapy and Reduction of Unnecessary Antibiotic Therapy for Patients Admitted with Acute Influenza
- 1806 Implementation of Rapid Diagnostic Testing without Active Stewardship Team Notification for Gram-Positive Blood Cultures in a Community Teaching Hospital
- 1807 The Impact of Rapid Diagnostic Testing and Antimicrobial Stewardship on the Time to Escalation/De-Escalation of Antimicrobial Regimens for Gram-Negative Bloodstream Infections at a Large Community Hospital

Poster Abstract Sessions (continued)

- 1808** Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) and Vitek 2 along with Antimicrobial Stewardship (ASP) Result in Faster Antimicrobial Therapy for Infected Patients: The CHI Health Experience
- 1809** Improved Vancomycin Utilization with Rapidly Available Xpert MRSA/SA BC PCR and Microbiologist Case Review
- 1810** Therapeutic Drug Monitoring of Azole Antifungals at an Academic Medical Center: Opportunities and Lessons Learned
- 1811** Minimizing Time to Optimal Therapy for Enterobacteriaceae Bloodstream Infections: Is Organism Identification Enough?
- 1812** Impact of Rapid Identification of Blood Cultures with Antimicrobial Stewardship at Three Community Hospitals within a Health System

219. Poster Abstract Session

Antimicrobial Stewardship: New Methods and Metrics

Saturday, 12:30 - 1:45 p.m.

- 1813** Development and Validation of Novel Ambulatory Antibiotic Stewardship Metrics
- 1814** External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections
- 1815** Effects of Syndrome-Based Antimicrobial Stewardship Prospective Audit and Feedback Interventions on Antimicrobial Use in an Urban Community Hospital
- 1816** Large-Scale Comparison of Antibiotic Prescription Guidelines Uncovers Disparities among Stewardship Approaches
- 1817** Benchmarking Outpatient Antimicrobial Use in Manitoba through Population-Based Research
- 1818** Characteristics of a Cohort of Patients on Broad-Spectrum Antibiotics Targeted for Prospective Audit and Feedback
- 1819** Antibiotic Prescribing Feedback: Description of Denominator Metrics to Standardize Prescribing Rates for Peer Comparison
- 1820** Indirect Standardization: A Convenient Benchmarking Approach to Antibiotic Utilization Based on Patient Mix
- 1821** Understanding the Components and Calculation of the SAAR, Illustrative Data
- 1822** Veterans Are Special: Clinical Decision Tree Misses ESBL Status in Bacteremic Veterans
- 1823** Signal or Noise? A Comparison of Methods to Identify Outliers in Antimicrobial Use (AU)
- 1824** Care Transformation in Infectious Diseases: Using a Novel Approach for Tracking Antimicrobial Stewardship Metrics
- 1825** Electronic Measure of Unnecessary Antimicrobial Use in U.S. Veterans Affairs Medical Centers

220. Poster Abstract Session

Antimicrobial Stewardship: Non-hospital Settings

Saturday, 12:30 - 1:45 p.m.

- 1826** Interventions to Enhance Clinical Nurse Partnership in Acute Care and Nursing Home (NH) Antibiotic Stewardship Efforts: A Scoping Review
- 1827** Clinical Staff Retention and Leadership Stability and Antibiotic Utilization in Nursing Homes
- 1828** Interrupted Time Series Analysis of a Population-Level Academic Detailing Intervention on UTIs in British Columbia's Nursing Homes
- 1829** A Systems Approach to Nursing Home Antimicrobial Stewardship
- 1830** Avoiding Routine Urinalysis (UA) and Improving Urine Culture (UC) Utilization: An Antibiotic Stewardship Imperative in Geriatric Psychiatry and Emergency Medicine (EM)
- 1831** Point Prevalence and Epidemiology of Antimicrobial Use in U.S. Nursing Homes, 2017
- 1832** Concordance in End-of-Life Antimicrobial Prescribing Practices among Medicine Subspecialists
- 1833** Impact of Antibiotic Stewardship on Antimicrobial use for Urinary Tract Infection at a Veteran's Affairs Long-Term Care Facility
- 1834** Implementation of the Core Elements of Outpatient Antibiotic Stewardship in Urgent Care Centers and Federally Qualified Health Centers in New York City, 2016–2017
- 1835** Evaluating Regional Nursing Home Antibigrams to Advance Stewardship at 233 Skilled Nursing Facilities in Georgia, USA
- 1836** Characteristics of Nursing Homes Associated with Self-Reported Implementation of Centers for Disease Control and Prevention (CDC) Core Elements of Antibiotic Stewardship
- 1837** Comparison of Antibiotic Use in Post-Acute and Long-Term Care Facilities Based on Proportion of Short Stay Residents Using a Long-Term Care Pharmacy Database
- 1838** Digging Deeper: A Closer Look at Core Elements of Antibiotic Stewardship for Long-Term Care Facilities

221. Poster Abstract Session

Antimicrobial Stewardship: Outpatient Settings

Saturday, 12:30 - 1:45 p.m.

- 1839** Expanding Antimicrobial Stewardship into the Community: Development of Patient and Provider Education Resources to Improve Antibiotic Awareness
- 1840** Development of an Innovative Antibiotic Prescribing Dashboard to Enhance Antimicrobial Stewardship in the Ambulatory Care Setting
- 1841** Implementation of an Outpatient Antimicrobial Stewardship Program to Reduce Fluoroquinolone Overprescribing at a Veterans Affairs Medical Center (VAMC)
- 1842** Fluoroquinolone Usage Reduction in the Outpatient Setting

Poster Abstract Sessions (continued)

- 1843** Prescribers' Characteristics and Unnecessary/Inappropriate Antimicrobial Prescription in the Emergency Department: An Observational Study at a Tertiary Care Center
- 1844** Improving Management of Community Acquired Pneumonia through Collaborative Integrated Care in an Antimicrobial Stewardship initiative
- 1845** Implementing Outpatient Antimicrobial Stewardship in a Primary Care Office through Pharmacist-Led Audit and Feedback
- 1846** Outpatient Antibiotic Use in Viral Acute Upper Respiratory Tract Infections at a Military Treatment Facility: A Target for Stewardship Intervention
- 1847** Impact of Antimicrobial Stewardship Commitment Posters on Antibiotic Prescribing for Upper Respiratory Tract Infections in a Rural Outpatient Setting
- 1848** Evaluation of Antibiotic Prescribing Practices in Outpatient Clinics for the Treatment of Skin & Soft Tissue Infections
- 1849** Identification of Antimicrobial Stewardship Targets in the Outpatient Setting
- 1850** Impact of Targeted Feedback on Ciprofloxacin Prescribing in Outpatient Clinic Areas
- 1851** Impact of an Antimicrobial Stewardship Initiative on Fluoroquinolone Utilization in the Outpatient Setting at an Academic Medical Center
- 1852** Rethinking Empirical Treatment for Urinary Tract Infections in the Outpatient Setting
- 1853** Impact of Antimicrobial Stewardship Interventions on Antimicrobial Utilization in Asymptomatic Bacteriuria
- 1854** Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
- 1855** Antimicrobial Stewardship (AMS) In the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting
- 1856** Comparison of Antibiotic Susceptibility in Hospitals versus Hospital-Based Emergency Departments
- 1857** Implementing Antibiotic Stewardship in Urgent Care Centers
- 1858** Use and Perceptions of an Institution-Specific Antibiotic Prescribing "App" among Emergency Department and Urgent Care Clinicians
- 1863** Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016
- 1864** Implementation of the National Healthcare Safety Network's (NHSN) Antimicrobial Use Option in the U.S. Veterans Affairs (VA) Medical Facilities
- 1865** Antibiotic Susceptibilities of Organisms Isolated from Urine Cultures of Patients Diagnosed with a Urinary Tract Infection (UTI) and Discharged from the Emergency Department (ED)
- 1866** Adverse Outcomes Associated with Potentially Inappropriate Antibiotic Use in Heart Failure Admissions
- 1867** A Regional Collaboration to Share Antimicrobial Stewardship Resources in Three Geographically Related Veterans Affairs Medical Centers
- 1868** Successful Use of Telemedicine versus On-site Infectious Diseases Consultation After Implementation of a System-wide Antimicrobial Stewardship-Led *Staphylococcus aureus* Bacteremia Care Bundle
- 1869** Telepharmacy Support of an Antimicrobial Stewardship Program in a Small Rural Canadian Acute Care Hospital
- 1870** Excess Antibiotic Duration in Patients Hospitalized for Pneumonia: A Multi-Hospital Cohort Study
- 1871** Identifying Time Periods of High and Low Vancomycin Use
- 1872** Antimicrobial Utilization Variability Among Training Services at an Academic Medical Center
- 1873** Next Steps in Predicting Anti-MRSA Antibiotic Prescribing
- 1874** Adherence to Practice Guidelines for Treating Diabetic Foot Infections: An Opportunity for Syndromic Stewardship
- 1875** How Many Different Antimicrobial Regimens Are There and Which are Emerging and Declining?
- 1876** Patient- and Hospital-Level Factors and Outcomes Associated with Treatment of Asymptomatic Bacteriuria in Hospitalized Patients: A Multi-Hospital Cohort Study
- 1877** Discrepant Susceptibilities have Minimal Impact on Antibiotic Prescribing for Patients with Two or More Blood Cultures Positive for Coagulase-Negative Staphylococci
- 1878** Expanding Kentucky's "One and Done" Tradition: Lipoglycopeptide Administration in the Emergency Department at a Tertiary, Academic Medical Center
- 1879** A Point Prevalence Study of Antibiotic Utilization in 61 Geographically Diverse Acute Care Hospitals (2017)
- 1880** Does the Label Matter: Initial Use of Newly Approved Antimicrobial Agents in Community Hospitals without Robust Antimicrobial Stewardship Programs
- 1881** Empiric Pseudomonal Monotherapy versus Combination Therapy for Community-Onset Pneumonia in Older Adults
- 1882** Resistance (R) Trends in Gram-Negative Bacilli (GNB) to Fluoroquinolones (FQ), [Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MOX)], Trimethoprim-sulfamethoxazole (TMP/SMX), and Nitrofurantoin (NFT) over a 7-year period: Pre- and Post- Implementation of FQ Restriction at a Tertiary Care Veterans Affairs Medical Center (VAMC)
- 1883** Acute Kidney Injury in Patients with Pneumonia on Concomitant Anti-Methicillin Resistant *Staphylococcus aureus* and Anti-Pseudomonal Beta-Lactam Therapy

222. Poster Abstract Session

Antimicrobial Stewardship: Potpourri

Saturday, 12:30 - 1:45 p.m.

- 1859** Prevalence of Antimicrobial Use in U.S. Hospital Patients, 2011 vs. 2015
- 1860** Small State, Big Collaboration: Creation of First New Hampshire Statewide Antibigram Guides Stewardship Efforts
- 1861** National Healthcare Safety Network's Electronic Antimicrobial Use and Resistance Surveillance—First Cohort of Hospital Reporters, 2011–2017
- 1862** The Role of Infection Preventionists in Antimicrobial Stewardship Programs in Acute Care Hospitals

Poster Abstract Sessions (continued)

1884 Assessment of Potential Antimicrobial-Related Harms in Hospitalized Adults with Common Infections

1885 Cost-Effectiveness of Ceftazidime-Avibactam Compared to Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia

223. Poster Abstract Session

Antimicrobial Stewardship: Qualitative Research

Saturday, 12:30 - 1:45 p.m.

1886 Provider's Close Approximation of Parental Desire for Antibiotics Doesn't Diminish Concern of Anticipated Conflict

1887 Primary Care Physicians' Attitudes and Perceptions towards Antibiotic Resistance and Outpatient Antibiotic Stewardship: A Qualitative Study

1888 Clinicians' Beliefs, Knowledge, Attitudes, and Planned Behaviors on Antibiotic Prescribing in Acute Respiratory Infections

1889 A Clinical Practice Assessment on *Clostridium difficile* Infection

1890 Healthcare Professionals' Knowledge, Attitudes, and Beliefs Regarding Factors that Contribute to Inappropriate Antibiotic Use

1891 Assessing the Needs for Antimicrobial Stewardship Education and Acceptance Across a Spectrum of Prescribers, Nurses, and Pharmacists at a Large Academic Medical Center

1892 Preparing for an Antibiotic Stewardship Intervention through Nursing Surveys of Knowledge and Safety

1893 Barriers and Facilitators to Nursing (RN) Involvement in Antibiotic Stewardship (AS): Multisite Qualitative Study of Prescribers

1894 Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians

224. Poster Abstract Session

Antiviral Therapies

Saturday, 12:30 - 1:45 p.m.

1895 The Anti-Parasitic Drug Atovaquone Inhibits Arbovirus Replication

1896 A Retrospective Cohort Analysis to Determine the Incidence of CMV Viremia and Progression to CMV Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation at an Academic Children's Hospital

1897 Letemovir Salvage for Complicated Cases of Resistant CMV

1898 Clinical Characteristics of Patients (pts) with Solid Organ Transplantation (SOT) and Norovirus (NV) Infections

1899 The Cellular Kinase Inhibitor OSU-03012 Inhibits Enterovirus 71 *In Vitro*

1900 Low Prevalence of Protective Antibodies to Measles among Young Adults in Argentina

1901 Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study

1902 A Survey of Pediatric Bone Marrow Transplant Centers Regarding Local Cytomegalovirus Prophylaxis Management Practices and Interest in a Future Randomized Trial

225. Poster Abstract Session

Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis

Saturday, 12:30 - 1:45 p.m.

1903 Cost Minimization Analysis of a Preferred ARV Prescribing Pathway for Treatment-Naïve HIV-Positive Patients

1904 Impact of Mail Order Pharmacy Use on Viral Suppression Among HIV-Infected Patients

1905 Real-World Insights into Quality Improvement across 11 HIV Clinics in the U.S.

1906 Hospitalization Rates among Persons with HIV Who Gained Medicaid or Private Insurance in 2014

1907 Barriers at the Last Hurdle: Implementing Advance Care Planning for People Living with HIV

1908 Development of an Electronic Health Record Generated Alert for Prophylaxis against *Pneumocystis Jirovecii* Pneumonia in the Setting of High Dose Steroids

1909 Do Infectious Disease Services Save Money? Accounting Analysis Before and After Introduction of a New Clinical Infectious Disease Service at a Tertiary Hospital in New Zealand

1910 Developing a Multi-Disciplinary Team for Infective Endocarditis: A Quality Improvement Project

1911 Implementation of Diabetes Medication Management by Pharmacists in a Multidisciplinary Limb-Salvage Clinic

1912 Implementation of Sepsis-3 Definition in the Emergency Department: Proposed of Case Detection in Real-Life Practice

1913 Clinical Performance of the qSOFA Score Among Non-ICU Inpatients with Infection at a Tertiary Hospital in Jamaica from 2015 To 2016

1914 Adherence to the Sepsis Bundle in Hospital-Onset v. Community-Onset Sepsis

1915 Predicting Real-Time Risk of Complications in the Postoperative Setting with Temperature as a Single Variable

1916 Diagnostic Stewardship in Infectious Diseases Molecular Viral Testing: A Pilot Project

1917 Diagnostic Errors in Bacterial Osteomyelitis in Children

1918 Is it Time to Assess the Role of Blood Cultures in the Current Practice of Medicine?

1919 Outpatient Care-Seeking Prior to Acute Respiratory Infection Hospitalization in the United States, 2012–2014

1920 Ocular Involvement in Candidemia Patients at an Urban Tertiary Care Center: Is Inpatient Ophthalmologic Consultation Essential?

1921 Attributable Inpatient Costs of Hospital-Onset *Clostridium difficile* Infection: A Nationwide Case-Control Study in Japan

1922 The Challenges of Caring for People Who Inject Drugs: An Opportunity for an Infectious Diseases Service

Poster Abstract Sessions (continued)

- 1923** OPAT or No-PAT? Evaluation of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Daptomycin or Ertapenem for “Ease of Administration”
- 1924** Most Patients Tolerate Penicillin Administration Despite History of Non-Anaphylactic Penicillin Allergy: A Systematic Review and Meta-analysis
- 1925** Vancomycin Treatment and Time to Adverse Drug Reactions during Outpatient Parenteral Antimicrobial Therapy (OPAT)
- 1926** Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy
- 1927** Preference for Intravenous versus Oral Antibiotics at Hospital Discharge
- 1928** Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who were Treated with Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
- 1929** Risk of Acute Kidney Injury in Combat-Injured Patients Associated with Concomitant Vancomycin and Extended-Spectrum β -Lactam Antibiotic Use

226. Poster Abstract Session

Clinical Practice Issues: OPAT

Saturday, 12:30 - 1:45 p.m.

- 1930** Developing an Electronic Medical Record System to Monitor Patients on Outpatient Parenteral Antibiotic Therapy at an Academic Medical Center
- 1931** Health-Related Social Vulnerabilities in a Pediatric Outpatient Antimicrobial Therapy (OPAT) Program
- 1932** Healthcare Utilization in Older versus Younger Adults on Outpatient Parenteral Antimicrobial Therapy According to Discharge Location
- 1933** Economic Evaluation of Outpatient Parenteral Antimicrobial Therapy in Children
- 1934** Who Really Benefits Financially from OPAT: Patients/Families or Healthcare Institutions?
- 1935** Outpatient Parenteral Antimicrobial Therapy in Nonagenarians
- 1936** Implementation of IV Push Antibiotics for OPAT in a Safety Net Hospital Following a National Fluid Shortage
- 1937** A Dedicated OPAT Program Reduces Readmission and Complications Rates
- 1938** Sustained Reduction in 30-day Readmission Rates after Implementation of an OPAT Program in an Academic Medical Center
- 1939** Socioeconomic Predictors of Hospital Readmission in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients
- 1940** Outcomes among Patients Enrolled in an Outpatient Parenteral Antibiotic Therapy Program at an Academic Medical Center
- 1941** Comparison of Patient Outcomes in a Pharmacist-Led Outpatient Parenteral Antimicrobial Therapy (OPAT) Program
- 1942** Expansion of Outpatient Parenteral Therapy Program with Addition of Advanced Practice Providers Can Lead to Reduced Readmission Rates

- 1943** Collateral Benefits of Diabetes Management Associated with Self-Administered Outpatient Parenteral Antimicrobial Therapy
- 1944** Patients with Prosthetic Joint Infections Receiving Outpatient Parenteral Antimicrobial Therapy: Characteristics and Readmission Rates
- 1945** Making the EMR Work for You—Modifications to Epic to Improve Management of Outpatient Parenteral Antibiotic Therapy (OPAT) Patients
- 1946** Heterogeneous Hospitalization Outcomes of People Who Use Drugs: The Type of Drug(s) Used Matters

227. Poster Abstract Session

Clinical Trials

Saturday, 12:30 - 1:45 p.m.

- 1947** Influenza Vaccination via Oral Tablet is Protective and Induces a Unique Mucosal Immune Response
- 1948** A Host-Response Assay Distinguishes Between Simple Influenza Patients and Influenza Patients with Bacterial Coinfection
- 1949** Safety and Efficacy of Ambulatory Outpatient Treatment of Febrile Neutropenia in Children with Cancer in Mexico: A Multicenter Randomized Controlled Trial
- 1950** Prevention of Recurrent *Clostridium difficile* at Six Months Following Treatment with Microbiota-Based Therapy RBX2660: Durability Results from a Phase 2 Open-Label Study
- 1951** Nephrotoxicity Associated with Imipenem/Cilastatin/Relebactam (IMI/REL) versus Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) bacterial infections
- 1952** Evaluation of Relapse and Reinfection Using Whole-Genome Sequencing of *Clostridium difficile* Isolates from Elderly Patients with *C. difficile* Infection (CDI) in the EXTEND Randomised, Controlled, Comparative Study of Extended-Pulsed Fidaxomicin and Vancomycin for the Treatment of CDI
- 1953** Comparative Effectiveness of High- Versus Standard-Dose Influenza Vaccine on Hospitalization for Acute Myocardial Infarction in Nursing-home Residents: A Post-Hoc Analysis from a Large Cluster-Randomized Trial
- 1954** A Randomized Study to Evaluate the Shedding and Immunogenicity of H1N1 Strains in Trivalent and Quadrivalent Formulations of FluMist in Children 24 to <48 Months of Age
- 1955** A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants ≤ 3 Months of Age
- 1956** Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
- 1957** Pharmacist Prescribing and Care in Patients with Uncomplicated Urinary Tract Infections in the Community: Efficacy and Safety Outcomes of the R_xOUTMAP Study

Poster Abstract Sessions (continued)

- 1958** Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants with Bronchiolitis, in the Phase 1b Study 53718678RSV1005
- 1959** Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes in Patients Infected with Ceftriaxone Non-Susceptible, Extended Spectrum Beta-Lactamase and Multidrug-Resistant Pathogens at Baseline
- 1960** Antibiotic Challenge Dose Testing Improves Patient Care and Lowers Costs in a Community Hospital: A Two-year Prospective Study
- 1961** A Randomized Controlled Trial of the Effect of Accelerated Copper Textiles on Healthcare-Associated Infections and Multidrug-Resistant Organisms: The “Investigating Microbial Pathogen Activity of Copper Textiles” (IMPACT) Study
- 1962** TRAIL Level and ImmunoXpert™ Score Complement Molecular Viral Detection in the Classification of Febrile Children: An Interim Analysis from the AutoPilotDx-Study
- 1963** Combined Microbiological Response Rates From Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4
- 1964** Microbiological Outcomes with Plazomicin (PLZ) versus Colistin (CST) in Patients (pts) with Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the CARE Study
- 1965** Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials
- 1966** Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived from a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent *Clostridium difficile* Infections (rCDI)
- 1967** Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) When Co-Administered with Other Vaccines in Healthy Adolescents
- 1968** Procalcitonin-Guided Antibiotic Therapy for Lower Respiratory Tract Infections in a U.S. Academic Medical Center
- 1969** Comparison of Adverse Event Rates Between Patients Treated with Ceftaroline or Ceftriaxone
- 1970** Phase 1 Clinical Trial of Intranasal Immunization with M2-deficient, Single Replication, Live Influenza Vaccine (M2SR): Safety and Immune Response in Adults
- 1971** A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
- 1972** Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared to PCV-13 in Healthy Older Adults Previously Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
- 1973** A Meta-Analysis of the Effectiveness of LAIV4 and IIV against Influenza A/H3N2 Strains in Children 2–18 Years of Age during the 2016–2017 Season
- 1974** Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis
- 1975** 1g versus 2g Daily Intravenous Ceftriaxone in the Therapy of Community Onset Pneumonia: a Propensity Score Analysis from a Data of Japanese Multicenter Registry
- 1976** Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections
- 1977** Comparative Effectiveness of Linezolid vs. Trimethoprim-Sulfamethoxazole for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) at a Veterans Affairs Hospital
- 1978** Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection
- 1979** Time to Viral Suppression does not Impact SVR in Patients Treated with Glecaprevir/Pibrentasvir for 8 Weeks
- 1980** Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed *Clostridium Difficile Infection* (CDI)
- 1981** Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry
- 1982** Multiplex PCR-Based Analysis of Enteric Pathogens in Fecal Samples from Patients with *Clostridium difficile* Infection in the Randomised, Controlled EXTEND Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin with Vancomycin Therapy
- 1983** Oral Therapy with Rifampin Associated with Minocycline or Moxifloxacin in Vertebral Osteomyelitis due to Gram-Positive Micro-organisms: A Retrospective Study of 64 Cases
- 1984** Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients with Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis)
- 1985** Atypical Symptoms and High Mortality Associated with Serogroup B Meningococcal Disease in Cartagena Colombia 2012-2016

228. Poster Abstract Session

Diagnostics: Bacteria and Mycobacteria

Saturday, 12:30 - 1:45 p.m.

- 1986** Rapid Identification and Antimicrobial Susceptibility Testing Utilizing the Accelerate Pheno™ System for Gram-Negative Bloodstream Infections and its Potential Clinical Impact
- 1987** Validation of a MALDI-TOF MS-Based Direct-On-Target Microdroplet Growth Assay (DOT-MGA) for Rapid Detection of Extended-Spectrum Beta-Lactamase (ESBL) and AmpC in Clinical *Enterobacteriaceae* Isolates

Poster Abstract Sessions (continued)

- 1988** Development of a Laboratory Stewardship Algorithm for *Anaplasma phagocytophilum* Polymerase Chain Reaction Testing
- 1989** Evaluation of Laser Light Scattering Technology in Rapid Diagnosis of Urinary Tract Infections in Children
- 1990** Reactivity and Specificity of a Research Use Only (RUO) Prototype of a Highly Multiplexed Sample-to-Answer PCR System for the Detection of Pathogens from Positive Blood Culture
- 1991** A Prospective Pilot Evaluation of a Research Use Only (RUO) Prototype of a Highly Multiplexed Sample-to-Answer PCR System for the Detection of Pathogens from Positive Blood Culture
- 1992** Automated Classification of Pulmonary Tuberculosis-Associated Radiograph in the U.S. Hospital-Scale Chest X-Ray Database by using Deep Convolutional Neural Network
- 1993** The Contribution of Commensal Bacteria on the Severity of Symptoms During the 2017-2018 Influenza Season
- 1994** Development of a Meningococcal Serogroup B Serum Bactericidal Assay Using Fetal Bovine Serum
- 1995** Implementation of *Helicobacter pylori* Stool Antigen Testing in a Large Metropolitan Centre: A Prospective Comparative Diagnostic Trial
- 1996** Addressing Pulmonary Nocardiosis Risk in Immunocompromised Patients: Development and Validation of a Commercially Available PCR
- 1997** Impact of Blood Culture Fill Volumes
- 1998** Urine Culture Incubation time: One vs two days
- 1999** Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves
- 2000** Rapid, Point-of-Care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-effectiveness and Budgetary Impact Analysis for India's Public Sector
- 2001** Susceptibility of *Aerococcus urinae* to Fluoroquinolones: Broth Microdilution and Gradient Diffusion
- 2002** Evaluation of the BioFire® Pneumonia Panel in ICU Patients with Suspected Ventilator-Associated Pneumonia
- 2003** Routine Use of Anaerobic Blood Cultures at Thammasat University Hospital, Thailand
- 2004** Clinical Application of Xpert SA Nasal Complete for Direct Detection of *Staphylococcus aureus* and Methicillin-Resistant *Staphylococcus aureus* in Nasal Swabs in Pediatric Care Setting
- 2005** T-SPOT®.TB Test for Latent Tuberculosis Infection Diagnosis and Treatment Guidance in Thai Healthcare Professionals
- 2006** Implementation of the T2 Biosystems T2Bacteria Panel in a Level-One Trauma Center, Safety Net Hospital
- 2007** To Treat or Not To Treat: Does a More Sensitive and Specific Testing Methodology Make the Treatment Decision More Clear?
- 2008** Effective & Early Diagnosis of Pneumonia in Patients with Acute Leukemia in a Comprehensive Cancer Center: How Can We Improve the Microbiological Diagnosis?
- 2009** Misidentification Rate of *Acinetobacter baumannii* Isolated from Invasive Infections in Children

229. Poster Abstract Session

Diagnostics: Biomarkers and Novel Approaches

Saturday, 12:30 - 1:45 p.m.

- 2010** Volatile Organic Compounds Patterns in Breath, Plasma, and Stool in Patients with *Clostridium difficile* Infection: A Cross-Sectional Proof of Concept Study
- 2011** Identification of *Streptococcus agalactiae* on Human Fetal Membrane Tissues using Raman Microspectroscopy
- 2012** FilmArray® Measurement of Host Response Signatures Rapidly Discriminates Viral, Bacterial, and Non-Infectious Etiologies of Illness
- 2013** Procalcitonin Current State Evaluation within a Large Health-System
- 2014** TLDA Validation of a Host Response Signature to Discriminate Bacterial, Viral, and Non-Infectious Causes of Illness
- 2015** Host Gene Expression Identifies Infectious Triggers of Asthma Exacerbation
- 2016** TaqMan Multiplex PCR of a Seven-Gene Host Biomarker to Discriminate Bacterial from Viral Infections
- 2017** Improving Timely Diagnosis of Meningitis and Encephalitis: The Effectiveness of Online CME
- 2018** Host Gene Expression Classifiers Distinguish Bacterial and Viral Infections in Sri Lankan Patients with Acute Febrile Respiratory Illness
- 2019** Host Gene Expression Signatures for Diagnosis of Acute Respiratory Infections in the Elderly
- 2020** Concordance of Direct Versus Indirect Pathogen Detection Using the BioFire® System
- 2021** An Ultra-Rapid Host Response Assay to Discriminate Between Bacterial and Viral Infections Using Quantitative Isothermal Gene Expression Analysis
- 2022** Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
- 2023** A Prospective, Multi-Center U.S. Clinical Trial to Determine Accuracy of FebriDx Point-of-Care Testing for Acute Upper Respiratory Infections With and Without a Confirmed Fever
- 2024** Modeled Impact of Rapid Diagnostics on the Treatment of Gram-Negative Bacteremia at a Tertiary-Care VA Medical Center
- 2025** Procalcitonin Reference Cutoff and Specimen Type Validation
- 2026** Phenotypic and Molecular Characterization of Drug Resistance and Biofilm Production in *Stenotrophomonas maltophilia* obtained in a ten-year period from a Mexican Hospital
- 2027** Immune Correlates of Protection against Herpes Zoster (HZ) in People Living with HIV (PLWH)
- 2028** ID Consultant EMR Hyperlinked Recommendation as a Tool to Curb "Routine" Following of Inflammatory Markers
- 2029** Comparison of Primers Amplifying Two Different Regions of the 16S Ribosomal RNA Gene for Microbiologic Diagnosis of Cardiovascular Implantable Electronic Device Infection

Poster Abstract Sessions (continued)

- 2030** How Machine-Learning Technique Using Artificial Neural Network Determines Whether the Fever is Actually Related to the Bacteremia
- 2031** False Positive Serologic Results Attributable to IVIG Therapy

230. Poster Abstract Session

Diagnostics: Mycology

Saturday, 12:30 - 1:45 p.m.

- 2032** Predictors of 6-week Mortality in Patients with Positive Bronchoalveolar Lavage (BAL) Galactomannan (GM)
- 2033** Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients (pts) At-Risk for Sepsis due to Invasive Candidiasis (IC)
- 2034** Natural Antibodies Affects the Formation of Titan Cells in *Cryptococcus neoformans* *in vitro*
- 2035** Detection of *Blastomyces dermatitidis* Antigen in Urine Using a Novel Quantitative Enzyme-Linked Immunosorbent Assay
- 2036** Plasma (1 \rightarrow 3)- β -D-Glucan Levels correlate with Neurocognitive Functioning in HIV infected Adults
- 2037** Utilization of the T2 Magnetic Resonance in the Early Detection of Invasive Candidiasis
- 2038** Invasive Mucormycosis Management: Mucorales PCR Provides Important, Novel Diagnostic Information
- 2039** New York State 2016-2018: Progression from *Candida auris* Colonization to Bloodstream Infection
- 2040** Clinical Application of *Aspergillus* Lateral Flow Device (AspLFD) in Bronchoalveolar Lavage (BAL) Fluid of Patients (pt) with Classic Risk Factors for Invasive Pulmonary Aspergillosis (IPA)
- 2041** Impact of T2 Candida Panel on Species Specific Anti-Fungal De-Escalation
- 2042** Clinical Application of AspID PCR Alone and in Combination with *Aspergillus* Lateral Flow Device (AspLFD) in Bronchoalveolar Lavage (BAL) Fluid of Patients (pt) with Classic Risk Factors for Invasive Pulmonary Aspergillosis (IPA)
- 2043** T2-Candida (T2MR) versus Beta-D-Glucan (BDG) for Preemptive Antifungal Stewardship in the Intensive Care Unit (ICU)
- 2044** Utility of Serum Beta-D Glucan Assay for Diagnosis of Invasive Fungal Infections in Solid Organ Transplant Recipients
- 2045** Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection.
- 2046** FungiScope™—News on the Global Emerging Fungal Infection Registry
- 2047** Study of Molecular Epidemiology, Risk Factor Analysis, and Comparison of Diagnostic Methods for Rapid Diagnosis of Fungal Pneumonia in Critically Ill Cirrhotics
- 2048** Comparison Between Endpoint and Real-Time (RT) Polymerase Chain Reaction (PCR) for the Diagnosis of *Pneumocystis* Pneumonia (PCP)

- 2049** *Pneumocystis jiroveci* Detection by Nested PCR in HIV-Infected Peruvian Patients
- 2050** Plasma Next-Generation Sequencing for Pathogen Detection in Pediatric Patients at Risk for Invasive Fungal Infection
- 2051** Detection of *Candida auris* among Previously Unidentified Yeasts Isolated from Ear Discharge Specimens in Japan
- 2052** Performance of the BioFire® Filmarray Meningitis/Encephalitis Panel in Cryptococcal Meningitis Diagnosis
- 2053** Tissue-Based Molecular Diagnostics: A Sensitive and Specific Way for the Identification of Invasive Fungal Infections in the Combat-Related Setting
- 2054** Physician Responses to Positive Rapid Diagnostic Tests for *Candida* Fungemia in the Absence of Concomitant Positive Blood Cultures
- 2055** Utility of *Aspergillus* Galactomannan Assay in Allogeneic Stem Cell Transplant Recipients

231. Poster Abstract Session

Diagnostics: Parasitology

Saturday, 12:30 - 1:45 p.m.

- 2056** *Trypanosoma cruzi* DNA Detection by PCR in Dried Blood Spots Preserved in Filter Paper
- 2057** Predictors for Gastrointestinal Protozoa Detection in U.S. Children Presenting with Acute Diarrhea

232. Poster Abstract Session

Diagnostics: Resistance Testing

Saturday, 12:30 - 1:45 p.m.

- 2058** Comparison of Drug Resistance Rates of *Mycobacterium tuberculosis* by the Conventional Drug Susceptibility Test and Sequencing Method
- 2059** Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant *Staphylococcus aureus* (MRSA): Results from a Multicenter Study
- 2060** Comparison of Plazomicin MIC Test Strip and Broth Microdilution MIC Results for 125 Enterobacteriaceae
- 2061** Impact of a Penicillin-Binding Protein 2a Rapid Diagnostic Test on Patients Who Present with *Staphylococcus aureus* Orthopedic Hardware Infections
- 2062** Evaluation of Susceptibility Testing Methods for Fosfomycin against *Enterobacteriaceae* and *Pseudomonas aeruginosa*
- 2063** Extracellular Release of β -lactamase is Responsible for the Cefazolin Inoculum Effect (CzIE) in Methicillin-Susceptible *Staphylococcus aureus*
- 2064** Rapid Detection of Carbapenemase-Producing *Klebsiella pneumoniae* (CPK) Directly from Respiratory Secretion and Clinical Characteristics of Patients with CPK from a 1200-Bed Tertiary Care Hospital in Thailand
- 2065** Whole Genome Sequencing for Antimicrobial Resistance Prediction in MRSA and VRE: A Real World Application

Poster Abstract Sessions (continued)

- 2066** Accelerated Detection of Carbapenem Resistance Mechanisms in Enterobacteriaceae by MALDI-TOF Mass Spectrometry Using the Direct-On-Target Microdroplet Growth Assay (DOT-MGA)
- 2067** Novel Methodology for Same-Day Antimicrobial Susceptibility Testing on VITEK®2 for Gram-Negative Rod Bacteremia
- 2068** Evaluation of Ceftazidime-Avibactam Disks from Different Commercial Manufacturers for Susceptibility Testing against Meropenem Non-Susceptible Enterobacteriaceae
- 2069** Automation Process Improving Microbiological Laboratory Efficiency
- 2070** Antibiotic Therapy Effects on Enterobacteriaceae Detection Directly from Blood: Pilot Study Implications for Future Clinical Trial Design
- 2071** Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
- 2072** Multicenter Evaluation of the Etest Versus Agar Dilution for Susceptibility Testing of *Helicobacter pylori*
- 2073** Positive Clinical Impact of MALDI-TOF for the Management of Inpatient Pneumonia Without Additional Antimicrobial Stewardship (AS) Support
- 2074** Performance and Impact Evaluation of Direct Rapid Antibiotic Susceptibility Testing on Antibiotic Treatment Accuracy in Clinical Setting
- 2075** The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program & Rapid Genotypic Organism/Resistance Marker Identification
- 2076** Expanded Antibiotic Menu Demonstration for Novel Rapid Phenotypic Antimicrobial Susceptibility Testing Platform
- 2077** Assessment of the Clinical Impact of Rapid Identification with Same-Day Phenotypic Antimicrobial Susceptibility Testing (Accelerate Pheno™ System) on the Management of Bloodstream Infections in Adult Patients with Antibiotic Stewardship Intervention: A Retrospective Observational Study

233. Poster Abstract Session

Diagnostics: Virology

Saturday, 12:30 - 1:45 p.m.

- 2078** Adherence to Laboratory Screening Recommendations for Neonatal Herpes Simplex Virus Infection at a Tertiary Children's Hospital
- 2079** The Relation Between Panel Reactive Antibody Assay and Cytomegalovirus Reactivation in Seropositive Solid Organ Transplantation Recipients
- 2080** Impact of the Implementation of a Rapid Meningitis/Encephalitis Multiplex Polymerase Chain Reaction Panel on Clinical Outcomes: Multicenter, Retrospective Cohort of Adult and Pediatric Patients
- 2081** Building a Decision Tree with Serial Serology Measurements Improves Classification in a Flavivirus Co-Circulation Region

- 2082** Using a Commercially Available Assay Measuring Cytomegalovirus (CMV)-Specific CD4+ and CD8+ T-Cell Immunity by Intracellular Cytokine Staining to Predict Clinically Significant CMV Events
- 2083** Rapid Diagnosis and Differentiation of Dengue During Peri-Monsoon Season in Tropical Resource Limited Facilities
- 2084** Prospective, Multi-Center Analysis of a BioFire® FilmArray® Childhood Systemic Infection (CSI) Panel for Detection of Viral Bloodstream Infections in a Pediatric Emergency Department Setting
- 2085** Evaluation of Panther Fusion Flu A/B/RSV, AdV/hMPV/RV and Paraflu Assays for the Detection of Respiratory Viruses in Children
- 2086** Perils of CMV PCR Primer/Probe Design: Emergence of Mutations in Clinical Samples from Two Pediatric Patients
- 2087** Comparison of Alere™ i Influenza Flu A & B 2 and Cobas® Influenza A/B Nucleic Acid Amplification Tests for Detection of Influenza A/B in Nasopharyngeal Swabs Collected from Children

234. Poster Abstract Session

Healthcare Epidemiology: Device-associated HAIs

Saturday, 12:30 - 1:45 p.m.

- 2088** Association Between Implementation of Prevention Practices and CLABSI Incidence: A National Survey
- 2089** Dwindling Utilization of Central Venous Catheter Tip Cultures: An Analysis of Sampling Trends and Clinical Utility at 128 U.S. Hospitals 2009-2014
- 2090** Decontamination of *Fusarium oxysporum* from a Central Line Needleless Access Device using a 70% Isopropyl Alcohol Impregnated Port Protector
- 2091** The Impact of Infection Control Cost Reimbursement Policy on Trends in Central Line Associated Bloodstream Infections
- 2092** How Long Should You Delay Insertion of a Long-Term Central Venous Catheter (LTCVC) in Patients with Candida Bloodstream Infection (CBSI)?
- 2093** Chlorhexidine Gluconate Bathing to Prevent Central Line Associated Infections: What To Do when the Patient Can Bathe Themselves
- 2094** Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
- 2095** Infections in Burn Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) at a Tertiary Military Medical Center
- 2096** Evaluation of a Midline Catheter Program and Effect on Central Line Associated Bloodstream Infections
- 2097** Do Catheter-Associated Bloodstream Infections Affect Patients' Perception of Care?
- 2098** Reduction of Central Line Associated Bloodstream Infection Rates: Impact of Minimizing Blood Cultures from Central Lines
- 2099** Catheter Related *Staphylococcus Aureus* Bacteremia and Septic Thrombosis: The Role of Anticoagulation and Duration of Intravenous Antibiotic Therapy

Poster Abstract Sessions (continued)

- 2100** Nitroglycerin-Citrate-Ethanol Catheter Lock Solution is Highly Effective in Eradicating *Candida auris* Biofilms
- 2101** Catheter-Related Infections Complicating Central Venous Catheter Access Device Insertion; A Retrospective Audit and Comparison of Two Cohorts
- 2102** Peripherally Inserted Central Catheter (PICC) placement: Indications and Financial Impact
- 2103** Clinical Profile of Patients with *Burkholderia cepacia* complex Bacteremia and Contaminated Ultrasound Gel as Possible Source of Infection
- 2104** Impact of a Supervision and Education Directed Bundle in Ventilator Associated Pneumonia (VAP) on a Pediatric Critical Care Unit of a Teaching Hospital
- 2105** Electronic Records of Daily Subglottic Suctioning Predict Infectious and Non-Infectious Adverse Ventilator-Associated Events During Critical Care
- 2106** What Metrics Should We Use to Evaluate CAUTI Performance for Inpatient Rehabilitation Units? An Evaluation of a Large, National Healthcare System
- 2107** Decision Trees vs. Neural Networks for Supervised Machine Learning-Based Prediction of Healthcare-Associated Urinary Tract Infections
- 2108** Perfluorocarbon Omniphobic Treatment Prevents Bacterial Colonization of Urinary Catheter in A Rat Model
- 2109** Reducing Catheter Associated Urinary Infections (CAUTI) in the Intensive Care Unit (ICU): Changing the Culture of Culturing
- 2110** Taurolidine-Citrate Lock Solution for the Prevention of Central-Line Associated Bloodstream Infection (CLABSI) in Pediatric Hematology-Oncology and Gastrointestinal Failure Patients with High Baseline CLABSI Rates
- 2111** Changing the Culture: A Quasi-Experimental Study Assessing the Burden of Urine Cultures and the Impact of Stewardship of Testing in an Urban Community Hospital
- 2112** Assessing the Accuracy of Catheter-Associated Urinary Tract Infections (CAUTI) Identification Using Urinalysis Results
- 2113** Process Change Implementation to Decrease Catheter-Associated Urinary Tract Infections
- 2114** How to Predict Multidrug-Resistance in Community-acquired Urinary Tract Infection? Performance of an Easy and Simple New Scoring Model
- 2115** A Successful Bundled Approach to Decrease Catheter-Associated Urinary Tract Infections in a Community Hospital
- 2116** Impact of an Evidence-Based Intervention on Urinary Catheter Utilization in Switzerland
- 2117** Catheter-Related Bacteremia in Hemodialysis Patients on Antibiotic Lock Therapy: Are Antibiotic Locks Ineffective?
- 2118** Healthcare-Associated Infection in Intensive Care Patients Infected and Non-Infected by Human Immunodeficiency Virus
- 2119** Reducing Catheter-Associated Urinary Tract Infections using an Evidence-Based Urine Culture Algorithm at an Academic Medical Center
- 2120** The Culture of Culturing Catheterized Patients: A Multi-Hospital Survey of Nurses and Physicians
- 2121** Shifting Surgical Site Infection Denominators and Implication on NHSN Reporting
- 2122** Can Chlorhexidine Reduce Bacterial Colonization in Surgical Drains and Surgical Site Infections after Breast Cancer Surgery? A Randomized Controlled Trial
- 2123** High Utilization of Post-Discharge Antibiotics after Mastectomy in a Nationwide Cohort of Commercially Insured Women
- 2124** A Bundled Intervention was Associated with Decreased Risk of Complex *Staphylococcus aureus* Surgical Site Infections among Patients Undergoing Clean Operative Procedures
- 2125** Cardiovascular Daytime Varying Effect on Surgical Site Infections and 1-year Mortality in Cardiac Surgery
- 2126** Comparative Effectiveness of Infection Prevention Interventions for Reducing Procedure-Related Cardiac Device Infections: Insights from the VA CART program
- 2127** The Role of Prophylactic Antibiotics for Reducing Infections Following Knee Arthroscopy
- 2128** Predictors of Post-Discharge Prophylactic Antibiotics Following Spinal Fusion
- 2129** Utilization of Post-Discharge Antibiotics in Spinal Fusion in a Nationwide Cohort of Commercially Insured Individuals
- 2130** Impact of Sarcopenic Obesity on Surgical Site Infection after Gastric Cancer Surgery: a Retrospective Study of 1038 Patients
- 2131** A Pre-operative Nursing Implemented Methicillin Resistant *Staphylococcus aureus* Decolonization Protocol to Decrease Surgical Site Infections
- 2132** Infections after Pediatric Ambulatory Surgery: Incidence and Risk Factors
- 2133** *Cutibacterium acne* Surgical Site Infections – Case Series from a University-Affiliated Hospital Network
- 2134** Risk of Surgical Site Infection Following Carpal Tunnel Release in the Operating Room Versus Clinic-based Procedure Room within a Veterans Affairs Medical Center
- 2135** Costs versus Earnings in Colon Surgery and Coronary Artery Bypass Grafting Under a Prospective Payment System: Sufficient Financial Incentives to Reduce Surgical Site Infections?
- 2136** Systematic Review of Surgical Wound Class Reveals Marked Service-Related Discrepancies and Can Improve Appropriateness of Classification Impacting the Expected Number of Infections and the Standardized Infection Ratio (SIR)
- 2137** Risk Factors for Surgical Site Infection After Joint Replacement Surgery: Data from the Swiss National Surveillance System
- 2138** Impact of De-Escalation of Antibiotic Surgical Prophylaxis in Lung Transplant Recipients
- 2139** Improving Peri-Operative Skin Prep Technique at a Large Tertiary Medical Center—a Quality Improvement and Educational Initiative

Poster Abstract Sessions (continued)

- 2140** Healthcare Associated Infection Outbreak Investigation of an Elevation of Surgical Site Infections at a Critical Access Hospital
- 2141** Characteristics and Prognosis of Patients With a Prosthetic Vascular Graft Infection (PVGI): A Prospective Cohort of 200 Patients
- 2142** Understanding Errors in Sterile Processing of Surgical Instruments that Lead to Need for Immediate Use Sterilization in the Operating Room
- 2143** Incidence of Infection in Patients Receiving Short versus Long Duration of Antimicrobial Prophylaxis in Neurosurgery
- 2144** Vital Signs are Vital in Identifying High-Risk Postoperative Patients
- 2145** Etiology, Incidence, and Risk Factors for Meningitis after Craniotomy
- 2146** Efficacy and Patterns of Antimicrobial Prophylaxis for Gunshot Wound Infection in a South African Hospital Setting: A Prospective Study Using Propensity Score-Based Analyses

236. Poster Abstract Session

Healthcare Epidemiology: Epidemiologic Methods

Saturday, 12:30 - 1:45 p.m.

- 2147** Sample Size Estimates for Cluster Randomized Trials in Infection Control and Antimicrobial Stewardship
- 2148** 100 Years of Sepsis: Using Topic Modeling to Understand Historical Themes Surrounding Sepsis
- 2149** Real-Time Nationwide Surveillance for Antimicrobial Resistance of Major Pathogens using Automated Data Collection System in Korea: A KARS-Net Study
- 2150** Discontinuation of *Vancomycin-resistant Enterococci* (VRE) Surveillance and Contact Isolation in ICU and Transplant Units
- 2151** Accuracy of Physician Adjudication of Infection in Patients with Systemic Inflammatory Response Syndrome (SIRS)
- 2152** Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
- 2153** Impact of Norovirus Testing Changes on Hospital-Acquired Norovirus Infections
- 2154** How Well are We Estimating the True Burden of Acute Gastroenteritis? Validation of Acute Gastroenteritis-Related ICD Codes in Pediatric and Adult U.S. Populations
- 2155** Elevated Temperature Results in Earlier Diagnosis of Infectious and Inflammatory Postoperative Complications
- 2156** Cyclical Continuum Modeling: A Process-Based Approach to Identifying and Quantifying Health Disparities in Patients with Serious Musculoskeletal Infections
- 2157** Design, Implementation, and Analysis Considerations for Cluster Randomized Trials in Infection Control and Hospital Epidemiology: A Systematic Review

237. Poster Abstract Session

Healthcare Epidemiology: HAI Surveillance

Saturday, 12:30 - 1:45 p.m.

- 2158** Introducing the Population Standardized Infection Ratio (SIR): A Metric that Marries the Device SIR to the Standardized Utilization Ratio (SUR)
- 2159** Methodological Threats to the Standardized Infection and Standardized Antimicrobial Administration Ratios
- 2160** Benchmarking Healthcare-Associated Infections for Prevention in Developing Countries
- 2161** Pilot Implementation of a Nationwide Automated Multidrug-Resistant Organism Tracking and Alert System in Veterans Affairs
- 2162** Factors Affecting the Geographic Variability of Antibiotic-Resistant Healthcare-Associated Infections in the United States using the CDC's Antibiotic Resistance Patient Safety Atlas
- 2163** Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010-2015)
- 2164** A Feasibility Study to Investigate the Spread of Antimicrobial Resistance in the Community Suggests Ongoing Dissemination within Households
- 2165** Risk Factors for CPE Colonization in Household Contacts of CPE Colonized/Infected Patients
- 2166** Preparedness for *Candida auris* in Canadian Nosocomial Infection Surveillance Program (CNISP) Hospitals, 2018.
- 2167** Predicting Carbapenem-Resistant *Enterobacteriaceae* (CRE) Carriage on Admission using Updated Statewide Hospital Discharge Data
- 2168** Regional Variation in Community-Onset and Hospital-Identified *Clostridium difficile* Infection, 2017
- 2169** Map the Gap: A Novel Approach Using Big Data to Determine the State of the Infectious Diseases Workforce and Fecal Transplant Centers with Regards to *Clostridium Difficile* Infection
- 2170** The National Burden of Pneumonia and Influenza in U.S. Nursing Homes, 2013-2015
- 2171** Comparing Surveillance Definitions for Non-Catheter Associated Urinary Tract Infections
- 2172** Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
- 2173** Surgical Site Infection Determination in Epic® ICON: A Utilization Model
- 2174** A 10-Year Review of Infection Burden In Hospitalized Burn Patients in the United States
- 2175** *In vitro* Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β -lactams Against *P. aeruginosa*
- 2176** Single β -lactams v. Combination Regimens: Assessing the Probability that an Active Agent Would be Selected When Considering Empiric Therapy for *P. aeruginosa*
- 2177** Use of an Analytic Application for Management of Infection Prevention Data
- 2178** Detection of Key Potential Healthcare Pathogens Using Periodic Point Prevalence Surveillance

Poster Abstract Sessions (continued)

- 2179** Variability in the Application of Surveillance Definitions for Central Line-Associated Bloodstream Infection Across U.S. Hospitals
- 2180** Incidence and Outcomes of Ventilator Associated Events, Utilising Centre for Disease Control Criteria in a Tertiary Intensive Care Unit, Victoria, Australia
- 2181** Efficacy of UV-C Disinfection with or without Sodium Hypochlorite Compared to Usual Disinfection of Hospital Environmental Surfaces: Pilot study
- 2182** Perceived Impact of Mandatory Reporting of Healthcare-Associated Infections on Infection Prevention and Control Departments in Acute Care Hospitals
- 2183** Financial Cost, Length of Stay, and Patient Experience Associated with Healthcare-Associated Infections Across a 43-Hospital Network
- 2184** Surveillance System of Healthcare-Associated Infection in High and Upper-Middle Income Countries: A Scoping Review
- 2185** Trend of Multidrug-Resistant Pathogens in a Burn Center during a 6-year Period: A Single Burn Center Study in South Korea
- 2186** High Adherence to Contact Precautions of Patients with Multidrug-Resistant Organisms (MDRO) and Low In-Hospital Transmission of MDROs
- 2187** Epidemiology and Risk Factors for Vascular Access-Associated Infections in Patients on Hemodialysis
- 2188** Effectiveness of a Risk-Stratified Measles Post-Exposure Prophylaxis Strategy to Prevent Nosocomial Transmission

238. Poster Abstract Session

Hepatitis A, B, and C

Saturday, 12:30 - 1:45 p.m.

- 2189** Hepatitis A Outbreak in San Diego County, 2016-2017: A Morphologic and Epidemiologic Review
- 2190** Assessing Case Definition During a Hepatitis A Outbreak, San Diego County, 2017-2018
- 2191** Hepatitis A Outbreak in Southeast Michigan: No Longer a Third-World Disease
- 2192** Hepatitis A in Greece 2009-2017: Time for Setting New Priorities
- 2193** Disparities in Hepatitis A Virus (HAV) Vaccination Coverage Among Adult Travelers to High-Risk Countries: The Role of Nativity and Race
- 2194** Hepatitis B Care Cascade within the VA Maryland Healthcare System
- 2195** Effectiveness of a Dual-Test Strategy and Software Modifications for Mitigating & Preventing Hepatitis B Virus (HBV) Exposures in a Dialysis Unit
- 2196** Effect of Depression, Anxiety, Stigma, and Disclosure on Quality of Life among People Living with Hepatitis B Infection in Dalian, China
- 2197** Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals
- 2198** Increased Global Incidence and Altered Demographic Profile of Hepatitis Delta Virus (HDV)
- 2199** Antiviral Therapy Use in Hepatitis B-Infected Pregnant Women
- 2201** Prevalence of Hepatitis C in Adults Presenting to Emergency Departments in a Large Hospital System in Texas
- 2202** The Hepatitis C Virus Cascade of Care at Stony Brook University Hospital: Risk Factors for Linkage to Care
- 2203** Risk Factors for Hepatitis C in Western Africa: An Observational Study in a STI Clinic
- 2204** In HCV-Infected Patients, Internalized Stigma, but not Experienced Stigma, is Correlated with Psychological State and Health-Related Quality of Life: Baseline Data from the PROP UP Study
- 2205** Mandatory Infectious Diseases or Hepatology Consult to Improve HCV Linkage to Care in the Inpatient Setting
- 2206** In a Non-Urban Hepatitis C Cohort, Linkage to an Infectious Diseases Clinic with Embedded Services is Associated with Better Outcomes than Linkage to a Gastroenterology HCV Clinic Without These Services for Those with Substance Abuse
- 2207** Barriers to HCV Treatment in a Safety-Net Hospital System
- 2208** Fibrosis Surveillance by Transient Elastography in Patients with Untreated Hepatitis C Infection
- 2209** Discordance Between FibroSure and FibroScan Results in Hepatitis C and Human Immunodeficiency Virus Co-Infected Patients Prior to Treatment for Hepatitis C Virus Infection
- 2210** An Online Survey of Hepatitis C Testing Attitudes and Practice Habits Among Residents at an Urban Medical Center
- 2211** Hepatitis C Testing and Linkage to Care in a Public Health Setting in North Carolina: Addressing Gaps along the Care Continuum
- 2212** Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for HCV?
- 2213** Hepatitis C Virus (HCV) Care Continuum Post-Implementation of Electronic Clinical Decision Support (eCDS) Tool to Increase HCV Screening among Baby Boomers in Large Urban Health System
- 2214** Chronic Hepatitis C: Closing the Gap Towards Eradication: Screening Young Adults vs. Baby Boomers
- 2215** Polymerase Chain Reaction (PCR) for Detection of Vertically-Acquired Hepatitis C Virus (HCV) Infection in Early Infancy
- 2216** Hepatitis C Treatment Wanted Yet Not Received: Barriers to Receiving HCV Treatment among People Who Inject Drugs
- 2217** Demographic Trends and Healthcare Utilization Among Children with Hepatitis C Virus Infection
- 2218** Low Hepatitis C Treatment Rates among Patients Screened as Inpatients at a Rural Academic Medical Center
- 2219** Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study

Poster Abstract Sessions (continued)

- 2220** Wirelessly Observed Therapy with a Digital Medicines Program to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment
- 2221** Active Substance Use Should Not Be a Contraindication for Hepatitis C Treatment in Hepatitis C and Human Immunodeficiency Virus Co-Infected Patients
- 2222** Impact of Sustained Virologic Response Achieved Through Newer Direct Acting Antivirals in Hepatitis C Infection on Diabetes Mellitus
- 2223** Effect of Direct-Acting Antivirals in Hemodialysis Patients with HCV: Real-Life Data
- 2224** Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status
- 2225** Acute Hepatitis C Virus Infections in HIV-Infected Persons in the Era of Direct-Acting Antiviral Therapy
- 2226** Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series
- 2227** Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
- 2228** Late Viral Relapse after Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
- 2229** Low Hepatitis C Virus Reinfection Rates after Sustained Viral Response in HIV Co-Infected Patients in Houston, TX
- 2230** Treatment Outcomes for Hepatitis C Patients from Two Federally Qualified Community Health Centers in SC

239. Poster Abstract Session

HIV and Viral Hepatitis Co-Infection

Saturday, 12:30 - 1:45 p.m.

- 2231** Long-Term Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: An Extension of a Randomized Controlled Trial
- 2232** Zinc Deficiency and Advanced Liver Fibrosis among HIV/HCV Co-Infected Persons in Russia
- 2233** Hepatitis C Eradication: Who is Being Left Behind in the HIV Population?
- 2234** Implementing a Co-Located HCV Clinic within an HIV Clinic: Four-Year Experience
- 2235** A Collaborative Drug Therapy Management Model for the Treatment of Hepatitis C Virus (HCV) in an Urban Clinic
- 2236** Direct-Acting Antivirals: Efficacy in a Real-World, Urban, Underserved, HIV-HCV Co-Infected Population
- 2237** Validity of Self-Reported HCV Status among Justice-Involved Persons Living with HIV
- 2238** Immunogenicity and Safety of 4- vs. 3-Standard Doses HBV Vaccination in HIV-Infected Adults with Isolated Anti-HBc Antibody

240. Poster Abstract Session

HIV: Malignancy

Saturday, 12:30 - 1:45 p.m.

- 2239** Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
- 2240** Characteristics of Lung Cancer Treatment in Recent ART-era HIV+ Patients
- 2241** Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
- 2242** Clinical Characteristics and Treatment Patterns of Prostate Cancer in HIV-Infected Veterans: A 10-Year Experience
- 2243** Improving HIV Outcomes among HIV-infected Patients Diagnosed with Cancer and Followed in an Integrated, Multidisciplinary, Infectious Disease / Cancer Clinic
- 2244** Non-AIDS Cancers Contribute to an Increasing Proportion of Deaths in Persons Living with HIV at a Single University-Based Clinic
- 2245** Primary Central Nervous System Lymphoma in Patients with HIV and Non-HIV: Should We Treat Them Differently?
- 2246** Assessment of Factors Impacting Cervical Cancer Screening Rates among Urban Women Living with HIV/AIDS

241. Poster Abstract Session

HIV: Metabolic, Cardiovascular, and Renal Complications

Saturday, 12:30 - 1:45 p.m.

- 2247** Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals
- 2248** Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort
- 2249** Insulin Resistance is Associated with Higher Viral Loads among HIV-1-Infected Patients Initiated on 12 Months of First-Line Antiretroviral Therapy
- 2250** Metformin for Preventing Diabetes Mellitus in HIV-infected Patients with Prediabetes: A Randomized Controlled Trial
- 2251** Comparing Statin Prescribing Rates in Eligible HIV vs. Non-HIV Infected Patients
- 2252** Predictors of Cardiovascular Outcomes in Older HIV-Infected Patients: CORE50 Cohort 10 Year Follow Up
- 2253** Comparison of Cardiovascular Risk in Patients Infected with HIV and Hepatitis C
- 2254** Adherence to Cardiovascular Disease Risk Management Guidelines Among HIV Providers at an Academic HIV Clinic
- 2255** Fibroblast Growth Factor 23, a Potential Risk Factor for Cardiovascular Diseases is Associated with Abacavir/Lamivudine Use in HIV Patients
- 2256** Racial Differences in Dyslipidemia Clinical Characteristics and Treatment Among Urban HIV Patients
- 2257** Non-Infectious Comorbidities Associated with High RDW in HIV-Infected Patients: A Cross-Sectional Study in Miami, FL

Poster Abstract Sessions (continued)

- 2258** Clinical Predictors of Acute Kidney Injury in HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate (TDF)
- 2259** Effect of Discontinuation of Tenofovir Disoproxil Fumarate (TDF) on Renal Function in Elderly Veterans
- 2260** HIV Transplantation Awareness and Attitudes Following Implementation of the HOPE Act
- 2261** Phosphaturia in HIV-exposed Uninfected Neonates Associated with Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy

242. Poster Abstract Session

HIV: Opportunistic Infections and other Infectious Complications

Saturday, 12:30 - 1:45 p.m.

- 2262** Not a Disease of the Past: A Case Series of Progressive Multifocal Leukoencephalopathy in the Established Antiretroviral Era
- 2263** HIV-TB Co-infection in Arizona from 1993 - 2016
- 2264** The Burden of Respiratory Viral Illness in HIV-Infected Patients
- 2265** The Changing Landscape of AIDS Defining CNS Infections in S. Alberta, Canada, Over 30 Years
- 2266** Persistent Inflammation in HIV patients with Community-Acquired Pneumonia and its Correlation with Lung Injury
- 2267** The Effect of Opportunistic Infection (OI) Prophylaxis on the Gastrointestinal Microbiome (GIM) and Immune Reconstitution (IR) in Veterans with HIV and AIDS
- 2268** Clinical Difference of *Mycobacterium haemophilum* Infections between HIV and Non-HIV Infected Patients

243. Poster Abstract Session

HIV: Sexually Transmitted Infections

Saturday, 12:30 - 1:45 p.m.

- 2269** HIV-Positive Individuals Who Report Being In Care Are Less Likely to be Co-Infected with an STI; An Analysis of "Network Testing", A Service Program Offering HIV and STI Testing Services to Individuals at Risk for HIV
- 2270** Frequency of Syphilis Annual Screening Testing, Prevalence of Infection and Re-infection, and Associated Characteristics among People Receiving Care for HIV in an HIV/AIDS Care Clinic in Mexico City (2001-2017)
- 2271** Adherence to Pre-Exposure Prophylaxis Is Associated with Sexually Transmitted Infections among Men Who Have Sex with Men in the Deep South
- 2272** High Interest in Doxycycline for Sexually Transmitted Infection Post-Exposure Prophylaxis (doxy-PEP) in a Multi-City Survey of Men Having Sex with Men (MSM) Using a Social-Networking App
- 2273** Neurosyphilis in Patients with HIV Infection: Clinical Presentation of 94 Cases
- 2274** Assessment of Anal Papanicolaou Smear Screening and Follow-up Rates in Eastern North Carolina for HIV-Positive Patients who are Men who have Sex with Men

244. Poster Abstract Session

Miscellaneous Vaccines

Saturday, 12:30 - 1:45 p.m.

- 2275** Parental Risk Factors for Fever in their Children 7–10 Days after the First Dose of Measles-containing Vaccines
- 2276** Immunogenicity of Takeda's Bivalent Virus-like particle (VLP) Norovirus Vaccine (NoV) candidate in Children from 6 months up to 4 years of Age
- 2277** Whooping Cough: Epidemiological Changes after Tdap Maternal Immunization Strategy in a Pediatric Hospital
- 2278** Maternal Immunization Rates with Tetanus-Diphtheria-Acellular Pertussis and Influenza Vaccines in the United States: A Retrospective Claims Database Analysis
- 2279** A Randomized Open-Label Trial of 2-Dose or 3-Dose Primary Rabies Immunization among Thai Children
- 2280** Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
- 2281** Impact of the Introduction of the *Haemophilus influenzae* Type B Conjugate Vaccine in Southern India
- 2282** Age-Stratified Analysis of Serotype-Specific Immunity Against Group B Streptococcus
- 2283** The Impact of a Booster Dose at the Age of 18 on Immunization Against Hepatitis B Four Years Later
- 2284** Ten-Year Effectiveness of Live Virus Herpes Zoster Vaccine
- 2285** Burden of Invasive and Non-invasive Group B Streptococcal Infections in Hospitalized Adults, Louisville, Kentucky: A Large Population-based Study
- 2286** Revisiting Immune Interference: Evaluation of Immune Response to Yellow Fever Vaccine at Various Time Points Following Live-Attenuated Influenza Vaccination
- 2287** Recently Approved HEPLISAV-B(R) [Hepatitis B Vaccine (Recombinant), Adjuvanted] Shows a Higher Proportion of Subjects Achieving Seroprotection with a More Consistent Immune Response Compared with Engerix-B(R) [Hepatitis B Vaccine (Recombinant)] in Three Comparative Trials
- 2288** Adherence to Hepatitis B Screening and Treatment Guidelines in Oncology Patients Starting Anti-CD20 Therapy

245. Poster Abstract Session

Molecular & Sequence Based Diagnostics

Saturday, 12:30 - 1:45 p.m.

- 2289** Accuracy of a Rapid Multiplex PCR Plus a Chromogenic Phenotypic Test Algorithm for the Detection of ESBL and Carbapenemase-Producing Gram-Negatives Directly from Blood Cultures
- 2290** Identification of Pathogens in Synovial Fluid Samples with an Automated Multiplexed Molecular Detection System
- 2291** A Real-Time Sequencing Approach for Simultaneous Metagenomic and Transcriptomic-Based Diagnosis of Infectious Diseases
- 2292** Comparison of Molecular Assays for the Diagnosis of Pertussis

Poster Abstract Sessions (continued)

- 2293** Evaluation of Three Rapid Molecular Assays for the Detection of Group A *Streptococcus*
- 2294** Evaluation of the Karius Plasma Next Generation Sequencing Cell-free Pathogen DNA Test to Determine the Etiology of Infection and Impact on Anti-Microbial Management in Patients with Severe Neutropenia and Fever
- 2295** *Streptococcus pneumoniae* Related Hemolytic Uremic Syndrome (pHUS) and the Identification of Matched Cross Country Serotypes by Plasma Next Generation Sequencing (NGS)
- 2296** Development of a Sequencing Based Assay for Detection of CMV Antiviral Resistance Mutations to Letemovir in UL56
- 2297** The Diagnostic Yield of 16/18S rRNA PCR of Sterile Site Samples in Pediatric Patients
- 2298** Identifying and Addressing Implementation Barriers to Whole Genome Sequencing (WGS) in State Public Health Laboratories
- 2299** Oral Microbiome of High Risk Children: A Cohort Study
- 2300** Molecular Epidemiology of Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) Causing Central-Line Associated Bloodstream Infections (CLABSI) In 3 ICU Units in Egypt
- 2301** *Streptococcus pneumoniae* Serotyping: Assessing the Performance of a PCR- and Sequencing-Based Testing Algorithm

246. Poster Abstract Session

Pediatric Healthcare Associated Infections

Saturday, 12:30 - 1:45 p.m.

- 2302** Bloodstream Infections due to Carbapenem Resistant Gram-Negative Bacteria in Pediatric Intensive Care Unit (PICU): Risk Factors and Outcomes
- 2303** Differential Effects on MRSA and MSSA Epidemiology in a Neonatal Intensive Care Unit (NICU) during a Year-Long Surveillance and Decolonization Effort
- 2304** Decreased Incidence of Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections after Implementation of Routine Surveillance and Decolonization in a Level IV Neonatal Intensive Care Unit (NICU)
- 2305** *Staphylococcus aureus* Screening and Decolonization for Pediatric Patients Undergoing Cardiovascular Surgery at Texas Children's Hospital (TCH): A Trainee Quality Improvement Initiative
- 2306** Molecular Epidemiology of and Risk Factors for *Staphylococcus aureus* (SA) colonization in a Chinese Neonatal Intensive Care Unit (NICU)
- 2307** Use of Whole Genome Sequencing to Determine Adhesin and Biofilm-associated Gene Profiles among Pediatric *Staphylococcus aureus* Device Related Infection Isolates Compared to Skin and Soft Tissue Infection Isolates
- 2308** The Prevalence of Antiseptic Tolerance Genes Among Gram-Positive Bloodstream Pathogens in Children
- 2309** Promoting Healthcare Worker (HCW) Use of Personal Protective Equipment in Pediatric Ambulatory Settings

- 2310** Reasons Pediatric Providers Obtain Endotracheal Aspirate Cultures and How Results Inform Patient management

247. Poster Abstract Session

Pediatric Bacterial Infections

Saturday, 12:30 - 1:45 p.m.

- 2311** Atypical Cat Scratch Disease Presentations
- 2312** *Bordetella holmesii* Bacteremia in Pediatric Patients: A Single-Center Experience
- 2313** Risk of Relapsed or Persistent Infection Caused by Enterobacter Species in Children
- 2314** Invasive *Haemophilus influenzae* Infections in Children: A Ten-Year Study
- 2315** *Neisseria meningitidis* Oro-Pharyngeal Carriage, Serogroups and Clonal Complex in Children and Adolescents In Argentina
- 2316** The Frequency of Multifocal Disease and Pyogenic Hip Arthritis in Neonates with Osteomyelitis
- 2317** Multicenter Retrospective Cohort Study of Pediatric Osteomyelitis
- 2318** Comparison of Musculoskeletal Infections Due to Non-Typhoidal Salmonella Species and *Staphylococcus aureus* in Immunocompetent Children
- 2319** Molecular Epidemiology of *Staphylococcus aureus* Isolated from Korean Children
- 2320** Decolonization of the Oropharynx, an Important and Neglected Reservoir of *Staphylococcus aureus* Colonization
- 2321** Epidemiology of *Staphylococcus aureus* Infections in Patients Admitted to Freestanding Pediatric Hospitals, 2009-2016
- 2322** Reduced Vancomycin Susceptibility among Pediatric *Staphylococcus aureus* Bloodstream Infections
- 2323** Unexpected Pediatric Presentation Patterns of Toxic Shock Syndrome
- 2324** Long-Term Health Outcomes of Children Evaluated for Unexplained Fevers in a Pediatric Infectious Diseases Clinic
- 2325** Bloodstream Infections in Hospitalized Children in the United States: Incidence, Pathogens, and Regional Differences
- 2326** Necessity of Anaerobic Blood Cultures for Identification of Pediatric Bloodstream Infections
- 2327** Microbiology and Prognostic Significance of Bloodstream Infections in Necrotizing Enterocolitis
- 2328** Community Onset Invasive Bacterial Infections in Infants Under Three Months-10 Years of Experience in Auckland, New Zealand
- 2329** Preliminary Safety and Effectiveness of Whole Body MRI in Pediatric Patients with Persistent Bacteremia or Febrile Illness
- 2330** Comparison of Clinical Symptoms in Children Who Present with Sore Throat who are Later Determined to be Carriers versus Acutely Infected
- 2331** Household Pets and Recovery of *Moraxella catarrhalis* and Other Respiratory Pathogens from Children with Asthma

Poster Abstract Sessions (continued)

- 2332** Higher Pediatric Vancomycin Dosing Trends Toward Improved Therapeutic Troughs
- 2333** Practice of Endotracheal Tube Suction Catheter Flushes with Polymyxin in Extremely Low Birthweight Neonates
- 2334** Risk Factors of Multidrug-Resistant Gram-Negative Bacterial Bloodstream Infections in Children's Hospitals in Japan
- 2335** *Acinetobacter baumannii* Infection: Clinical Profile, Drug Resistance, and Presence of Virulence Factor *AdeRS*: Experience from a Pediatric Tertiary Care Centre in North India
- 2336** Resistance Mechanisms and Factors Associated with CTX-M-9 Group Extended-Spectrum Beta-Lactamase (ESBL)-Producing *Enterobacteriaceae* Infections in Children
- 2337** Clinical Characteristics of Children Infected with Macrolide-Resistant *Mycoplasma Pneumoniae* In Central Ohio: Preliminary Data
- 2338** Change in Genetic Structure of *Streptococcus pneumoniae* Isolates from Invasive Diseases after National Immunization Program of Extended-Valency Pneumococcal Conjugate Vaccines in Korea
- 2339** Perianal Infections in Children with Acute Myeloid Leukemia: A Report from the Canadian Infection in Acute Myeloid Leukemia Research Group
- 2340** Pneumococcal Colonization in Pediatric Patients Undergoing Bone Marrow Transplantation
- 2351** Epidemiology and Clinical Characteristics of Parainfluenza Virus Type 4 in Korean Children, 2015-2017
- 2352** Increased on Childhood Recurrent Wheezing and Asthma after Respiratory Syncytial Viral (RSV) Infection in Full-Term Infants
- 2353** Respiratory Syncytial Virus (RSV) in Preterm Infants: Epidemiology, Clinical Pattern, and Risk Factors in a Pediatric Hospital in Argentina
- 2354** Performance of Novel Clinical Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis
- 2355** Clinically versus Serologically Identified Varicella: A Hidden Infection Burden. Lessons of 10-Year Follow-Up in Varicella Endemic Countries
- 2356** Neurological Disorders and Radiological Findings. How Are They Related in Congenital Zika Syndrome?
- 2357** Radiological Findings in Microcephaly Cases During 2015-2016 Zika Outbreak: A Descriptive Study
- 2358** Acute Flaccid Myelitis Among Hospitalized Children in Texas, 2016
- 2359** Validation of a Novel Scoring Criteria for Assessing the Severity of Viral Respiratory Infections in Children

248. Poster Abstract Session

Pediatric Viral Infections

Saturday, 12:30 - 1:45 p.m.

- 2341** Trends in Adenovirus Infections in Singapore Children and Outcomes of Cidofovir Treatment in the Severely Ill
- 2342** Treatment Implications of Herpes Simplex Virus Central Nervous System Infection in Canadian Infants <90 days Old: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study
- 2343** A Multicenter Study on Clinical Outcome of Symptomatic Neonatal Herpes Simplex Virus Infection in Korea
- 2344** FDA analysis of CD4⁺ Cell Count Declines Observed in HIV-Infected Children Treated with Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide
- 2345** Knowledge, Practices, and Attitudes of Youth Providers about STI, HIV Testing, and PrEP
- 2346** Severe Head and Neck Infections Following Influenza Virus Infection in Children
- 2347** Antiviral Use is Associated with a Decrease in Rate of Influenza-Related Complications and Resource Utilization
- 2348** Influenza Complications Among Pediatric Inpatients in Singapore, A Tropical Country
- 2349** Long-Term Neurological Outcome and Neutralizing Antibody Titers against Parachovirus-A3 (PeV-A3) in Children Who Developed PeV-A3-Related Diseases in Neonatal and Infantile Periods
- 2350** Parainfluenza Virus Infection Factors: 18 Years' Active Surveillance in a Pediatric Hospital
- 249. Poster Abstract Session**
- Skin and Skin Structure Infection**
- Saturday, 12:30 - 1:45 p.m.
- 2360** Clinical Outcomes of Clindamycin Use in Skin and Soft Tissue Infections (SSTIs) in Pediatrics
- 2361** Factors Associated with Sepsis Development in Cellulitis. A Prospective Analysis of 606 Episodes in Adult Patients
- 2362** Emergency Department Resource Utilization after Implementation of a Dalbavancin Pathway for Skin and Soft Tissue Infections
- 2363** Identification of Risk Factors to Predict *Pseudomonas aeruginosa* and Methicillin Resistant *Staphylococcus aureus* in Patients with Infected Chronic Foot Ulcers
- 2364** Evaluation of Renal Function Changes in Patients with Prolonged Telavancin Therapy (>21 days): Results from the Telavancin Observational Use Registry (TOUR™)
- 2365** Post-Operative Vertebral Osteomyelitis—a Disease with Distinct Clinical and Microbiological Characteristics
- 2366** Treatment Characteristics and Predictors of Mortality in Patients with Infected Chronic Pressure Ulcers in Detroit
- 2367** Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
- 2368** Cellulitis in Adult Patients: A Large, Multicenter, Observational, Prospective Study of 606 Episodes and Analysis of the Factors Related to the Response to Treatment
- 2369** Clinical Experience with Telavancin for Treatment of Patients with Monomicrobial *S. aureus* Infections (Vancomycin MIC ≥ 1 $\mu\text{g/mL}$) from TOUR™
- 2370** Dalbavancin Use in Emergency Department and Observation Unit to Prevent Inpatient Admission for Acute Bacterial Skin and Skin Structure Infection (ABSSI)
- 2371** Monomicrobial Gram-Negative Necrotizing Fasciitis: An Uncommon But Fatal Syndrome

Poster Abstract Sessions (continued)

- 2372** Multidisciplinary Care Teams to Reduce Major Amputations for Patients with Diabetic Foot Ulcers: A Systematic Review
- 2373** Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
- 2374** Genomic Characteristics of Recurrent *Staphylococcus aureus* Skin and Soft Tissue Infection among U.S. Army Trainees
- 2375** Skin and Soft Tissue Infections in Patients with Obesity or Heart Failure
- 2376** *In Vitro* Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections in Latin America: AWARE Surveillance Program 2017
- 2377** Outcomes in Patients with History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) with Delafloxacin (DLX) vs Vancomycin/Aztreonam (VAN/AZ)
- 2378** Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with Delafloxacin (DLX) IV/Oral Therapy

250. Poster Abstract Session

Treatment of AMR Infections

Saturday, 12:30 - 1:45 p.m.

- 2379** Multicenter Evaluation of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
- 2380** Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers (POICs)
- 2381** Ceftolozane/tazobactam in the Treatment of Experimental *Pseudomonas aeruginosa* Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Resistance
- 2382** Ceftolozane/tazobactam for the Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Infections in Immunocompromised Patients: A Multi-Center Study
- 2383** *In Vitro* Activity of Ceftolozane-Tazobactam in Comparison with Ceftazidime-Avibactam Versus Antimicrobial Non-Susceptible *Pseudomonas aeruginosa* Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007-2017
- 2384** Multidrug-Resistant Gram-Negative Infections Treated with Ceftolozane-Tazobactam: Impact of Delayed Initiation
- 2385** Ceftazidime-Avibactam in Combination with Fosfomycin: A Novel Therapeutic Strategy against Multidrug-Resistant *Pseudomonas aeruginosa*
- 2386** Efficacy of Lefamulin (LEF) Versus (vs) Moxifloxacin (MOX) Against Common Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Results from the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
- 2387** Selecting *Clostridium difficile* Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
- 2388** Efficacy of Humanized Cefiderocol Exposures over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
- 2389** Effect of Rezafungin on QT Interval in Healthy Subjects
- 2390** Avibactam Sensitizes NDM *Klebsiella pneumoniae* to Innate Immune Killing by Human Cathelicidin LL-37, Serum, Neutrophils, and Platelets
- 2391** Liposomal Vancomycin and Cefazolin Combinations for *S. aureus* Biofilms
- 2392** Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade
- 2393** Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis
- 2394** Different *Clostridioides difficile* Ribotypes among Patients with Colonization, Initial Clinical Disease, and Recurrent Clinical Disease
- 2395** Mechanism-Based-Susceptibility Testing (MBST) using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug Resistant *Pseudomonas aeruginosa* (MDR-XDR-*Pa*) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-*Pa*?
- 2396** Fosfomycin Resistance among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
- 2397** Comparing Predictive Performance of INCREMENT Scores on Mortality Among Patients with Carbapenem-Non-Susceptible (CNS) *Klebsiella pneumoniae* (*Kp*) and *Enterobacter cloacae* Complex (*Ecc*) Bloodstream Infections (BSI) in the Veterans Health Administration (VHA)
- 2398** Utilization Practices of Ceftazidime-Avibactam at Academic Medical Centers in the United States
- 2399** Beta-Lactam Therapy for Potential AmpC-Producing Organisms: A Cohort Study and an Updated Systematic Review and Meta-analysis
- 2400** Activity of a Long-Acting Echinocandin, Rezafungin, Tested against Invasive Fungal Isolates Collected Worldwide
- 2401** Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal Disease (IPD) in Toronto, Canada, 2012-2017
- 2402** Daptomycin Pulmonary Eosinophilia: Review of Cases and New Hyperacute Syndromic Presentation
- 2403** Comparison of Daptomycin Combination Therapy with Ceftaroline or Oxacillin Against Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates Causing Persistent Bacteremia
- 2404** Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
- 2405** *In Vitro* Synergistic Activity of Sitafloxacin in Combination with Colistin Against Clinical Isolates of Multidrug-Resistant *Acinetobacter baumannii* in Thailand
- 2406** "Real World" Treatment of Multidrug-Resistant (MDR) or Extensively-drug Resistant (XDR) *P. aeruginosa* Infections with Ceftolozane/Tazobactam (C/T) versus a Polymyxin or Aminoglycoside (Poly/AG) Based Regimen: A Multicenter Comparative Effectiveness Study

Poster Abstract Sessions (continued)

- 2407** Emerging Piperacillin/Tazobactam Resistance in *Escherichia coli* and *Klebsiella sp.*
- 2408** Delayed Appropriate Antimicrobial Therapy Does Not Affect the Clinical Outcome of Patients with Acute Pyelonephritis by Extended-spectrum β -lactamase-producing *Enterobacteriaceae*
- 2409** Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients treated with Aztreonam and Ceftazidime
- 2410** Clinical Outcomes Associated with Various Treatment Options for Infections Caused by Carbapenem-Resistant *Enterobacteriaceae*
- 2411** Expanded Susceptibility and Resistance Mechanism Testing among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
- 2412** Our Experience with IV Fosfomycin
- 2413** The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug, and Pandrug Resistant *Acinetobacter baumannii*: A Systematic Review of Clinical Evidence
- 2414** Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated with Ceftolozane/Tazobactam Across 253 U.S. Hospitals
- 2415** Comparison of Minocycline MIC's Obtained by Etest to Those Obtained by Broth Microdilution in a Bank of Isolates of *Acinetobacter baumannii* Collected in Southeastern Michigan
- 2416** Risk Factors and Outcomes of Bacteremia Caused by Carbapenem Resistant Enterobacteriaceae Compared to Carbapenem Susceptible Enterobacteriaceae
- 2417** Risk Factors, Response to Empiric Therapy, and Healthcare Utilization among Children with UTI Due to Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae
- 2418** Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-Term Acute Care Hospital
- 2419** Standard vs Alternative Therapy for *Stenotrophomonas maltophilia* Infections: Focus on Trimethoprim-Sulfamethoxazole, Minocycline, and Moxifloxacin Monotherapy
- 2420** A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections
- 2421** Tedizolid is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses
- 2422** Efficacy of Cefoxitin for the Treatment of Urinary Tract Infection (UTI) due to ESBL-Producing *E. coli* and *K. pneumoniae* Isolates
- 2423** Effectiveness and Safety of Ceftolozane/Tazobactam (TOL/TAZ) Use for Carbapenem-Resistant *Pseudomonas* Infections in Children
- 2424** Review of Antimicrobial Susceptibility Profile of Different *Nocardia* Species: A Tertiary Center Experience
- 2425** Clinical and Microbiologic Outcomes Among Patients with Monomicrobial *Stenotrophomonas maltophilia* Infections
- 2426** Ceftaroline-Associated Neutropenia: Retrospective Study and Systematic Review of Incidence, Risk Factors, and Outcomes
- 2427** Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam *In Vitro* Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers (2017)
- 2428** Lower Rates of Antibiotic Treatment of Vancomycin Resistant Compared to Vancomycin Susceptible Enterococcal Bacteriuria
- 2429** The Epidemiology and Outcomes of *Enterobacter cloacae* Bloodstream Infections in Children
- 2430** Impact of USCAST Proposed Breakpoint Changes to Aminoglycosides, Cyclines, and Levofloxacin on Carbapenem-Resistant *Enterobacteriaceae* at a U.S. Tertiary Referral Academic Medical Center
- 2431** Evaluation of Clinical Outcomes in Bacteremia Due to AmpC β -lactamase Producing Organisms Stratified by Treatment
- 2432** Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
- 2433** Evaluation of Meropenem (MEM) in Combination with Colistin (COL) Against Colistin Resistant Extensively Drug Resistant (XRD) Gram-Negative Bacteria
- 2434** Review of Linezolid (LZD) Use and Onset of Toxicity in 4 Belgian Hospital Centers: A Retrospective Study
- 2435** Clinical Outcomes with Ceftolozane-Tazobactam in Patients with Multidrug-Resistant (MDR) *Pseudomonas aeruginosa* Bloodstream Infections: A Multi-Center Study
- 2436** Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections due to *Serratia*, *Citrobacter*, or *Enterobacter*
- 2437** Colistin Usage: Do We Need to Worry About its Toxicity Among Children with Cancer?
- 2438** Ceftolozane/Tazobactam (C/T) against Multidrug-Resistant *Pseudomonas aeruginosa* (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance
- 2439** Outcomes of Minocycline Use on Gram-Negative Infections and Implications of MIC
- 2440** Weight-Adjusted Piperacillin-Tazobactam (PIP/TAZ) Therapy in Obese Patients versus Optimized Doses in Non-obese Patients: A Retrospective Cohort Study
- 2441** Outcomes of Patients with Vancomycin-Resistant *Enterococcus* Bloodstream Infections (BSI) Treated with Daptomycin
- 2442** Outcomes in ESBL Bacteremia Empirically Treated with Piperacillin/Tazobactam or Carbapenems
- 2443** Searching for the Optimal Treatment Regimen for Metallo- β -Lactamase Producing *Enterobacteriaceae*: Aztreonam plus Ceftazidime-Avibactam vs. Aztreonam plus Meropenem-Vaborbactam
- 2444** Incidence of Daptomycin Toxicity Among Patients with Vancomycin-resistant *Enterococcus* Bloodstream Infections
- 2445** Efficacy and Tolerability of Linezolid for Treatment of Infectious Spondylitis
- 2446** Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem Resistant Enterobacteriaceae
- 2447** Ertapenem and Faropenem for the Treatment of Drug-Resistant Tuberculosis

Poster Abstract Sessions (continued)

- 2448** *In vitro* Activity of Ceftazidime-Avibactam against *Enterobacteriaceae* Causing Intra-abdominal, Urinary Tract, and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012-2016
- 2449** Validation of *In vitro* Activity of Aminoglycosides Against Recently Isolated *Helicobacter pylori* for Commercialization of Gentamicin-intercalated Smectite Hybrid as a New Therapeutic Agent
- 2450** Antibiotic Treatment for Carbapenem-Resistant *Enterobacteriaceae* (CRE) and Outcomes in Veterans with Spinal Cord Injury/Disorder (SCI/D)
- 2451** Synergistic Activity of Ceftazidime-Avibactam in Combination with Polymyxin B against Carbapenem-Resistant *Klebsiella pneumoniae*
- 2452** Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections
- 2453** Repeated Exposures to Minocycline/Rifampin and + Chlorhexidine Combination Used to Coat Catheters Fails to Induce Antimicrobial Resistance

251. Poster Abstract Session

Adolescent Vaccines

Saturday, 12:30 - 1:45 p.m.

- 2454** Pertussis Vaccine Effectiveness and Waning Immunity in Alberta, Canada: 2004-2015
- 2455** Is Category B Working? Uptake Patterns of Meningococcal Group B Vaccine among U.S. Adolescents and Young Adults
- 2456** Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4-6 Years after Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy U.S. Adolescents and Adults
- 2457** Multivariate Analyses of Socio-Economic Inequities in Parental Awareness and Utilization of Meningococcal Serogroup B Vaccines
- 2458** Disparities in Healthcare Providers' Interpretation and Implementation of ACIP's Meningococcal Vaccine Recommendations
- 2459** Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the U.S.: How Compliant Are We with the Advisory Committee on Immunization Practices (ACIP) Recommendations?
- 2460** Factors Associated with Uptake of Meningococcus B Vaccination After an ACIP Category B Recommendation
- 2461** Safety of Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid-Conjugate Vaccine in Adolescents
- 2462** Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older
- 2463** Post-Licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014-2017
- 2464** A Significant Portion of College Students are Not Aware of HPV Disease and HPV Vaccine Recommendations

- 2465** A Pilot Program to Improve Human Papillomavirus Vaccination Status of Adolescents at a School-Based Health Center

252. Poster Abstract Session

Vaccine Policy and Hesitancy

Saturday, 12:30 - 1:45 p.m.

- 2466** Evaluation of Immunization on the Neonatal Intensive Care Unit at British Columbia Women's Hospital
- 2467** Timeliness of Childhood Vaccination with the Combination Measles-Mumps-Rubella-Varicella Vaccine versus the Separate Measles-Mumps-Rubella and Varicella Vaccines in the United States
- 2468** Impact of a Herd Immunity Educational Intervention on Parental Concern About Measles
- 2469** Knowledge, Attitudes, Confidence, and Hesitancy Towards Vaccines among Residents in Pediatric and Family Practice Programs
- 2470** The Effect of Information—Motivation—Behavioral Skills Model-Based Continuing Medical Education on Pediatric Influenza Immunization Uptake: A Randomized, Controlled Trial
- 2471** The State of Cost-utility Analyses in Vaccines: A Systematic Review
- 2472** The Impact of State Medicaid Policies on Adult Vaccination Post Affordable Care Act Implementation
- 2473** How Does Acquiring a Vaccine-Preventable Disease Impact Parental and Physician Responses to Vaccine Hesitancy?
- 2474** Early Feedback from a Pilot of a Cognitive Computing System to Analyze Immunization Data
- 2475** Hepatitis B Vaccination Coverage Among Asian-American Adults: A Population-Based Study of the Role of Race and Gender

253. Poster Abstract Session

Vaccines for Herpes Zoster Virus

Saturday, 12:30 - 1:45 p.m.

- 2476** Impact of the Vaccination Strategy on Varicella Burden Disease in Argentina
- 2477** Impact of Varicella Vaccination in the United States (U.S.): a Dynamic Model-Based Analysis
- 2478** Impact of 20 Years of Varicella Vaccination on the Epidemiology of Herpes Zoster in the United States: An Interrupted Time Series Analysis
- 2479** Varicella Zoster Immune Globulin Is Effective up to 10 Days Following Varicella Exposure in Pregnant Women, Immunocompromised Patients, and Infants: Results from a Large, Open-Label Expanded-Access Program
- 2480** Real-World Effectiveness of the Live Zoster Vaccine in Preventing Herpes Zoster: A Systematic Review
- 2481** Impact of Sex And Race/Ethnicity on The Effectiveness of Live Zoster Vaccine

Poster Abstract Sessions (continued)

2482 Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients

2483 Twelve-Month Immunogenicity and Safety of an Adjuvanted Recombinant Zoster Vaccine in Immunosuppressed Adults Post Renal Transplant: A Phase III Randomized Clinical Trial

254. Poster Abstract Session

Vaccines for the Elderly and Immune Compromised

Saturday, 12:30 - 1:45 p.m.

2484 Pre-Transplant Vaccination Adherence in Pediatric Solid Organ Transplant Patients at a Large Academic Medical Center

2485 Circulating T Follicular Helper Cells and Immune Response Induced by Influenza Vaccine in Children with Acute Lymphoblastic Leukemia During Maintenance Therapy

2486 The Effectiveness of High-Dose Hepatitis B Vaccination in Patients Receiving Immunomodulatory Therapy

2487 Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?

2488 The Impact of Reactogenicity after Administration of the Recombinant Zoster Vaccine upon the Physical Functioning and Quality of Life of Older Adults

2490 A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥ 65 Years of Age

255. Poster Abstract Session

Virology Potpourri

Saturday, 12:30 - 1:45 p.m.

2491 Post-Exposure Prophylaxis with Ribavirin Plus Lopinavir/Ritonavir for Middle East Respiratory Syndrome in Healthcare Workers

2492 Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of U.S. Patients

2493 Marburg Virus Disease: Virulence of Angola Versus Musoke Strain in *Cynomolgus* Macaques

2494 Influenza B Hospitalizations are Associated with Mortality in Children, FluSurv-NET, 2011-2017

2495 Real-World Burden of Transmission and Care Seeking among Family Members with a Primary Influenza Infection

2496 A Comparative Evaluation of the Burden of Disease Caused by Influenza A and Influenza B During the 2011/2012, 2012/2013, and 2013/2014 Influenza Seasons in Canada

2497 Acute Flaccid Paralysis: 17-Year's Active Epidemiological Surveillance in a Pediatric Hospital in Argentina

2498 Association of Increasing Age with Hospitalization Rates, Clinical Presentation, and Outcomes among Older Adults Hospitalized with Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET)

2499 Burden of Influenza Like Illness (ILI) among Congregate Military Populations

2500 Incidence of Herpes Zoster in the Pre and Post Vaccine Era: Do Trends Differ Between Blacks and Whites?

2501 Impact of Influenza A and B Infection on Stem Cell Transplant Patients During the 2017-2018 Season at a Single Center

2502 Host Susceptibility to Andes Hantavirus Infection Associates to a Single Nucleotide Polymorphism at the $\alpha V\beta 3$ Integrin

2503 Assessment of State-Level Influenza Season Severity, Utah, 2017–2018

2504 Influenza Surveillance and Outbreaks in the U.S. Department of Veterans Affairs (VA): 2017-2018 Season

2505 A Novel Mobile Phone Application for Remote Research Data Collection is Effective in Monitoring Chronic Sequelae after Acute Viral Infections

2506 Reactivation of Latent Cytomegalovirus Infection Following Major Surgery: Risk Factors and Outcomes

2507 Active Norovirus Surveillance in Children Under 5 years with Diarrhea following Rotavirus Vaccine Introduction in Argentina

2508 Absolute Lymphocyte Count and Adenovirus-specific CD8+ T-Cell Immunity as Immunological Predictors of Severe Adenovirus Disease after Kidney Transplantation

2509 High-Risk Human Papillomavirus Infection and the Risk of Cardiovascular Disease: A Cohort Study

2510 Epidemiological Change of Cytomegalovirus Diseases in the Developed Country with High Cytomegalovirus-Seropositive Rate: Nationwide, Whole Population-based Study

2511 Estimating Numbers of Influenza Excess Deaths and Hospitalizations at the State-Level

2512 The Trend in the Incidence of Herpes Zoster and Effect of Immune Status on Severity and Healthcare Utilization: Population Based Study of Korea, 2003-2015

2513 The Utility of Next Generation Sequencing for Detection of Causative Viruses in Sera of Patients with Acute Myocarditis

2514 Pediatric Medically Attended Shingles in Alberta, Canada, 2016: Preliminary Results

2515 Impact of Human Parainfluenza Virus Type 4 in Hospitalized Children in Korea

2516 Predictors of Zika Virus Disease Severity within Veterans Affairs (VA)

2517 Seasonal Influenza 2017-2018: Epidemiological Review and Experience at a Veterans Affairs Medical Center in New York

2518 The Role of Non-Influenza Viruses in the Seasonal Viral Respiratory Illness: A Epidemiologic study from October 2016 - March 2017

2519 The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Crimean-Congo Haemorrhagic Fever

2520 Epidemiology, Clinical Manifestations, and Outcomes of the 2017-2018 Influenza Season among Hospitalized Patients at a Tertiary Care Center

2521 The Potential Rise in the Incidence of *Rotavirus* G3P[8] in Kuwait

IDSA Board of Directors

Paul G. Auwaerter, MD, FIDSA, President, Johns Hopkins University School of Medicine, Baltimore, MD

Cynthia L. Sears, MD, FIDSA, President-Elect, Johns Hopkins University School of Medicine, Baltimore, MD

Thomas File, Jr., MD, FIDSA, Vice President, Summa Health, Akron, OH

Larry K. Pickering, MD, FIDSA, Secretary, Emory University School of Medicine, Atlanta, GA

Helen W. Boucher, MD, FIDSA, Treasurer, Tufts University School of Medicine, Boston, MA

William G. Powderly, MD, FIDSA, Immediate Past President, Washington University School of Medicine, St. Louis, MO

Angela M. Caliendo, MD, FIDSA, Brown University/Rhode Island Hospital, Providence, RI

Henry F. Chambers, MD, FIDSA, University of California, San Francisco, San Francisco, CA

Susan J. Rehm, MD, FIDSA, Cleveland Clinic, Cleveland, OH

Tina Q. Tan, MD, FIDSA, Northwestern University, Chicago, IL

Victoria J. Fraser, MD, FIDSA, FSHEA, Washington University School of Medicine, St. Louis, MO

Daniel P. McQuillen, MD, FIDSA, Lahey Hospital & Medical Center, Burlington, MA

Thomas A. Moore, MD, FIDSA, IDC of Kansas, Wichita, KS

Trish M. Perl, MD, MSc, FIDSA, FSHEA, UT Southwestern Medical Center, Dallas, TX

Ighowerha Ofotokun, MD, MSc, FIDSA, HIVMA Representative, Emory University School of Medicine, Atlanta, GA

Janet Gilsdorf, MD, PIDS Liaison, University of Michigan Medical Center, Ann Arbor, MI

Hilary M. Babcock, MD, MPH, SHEA Liaison, Washington University School of Medicine, St. Louis, MO

Chris Busky, CAE, CEO, Infectious Diseases Society of America, Arlington, VA

SHEA Board of Trustees

Keith Kaye, MD, MPH, FIDSA, FSHEA, President, University of Michigan Medical School, Ann Arbor, MI

Hillary Babcock, MD, MPH, President-Elect, Washington University School of Medicine, St. Louis, MO

David K Henderson, MD, FIDSA, FSHEA, Vice President, Bethesda, MD

Grace Lee, MD, MPH, FPIDS, Secretary, Stanford University, Stanford, CA

Eli Perencevich, MD, MPH, FIDSA, FSHEA, Treasurer, University of Iowa Carver College of Medicine, Iowa City, IA

Sara E. Cosgrove, MD, MS, FIDSA, FSHEA, Past President, Johns Hopkins University School of Medicine, Baltimore, MD

Gonzalo Bearman, MD, MPH, FIDSA, FSHEA, Virginia Commonwealth University, Richmond, VA

Kristina Bryant, MD, FPIDS, PIDS Liaison, University of Louisville, Louisville, KY

Mirian Dal Ben, MD, MSc, Hospital Sírio Libanês, São Paulo, Brazil

Aaron Milstone, MD, FIDSA, FSHEA, Johns Hopkins University, Baltimore, MD

Dan Morgan, MD, MS, FIDSA, FSHEA, University of Maryland School of Medicine, VA Maryland, Baltimore, MD

Roger Scott Stienecker, MD, FIDSA, FSHEA, Community-Based Healthcare Epidemiologist Liaison, Parkview Health, Ft. Wayne, IN

David J. Weber, MD, MPH, FIDSA, FSHEA, University of North Carolina at Chapel Hill, Chapel Hill, NC

Eve Humphreys, MBA, CAE Executive Director, The Society for Healthcare Epidemiology of America, Arlington, VA

HIVMA Board of Directors

Melanie Thompson, MD, Chair, AIDS Research Consortium of Atlanta, Atlanta, GA

W. David Hardy, MD, Chair-Elect, Whitman Walker Health, Washington, DC

Judith Feinberg, MD, Vice Chair, West Virginia School of Medicine, Morgantown, WV

Wendy Armstrong, MD, FIDSA, Immediate Past Chair, Emory University, Atlanta, GA

Igho Ofotokun, MD, MSc, FIDSA, IDSA Representative, Emory University, Atlanta, GA

Michelle S. Cespedes, MD, MS, Icahn School of Medicine at Mount Sinai, New York, NY

Michelle Collins Ogle, MD, PIDS Liaison, Warren-Vance Community Health Center, Henderson, NC

Demetre Daskalakis, MD, MPH, NYC Department of Health and Mental Hygiene, Gotham Center, Queens, NY

Donna Futterman, MD, Albert Einstein College of Medicine, Bronx, NY

Marwan S. Haddad, MD, MPH, Community Health Center, Inc., New Haven, CT

Colleen F. Kelley, MD, MPH, Emory University, Atlanta, GA

Lynsay MacLaren, MPH, MPAS, PA-C, Whitman Walker Health, Washington, DC

James M. Sosman, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI

Alice C. Thornton, MD, FIDSA, University of Kentucky School of Medicine, Lexington, KY

William Towner, MD, FIDSA, Kaiser Permanente, Los Angeles, CA

Rochelle Walensky, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA

Ira Wilson, MD, MSc, Brown University School of Public Health, Providence, RI

Kimberly Scarsi, PharmD, MS, University of Nebraska Medical Center, College of Pharmacy, Omaha, NE

Andrea Weddle, MSW Executive Director, HIV Medicine Association, Arlington, VA

PIDS Board of Directors

Paul W. Spearman, MD, FIDSA, FPIDS, President, Cincinnati Children's, Cincinnati, OH

Janet R. Gilsdorf, MD, FIDSA, FPIDS, Past President, University of Michigan Medical Center, Ann Arbor, MI

Kristina A. Bryant, MD, FPIDS, President-Elect, University of Louisville, Louisville, KY

C. Buddy Creech, MD, MS, FPIDS, Secretary-Treasurer, Vanderbilt University Medical Center, Nashville, TN

Susan E. Coffin, MD, FPIDS, FSHEA, Children's Hospital of Philadelphia, Philadelphia, PA

Ravi Jhaveri, MD, FIDSA, FPIDS, University of North Carolina School of Medicine, Chapel Hill, NC

Grace Lee, MD, MPH, FPIDS, Stanford University, Stanford, CA

Yvonne A. Maldonado, MD, FPIDS, Stanford University, Stanford, CA

Jason Newland, MD, MEd, FPIDS, Washington University, St. Louis, MO

Ann-Christine Nyquist, MD, MSPH, FPIDS, Children's Hospital Colorado, Denver, CO

Debra Palazzi, MD, MEd, FPIDS, Baylor College of Medicine, Houston, TX

Jennifer S. Read, MD, MPH, DTMH, FIDSA, FPIDS, Burlington, VT

Andi L. Shane, MD, MPH, MSc, FPIDS, Emory University School of Medicine, Atlanta, GA

William Steinbach, MD, FPIDS, Duke University Medical Center, Durham, NC

Terri Christene Phillips, MSA, Executive Director, Pediatric Infectious Diseases Society, Arlington, VA

See You Next Year!

October 2-6 • Washington, DC • www.idweek.org



IDWeek ²⁰¹⁹™

Advancing Science, Improving Care



IDSA

The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.



IDS, in conjunction with ProCE, Inc., will provide continuing education (CE) for pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Visit our websites:

www.idsociety.org • www.shea-online.org • www.hivma.org • www.pids.org